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Adenosine A1 receptor (A1AR), cannabinoid type 1 receptor (CB1R) and cannabinoid 
type 2 receptor (CB2R) are class A G protein-coupled receptors (GPCRs) and play 
important roles in human pathophysiological conditions such as cardiovascular, 
neurological, metabolic and immunological disorders. Fluorescent ligands are powerful 
tools to investigate processes such as receptor expression, localisation, trafficking and 
receptor-protein interactions in the native cell environment. Fluorescent ligands can also 
be used as tracers in pharmacological assays, instead of the commonly used radioligands 
that carry inherent safety risks. The development of fluorescent ligands with high affinity, 
selectivity and suitable imaging properties for A1AR, CB1R and CB2R would greatly 
contribute to an increased understanding of receptor biology and thus facilitate the drug 
development process. Development of fluorescent ligands with sufficient polarity for 
cannabinoid receptors (CBRs), which have lipid-based endogenous ligands, is an 
especially challenging task. This thesis describes the development of small molecule-
based fluorescent ligands for A1AR, CB1R and CB2R, via attachment of a linker and 
fluorophore to a ligand. 
 
(Benzimidazolyl)isoquinolinols, analogues of previously reported high affinity A1AR 
(benzimidazolyl)isoquinolines, were explored in chapter 2 for the development of A1AR 
fluorescent ligands. A procedure for 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) 
mediated aromatisation of tetrahydroisoquinolines and multistep synthesis for the 
preparation of (benzimidazolyl)isoquinolinols was developed. Based on the previously 
reported structure–activity relationship (SAR), linkers (and linker plus fluorophore 
conjugates) were introduced in the C-6 or C-7 position of (benzimidazolyl)isoquinolinols. 
Unfortunately, these fluorescent ligands did not exhibit any significant affinity for A1AR 
in a bioluminescence resonance energy transfer (BRET) assay using the NanoLuc 
luciferase and it was concluded that (benzimidazolyl)isoquinolinols might not be a 
suitable scaffold for the development of A1AR fluorescent ligands. NMR spectroscopy 
and reverse phase HPLC studies showed (benzimidazolyl)isoquinolinols exhibit 
tautomerism. 
 
Chromenopyrazoles, previously reported as high affinity CB1R ligands, were investigated 
for development into CB1R fluorescent ligands in chapter 3. Based on previous SAR, 
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linkers then fluorophores were introduced at six different chromenopyrazole positions. 
Disappointingly, fluorescent chromenopyrazoles did not exhibit high affinity for CB1R 
in a radioligand binding assay. However, several chromenopyrazoles including a linker 
conjugate 3.22 and a peptide linker conjugate 3.39 exhibited high affinity for CB2R that 
were promising candidates for development of CB2R fluorescent ligands. All of the 
chromenopyrazoles that were evaluated in a cyclic adenosine monophosphate (cAMP) 
functional assay behaved as agonists at CB2R. Docking studies were carried out using a 
CB2R homology model and showed that high affinity CB2R chromenopyrazoles with 
linkers attached likely exit via a cavity located between transmembrane helix (TM) 1 and 
TM7. 
 
In chapter 4, efforts were made to develop high affinity CB2R fluorescent ligands and 
more polar CB2R linker conjugates that built on the results of chapter 3. The highest 
affinity CB2R linker conjugate 3.22 (obtained in chapter 3) was conjugated to four 
different fluorophores (BODIPY-FL, Cy5, TAMRA, BODIPY-630/650) and two high 
affinity CB2R fluorescent ligands (4.01, 4.02) were obtained. The highest affinity CB2R 
fluorescent ligand 4.02 (Ki = 41.8 ± 4.5 nM at hCB2R; 5856 ± 1264 nM at hCB1R) 
behaved as an inverse agonist (4.02, EC50 = 142.0 ± 13.1 nM at hCB2R, 196.7 ± 9.11 % 
of forskolin response at hCB2R) in the cAMP functional assay and showed CB2R-
specific-binding in widefield imaging experiments using CB2R expressing HEK-293 
cells. Fluorescent ligand 4.02 exhibited higher affinity for CB2R than any other reported 
CB2R fluorescent ligands and is the first high affinity CB2R fluorescent ligand for which 
functional data has been reported (as of July 2018). Fluorescent ligand 4.02 possesses 
suitable CB2R imaging properties and will be a useful tool for researchers studying CB2R 
biology in techniques such as fluorescence-based assays, widefield microscopy and flow-
cytometry and can be used in resonance energy transfer experiments with other 
fluorescent partners. In addition, three high-moderate affinity peptide linker conjugates 
(4.06, 4.07, 4.08) with considerably higher polarity compared to commonly used 
cannabinoid receptor ligand CP55,940 were obtained, all of which behaved as CB2R 
agonists.  
 
Development of high affinity CB1R ligands based on a reported pyridyl scaffold was 
explored in chapter 5. Fluorescent ligands were designed using previously reported SAR 
coupled with results obtained from CB1R docking using the reported CB1R crystal 
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structure. O-Linker pyridyl-2-carboxamides and corresponding fluorescent conjugates 
were prepared via a multistep synthesis. Unfortunately, none of the fluorescent ligands 
exhibited any significant affinity for CB1R, however, three moderate affinity CB1R linker 
conjugates (5.33, 5.34, 5.35) were obtained. It was therefore concluded that optimised 
derivatives of pyridyl-2-carboxamide with different O-linkers or with linkers conjugated 
at different positions of the pyridine could be another strategy for the development of 
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Chapter 1 Introduction 
1.1 G protein-coupled receptors 
 
G protein-coupled receptors (GPCRs) constitute the largest family of human 
transmembrane proteins with approximately 800 members.1 GPCRs play an important 
regulatory role in numerous physiological processes and are responsible for the signal 
mediation of various bioactive substances such as peptides, lipids, carbohydrates, 
proteins, and small organic molecules as well as other stimuli such as light and ions.1-2 
These receptors have been the subject of intense drug discovery effort and approximately 
34% of all currently marketed drugs target GPCRs.1 GPCRs are grouped into five major 
families: class A rhodopsin-like, class B secretin-like, class C metabotropic 
glutamate/pheromone, cyclic adenosine monophosphate (cAMP) receptors, vomeronasal 
receptors (V1R and V3R), and taste receptors T2R.3 Among these families, class A 
rhodopsin-like is the most studied and the largest family accounting for 80% of all known 
GPCRs.1 Adenosine A1 receptor (A1AR)
** and cannabinoid receptors (CBRs)†† belong to 
the family of class A GPCRs. 
 
Structurally, GPCRs consist of an extracellular N-terminal and an intracellular C-
terminal, which are connected by seven transmembrane α-helices (TMs) (Figure 1.1, 
panel A). An alternate sequence of three intracellular (IL) (IL1, IL2, and IL3) and three 
extracellular loops (EL) (EL1, EL2, and EL3) connect the seven transmembrane helices. 
GPCRs exhibit structural similarity in the transmembrane region, however, large 
structural diversity is observed in the loop regions.  
 
X-ray crystallography is widely used to determine the structure of proteins at the atomic 
level. However, determination of the X-ray crystal structure of GPCRs has been 
challenging due to the difficulties encountered in the crystallisation of membrane 
proteins. These difficulties arise from the instability of GPCRs in detergents, structural 
heterogeneity (from the presence of receptors in glycosylated, phosphorylated, and 
palmitoylated forms), and conformational heterogeneity due to the inherent flexible 
                                                 
** human (h) adenosine receptors, unless specified, throughout this thesis  
†† human (h) cannabinoid receptors, unless specified, throughout this thesis 
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nature of GPCRs.4 Nevertheless, remarkable progress has been made recently and there 
are now 44 distinct GPCR X-ray crystal structures reported (as of July 2018).1 However, 
the static nature of structures obtained from X-ray crystallography coupled with a number 
of thermostabilising receptor mutations usually incorporated for successful crystallisation 
has to be taken into account when studying dynamic receptor structure and processes in 
the native cell environment. In addition to X-ray crystallography, nuclear magnetic 
resonance (NMR) spectroscopy is also used to study GPCR structures5 and more recently 
cryoelectron microscopy has been increasingly used to determine GPCR structures.6-8 
 
GPCR signalling is primarily mediated by heterotrimeric G proteins,9-10 which consist of 
three subunits: Gα, Gβ, and Gγ (Figure 1.1, panel B shows β2 adrenergic receptor (β2ADR) 
bound to heterotrimeric G protein). Close to the submission date of this thesis a 
cryoelectron microscopy structure of A1AR complexed with G protein was also reported
8 
(not shown in Figure 1.1). Activation of a GPCR, often with an agonist, promotes the 
exchange of guanosine diphosphate (GDP) by guanosine triphosphate (GTP) in the Gα 
subunit. This Gα.GTP complex then dissociates from Gβ and Gγ subunits and modulates 
downstream pathways. 
 
According to the structure and function of the α subunit, G proteins can be classified into 
four types: Gαs, Gαi/o, Gαq/11, and Gα12/13. Once activated, Gαs stimulates enzyme adenyl 
cyclase which catalyses the production of cyclic adenosine monophosphate (cAMP) from 
adenosine triphosphate (ATP), whereas Gαi/o inhibits the activity of adenyl cyclase. Gαq/11 
activates enzyme phospholipase C (PLC) which then produces inositol 1,4,5-
trisphosphate (IP3) and diacylglycerol (DAG) from hydrolysis of membrane bound 
phosphatidylinositol 4,5-bisphosphate (PIP2). The G12/13 subunit is involved in the 
activation of RhoGEF (guanine nucleotide exchange factor).9-10 All of these messengers 





Figure 1.1 Panel (A) Cartoon representation as a forest green ribbon of a β2ADR (a class A GPCR, Protein 
Data Bank (PDB) ID: 3P0G) with bound agonist BI-167107 (cyan carbons, red oxygens, blue nitrogen).11 
Heterotrimeric G proteins, T4 lysozyme, and a stabilising nanobody are not shown. TM helices 1-7 labelled. 
Panel (B) Crystal structure of β2ADR (forest green, PDB ID: 3P0G,11 also shown in panel (A)) with 
heterotrimeric G proteins – Gαs (orange), Gβ (magenta), and Gγ (blue). T4 lysozyme and stabilising 
nanobody used to facilitate crystallisation are not shown. 
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In addition to signalling via heterotrimeric G proteins, GPCRs can also signal by G 
protein-independent mechanisms. The G protein-independent signalling commences with 
the phosphorylation of agonist-bound GPCR by G protein-coupled receptor kinases 
(GRKs). The phosphorylated GPCR subsequently binds to β-arrestin which leads to 
receptor desensitisation, internalisation, ubiquitination, and initiates G protein-
independent signalling (which includes extracellular signal regulated kinase (ERK), c-
Jun N-terminal kinase (JNK), and SRC proto-oncogene non-receptor tyrosine kinase c-
Src).12-15 
 
There has been growing interest towards preparing small molecules with biased 
signalling, that is preference for one signalling pathway over another (for example, β-
arrestin signalling over G protein signalling) in order to reduce the associated side effects 
of an unbiased ligand.16 For example, a selective μOR (μ-opioid receptor) agonist PZM21 
with preference for G protein signalling over β-arrestin signalling was prepared and 
showed analgesic activity without opioid associated respiratory depression in mouse 
models.17 However, in a later study, PZM21 was found to activate both G protein and β-
arrestin signalling and depressed respiration in a mouse model.18 GPCRs have also been 
shown to signal from both cell membrane as well as intracellular compartments,19 and a 
location bias for signalling has been demonstrated.20 Increasing evidence has indicated 
that GPCRs signal via oligomers, which can be targeted with a bivalent ligand.21 
Allosteric modulation of GPCR signalling is another key area of research with potential 
to provide ligands with therapeutic benefits without associated side effects of orthosteric 
ligands.22-23 As this thesis is focused on the development of fluorescent ligands as tools 
to study GPCRs, these concepts will not be covered in more depth.  
 
1.2 Chemical tools to study Class A GPCRs 
 
Considering the central role GPCRs play in human pathophysiology, significant efforts 
have been invested in understanding the pharmacology of these receptors. Chemical tools 
are commonly used to study GPCRs in both in vivo and in vitro experiments and can 
provide crucial information regarding the role of the GPCRs in pathophysiological 
conditions.24 Aside from small molecule ligands, tools can be designed with some 
traceability or read out – for example radioligands, covalent ligands and fluorescent 
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ligands. Chemical tools for lipid-binding receptors (for example CBRs) have recently 





Radioligands used in pharmacological studies are compounds which exhibit high affinity 
and selectivity for a particular receptor or protein of interest and contain a radioisotope 
such as 3H, 123I, 125I, 35S, 11C, and 18F. The incorporated radioisotope undergoes nuclear 
decay to emit β particles, positrons, or γ radiation, which can be detected and consequently 
the amount of radioligand bound to the receptor can be quantified. The most common 
radioisotope used is 3H. For a radioligand to be used successfully in GPCR 
pharmacological studies, it should have a minimal amount of non-specific membrane 
interactions. 
 
Radioligands are significant tools in the identification of GPCR subtypes and in studying 
GPCR distribution. The parameters obtained from the study of radioligand-receptor 
interactions such as dissociation constant (Kd), inhibitor constant (Ki), and receptor 
density provide a quantitative description of the drug-receptor interaction, which can be 
used to propose and validate receptor activation models. Radioligands have been used for 
in vivo studies of GPCRs using techniques such as positron emission tomography and 
single-photon emission computed tomography to identify changes in the receptor 
expression in healthy and disease conditions, for example [18F]MK-947026-28 (a high 
affinity cannabinoid type 1 receptor (CB1R) inverse agonist). 
 
Radioligands are extensively used to study GPCRs in vitro. One of the most common 
applications of radioligands is in the determination of the affinity (Ki) of a test compound 
by displacement of the radioligand in a competition-binding assay. It is particularly 
challenging to prepare radioligands of adequate polarity for GPCRs whose endogenous 
ligands are lipid-based compounds, as is the case with CBR. For example, most CBR 
radioligands are lipophilic compounds with logD7.4 in the range of 3.3 - 6.0. Radioligands 
with high lipophilicity often exhibit a high level of non-specific membrane interactions.29 




30 and [3H]-CP55,940 (Kd = 0.54 ± 0.07 nM at human 
cannabinoid type 1 receptor (hCB1R)
31, 2.55 ± 0.19 nM at human cannabinoid type 2 
receptor (hCB2R)
32) are commonly used for in vitro studies of A1AR and CBR 
respectively (Figure 1.2). 
 
 
Figure 1.2. Commonly used radioligands [3H]-DPCPX and [3H]-CP55,940 for studying A1AR and CBRs. 
 
1.2.2 Covalent ligands 
 
A covalent ligand binds with moderate to high affinity to the target receptor and forms a 
covalent bond with a receptor amino acid residue(s). This binding can be irreversible or 
reversible depending on the structure of covalent adduct formed. Covalent ligands belong 
to two main categories – electrophilic ligands and photoactivatable ligands. The 
electrophilic covalent ligands contain an electrophilic moiety such as isothiocyanates, 
halomethyl ketones, thiols, Michael acceptors and nitrogen mustards, which react with a 
nucleophilic residue of the target receptor. Photoactivatable ligands, on the other hand, 
contain an inert moiety, such as a benzophenone, azide, and diazirine, which, after 
irradiation with light of suitable wavelength, convert to a reactive moiety such as a 
carbene or nitrene that undergoes reaction with amino acids of the target receptor.  
 
Use of covalent ligands along with computational and mutagenesis studies is a powerful 
approach to identify key amino acids involved in ligand-receptor binding and receptor 
activation.25 For example, one study with a commonly used CBR covalent ligand AM841 
(Figure 1.3) showed the involvement of both central and peripheral mCBR in the anti-
inflammatory action of CBR ligands.33 Recently, a photoactivatable diazirine based 
covalent ligand LEI121 for studying cannabinoid type 2 receptor (CB2R) expression and 
for use in CB2R isolation was reported.
34 Covalent ligands have also been used to stabilise 
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GPCRs for structure determination by X-ray crystallography, for example the covalent 
antagonist DU172 (Figure 1.3) was used to stabilise A1AR in a report of the A1AR crystal 
structure by Glukhova et al.35 
 
 
Figure 1.3 CB1R covalent ligand AM841 CB2R covalent ligand LE1121 and A1AR covalent ligand DU172; 




Fluorescence is widely used in molecular pharmacology. Absorption of a photon (from 
irradiated light) by a compound excites an electron from the ground state (S0) to an excited 
state (S1). When the excited electron relaxes, a photon (of emitted light) of lower energy 
is emitted along with some energy loss, which occurs by a non-radiative relaxation 
process such as heat. The wavelength of emitted light (Eem) is longer than the wavelength 
of irradiated light (Eex) and the difference between Eem and Eex is called the Stokes shift. 
A large Stokes shift allows for easier separation of excitation light from emission light 
with optical filters during biological experiments. A crucial parameter directly related to 
the brightness of the fluorophore (and consequently sensitivity of biological experiments) 
is determined by quantum yield and is the ratio of the number of photons emitted to the 
number of photons absorbed by a fluorophore. The loss (or reduction) of the fluorescence 
of a fluorophore after repetitive excitation is called photobleaching, that can adversely 
affect sensitivity of the experiment. This loss of fluorescence can occur due to a change 




Use of fluorescence to study GPCRs is wide ranging, for example green fluorescent 
protein and yellow fluorescent protein (YFP) -tagged receptors have been used to study 
receptor localisation, trafficking, and oligomerisation.36-38 Receptor selective antibodies 
conjugated to fluorophores are also used to study GPCR distribution.37 However, a 
number of antibodies developed chiefly for CBRs, were shown to lack receptor 
specificity.39-41 Only small molecule-based fluorescent ligands will be discussed further 
in this chapter. 
 
1.2.3.1  Fluorescent ligands 
 
A fluorescent ligand should exhibit affinity and selectivity for a molecular target 
(receptors, enzymes, proteins etc.) and emit detectable fluorescent radiation. Some 
examples of such fluorescent ligands are – small fluorescent molecules,24 antibody 
conjugates, and quantum dots.42  
 
Small molecule fluorescent ligands with a fluorophore included as a substructure of the 
core ligand have been reported (for example– NMP6, described in section 1.4.4). Another 
approach to prepare fluorescent ligands is via in situ reaction of the fluorophore and the 
ligand partners, which have been previously derivatised with a biorthogonal functional 
groups such as an alkyne or azide, or with biotin or streptavidin (for example 2-
arachidonylglycerol ether (2-AGE)-biotin-3b, biotin-HU210-1, and biotin-HU308-3 
described in section 1.4.4). More commonly, small molecule-based fluorescent ligands 
for studying GPCRs have been developed by tethering a high affinity ligand to a 
fluorophore via a linker as a single chemical entity before using as a tool (Figure 1.4). 
The selection of the ligand is guided by the previous structure–activity relationship (SAR) 
data indicative of receptor affinity and subtype selectivity, the ability to accommodate 
bulky substituents, synthetic feasibility, and desired application of the ligand (agonist or 
antagonist etc.).  
 
A fluorophore is attached via a linker of sufficient length to a ligand such that the binding 
of the ligand with the receptor is not affected by the usually large sized fluorophore 
(compared to ligand). Fluorescent ligands with high affinity for a target GPCR and 
appreciable polarity are desired to obtain high sensitivity in the imaging studies and 
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pharmacological assays. Peptide linkers are particularly useful in improving polarity and 
receptor affinity (by introduction of hydrogen bond donors and acceptors) of the ligand. 
Peptide linkers can also provide subtype specificity to a particular receptor as has been 
demonstrated in the case of adenosine receptors (AR).43 Fluorophores are selected based 
on the excitation Eex and emission Eem profile, quantum yield, stability to photobleaching, 
chemical structure, and spectral sensitivity to environmental factors such as the pH and 
polarity of the medium. A number of fluorophores are commercially available with 
amine-reactive functional groups such as succinimidyl esters (SE), sulfonyl chlorides, 
isothiocyanates, and tetrafluorophenyl esters for facile preparation of fluorescent ligands; 
for example borondipyrromethene (BODIPY, structure of a BODIPY derivative –
BODIPY-630/650 – shown in Figure 2.2, chapter 2), cyanine (structure of a cyanine 
fluorophore – Cy5 – shown in Figure 4.2, chapter 4), Alexa Fluor® (structure of an Alexa 
fluorophore – Alexa488 – shown in Figure 4.2, chapter 4), and rhodamine (structure of 
TAMRA, a rhodmine derivative shown in Figure 4.2, chapter 4). 
 
 
Figure 1.4. Schematic representation of a small molecule-based fluorescent ligand consisting of a high 
affinity ligand conjugated to a fluorophore via a linker. 
 
The development of fluorescent ligands is challenging notably for GPCRs with 
endogenous lipid-based ligands such as CBRs due to the conflicting requirement of 
preparing a ligand with sufficient polarity for obtaining a suitable imaging agent. 
  
The functional activity of the fluorescent ligand may be different to the individual parent 
ligand. Despite this possibility, many reported fluorescent ligands have not been 
characterised for functional activity (none of the literature reported CBR fluorescent 
ligands are characterised for functional activity, section 1.4.4). Development of 
fluorescent ligands for GPCRs is a relatively new field compared to radioligands. 
Notwithstanding this, there are now many fluorescent ligands reported for studying 




1.2.3.2 Applications of fluorescent ligands 
Fluorescent ligands are extensively used to study receptor pharmacology.25 Fluorescent 
ligands have been used in confocal microscopy to study processes such as receptor 
expression, localisation, distribution, and internalisation at the single cell level.24, 44-45 
Resonance energy transfer techniques (FRET and BRET) with fluorescent ligands have 
been used to study processes such as receptor oligomerisation, receptor-fluorescent ligand 
and receptor-protein interactions.24, 42, 44-45 Flow cytometry has been used for sorting cells 
based on the binding of fluorescent ligands to a particular receptor expressed by cells, for 
example NMP646 and HU210-Alexa48847 (described in section 1.4.4). HTS with 
fluorescent ligands has been used to identify novel orthosteric and allosteric ligands, for 
example T111748 and NIR-mbc9449 (described in section 1.4.4). Progress has also been 
made on the use of near-infrared (NIR) fluorescent ligands for the diagnostic imaging of 
GPCRs in healthy versus disease conditions (see section 1.4.4). The development of a 
high affinity fluorescent ligand also provides a robust platform for the preparation of other 
conjugates/chemical tools such as multivalent ligands, magnetic resonance active ligands, 
covalent ligands, and theranostic agents. 
 
1.3 Adenosine A1 receptor  
 
Adenosine receptors (ARs) are class A GPCRs and are classified in four distinct subtypes 
- A1AR, A2A adenosine receptor (A2AAR), A2B adenosine receptor (A2BAR) and A3 
adenosine receptor (A3AR).
50 The endogenous nucleoside adenosine acts as an agonist at 
all AR subtypes and exhibits high affinity for A1AR, A2AAR and low affinity for A2BAR, 
A3AR.
51 Adenosine is clinically used for the treatment of supraventricular tachycardia. 
Initial indication for the existence of AR came from an increase in cAMP production by 
adenosine in guinea pig brain slices.52 Later, each AR subtype was characterised based 
on the responses in pharmacological assays with agonists, antagonists and molecular 
cloning experiments.53  
 
Activation of A1AR and A3AR inhibits adenyl cyclase via G protein Gαi/o and therefore 
decreases cAMP production. Activation of A2AAR and A2BAR stimulates adenyl cyclase 
via G protein Gαs/o and thus increases cAMP production.
51 Besides cAMP, AR also 
mediates signalling via modulation of messengers such as PLC, mitogen-activated protein 
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kinases (MAPK), ERK, and β-arrestin.54 AR subtypes are expressed by many cells 
throughout the body with predominant expression in CNS, heart, lung, spleen, thymus, 
leukocytes, and platelets.55 ARs are important drug targets for cardiovascular, renal, 
metabolic, immunological, and neurological disorders.55 Regadenoson, an A2AAR 
agonist, is commonly used for the diagnosis of coronary artery disease.56  
 
A1AR is primarily expressed in brain (cortex, hippocampus, cerebellum), spinal cord 
(dorsal horn), heart, eye, adrenal gland and its amino acid sequence is highly conserved 
among different species (≥94% sequence identity among six species).53, 57 A1AR 
modulation by synthetic small molecules is being pursued to treat various pathological 
conditions such as supraventricular tachycardia, angina pectoris, atrial fibrillation, 
myocardial infarction, congestive heart failure, hypertriglyceridaemia, diabetes, 
glaucoma, pain, liver fibrosis, Alzheimer’s disease, Parkinson’s disease, renal and 
immunological disorders.58-61 Conversely, many such attempts have not been successfully 
translated into clinically used medicines. For example, one of the clinical trials conducted 
for rolofylline (a selective A1AR antagonist) for the treatment of heart failure failed due 
to a lack of efficacy and increased occurrences of seizures and stroke compared to 
placebo.62  
 
Adenosine A1 receptor structure  
 
Two A1AR crystal structures were published in 2017 by Glukhova et al.
35 and Cheng et 
al.63 (Figure 1.5). Glukhova et al. reported a 3.2 Å structure of A1AR bound to A1AR 
selective covalent antagonist DU172 (Figure 1.3) and Cheng et al.63 reported a 3.3 Å 
structure of A1AR (Figure 1.5) bound to A1AR selective antagonist PSB36. Both of these 
crystal structures were obtained by incorporating a number of thermostabilising mutations 
in wild-type (WT) A1AR to aid in the crystallisation process. Overall, the two structures 
were very similar to each other and both showed a difference in the conformation of EL2 
compared to a previously reported A2AAR crystal structure by Segala et al.
64 A 
cryoelectron microscopy structure of A1AR complexed with a G protein was also reported 




Figure 1.5. Crystal structure of A1AR-PSB36 complex reported by Cheng et al.63 (PDB ID 5N2S), 
hydrogen bond between PSB36 (cyan carbons, red oxygens, blue nitrogens) and N254 are shown as yellow 
lines, A1AR (forest green ribbon). Side chain residues forming hydrogen bonds or hydrophobic interactions 
with PSB36 are shown as sticks (leaf green). 
 
1.3.1 Small molecule ligands for Adenosine A1 receptor 
 
A brief overview of reported small molecule-based A1AR ligands is provided in the 
following section. For a comprehensive review of these ligands, refer to reviews by 




The discovery of xanthines such as caffeine (Figure 1.6, Ki = 10,700 nM at hA1AR; 
23,400 nM at human A2A adenosine receptor (hA2AAR); 33,800 nM at human A2B 
adenosine receptor (hA2BAR); 13,300 nM at human A3 adenosine receptor (hA3AR))
67-69 
as AR antagonists led to intensive exploration of this scaffold for the development of AR 
ligands. Many reported xanthine-based AR ligands lack subtype selectivity, though A1AR 
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selective xanthine analogues have been prepared. The xanthine based A1AR selective 
antagonists mostly contain a cycloalkyl moiety at C-8 position, for example C-8 
cyclopentyl xanthine DPCPX (Figure 1.2).66 Some other xanthine-based high affinity and 
selective A1AR antagonists (Figure 1.6) are – rolofylline (Ki = 0.72 nM at hA1AR; 108 
nM at hA2AAR; 296 nM at hA2BAR; 4930 nM at hA3AR),
70-71 naxifylline (Ki = 0.45 nM 
at hA1AR; 1100 nM at hA2AAR; 611 nM at hA2BAR; 4810 nM at hA3AR)
70, 72 and 
tonapofylline (Ki = 7.4 nM at hA1AR; 6410 nM at hA2AAR; 90 nM at hA2BAR; 10,000 
nM at hA3AR).
71 Rolofylline, naxifylline, and tonapofylline were investigated for the 




Figure 1.6. Non-selective xanthine AR antagonist caffeine and high affinity, A1AR selective xanthine 
antagonists. 
 
Most A1AR agonists are derivatives of adenosine and contain a ribose moiety, which 
likely also contributes to the high affinity for A1AR.
66 Tecadenoson (Ki = 0.45 nM at 
porcine A1 adenosine receptor (pA1AR); 2315 nM at hA2AAR,) and selodenoson (data 
not reported in the literature) (Figure 1.7) are examples of selective xanthine A1AR 





Figure 1.7. A1AR selective xanthine agonists. 
 
Non-xanthine based ligands 
 
A number of non-xanthine-based A1AR antagonists have been reported. These include 
monocyclic pyrazoles, pyrimidines, triazines, thiazoles, fused bicyclic 
pyrazolopyrimidines, imidazopyridines, benzimidazoles, pyrazolopyridines, 
pyrrolopyrimidines, and fused tricyclic imidazoquinolines, pyrazoloquinolines.74 
SLV320 (Figure 1.8, Ki = 1.0 nM at hA1AR; 398 nM at hA2AAR; 3981 nM at hA2BAR; 
200 nM at hA3AR) is a non-xanthine A1AR antagonist which was investigated for the 
treatment of congestive heart failure.75 (Benzimidazolyl)isoquinoline-based selective 
A1AR antagonists have been reported,
76 and were investigated for the development into 
A1AR fluorescent ligands in this thesis (chapter 2). 
 
 
Figure 1.8. Non-xanthine A1AR selective antagonist SLV320, and A1AR, and A2BAR selective agonist 
Capadenoson. 
 
There are few reported non-adenosine-based A1AR agonists.
77-78 Capadenoson79 (Figure 
1.8, EC50 = 0.1 nM at hA1AR; >900 fold selectivity over hA2AAR and hA2BAR
61), the 
first non-xanthine A1AR agonist, was in clinical trials in patients suffering from atrial 
fibrillation but failed to show efficacy.78 Although initially reported as a selective A1AR 




1.3.2 Fluorescent ligands of the adenosine A1 receptor 
 
As discussed in section 1.3, ARs are valuable drug targets and efforts have been made to 
develop fluorescent ligands for studying these receptors. Since the first report of an AR 
fluorescent ligand by Jacobson et al.81, a number of AR fluorescent ligands based on 
adenosine, xanthine, and other fused ring heterocycles have been reported.81-85 86-88 Most 
of the xanthine-based fluorescent ligands lack selectivity for AR subtypes.83, 89 AR 
fluorescent ligands have been used to study various receptor processes such as receptor 
internalisation, and as tracers in fluorescence-based assays.84, 90-91 
 
CA200645 (Figure 9; Kb = 3.98 nM at hA1AR; 2.95 nM at hA3AR) has been reported as 
a non-AR-subtype-selective fluorescent ligand and was used in chapter 2 of this thesis for 
determining AR affinity of the (benzimidazolyl)isoquinoline-based ligands.92 Fluorescent 
ligands with high affinity and selectivity for hA2AAR, hA2BAR, and hA3AR have been 
reported.43, 82, 86, 93 Some examples of such fluorescent ligands include hA3AR selective 
AV039 (Kd = 0.43 nM at hA3AR; 275 nM at hA1AR; >1000 nM at hA2BAR);
54 hA2AAR 
selective BODIPY-650/665 derivative-14 (Ki = 15.1 ± 1.8 nM at hA2AAR; 58 ± 4% 
inhibition at hA1AR; 28 ± 3% inhibition at hA3AR),
93 and A2BAR selective PSB-12105 
(Ki = 1.83 ± 0.76 nM at hA2BAR; >10,000 nM at hA2AAR; >10,000 nM at hA1AR; 





Figure 1.9. Reported high affinity AR fluorescent ligands CA200645, AV039, BODIPY-650/665 
analogue-14, and PSB-12105. 
 
There is a lack of a high affinity and selective A1AR fluorescent ligands. Macchia et al.
94 
reported rat A1 adenosine receptor (rA1AR) selective fluorescent ligands by modification 
of a non-selective AR agonist NECA (N-ethylcarboxamidoadenosine). Alkyl linkers of 
varying length were conjugated to NECA and the dansyl fluorophore (Eex = 340 nM; Eem 
= 520 nm) was attached at the other end of the linker. Among the fluorescent ligands 
reported by Macchia et al.94, dansyl derivative-1c (Figure 1.10, Ki = 27 ± 3 nM at rA1AR; 
4300 ± 400 nM at rat A2A adenosine receptor (rA2AAR); 3600 ± 260  nM at rat A3 
adenosine receptor (rA3AR)) displayed the highest affinity for rA1AR and selectivity over 
other AR subtypes. Fluorescent ligand dansyl derivative-1c was used for imaging rA1AR 
in rat cerebral cortex. This dansyl fluorophore present in fluorescent ligand dansyl-1c 
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exhibits short excitation/emission wavelengths, which limit the application in imaging 
experiments. Macchia et al.95 then developed a second series of fluorescent ligands by 
substituting the dansyl fluorophore of dansyl derivative-1c with nitrobenzoxadiazole 
(NBD) (Eex = 465 nM; Eem = 535 nm). Nonetheless, the newly prepared fluorescent 
ligands did not exhibit significant affinity for A1AR but exhibited high affinity for A3AR. 
The highest affinity A3AR fluorescent ligand of this series was NBD derivative-2d 
(Figure 1.10, Ki = 7.44 ± 2.38 nM at hA3AR; 3476 ± 521 nM at hA1AR; 5096 ± 764 nM 
at hA2AAR). 
 
Macchia et al.96 subsequently prepared dansyl conjugates of a selective A1AR antagonist 
naphthyridine. The naphthyridine-based dansyl derivative-3 (Figure 1.10) showed high 
affinity and selectivity at bovine A1 adenosine receptor (bA1AR) (Ki = 13 ± 2 nM) over 
bovine A2A adenosine receptor (bA2AAR) (Ki = 1430 ± 40 nM) and A3AR (Ki = 1560 ± 
36 nM at hA3AR). Affinity data of the dansyl derivative-3 at A1AR was not reported. 
 
 
Figure 1.10. Previous attempts on the development of A1AR selective fluorescent ligands. 
 
In addition to these reports, other high affinity A1AR fluorescent ligands that are non-
AR-subtype-selective (or for which data at other AR subtypes is not reported) have been 
described in the literature.81, 86, 89, 97-98 43, 88  
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1.4 Cannabinoid receptors 
 
Cannabinoid receptors (CBRs) are class A GPCRs and there are two subtypes – CB1R 
and CB2R. These receptors, along with endogenous CBR ligands such as anandamide 
(AEA; Figure 1.12) and regulatory proteins including enzymes and transporters, 
constitutes the endocannabinoid system.99-100 
 
Two CBR agonists are in clinical use in New Zealand – nabilone (a derivative of (−)-
trans-Δ⁹-tetrahydrocannabinol (Figure 1.13; THC) derivative) for neuropathic pain and 
dronabinol (THC) for chemotherapy-associated vomiting.  
 
1.4.1 Cannabinoid type 1 receptor 
 
Initial evidence for the existence of CBR was provided by specific binding of the CBR 
radioligand [3H]-CP55,940 to rat brain membrane,101 and CB1R was cloned in 1990.
102 
CB1R is one of the most highly expressed GPCRs in the CNS with the highest expression 
in substantia nigra, basal ganglia, globus pallidus, cerebellum, hippocampus and low 
expression in peripheral organs.103-105 CB1R primarily signals via coupling to G protein 
Gαi/o, though recently signalling via coupling to Gαs and/or Gαq has also been reported.
106 
Activation of CB1R results in inhibition of adenyl cyclase and reduction in the production 
of cAMP in CB1R expressing cells.
106 CB1R also mediates signals via modulation of other 
messengers such as PLC, MAPK, ERK, calcium, and potassium channels.106-107 CB1R, 
located in the presynaptic terminal of the neurons, participates in the retrograde signalling 
by inhibition of release of excitatory and inhibitory neurotransmitters.107 Further, CB1R 
is known to signal via β-arrestin108 and a study109 conducted with β-arrestin 2 knockout 
mice suggested that CB1R ligands showing preference for G protein signalling over β-
arrestin-2 signalling might show analgesic activity with reduced side effects associated 
with CBR ligands. 
 
CB1R is involved in the regulation of a variety of pathological processes including 
obesity, pain, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's 
disease, myocardial infarction, heart failure, atherosclerosis, stroke, liver cirrhosis, 
pancreatitis, anxiety, schizophrenia, rheumatoid arthritis, and cancer.99, 110 SR141716A 
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(Rimonabant; Figure 1.14), a selective CB1R inverse agonist, was approved by the 
European Medicines Agency for the treatment of obesity but was withdrawn due to 
associated psychiatric disorders including suicide.25  
 
Cannabinoid type 1 receptor structure  
 
The first three crystal structures of CB1R were published in 2016 and 2017. Shao et al.
111 
reported a 2.6 Å structure of CB1R complexed to CB1R selective inverse agonist 
taranabant. Hua et al.112 reported a 2.8 Å structure of CB1R complexed to CB1R 
antagonist AM6538 and subsequently a 2.8 Å structure of CB1R complexed to CB1R 
agonist AM11542113 (Figure 1.11). The inverse agonist taranabant complex and 
antagonist AM6538 bound structure showed overall similarity. Significant structural 
differences were observed in the agonist AM11542-CB1R structure compared to the 
inverse agonist and antagonist-CB1R structures, including major conformational changes 
in the TM1, TM2, and TM6. In agreement with the crystal structure of the active state 
β2ADR (bound to Gαs),
114 the agonist AM11542-CB1R structure showed outward 
movement of cytoplasmic part of TM6. Notably, a large reduction in the volume of the 
ligand-binding pocket in the agonist AM11542-CB1R structure compared to antagonist 
AM6538-CB1R structure was observed.  
 
The differences observed in the agonist-CB1R and antagonist-CB1R structures emphasise 
the importance of choosing a suitable agonist/antagonist structure for docking studies of 
CBR ligands. The CB1R crystal structure (PDB ID: 5XRA) reported by Hua et al.
113 was 





Figure 1.11. Crystal structure of CB1R-AM11542 complex (PDB ID: 5XRA) reported by Hua et al.113, the 
hydrogen bond between AM11542 (cyan carbons, red oxygens, blue nitrogens) and S383 is shown as a 
yellow line, CB1R (forest green ribbon). Side chain residues forming hydrogen bonds or hydrophobic 
interactions with AM11542 are shown as sticks (leaf green). 
 
1.4.2 Cannabinoid type 2 receptor 
 
The CB2R was cloned in 1990
102 and is primarily expressed in immune cells, spleen, 
tonsils,115 with low expression in CNS.116 Similar to CB1R, CB2R primarily signals via 
coupling to G protein Gαi/o and modulates messengers such as adenyl cyclase, MAPK, 
ERK, potassium, and calcium channels.117 CB2R is also recognised to signal via β-arrestin 
pathway.118-119 
 
CB2R plays an important role in a number of pathological processes including 
inflammation, pain, atherosclerosis, multiple sclerosis, HIV-induced encephalitis, cancer, 
Parkinson's disease, Alzheimer's disease, Huntington's disease, myocardial infarction, 
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heart failure, atherosclerosis, stroke, liver cirrhosis, pancreatitis, and rheumatoid 
arthritis.99, 110, 117, 120 In contrast to CB1R, agonists targeting CB2R are thought to exhibit 
reduced or no psychoactive side effects due to the low abundance of CB2R in the brain.
117 
A number of CB2R agonists are being investigated in clinical trials for analgesic 
activity.121  
 
At the time of writing this thesis, the crystal structure of CB2R was not reported. CB1R 
and CB2R have 44% overall sequence identity and 68% sequence identity in the TM 
region,122 and a number of ligands activate both CB1R and CB2R including the 
endogenous ligands AEA and 2-arachidonylglycerol (2-AG; Figure 1.12.). Hence, it is 
likely that these receptors share substantial structural similarity and possess a similar 
orthosteric ligand-binding pocket. Homology modelling is commonly used to generate a 
structure of a protein based on the structure of a closely related protein. In chapter 3 
(section 3.4) of this thesis, a homology model of CB2R was built using CB1R crystal 
structure (PDB ID: 5XRA) reported by Hua et al.113 and was used for ligand docking 
studies.   
 
1.4.3 Small molecule ligands for cannabinoid receptors 
 
Small molecule CBR ligands have been comprehensively covered in reviews by Pertwee 
et al.107, Ganesh et al.123, Tabrizi et al.124, and only a brief overview of small molecule 
CBR ligands is provided here.  
 
Endogenous cannabinoid receptor ligands 
 
The most studied endogenous CBR ligands are arachidonic acid derivatives – AEA (Ki = 
70 ± 30 nM at hCB1R; 180 ± 20 nM at hCB2R)
125, 2-AG (Ki = 480 ± 12 nM at hCB1R; 
1300 ± 215 nM at hCB2R)
125 (Figure 1.12) and both act as agonists at CBRs. Most of the 
endogenous CBR ligands show modest selectivity for CB1R over CB2R and contain a 
hydrophobic chain joined to a polar head group.121 In contrast to the typical 
neurotransmitters (such as serotonin, epinephrine, dopamine, and histamine), these 
endogenous CBR ligands are not stored in vesicles but are synthesised on demand by 
specific enzymes from membrane phospholipids, and after participating in signalling via 
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interaction with CBRs are degraded by regulatory enzymes.126 Inhibitors of regulatory 
enzymes such as fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase are 
being developed as therapeutic agents for CBR associated diseases.127 One such FAAH 
inhibitor BIA 10-2474 produced mild to severe neurotoxicity in some volunteers in a 
phase 1 clinical trial.128 In a later study129, BIA 10-2474 was shown to inhibit many other 
serine hydrolases besides FAAH and this lack of selectivity might have contributed to the 
neurotoxicity of BIA 10-2474. 
 
 
Figure 1.12. Endogenous CBR ligands anandamide and 2-arachidonylglycerol. 
 
Cannabis-derived cannabinoid receptor ligands  
 
THC (Figure 1.13, Ki = 40.7 ± 1.70 nM at hCB1R; 36.4 ± 10.0 nM at hCB2R),
130 a non-
selective CBR agonist, was identified as the primary psychoactive constituent of 
Cannabis sativa in 1964 by Gaoni et al.131 Since then a number of structural derivatives 
of THC have been synthesised and comprehensive SAR data is available.132 Among the 
THC analogues, a side chain of seven carbons is observed to be optimal for CBR 
binding.132 Most of the THC analogues are non-selective CBR ligands, however, CB2R 
selective compounds have been prepared by removal of the C-1 hydroxyl.121, 132 
 
Most of the CBR ligands exhibit high lipophilicity and a water-soluble prodrug of a THC 
derivative – O-1057 (Figure 1.13), has been reported.121, 133 A bicyclic analogue of THC 
– CP55,940 (Figure 1.2; Ki = 0.55 nM at hCB1R; 3.63 nM at hCB2R)
119 exhibits high 
affinity for both CBRs and the 3H labelled analogue [3H]-CP55,940 (Figure 1.2) is a 
commonly used tracer in the pharmacological experiments. Cannabidiol (Figure 1.13, Ki 
= 4350 ± 390 nM at hCB1R; 2860 ± 1230 nM at hCB2R)
121 is a major constituent of 
cannabis extract, which exhibits weak affinity and high potency antagonism at CBRs.134-
135 Cannabidiol is currently being investigated in clinical trials for the treatment of a 
number of inflammatory diseases136 and was recently recommended by the Food and 
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Drug Administration (FDA) for investigation in the treatment of Lennox-Gastaut 
syndrome and Dravet syndrome. Chromenopyrazole CBR ligands,137 which are structural 
derivatives of cannabinol (CBN; Figure 1.13, Ki = 211.2 ± 35.0 nM at rat cannabinoid 
type 1 receptor (rCB1R); 126.4 ± 26.0 nM at hCB2R)
138 were explored in this thesis for 
the development of CBR fluorescent ligands (chapters 3 and 4). 
 
 
Figure 1.13. Representative examples of plant-derived CBR ligands – THC, cannabidiol, and prodrug O-
1057. 
 
Synthetic cannabinoid receptor ligands 
 
The development of ligands antagonising CB1R has undergone a significant change in 
direction since the associated psychiatric side-effects of CB1R antagonists became known 
with the clinical trial results of SR141716A. Since then, most of the medicinal chemistry 
efforts targeting CBR have focused on the development of CB2R agonists, biased CB1R 
agonists, and peripherally-restricted CB1R agonists.
117, 139-140 A number of heterocyclic 
derivatives exhibiting excellent selectivity and affinity for CB1R or CB2R are reported in 
the literature.107, 124, 141 The most studied of these CBR ligands contain pyrazole or indole 
heterocycles. 
 
Most of the pyrazole CBR ligands contain aryl groups at N-1 and C-5 positions and a 
carboxamide moiety at the C-3 position (Figure 1.14). Notable pyrazole CBR ligands are 




SR144528 (Figure 1.14, Ki = 437 ± 33 nM at hCB1R; 0.60 ± 0.13 at hCB2R)
143 developed 
by Sanofi. SR141716A is a high affinity, selective CB1R inverse agonist which inhibits 
many in vitro and in vivo effects produced by CB1R activation and along with its tritiated 
form [3H]-SR141716A (Figure 1.14, Kd = 1.05 ± 0.19 nM at hCB1R)
144 is frequently used 
in pharmacological experiments.141 SR144528 is a selective CB2R antagonist which 
counters many of the in vitro effects produced by CB2R activation and is also commonly 
used in pharmacological experiments.141 
 
 
Figure 1.14. Representative examples of pyrazole cannabinoid receptor ligands – SR141716A, [3H]-
SR141716A, and SR144528. 
 
Most of the indole-based CBR ligands contain a carboxamide moiety at the C-3 position 
and an alkyl chain at the N-1 position (Figure 1.15). A notable CBR indole-based ligand 
is R-(+)-WIN55212 (Figure 1.15, Ki = 40.9 ± 1.7 nM at hCB1R; 2.9 ± 0.3 nM at 
hCB2R),
145 which along with its tritiated form [3H]-WIN55212 (racemic mixture, Kd = 
11.9 ± 1.9 nM at hCB1R
146; 2.1 ± 0.2 nM at hCB2R
147) are commonly used as CBR 
agonists in pharmacological studies. A number of analogues of the indole scaffold have 
also been prepared as CBR ‘designer drugs’ or better known in New Zealand as ‘legal 
highs’ (although now illegal), for example, AB-FUBICA (Figure 1.15, EC50 = 21 nM at 






Figure 1.15. Representative examples of indole cannabinoid receptor ligands – R-(+)-WIN55212 and AB-
FUBICA. 
 
In addition to the small molecule CBR radioligands shown in this chapter that are used 
primarily in in vitro studies, a number of highly selective CBR radioligands for in vivo 
imaging have been reported. For example [11C]OMAR (Ki = 11 ± 7 nM at hCB1R),
149 
[18F]MK-9470 (IC50 = 0.7 nM at hCB1R; 44 nM at hCB2R)
150 and [11C]NE40 (Ki > 1000 
nM at hCB1R; 9.6 nM at hCB2R).
151  
 
1.4.4 Fluorescent ligands for cannabinoid receptors 
 
Fluorescent ligands for in vitro experiments 
 
Earliest reports of CBR ligands-based fluorescent compounds detailed the preparation of 
dansyl derivatives of THC152 in 1971 and benzoxadiazole derivatives of AEA153 in 1995. 
Both of these reports prepared fluorescent ligands as tools to study the bio-distribution of 
AEA and chromatographic studies of AEA and THC.  
 
The first development of fluorescent ligands for specifically studying CBR was of NBD 
derivatives of CB2R agonist JWH-015 by Yates et al.
154 in 2005. This NBD derivative 
was designed using de novo drug design and the position of linker attachment to JWH-
015 was identified with docking studies using a CB2R homology model. Unfortunately, 
the NBD-JWH-015 derivative did not exhibit significant CB2R affinity (for example only 
25% displacement of [3H]-CP55,940 from hCB2R at 10 µM of one NBD derivative) and 
in confocal microscopy experiments showed non-specific accumulation in the cytosol.154 
Cooper et al.155 also reported indole-based CB2R fluorescent ligands. Among the different 
indole positions explored for linker attachment, a C-7 O-propyl linker derivative 
26 
 
(Ki = 504.6 ± 148.2 at hCB1R; 5.7 ± 1.4 nM at hCB2R) exhibited the highest affinity for 
CB2R out of the various derivatives reported. Interestingly, a positional dependence of 
functional activity was observed with C-5 indole derivatives being agonists and C-7 
indole derivatives being inverse agonists in a cAMP BRET assay. Unfortunately, none of 




Petrov et al.46 reported a derivative of the CBR ligand isatin acylhydrazone where the 
morpholine group was substituted with a NBD fluorophore to provide a CB2R selective 
fluorescent ligand NMP6 (Figure 1.16, Ki = 387 nM at hCB2R; <40% displacement of 
[3H]-CP55,940 at hCB1R at 10 µM). This substitution was based on the assumption that 
the lipophilic CB2R cavity, believed to interact with the morpholine moiety of the parent 
ligand, would accommodate the NBD fluorophore. Confocal imaging with NMP6 showed 
specific binding of NMP6 to CB2R expressing CD4
+ T-cells, which was abolished by 
preincubation with selective CB2R agonist GW842166X. NMP6 was also shown to be 
useful in flow cytometry experiments to study CB2R expression in mouse lung 
mononuclear B cells.46 The functional activity of NMP6 at CBRs was not reported.46 The 
NBD (Eex = 465 nM; Eem = 535 nm) fluorophore in NMP6 shows short 
excitation/emission wavelengths, which limit its use in other imaging experiments. 
 
T1117 (tocrifluor 1117, Figure 1.16) is a commercially available fluorescent ligand, and 
can be prepared by conjugation of a AM251 derivative to a 2-(3,6-
bis(dimethylamino)xanthylium-9-yl)-5-carboxybenzoate (TAMRA) fluorophore. 
Contradictory pharmacological results have been reported for T1117. Daly et al.156 
reported T1117 to exhibit only weak affinity for CB1R with binding at GPR55 (indicated 
by the increased Ca2+ response in GPR55 expressing human embryonic kidney (HEK)-
293 cells). However, in a subsequent study, T1117 (Kd = 460 ± 80 nM at rCB1R) was 
reported to exhibit a moderate affinity for CB1R.
48 T1117 was used as a tracer in a 
fluorescence-based HTS at CB1R to identify orthosteric ligands AEA, AM251 (with 
obtained IC50 values in agreement with those reported in the literature) and allosteric CBR 
ligand ORG27569.48 However, T1117 showed non-specific membrane binding which 





Figure 1.16. Fluorescent CBR ligands for in vitro imaging reported in the literature. 
 
Martín-Couce et al.157 reported biotin or alkyne derivatives of endocannabinoids AEA, 
2-AG, and 2-AGE for the subsequent in situ labelling with a streptavidin-fluorophore or 
a ‘click’ reaction partner. The alkyne derivative of 2-AGE (Ki = 84.7 ± 0.8 nM at hCB1R; 
84.9 ± 0.6 nM at hCB2R) exhibited the highest affinity but lacked subtype selectivity 
whereas biotin derivative 2-AGE-biotin-3b (Figure 1.16, Ki = 221 ± 8 nM at hCB1R; 
450±11 nM at hCB2R) showed some subtype selectivity. Imaging studies were carried 
out with 2-AGE-biotin-3b and streptavidin-Alexa488 fluorophore in CB1R expressing 
mouse hippocampal cells. However, some background fluorescence in control 
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experiments with non-transfected mouse hippocampal cells or on co-treatment with 
unlabelled CBR agonist HU210 was observed. As endocannabinoids such as 2-AGE are 
lipid derivatives, high non-specific membrane binding is likely and emphasises the 
advantages of using non-lipid-based ligands as the basis for the development of 
fluorescent ligands. 
 
In further work, Martín-Couce et al. described biotin derivatives of high affinity CBR 
ligands HU210 and HU308 for subsequent in situ conjugation with a streptavidin-
fluorophore conjugate.158 Biotin-HU210-1 (Figure 1.16, Ki = 2.4 ± 0.4 nM at hCB1R; = 
1.6 ± 0.4 nM at hCB2R) exhibited high affinity for CBR but lacked subtype selectivity 
whereas biotin-HU308-3 (Figure 1.16, Ki = 44 ± 4 nM at hCB2R; >5000 nM at hCB1R) 
showed high CB2R selectivity. Biotin-HU210-1 and biotin-HU308-3 together with in situ 
reaction partner streptavidin-Alexa488 fluorophore were used to study CBR expression 
in neurons and microglia and specific binding was established by treatment with 
unlabelled HU210.158 In a subsequent report by the same research group, biotin-HU210-
1 along with an in situ reaction partner streptavidin-Alexa488 fluorophore were used to 
show high CB1R expression in B,T, and dendritic cells of donors suffering from rhinitis, 
atopic dermatitis or food allergies.159 
 
The same group of researchers subsequently reported a high affinity and CB1R selective 
fluorescent ligand HU210-Alexa488 (Figure 1.16, Ki = 27 ± 4 nM at hCB1R; 800 ± 200 
nM at hCB2R), prepared by conjugation of HU210 with fluorophore Alexa488.
47 HU210-
Alexa488 was used to study CB1R expression in immune cells by flow cytometry and 
confocal microscopy. A change in membrane CB1R expression following prolonged 
stimulation with a CBR agonist was also studied using HU210-Alexa488. Mononuclear 
cells were treated with CBR agonist HU210 or WIN55212 for 18 h and subsequent 
analysis by flow cytometry using HU210-Alexa488 showed a decrease in the percentage 
of mononuclear cells expressing CB1R.
47 The functional activity of HU210-Alexa488 at 
CBRs was not reported.47 The Alexa488 (Eex = 490 nM; Eem = 525 nm) fluorophore 
present in HU210-Alexa488 displays short excitation/emission wavelengths, which might 






Fluorescent ligands with near-infrared wavelength fluorophores  
 
A number of NIR fluorescent ligands amenable to in vivo imaging of CB2R have been 
reported. NIR fluorophores with fluorescence in the NIR region (700-900 nm) or NIR-II 
region (1,000-1,700 nm) are attractive for in vivo imaging as can be detected at a tissue 
depth of 5-7 mm.  
 
Bai et al.160 prepared mbc94 (Figure 1.17, Ki = 15 nM at murine cannabinoid type 2 
receptor (mCB2R)) by conjugation of a linker to SR144528 (a selective CB2R inverse 
agonist, Figure 1.14). Conjugation of mbc94 to IRDye 800CW provided fluorescent 
ligand NIR-mbc94 (Figure 1.17, Ki = 260 nM at mCB2R) with some loss in CB2R affinity 
compared to mbc94.49 A HTS assay was developed to identify CB2R ligands using NIR-
mbc94 and CB2R-mid DBT cells (mouse delayed  brain tumour cells transfected with 
CB2R). However, imaging experiments with NIR-mbc94 at mouse microglia cells that 
natively expressed CB2R showed a high degree of non-specific binding.
49 
 
The same team of researchers subsequently reported NIR760-mbc94 (Figure 1.17, Kd = 
26.9 ± 3.7 nM at mCB2R), prepared by the conjugation of previously reported mbc94 
with a NIR760 fluorophore.161 Experiments were carried out to determine specific 
binding of NIR760-mbc94 by incubation with CB2R-mid DBT cells in the presence and 
absence of non-fluorescent SR144528. CB2R-mid DBT cells preincubated with 
SR144528 showed 40% reduction in fluorescence compared to CB2R-mid DBT cells 
incubated with only NIR760-mbc94. The residual fluorescence indicated non-specific 
binding and according to authors arose from non-specific protein binding of negatively 
charged NIR760-mbc94. As CB2R plays important role in inflammation, NIR760-mbc94 
was used by Zhang et al.162 for in vivo imaging of mCB2R expression in Freund’s 
adjuvant-induced inflammation mouse model, however high non-specific binding of 
NIR760-mbc94 as indicated by appearance of fluorescence all over the mouse body was 
observed. 
 
The same research group reported NIR760-Q (Figure 1.17, Kd = 75.51 ± 27.97 nM at 
hCB2R), prepared by conjugation of a quinolone ligand with a NIR760 fluorophore.
163 
Imaging experiments with NIR760-Q in Jurkat cells that naturally express CB2R showed 
non-specific binding of NIR760-Q, which the authors attribute to the negative charge of 
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NIR760-Q. The same researchers then reported zwitterionic NIR-fluorophore-derivative 
ZW760-mbc94 (Figure 1.17, Kd = 53.9 ± 13.0 nM at mCB2R). In vitro experiments by 
incubating CB2R-mid DBT cells with ZW760-mbc94 in the presence or absence of 
unlabelled CB2R ligand 4Q3C (a non-fluorescent, high affinity, selective CB2R agonist) 
showed some CB2R-specific binding. In vivo imaging experiments in a mouse cancer 
model (mouse injected with CB2R-mid DBT cells in right flank) showed low CB2R 
specific binding with high fluorescence in the liver and throughout the whole body.163 
 
The same team of researchers then conjugated a pyrazolopyrimidine ligand to a NIR760 
fluorophore to give NIR760-XLP6 (Figure 1.17, Kd = 169.1 ± 66.09 nM at mCB2R; > 
10,000 nM at murine cannabinoid type 1 receptor (mCB1R)).
164 In vivo imaging 
experiments to determine CB2R specific binding were carried out and showed 40% higher 
fluorescence in mice with CB2R-mid DBT tumours compared to mice with CB1R-mid 
DBT tumours (mice injected with hCB1R transfected mid DBT cells) indicating non-





Figure 1.17. Fluorescent CB2R ligands amenable to in vivo imaging reported in the literature. 
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In photodynamic therapy, photosensitisers (compounds that absorb light of a particular 
wavelength to produce cytotoxic oxygen reactive species) are used for the treatment of a 
number of diseases including cancer. Zhang et al.165, part of the same research group as 
Bai et al., have described a CB2R photosensitiser – IR700DX-mbc94 (Figure 1.17, Kd = 
42.0 ± 19.6 nM at mCB2R) by conjugating fluorophore IR700DX to mcb94. Irradiation 
with light (wavelength 670-710 nm) in photosensitiser IR700DX-mbc94 injected mice 
inhibited the growth of CB2R-mid DBT tumours and not that of the CB2R negative-
tumours. The same group of researchers has also reported SR144528 derivatives 
conjugated to an IRDye800CW fluorophore, a topoisomerase inhibitor (such as 
etoposide), and a gadolinium chelate in a patent report.166  
 
As described in this section, progress has been made in the development of CBR 
fluorescent ligands. However, most of the reported CBR fluorescent ligands either lack 
high affinity and selectivity at CBR subtypes, exhibit high non-receptor-specific binding 
in imaging studies, and/or contain short wavelength fluorophores (for example NBD and 
Alexa488, with fluorescence spectra susceptible to interference from the fluorescence of 
cellular components), and thus have drawbacks in imaging studies and in studying CBR 
in native cell environments. 
 
1.5 Biological evaluation of ligands described in this 
thesis 
 
Biological evaluation of the compounds synthesised as potential A1AR ligands (chapter 
2) was carried out by members of Professor Stephen Hill’s research group at the 
University of Nottingham, United Kingdom. Therefore these pharmacological assays are 
not described herein (for details refer to the published manuscript of this work167). 
Biological evaluation of CBR ligands synthesised in this thesis (chapters 3-5) was carried 
by myself with the training and assistance of collaborators at the University of Auckland. 






1.5.1 Radioligand binding assays for cannabinoid receptors 
 
A competition radioligand binding assay with radioligand [3H]-CP55,940 and CB1R or 
CB2R expressing HEK-293 cells was used for determining the binding affinity of novel 
ligands (refer to chapter 7, experimental section 7.1.2 for experimental details). A fixed 
concentration of radioligand and membrane preparation expressing CB1R or CB2R are 
treated with an increasing concentration of a test compound. The membrane preparation 
bound radioligand is separated from the free radioligand and the radioactivity of the 
membrane preparation is measured. A high affinity test compound would better compete 
with radioligand for the receptor binding site and hence a lower radioactivity for the 
membrane preparation (compared to a weak affinity test compound) would be measured.  
 
The affinity (Ki) of the test compound is then calculated by non-linear regression using 
the amount of radioactivity retained in the membrane preparation and by using a 
previously measured Kd for the radioligand. Competition radioligand binding assay data 
of some high affinity compounds are presented in the form of a sigmoid curve by plotting 
bound radioligand (radioactivity count) against the logarithm of test ligand concentration. 
 
1.5.2 Functional assays for cannabinoid receptors 
 
Radioligand binding assays provide information about the affinity of a ligand to a 
receptor, but do not provide information about the functional nature of a ligand, that is 
agonist, antagonist, or inverse agonist. There are a number of CBR signalling pathways 
(described in section 1.4.1 and 1.4.2), and there are a range of reported assays that can be 
used to measure the activity of a CBR ligand in each pathway. Some of the commonly 
used assays used to determine functional activity of CBR ligands are by measurement of 
cAMP production, GTPγS binding, β-arrestin recruitment, G protein-coupled inwardly-
rectifying potassium channels (GIRK), and phosphorylation of ERK activation.32, 117, 119, 
168 
 
The function of CBR ligands described in chapters 3-5 was evaluated using a cAMP 
BRET assay as described previously by Cawson et al.169 and Jiang et al.170 As mentioned 
previously in sections 1.4.1 and 1.4.2, both CB1R and CB2R are Gαi coupled receptors, 
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which upon activation by an agonist, inhibit adenyl cyclase and consequently decreases 
the production of cAMP. 
 
 
Figure 1.18. Schematic representation of BRET CAMYEL sensor for real-time cAMP measurement 
reported by Cawson et al.169 and Jiang et al.170 
 
The cAMP BRET assay reported by Cawson et al.169 and Jiang et al.170 probes the 
function of CBR ligands by measuring the change in intracellular cAMP concentration 
upon incubation of CBR expressing cells with the test ligand. Cawson et al.169 and Jiang 
et al.170 used a cAMP sensor (YFP-Epac-RLuc (CAMYEL)) for measuring the change in 
the cAMP concentration. The CAMYEL sensor contains a cAMP binding domain – 
Epac1 (exchange factor directly activated by cAMP 1) that separates BRET pairs of YFP 
and RLuc (Figure 1.18; Renilla luciferase). cAMP binding to Epac1 induces a 
conformational change in CAMYEL, increasing the distance between YFP and RLuc and 
thus interrupting energy transfer between these two BRET pairs (Figure 1.18). Therefore, 
with increasing intracellular cAMP concentration the ‘inverse BRET ratio’ (ratio of Rluc 
(energy donor) signal at 460 nm to YFP (energy acceptor) signal at 535 nm) also 
increases. Accordingly, a CBR agonist will decrease cAMP production and a 
corresponding decrease in the inverse BRET ratio will be observed, whereas the reverse 
will be true for an inverse agonist. A neutral antagonist would not change forskolin-
stimulated cAMP production and consequently no change in BRET ratio would be 
observed. The raw data obtained from a cAMP functional assay can be analysed by non-




1.6 Aims and objectives of this PhD thesis 
 
This PhD thesis aimed to: 
 
a) Develop fluorescent ligands for adenosine A1 receptor  
b) Develop fluorescent ligands for cannabinoid receptors  
 
These aims were to be achieved by: 
 
1) A literature review to identify high affinity A1AR and CBR ligands with suitable 
properties, including SAR that indicates positions on the selected ligands 
amenable for conjugation of linkers and fluorophores.  
2) Design of new A1AR and CBR ligands based on the literature SAR with 
or without the aid of computational studies. 
3) Synthesis of newly designed A1AR and CBR ligands (including linker and linker-
fluorophore conjugates). 
4) Measurement and evaluation of the binding affinity and functional activity of the 
newly synthesised CBR ligands, and evaluation of the A1AR biological data.   
5) Design and synthesis of a follow up series of A1AR and/or CBR ligands as 




Chapter 2 Synthesis of (benzimidazolyl)- 
isoquinolinols as potential fluorescent ligands for 
Adenosine A1 receptor 
2.1 Design rationale for (benzimidazolyl)isoquinolinol-
based fluorescent ligands 
 
Xanthine-based adenosine receptor (AR) ligands (for example high affinity and selective 
A1AR ligand DPCPX; shown in chapter 1, Figure 1.2) are attractive lead compounds for 
the development of A1AR fluorescent ligands because of the availability of a large amount 
of SAR data171 (AR xanthine ligands described in chapter 1, section 1.3.1). However, 
xanthine amine congener-fluorescent conjugates were previously reported as either non-
AR subtype selective or A3AR
43 selective and accordingly were not considered for the 
development of A1AR selective fluorescent ligands in this thesis. 
 
Novellino et al.172 reported a series of (benzimidazolyl)quinoxalines (representative 
compounds 2.1-2.2 shown in Table 2.1) as AR antagonists, which were identified by the 
pharmacophore substructure search in the Cambridge Structural Database (CSD)173 of 
previously reported selective A1AR and A3AR antagonists. In a subsequent study, 
Cosimelli et al.76 (part of the same research group as Novellino et al.172) published 1- and 
3-(benzimidazolyl)isoquinolines (representative compounds 2.3-2.8 shown in Table 2.1) 
as high affinity AR antagonists (including selective A1AR antagonists 2.5-2.8, Table 2.1). 
The (benzimidazolyl)quinoxaline 2.2 and 3-(benzimidazolyl)isoquinoline 2.5 were 
evaluated in a functional assay carried out at smooth muscle preparations of human colon 
and behaved as antagonists.76 Based on the high affinity for A1AR and selectivity over 
other ARs, the 1- and 3-(benzimidazolyl)isoquinolines (2.5-2.8) were selected as lead 
compounds for the development of A1AR fluorescent ligands.  
 
The 1- and 3-(benzimidazolyl)isoquinolines reported by Cosimelli et al.76 (including 2.3-
2.8, Table 2.1) contained only small lipophilic substituents on the benzamidazole (methyl, 
ethylthiol, and chlorine) and lacked a bulky substituent (which would indicate a position 
tolerant of accommodating a bulky linker). Based on the high A1AR affinity of 1- and 3-
(benzimidazolyl)isoquinolines76 (including 2.3-2.8, Table 2.1) containing these small 
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lipophilic substituents, it was thought that the benzimidazole moiety might be interacting 
with an A1AR lipophilic cavity. Linkers were also not appended from 1- ,3- and 4- 
position of isoquinoline as 1,3-substituted isoquinoline analogue VUF5455174 and 2,4-
substituted quinoline analogue LUF6096175 were previously reported as allosteric A3AR 
ligands. Hence, it was decided to conjugate linkers at the C-6 – C-7 position of the 
benzene ring of the isoquinoline moiety. 
 
Table 2.1. Previously reported (benzimidazolyl)quinoxalines and 1- and 3-
(benzimidazolyl)isoquinolines AR antagonists in literature76, 172  
 
 
 R1 R2 
Ki hA1AR(nM ± 
SEM)* 
Ki hA2AAR(nM ± 
SEM)* 
Ki hA3AR(nM ± 
SEM)* 
Ref 
2.1 H H 50.0 ± 15.0 561.0 ± 17.0 763.0 ± 13.0 172 
2.2 SC2H5 H 0.50 ± 0.01 3440.0 ± 980.0 955.0 ± 215.0 172 
2.3 H H 3.2 ± 0.2 3750.0 ± 245.0 156.0 ± 13.4 76 
2.4 H CH3 3.5 ± 0.3 >10000 264.7 ± 23.0 
76 
2.5 SC2H5 H 1.4 ± 0.1 >10000 >1000 
76 
2.6 H H 14.1 ± 1.6 >10000 >1000 76 
2.7 H Cl 6.3 ± 0.4 >10000 >1000 76 
2.8 H CH3 6.6 ± 0.5 >10000 >1000 76 
*Binding affinity (Ki) obtained by competition binding assay performed on membranes obtained from 
chinese hamster ovary (CHO) cells expressing hA1AR (using [3H]-DPCPX as radioligand) or CHO cells 
expressing hA2AAR (using [3H]-NECA as radioligand) or CHO cells expressing hA3AR (using [125I]-
ABMECA as radioligand). 
 
The benzene ring of isoquinoline in compounds such as 2.8 lacks a reactive substituent 
for the conjugation of a linker and subsequent fluorophore. Therefore hydroxyl 
derivatives of 1- and 3-(benzimidazolyl)isoquinolines (1- and 3-(benzimidazolyl)-
isoquinolinols) were designed (Figure 2.1). The hydroxyl group offers a good handle to 
introduce linkers, for example by an ether bond that is non-ionised at physiological pH. 
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It was decided to prepare alkyl, polyethylene glycol (PEG) and peptide linker derivatives 
of (benzimidazolyl)isoquinolinols (Figure 2.1) to evaluate the effect of variations in the 
chemical structure and physicochemical properties on A1AR biological activity. Only a 
selected subset of (benzimidazolyl)isoquinolinols (as shown in Figure 2.1) would be 
prepared due to limitations of the purchase of commercial fluorophores and limitations 




Figure 2.1. Design of (benzimidazolyl)isoquinolinols as potential A1AR ligands. 
 
It was decided that the (benzimidazolyl)isoquinolinol-based fluorescent ligands would be 
prepared by reaction of (benzimidazolyl)isoquinolinol-linker conjugates with the (E)-6-
(2-(4-(2-(5,5-difluoro-7-(thiophen-2-yl)-5H-5λ4,6λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]-
diazaborinin-3-yl)vinyl)phenoxy)acetamido)hexanoyl-succinimidyl ester- (BODIPY-
630/650-SE) fluorophore (Figure 2.2). BODIPY-630/650 was selected because of its 
success as fluorophore in previously reported fluorescent ligands for GPCRs24, 87, 176 and 
its suitable spectroscopic properties as an acceptor in a previously reported 
bioluminescence resonance energy transfer (NanoBRET) assay using the luciferase 
NanoLuc (NLuc; Promega Corporation, USA) to directly measure A1AR activity.
90 The 
(benzimidazolyl)isoquinolinol-linker conjugates would be synthesised by reaction of 
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corresponding short linker-(benzimidazolyl)isoquinolinols with different linker 
derivatives. The (benzimidazolyl)isoquinolinols would be prepared by condensation 
reaction of phenylenediamine with isoquinoline carboxylic acids, which would be 
prepared from the aromatisation reactions of hydroxytetrahydroisoquinoline carboxylic 
acids (Figure 2.2).  
 
 




2.2 Synthesis and structural characterisation 
2.2.1 Synthesis of linkers 
 
The synthesis of alkyl linker 2.10 (Scheme 2.1), PEG linker 2.12 (Scheme 2.2) and 
peptide Alanine-Alanine (Ala-Ala) linker 2.18 (Scheme 2.3), used in the synthesis of 
(benzimidazolyl)isoquinolinol linker conjugates (synthesis described in section 2.2.2, 
2.2.3 and 2.2.4 respectively), is described in this section.  
 
The N-Boc protected linker 2.10 was prepared by reaction of commercially available 
alkyl diamine 2.9 with (Boc)2O according to a previously reported synthesis
177 (Scheme 
2.1). Selective mono N-Boc protection was achieved by a slow, controlled addition of a 




Scheme 2.1. (i) (Boc)2O, 1,4-dioxane, 75%. 
 
Boc-protection of commercially available PEG amine 2.11 with (Boc)2O, according to a 
previously reported literature synthesis,178 provided 2.12 (Scheme 2.2). Similar to 2.10, 
mono N-Boc protected product 2.12 was prepared by a controlled addition of a solution 
of (Boc)2O in DCM to a solution of amine 2.11 in DCM.  
 
 
Scheme 2.2. (i) (Boc)2O, DCM, 89%. 
 
The synthesis of peptide (Ala-Ala) linker 2.18 was carried out using solution phase 
peptide synthesis (Scheme 2.3). The commercially available Fmoc-Ala-OH 2.13 was 
coupled with N-Boc-ethylenediamine 2.14 using HBTU, HOBt.H2O and DIPEA to give 
2.15. Fmoc deprotection of 2.15 with diethylamine gave amine 2.16, which was not 
purified and reacted with Fmoc-Ala-OH 2.13 using coupling reagents HBTU, HOBt.H2O, 
and DIPEA as a base to provide 2.17. Fmoc deprotection of 2.17 with diethylamine gave 
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Scheme 2.3. (i) HBTU, HOBt.H2O, DIPEA, DMF, 86%. (ii) Diethylamine, DCM. (iii) 2.13, HBTU, 
HOBt.H2O, DIPEA, DMF, 82%. (iv) Diethylamine, DCM, MeOH. 
 
2.2.2 Synthesis of 1-(benzimidazolyl)isoquinoline-6-ol 
derivatives 
 
According to a previously reported procedure,179 demethylation of the commercially 
available 2.19 with aqueous HBr solution (48% w/w) provided amine salt 2.20, which 
was not purified (Scheme 2.4). Initial attempts to carry out a Pictet–Spengler reaction of 
3-(2-aminoethyl)phenol hydrobromide 2.20 with glyoxylic acid monohydrate following 
a previously reported synthesis of 2.21 by Li et al.,179 were unsuccessful and starting 
material 2.20 was recovered as such. Pleasingly, 2.21 was obtained in good yield by 
instead following the synthesis reported by Maillard et al..180 In contrast to the procedure 
reported by Li et al.,179 the Maillard et al.180 procedure reported addition of Et3N to the 
amine hydrobromide salt before the addition of glyoxylic acid monohydrate. It seems 
likely that the higher amount of free amine generated from the neutralisation of amine 
salt 2.20 with Et3N reacts with glyoxylic acid monohydrate to form the corresponding 
imine (mechanism shown in the rectangle box drawn in scheme 2.4), which drives the 






Scheme 2.4. (i) Aqueous (Aq.) HBr solution (48% w/w), 100 °C. (ii) Et3N, glyoxylic acid monohydrate, 
EtOH, 71%. (iii) SOCl2, MeOH, 65 °C, quantitative. Imine fomation between 2.20 (free amine) and 
glyoxic acid likely occurs by the mechanism shown in rectangle. 
 
Attempts to aromatise carboxylic acid 2.21 with MnO2 or 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone (DDQ) (with optimised conditions later discussed and used for the 
preparation of 2.24, synthesis shown in Scheme 2.5) were unsuccessful. The 
aromatisation of carboxylic acid 2.21 was not pursued further because of the difficulties 
encountered in analysing the polar reactant and likely polar product(s) in the reaction 
mixture. Therefore carboxylic acid 2.21 was esterified to give methyl ester 2.22 (synthesis 
of 2.22 was previously reported by Ma et al.181 but no spectroscopic data was reported). 
 
Initial attempts to carry out aromatisation of hydroxytetrahydroisoquinoline 2.22 with 
DDQ following a procedure described for the DDQ-mediated aromatisation of 2.53182 
(synthesis shown in Scheme 2.9 and described later in section 2.2.4) proved futile. 
Attempts were made to change the reaction solvents (THF or 1,4-dioxane or toluene) or 
temperature (rt, 45 °C or 100 °C) or to carry out reactions under either a N2 atmosphere 
or in a closed reaction vessel. However, all of these failed to produce the aromatised 
product. In one attempt, heating a solution of 2.22 and DDQ in THF and 1,4-dioxane at 
110 °C under N2 atmosphere provided the partially oxidised dihydroisoquinoline 2.23 as 
the major product (Scheme 2.5). Reaction of 2.22 with DDQ at moderate temperature and 
with vigorous stirring in a flask open to the atmosphere was instead carried out, which 
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gave desired product 2.24 in moderate yield. The reasons for the moderate yield of DDQ-
air mediated aromatisation of 2.22 is not known but may be due to low solubility of 2.24 
in organic solvents and the susceptibility to ester hydrolysis during basic work up. The 
isoquinoline 2.24 has only been reported once before in the literature in a Japanese 
patent183 without any spectroscopic data. 
 
As the aromatisation of hydroxytetrahydroisoquinoline 2.22 did not occur in the absence 
of atmospheric air, it is likely that dihydroisoquinoline 2.23 (formed from reaction with 
DDQ) is formed in this reaction as an intermediate and then aromatised by oxygen to give 
isoquinoline 2.24. Oxygen has been used previously as an oxidant in aromatisation 
reactions reported in literature.184-185 In one such study, Dong et al.186 used oxygen with 
a base in DMSO to convert N-tosyltetrahydroisoquinolines into isoquinolines. Analogous 
to the partially oxidised imine 2.23 isolated in this thesis with the exclusion of air, Dong 
et al.186 also obtained an imine under an argon atmosphere instead of the aromatised 
isoquinoline product. In a previous literature report of DDQ-based cross-dehydrogenative 
coupling reactions of tetrahydroisoquinolines, an iminium ion (analogous to 3,4-
dihydroisoquinoline) was observed as an intermediate.187 
 
 
Scheme 2.5. (i) DDQ, 1,4-dioxane, THF, 110 °C, 32%, reaction carried out under N2 atmosphere. (ii) 
DDQ, 1,4-dioxane, THF, 45 °C, atmospheric oxygen, 49%. 
 
Hydrolysis of ester 2.24 with aqueous LiOH provided carboxylic acid 2.25, which was 
condensed with commercially available diamines (o-phenylenediamine or 3,4-
diaminotoluene) using hot polyphosphoric acid (PPA) to provide 1-
(benzimidazolyl)isoquinolinols (2.26 and 2.27) in low yield (Scheme 2.6). The low yields 
of PPA mediated condensation reactions are likely due to a number of factors, including 
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poor dehydration yield and a difficult isolation of the polar 1-
(benzimidazolyl)isoquinolinols (2.26 and 2.27) from the viscous reaction mixture.  
 
 
Scheme 2.6. (i) LiOH, THF, H2O, 96%. (ii) 3,4-Diaminotoluene or o-phenylenediamine, PPA, 250 °C, 18-
21%. (iii) tert-Butyl bromoacetate, K2CO3, THF, 60 °C, 93-96%. (iv) TFA, DCM, 64% - quantitative. (v) 
2.10 or 2.12 or 2.18, HATU, DIPEA, DMF, 29-69%. (vi) TFA, DCM, quantitative (vii) BODIPY-630/650-




The yield of the condensation reaction for the preparation of 
(benzimidazolyl)isoquinolinols was slightly improved by using a mixture of phosphorus 
pentoxide and PPA. For example, reaction of 2.45 (Scheme 2.8) with 3,4-diaminotoluene 
and a mixture of phosphorus pentoxide and PPA (~20% w/w) provided 2.46 (Scheme 2.8) 
in 37% yield, whereas reaction with PPA alone provided 2.46 in 24% yield). The 
(benzimidazolyl)isoquinolinols (2.26 and 2.27) were reacted with tert-butyl bromoacetate 
using K2CO3 as a base to afford corresponding tert-butyl esters (2.28 and 2.29), which 
were reacted with TFA to give carboxylic acids (2.30 and 2.31; Scheme 2.6). The reaction 
of carboxylic acid 2.30 with PEG linker 2.12 (Scheme 2.2) using HATU as a coupling 
reagent and DIPEA as base gave (benzimidazolyl)isoquinolinol-linker conjugate 2.34. 
Similarly, the coupling of 2.31 with linkers (2.10, 2.12 and 2.18) gave 
(benzimidazolyl)isoquinolinol-linker conjugates 2.32, 2.33 and 2.35. The 
(benzimidazolyl)isoquinolinol-linker conjugates (2.32-2.35) were reacted with TFA to 
give the Boc-deprotected 2.32-2.35 as amino trifluoroacetate salts, which were purified 
by semi-preparative reverse phase-high performance liquid chromatography (RP-HPLC) 
and the purified amino salts reacted with BODIPY-630/650-SE to afford fluorescent 
ligands (2.36-2.39; Scheme 2.6). All of the fluorescent ligands prepared in this thesis were 
purified by semi-preparative RP-HPLC. 
 
The fluorescence spectra of (benzimidazolyl)isoquinolinol-based fluorescent ligands were 
measured by collaborators at the University of Nottingham to check if these fluorescent 
ligands exhibit similar absorption and emission maxima as the ‘free’ BODIPY630/650 
fluorophore. The fluorescence spectra of compounds 2.36–2.39 (Scheme 2.6), 2.50 (Scheme 
2.8), 2.61 and 2.62 (Scheme 2.9) showed excitation maxima at 624 nm and emission maxima 
at either 641 or 642 nm (detailed in experimental chapter 7, section 7.2.1), similar to that of 
‘free’ BODIPY-630/650.  
 
2.2.3 Synthesis of 1-(benzimidazolyl)isoquinoline-7-ol- 
derivatives 
 
Attempts to prepare the tetrahydroisoquinoline 2.41 (Scheme 2.7) from commercially 
available tyramine 2.40 and glyoxylic acid monohydrate using a similar procedure as 
described for the preparation of 2.21 (section 2.2.2; except without using Et3N as amine 
2.40 was not a salt) were unsuccessful and starting material 2.40 was recovered. Failure 
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of this condensation reaction is likely due to the lack of an activating group in tyramine 
2.40, compared to the presence of an activating para hydroxyl relative to the point of 
condensation for 2.20 (Scheme 2.4).  
 
 
Scheme 2.7. (i) Glyoxylic acid monohydrate, EtOH. 
 
Instead, 1-(benzimidazolyl)isoquinoline-7-ol- derivatives were prepared using a synthetic 
route reported for the synthesis of N-Fmoc protected 2.41 by Maillard et al.180 Thus, Fmoc 
protection of commercially available tyramine 2.40 gave 2.42 (Scheme 2.8). Reaction of 
2.42 with glyoxylic acid monohydrate gave N-Fmoc protected 2.41 (not shown in Scheme 
2.8, reported by Maillard et al.180), which was esterified to give 2.43 in low yield over 
two steps (Scheme 2.8). The NMR spectra of ester 2.43 showed a mixture of isomers that 
were elucidated to be rotamers rather than regioisomers via variable temperature NMR 
experiments (described in experimental chapter 7, section 7.2.1). 
 
The Fmoc-protected ester 2.43 was initially reacted with diethylamine for Fmoc 
deprotection, however subsequent reaction of Fmoc-deprotected 2.43 (compound not 
purified) with DDQ provided poor yield of 2.44, most likely due to the residual 
diethylamine. Fmoc deprotection of 2.43 was observed in high temperature NMR spectra 
in DMSO-d6 that was carried out to study rotamers, and indeed there is literature 
precedent that Fmoc cleavage can be conducted in neat DMSO at high temperature.188 
Hence, Fmoc deprotection of 2.43 in DMSO, followed by reaction with DDQ (using the 
optimised procedure described for the preparation of 2.24 (Scheme 2.5, section 2.2.2)) 
provided 2.44 (Scheme 2.8). 
 
Subsequent synthesis of (benzimidazolyl)isoquinolinol-linker conjugate 2.49 and 
BODIPY-630/650 conjugate 2.50 was carried out using a similar methodology as 
described in section 2.2.2. Hydrolysis of 2.44 with aqueous LiOH gave carboxylic acid 
2.45, which was reacted with 3,4-diaminotoluene to give (benzimidazolyl)isoquinolinol 
2.46 (Scheme 2.8). Alkylation of 2.46 with tert-butyl bromoacetate gave 2.47, which was 
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reacted with TFA to give 2.48. Reaction of the carboxylic acid 2.48 with PEG linker 2.12 
(Scheme 2.2, section 2.2.1) using HATU as a coupling reagent and DIPEA as a base 
provided 2.49. (Benzimidazolyl)isoquinolinol-linker conjugate 2.49 was reacted with 
TFA to give Boc-deprotected 2.49 as an amino trifluoroacetate salt, which was purified 
by semi-preparative RP-HPLC and the purified amino salt reacted with BODIPY-
630/650-SE to afford fluorescent ligand 2.50. 
 
 
Scheme 2.8. (i) Fmoc-Cl, DIPEA, DCM, 82%. (ii) Glyoxylic acid monohydrate, H2SO4, CH3CO2H. (vii) 
SOCl2, MeOH, 18% over two steps. (iv) DMSO, MeOH, 60 °C. (v) DDQ, THF, 1,4 dioxane, 45 °C, 61% 
over two steps from 2.43. (vi) LiOH, THF, H2O, 70%. (vii) 3,4-Diaminotoluene, PPA, 250 °C, 24%, (37% 
with a mixture of P2O5 and PPA (~20% w/w)) (viii) tert-Butyl bromoacetate, K2CO3, THF, 60 °C, 66%. 
(ix) TFA, DCM. (x) 2.12, HATU, DIPEA, DMF, 43%. (xi) TFA, DCM, quantitative. (xii) BODIPY-





2.2.4 Synthesis of 3-(benzimidazolyl)isoquinoline-6-ol- 
derivatives 
 
Synthesis of 3-(benzimidazolyl)isoquinoline-6-ols was carried out following similar 
synthetic methodology as described for the preparation of 1-
(benzimidazolyl)isoquinoline-6-ols (section 2.2.2). Reaction of the commercially 
available (+/-)-m-tyrosine 2.51 with formaldehyde, according to a literature synthesis,189 
gave 2.52. The carboxylic acid 2.52 was esterified to give 2.53 and then aromatised with 
DDQ to provide 2.54 (using optimised reaction conditions described for the preparation 
of 2.24, section 2.2.2; Scheme 2.5). The synthesis of methyl ester 2.54 from 2.53 has 
previously been reported in iterature182, 190-193 including in a patent report13. Attempts at 
aromatisation of 2.53 and 2.22 (section 2.2.2) following the method described in this 
patent report13 were unsuccessful. None of these reported syntheses include spectroscopic 





Scheme 2.9. (i) HCl (0.05 M, aqueous solution), formaldehyde (37 wt. % in H2O), 90 °C, 48%. (ii) H2SO4, 
MeOH, 96%. (iii) DDQ, THF, 1,4 dioxane, 45 °C, 52%. (iv) LiOH, THF, H2O, 90%. (v) 3,4-
Diaminotoluene, PPA, 250 °C, 26%. (vi) tert-Butyl bromoacetate, K2CO3, THF, 60 °C, 94%. (vii) TFA, 
DCM. (viii) 2.12 or 2.18, HATU, DIPEA, DMF, 37-39%. (ix) TFA. (x) BODIPY-630/650-SE, DIPEA, 
DMF, 73-86%. 
 
Alkaline hydrolysis of ester 2.54 gave carboxylic acid 2.55, which was condensed with 
3,4-diaminotoluene to give (benzimidazolyl)isoquinolinol 2.56 (Scheme 2.9). Alkylation 
of 2.56 with tert-butyl bromoacetate gave 2.57, which was reacted with TFA to give 2.58. 
The coupling of carboxylic acid 2.58 with PEG linker 2.12 (synthesis described in section 
2.2.1) or peptide linker 2.18 (synthesis described in section 2.2.1) using HATU as a 
coupling reagent yielded linker conjugates 2.59 or 2.60 respectively. Reaction of the 
linker conjugates (2.59 and 2.60) with TFA gave Boc-deprotected 2.59 and 2.60 as amino 
trifluoroacetate salts, which were purified by semi-preparative RP-HPLC and the purified 
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amino salts reacted with BODIPY-630/650-SE to afford fluorescent ligands 2.61 and 2.62 
(Scheme 2.9). 
 
2.2.5 Synthesis of 1‐(1H‐1,3‐benzodiazol‐2‐yl)isoquinoline 
 
(Benzimidazolyl)isoquinoline 2.6 (Ki = 14.1  1.6 nM at hA1AR, Table 2.1), a high-
affinity A1AR antagonist previously reported by Cosimelli et al.
76, is not commercially 
available so was synthesised for use as a literature control in pharmacological 
experiments (section 2.3). According to a previous synthesis,76 literature compound 2.6 
was prepared by condensation of commercially available isoquinoline‐1‐carboxylic acid 
2.63 with commercially available o-phenylenediamine using PPA (Scheme 2.10).  
 
 





















2.2.6 Conformers of 1-(benzimidazolyl)isoquinoline-6-ol (2.26) 
 
This section describes the investigation of the NMR spectra and RP-HPLC spectra of 
novel (benzimidazolyl)isoquinolinols.  
 
The NMR spectra of (benzimidazolyl)isoquinolinols (2.26, 2.27, 2.46 and 2.56, synthesis 
described in section 2.2.2, section 2.2.3 and section 2.2.4) showed broadened peaks (1H 
NMR spectra, solvent MeOD-d4) or multiple sets of peaks (
1H and 13C NMR spectra, 
solvent DMSO-d6). These peculiar NMR spectra peaks were investigated using 2.26 as a 
model compound. The peculiar NMR spectra peaks of 2.26 could arise from either the 
presence of discrete chemical entities (for example regioisomers or chemical impurities) 
or from conformational isomers (tautomers and/or rotamers). The chemical exchange of 
protons between N-9 and N-11 (usually with the participation of solvent molecules) in 
2.26 would give rise to tautomers of 2.26 (Figure 2.3 (A)). On the other hand, the 
restricted rotation around the C-1–C-10 bond of 2.26 (the bond connecting the 
benzimidazole and isoquinoline heterocycles) would give rise to rotamers of 2.26 (Figure 
2.3 (B)). 
 
The rate of interconversion of conformers is dependent on factors such as solvent type 
(different hydrogen bond acceptor or donor ability), change in temperature and 
concentration of the compound. Consequently, if peak appearance and multiplicity in 
NMR and RP-HPLC spectra are sensitive to factors such as solvent, temperature and 
concentration of compound, it would indicate the presence of conformers (tautomers or 
rotamers) rather than discrete chemical entities (regioisomers or chemical impurities).  
 
The most non-equivalent NMR signals should be observed between the atoms which are 
exposed to different spatial surrounding in the conformers. Therefore, a number of NMR 
spectroscopy and RP-HPLC experiments were carried out using 2.26 as a model 
(benzimidazolyl)isoquinolinol to evaluate whether interconvertible conformers 






Figure 2.3. Interconversion of possible (A) tautomers or (B) rotamers of 2.26.  
 
2.2.6.1 NMR spectroscopic studies  
 
The 1H NMR spectrum of 2.26 in MeOD-d4 (Figure 2.4, section 2.2.6.4) showed sharp 
peaks for the isoquinoline protons but broadened peaks for the benzimidazole protons. 
Similarly, the 13C NMR spectrum of 2.26 in MeOD-d4 (Figure 2.5, section 2.2.6.4) 
showed sharp peaks for the isoquinoline carbons but weak intensity peaks or no peaks for 
the benzimidazole carbons (refer to experimental chapter 7, section 7.2.1 for peak lists in 
MeOD-d4). Interestingly, more signals were seen in the 
1H NMR spectrum (Figure 2.6) 
and 13C NMR spectrum (Figure 2.7) of 2.26 in DMSO-d6 than observed in the 
corresponding NMR spectra in MeOD-d4. 
 
1H and 13C NMR spectra signals of 2.26 were assigned using spectra obtained from 
gradient homonuclear correlation spectroscopy gCOSY, gradient heteronuclear single 
quantum coherence spectroscopy (gHSQC) and gradient heteronuclear multiple bond 
correlation spectroscopy (gHMBC) (Appendix, Figure A.2-A.7). The atom numbering of 




2.26 1H NMR (400 MHz, DMSO-d6) δ 2.45 (s, 2.84H, 16-H), 7.07 (d, 0.62H, J = 7.6 Hz, 
14-H), 7.12 (d, 0.41H, J = 8.0 Hz, 14-H), 7.21 (d, 1H, J = 2.4 Hz, 5-H), 7.33 – 7.40 (m, 
1.53H, 7-H and 12-H), 7.47 (d, 0.41H, J = 8.3 Hz, 15-H), 7.60 (s, 0.41H, 12-H), 7.68 (d, 
0.60H, J = 8.3 Hz, 15-H), 7.74 (d, 0.96H, J = 5.6 Hz, 4-H), 8.49 (d, 1.0H, J = 5.6 Hz, 3-
H), 9.90 – 9.99 (m, 1.02H, 8-H), 10.53 (s, 1.53H, 17-H), 12.98 (s, 0.63H, 9-H), 12.99 (s, 
0.40H, 9-H). (Additional 1H NMR signals than were expected by magnetic equivalence 
for one chemical structure of 2.26, are due to the presence of another conformer)  
 
2.26 13C NMR (101 MHz, DMSO-d6) δ 21.33 (16-C), 21.48 (16-C), 107.63 (5-C), 111.52 
(15-C), 111.59 (12-C), 119.18 (12-C and 15-C), 120.78 (4-C), 121.07 (7-C), 123.54 (14-
C), 125.02 (14-C), 130.12 (8-C), 130.78 (13-C), 132.01 (11a-C or 15a-C), 132.86 (13-C), 
134.21 (11a-C or 15a-C), 139.16 (8a-C or 4a-C), 141.68 (3-C), 142.24 (11a-C or 15a-C), 
144.40 (11a-C or 15a-C), 146.19 (8a-C or 4a-C), 150.97 (10-C), 151.31 (1-C), 158.93 (6-
C). (Additional 13C NMR signals then were expected by magnetic equivalence for one 
chemical structure of 2.26, are due to the presence of another conformer). 
 
Twenty-three aromatic carbon signals were observed in the 13C NMR spectrum of 2.26 
in DMSO-d6, however only seventeen carbons are present in 2.26. Twelve C-H 
correlations were observed in the gHSCQ spectrum of 2.26 (Appendix, Figure A.6), 
however 2.26 has only nine carbons with at least one hydrogen attached. The gHSQC 
correlations with data from gCOSY and gHMBC spectra revealed that an additional three 
C-H correlations in gHSQC spectrum and additional carbon signals in 13C NMR spectrum 
were from atoms belonging to the benzimidazole moiety (gCOSY and gHMBC spectra 
reported in Appendix, Figure A.5, A.7). The identification of atoms belonging to 
benzimidazole moiety was primarily based on the gHSQC and gHMBC correlations to 
the clearly identifiable H-16 protons. 
 
Variable temperature 1H NMR spectra 
The rate of interconversion of conformers is dependent on temperature. Therefore, a 
complex NMR spectrum of two conformers should simplify (or start to simplify) at a 
higher temperature as the rate of conversion of conformers increases and reaches beyond 
that observable on NMR timescale. 1H NMR spectra of 2.26 carried out in DMSO-d6 at 
three different temperatures (Figure 2.8) showed coalescence of proton signals as 
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temperature increased, supporting the presence of conformers rather than discrete non-
interchangeable chemical entities.  
 
Addition of D2O 
It was thought that the strong hydrogen bond accepting property of DMSO-d6 compared 
to MeOD-d4 might be responsible for the complex NMR spectra of 2.26 in DMSO-d6. 
Accordingly, the addition of D2O to a solution of 2.26 in DMSO-d6 should weaken a 
hydrogen bond thought to exist between NH of benzimidazole and DMSO-d6. The 
weakening of this hydrogen bond should increase the rate of interconversion of 
conformers and a less complex NMR spectra should be observed. In agreement with this 
hypothesis, less complex signals were observed in both 1H and 13C NMR spectra of 2.26 
in DMSO-d6 spiked with D2O (Figure 2.9, Figure 2.10). 
 
Tautomer or rotamer?  
It seemed likely that 2.26 exhibited tautomerism as the NMR spectra showed that only 
the benzimidazole atoms were affected by the change in NMR solvent and temperature. 
If rotamers of 2.26 were predominantly present, then the isoquinoline atoms would also 
be affected (Figure 2.3 (B)). Presumably, exchange of hydrogen between N-9 and N-11 
in MeOD-d4 exposes neighbouring atoms: 11a, 12, 13, 14, 15 and 15a to a fluctuating 
local chemical environment resulting in either broadening or absence of 1H/13C NMR 
spectra signals of their corresponding atoms (Figures 2.4 and 2.5). 
 
It seems likely that a strong hydrogen bond exists between the benzimidazole NH of 2.26 
and DMSO-d6, which slows down the rate of exchange of hydrogen between N-9 and N-
11 and consequently the rate of interconversion of tautomers, hence leading to the 
observation of both tautomers in the NMR time scale (Figures 2.6, 2.7). 
 
2.2.6.2 RP-HPLC studies  
 
The peak shape in the analytical RP-HPLC chromatogram of 
(benzimidazolyl)isoquinolinols (2.26, 2.27, 2.46 and 2.56) (synthesis described in section 
2.2.2, section 2.2.3 and section 2.2.4) was observed to be concentration dependent. This 
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was investigated using 2.26 as the model compound, which at higher concentration 
showed an elongated, square shoulder peak (Figure 2.11). 
 
It was thought that the peculiar RP-HPLC spectra peak shape might be due to the presence 
of conformers (rotamers or tautomers), peak tailing, or the presence of discrete chemical 
entities (for example regioisomers or chemical impurities). 
 
Analytical RP-HPLC chromatograms from of 2.26, 2.27, 2.46 and 2.56 revealed that peak 
shape was concentration dependent. Again using 2.26 as the model compound, at higher 
concentrations, an elongated, square shoulder peak was observed (Figure 2.11). Further 
RP-HPLC experiments were carried out to exclude the presence of discrete chemical 
entities (regioisomers or chemical impurities). Semi-preparative RP-HPLC of 2.26 was 
carried out and the peak containing 2.26 (Figure 2.12) was fractionated into ten separately 
timed fractions. An analytical RP-HPLC spectrum of each fraction was run (Figure 2.13 
(A), which revealed broad peaks for fractions with high concentration and sharp peaks 
for fractions with low concentration. Analysis of the dilute solution prepared by 
combination of aliquots from each fraction by analytical RP-HPLC showed a single peak 
(Figure 2.13 (B)), which made the presence of discrete chemical entities (regioisomers or 
chemical impurities) unlikely. Variable temperature RP-HPLC experiments (at 25 - 40 
°C) were also carried out to investigate the effect of temperature on the more concentrated 
analytical RP-HPLC chromatogram of 2.26 (Figure 2.11). However, a significant change 
in chromatogram peak shape was not observed in this temperature range. It seems likely 
that a much higher temperature would be required to see a significant change in the 
chromatogram of 2.26, in accordance with 1H NMR spectra results that showed little 
change from 25 °C to 45 °C but a much larger change at 60 °C. Variable temperature RP-
HPLC experiments at higher temperature (> 40 °C) were not carried due to 
incompatibility of solvent and column with higher temperatures.  
 
2.2.6.3 Summary of NMR spectroscopy and RP-HPLC studies   
 
The NMR spectroscopy and RP-HPLC experiments suggest that 2.26 is a mixture of 
interconvertible tautomers. The synthetic route used for the preparation of 
(benzimidazolyl)isoquinolinols made it unlikely that regioisomers would be present and 
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this was supported by the high-temperature NMR spectroscopy and RP-HPLC 
experiments. As the high-resolution electrospray ionisation mass spectra (HRMS) 
spectrum of 2.26 matched the expected molecular formula mass and no other major peaks 
were observed, the presence of an impurity with different molecular formula is unlikely 
(this is also supported by RP-HPLC experiments). It can be concluded that the peculiar 
NMR and RP-HPLC spectra observed for (benzimidazolyl)isoquinolinol 2.26 arose from 
the presence of tautomers. This conclusion is supported by the fact that benzimidazole 





2.2.6.4 NMR Spectra and RP-HPLC chromatograms  
 
 
















Figure 2.8. 1H NMR experiments of 2.26 in DMSO-d6 were carried at three different temperatures: Top (25 °C in blue), middle (45 °C in green), bottom (60 °C in red), the inset 












Figure 2.11. Analytical RP-HPLC chromatogram of 2.26 at high concentration showed a shoulder peak.  
The following Analytical RP-HPLC method was used for obtaining analytical RP-HPLC chromatograms 
reported in Figure 2.11 and Figure 2.13 (A), (B) - 5% solvent B 1 min, gradient of 5-20% solvent B 1-51 








Figure 2.13. (A) Analytical RP-HPLC chromatogram of 10 separate fractions collected from peak 
corresponding to 2.26 (14.5 to 15.5 min) in the semi-preparative RP-HPLC chromatogram (Figure 2.12). 
(B) Analytical RP-HPLC chromatogram of combined fractions.   
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2.3 Biological studies 
 
All biological experiments of (benzimidazolyl)isoquinolinols (synthesis described in 
section 2.2) were carried out by members of Professor Stephen Hill’s group at the 
University of Nottingham, Nottingham, United Kingdom. Detailed experimental methods 
are described in the published research article reporting these novel compounds and their 
biological activity (Singh et al. 2018167).  
 
A previously reported NanoBRET assay using the luciferase NanoLuc (NLuc; Promega 
Corporation, USA) was used for determining the A1AR affinity of BODIPY-630/650 
analogues of (benzimidazolyl)isoquinolinols 2.36-2.39, 2.50, 2.61 and 2.62 (section 
2.2.2, 2.2.3 and 2.2.4).90 The NanoBRET assay is a bioluminescence resonance energy 
transfer-based binding assay, which uses NanoLuc luciferase instead of the more 
commonly used Firefly and Renilla luciferases. NanoLuc luciferase is smaller and 
exhibits greater stability and brightness compared to firefly and Renilla luciferases.200 
The NanoBRET assay offers a direct measurement of the interaction of a fluorescent 
ligand with the receptor without depending on the indirect displacement of the radioligand 
by a test ligand. In this NanoBRET assay, HEK-293 cells expressing N-terminal NanoLuc 
labelled A1AR were treated with increasing concentrations of the 
(benzimidazolyl)isoquinolinol fluorescent ligands (2.36-2.39, 2.50, 2.61 and 2.62). Non-
specific binding was determined by incubation with DPCPX (a high affinity, non-
fluorescent, selective A1AR antagonist).  
 
Unfortunately, none of the tested fluorescent ligands (2.36-2.39, 2.50, 2.61 and 2.62) 
showed significant binding at NanoLuc-A1AR. For example, data is shown for 2.37 and 
2.38 (Figures 2.14 (a-b)). As some of the structurally analogous compounds (for example 
2.1-2.4, Table 2.1) were reported as A3AR antagonists, it was decided to evaluate some 
fluorescent ligands (2.36-2.39) at NanoLuc-A3AR in a similar NanoBRET assay. Non-
specific binding of the new fluorescent ligands was accessed by incubation with 
MRS1220 (a high affinity, non-fluorescent, selective A3AR antagonist). A small degree 
of binding to NanoLuc-A3AR was observed for (benzimidazolyl)isoquinolinol 2.38 and 
to a lesser extent for 2.37 (Figures 2.12 (c-d)). A small window of specific binding was 
observed and there was a large error in the calculated Kd values (2.37 Kd = 534 ± 254 nM 
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at A3AR; 2.38 Kd = 162 ± 65.5 nM at A3AR). The (benzimidazolyl)isoquinolinols 2.36 
and 2.39 did not show any specific binding to NanoLuc-A3AR (data in appendix, Figure 
A.9). 
 
The non-specific binding for fluorescent ligands (2.36-2.39) at NanoLuc-A1AR 
expressing HEK-293 cells or NanoLuc-A3AR expressing HEK-293 cells in the 
NanoBRET assay was determined by measuring BRET in the presence of non-fluorescent 
ligands DPCPX or MRS1220 respectively. This non-specific binding is a measure of the 
ability of the non-fluorescent ligand to prevent the binding of a fluorescent ligand by 
interacting with the same or an overlapping area of the receptor ligand-binding pocket. 
The non-specific binding component (obtained in the presence of DPCPX) for NanoLuc-
A1AR is linear (Figure 2.14 (a-b)). However, for NanoLuc-A3AR, it can be seen from 
Figure 2.14 (c-d) that the non-specific binding component (obtained in the presence of 
MRS1220) is not linear and is better fitted to a saturable binding curve. Hence, a 
possibility remains (along with non-specific membrane binding) that an A3AR ligand-
binding pocket for (benzimidazolyl)isoquinolinol 2.37 and 2.38 is different from the 




Figure 2.14. HEK-293 cells expressing N-terminally NanoLuc-tagged hA1AR or hA3AR were treated with increasing concentrations of fluorescent ligand (2.38 or 2.37) and 
the BRET ratio measured after addition of the NanoLuc substrate furimazine (10μM).90 Non-specific binding was assessed in the absence and presence of 1M DPCPX 
(NanoLuc-hA1AR) or 1M MRS1220 (NanoLuc-hA3AR). Pooled data of raw BRET ratios was baseline corrected (minus vehicle + furimazine BRET ratios) so that data is 
expressed as fold increase in BRET ratios over basal. (a) NanoLuc-hA1AR and 2.38, (b) NabnoLuc-hA1AR and 2.37, (c) NanoLuc-hA3AR and 2.38 and (d) NanoLuc-hA3AR 
and 2.37. Data represents four - seven independent experiments (in triplicate) and is expressed as mean ± SEM. Data is generated by members of Professor Stephen Hill’s group 
at the University of Nottingham. 
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There is a possibility that lack of NanoLuc-A1AR binding of fluorescent ligands (2.36-
2.39, 2.50, 2.61 and 2.62) might be due to the steric hindrance arising from the presence 
of the N-terminal NanoLuc tag. This possibility was explored by collaborators, who 
carried out the NanoBRET assay with a known fluorescent non-selective AR ligand 
CA200645 (structure shown in chapter 1, Figure 1.9) at NanoLuc-A1AR. In the 
NanoBRET assay, CA200645 showed specific binding with a large observation window 
(Figure 2.15 (A); Kd = 110 nM ± 18.46 at hA1AR), which is in accordance with previously 
reported high affinity for CA200645 at NanoLuc-A1AR (Kd = 7.5 ± 2.4 nM at hA1AR).
90 
These results indicate that the NanoLuc tag does not hinder binding of CA200645 to the 
receptor, hence it seems unlikely that NanoLuc tag is responsible for the poor affinity of 




Figure 2.15. HEK-293 cells stably expressing N-terminal NanoLuc tagged hA1AR were treated with increasing concentrations of CA200645 (5-500nM; 1 hr at 37°C; A). Non-
specific binding was defined using 1 μM DPCPX, an A1AR selective antagonist. The NanoLuc substrate furimazine was added (10 μM), with luminescence and fluorescence 
emissions recorded using a Pherastar FS. Data was pooled from independent experiments (n=5) and baseline corrected (minus vehicle + furimazine BRET ratios) so that data 
is expressed as fold increase in BRET ratios over basal and where appropriate fit using one site saturation binding (mean ± SEM). For competition experiments (B), NanoLuc-
hA1AR were co-incubated with a fixed concentration of CA200645 and increasing concentrations of unlabelled ligand (2.6 or 2.27 or 2.56; 1 hr at 37°C). Total CA200645 
binding and vehicle are shown by the black and white bars respectively. Data was pooled from five independent experiments and is expressed as mean ± S.E.M. All data 
generated by members of Professor Stephen Hill’s group at the University of Nottingham. 
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As significant binding was not observed for the fluorescent ligands (2.36-2.39, 2.50, 2.61 
and 2.62) at NanoLuc-A1AR, it was decided to test a subset of 
(benzimidazolyl)isoquinolinols (2.26, 2.27, 2.33, 2.46, 2.49, 2.56 and 2.59, described in 
sections 2.2.2, 2.2.3, and 2.2.4, and literature (benzimidazolyl)isoquinoline 2.6, Table 
2.1) in the NanoBRET assay. Since the (benzimidazolyl)isoquinolinols (2.26, 2.27, 2.33, 
2.46, 2.49, 2.56 and 2.59) do not contain a fluorophore capable of interacting with 
NanoLuc tag via BRET, instead the competitive displacement of fluorescent ligand 
CA200645 by the (benzimidazolyl)isoquinolinols was measured by collaborators at the 
University of Nottingham. DPCPX was used as a positive control. Displacement of 
CA200645 was only observed when the concentration of benzimidazolyl)isoquinolinol 
(2.26, 2.27, 2.33, 2.46, 2.49, 2.56 or 2.59) was greater than 10-6 M (Figure 2.15 (B); 2.6 
and representative (benzimidazolyl)isoquinolinols 2.27 and 2.56 shown; data for 2.26, 
2.33, 2.46, 2.49 and 2.59 shown in Appendix, Figure A.10). Except for DPCPX (pKi; 8.82 
± 0.16 nM, at hA1AR), collaborators could not calculate the pKi for any of the test 
compounds. Surprisingly, displacement of CA200645 with literature 
(benzimidazolyl)isoquinoline 2.6 was not observed. The (benzimidazolyl)-isoquinoline 
2.6 was previously reported as a selective and high affinity A1AR antagonist (Ki = 14.1  
1.6 nM at hA1AR, Table 2.1) in a competition radioligand binding assay using CHO cells 
overexpressing A1AR, using [
3H]DPCPX as the radioligand.76 Interestingly, better 
binding to NanoLuc-A1AR (although still limited) was observed for 1-(1H-1,3-
benzodiazol-2-yl)isoquinolin-6-ol 2.27 and 3-(6-methyl-1H-1,3-benzodiazol-2-
yl)isoquinolin-6-ol 2.56 compared to the literature (benzimidazolyl)isoquinoline 2.6 
(Figure 2.15 (B)). The reasons for low A1AR binding affinity of literature 







Novel (benzimidazolyl)isoquinolinols along with linker (alkyl, PEG, and peptide (Ala-
Ala)) conjugates and BODIPY-630/650 conjugates (section 2.2) were synthesised with 
the aim of developing a high affinity, selective A1AR fluorescent ligands. Synthesis of 
isoquinolinols from tetrahydroisoquinolinols involved the development of a procedure 
using DDQ and atmospheric air mediated aromatisation. As there are only two previous 
reports182, 201 (with unclear experimental details and poor product characterisation) of 
metal-free aromatisation reaction of unprotected tetrahydroisoquinolinols to 
isoquinolinols, the mild aromatisation method reported here will be useful in the 
preparation of pharmacologically interesting isoquinolines and isoquinolinols. The NMR 
spectra peak multiplicity and peak broadening of novel (benzimidazolyl)isoquinolinols 
was investigated for a representative compound (2.26) via NMR spectroscopy and RP-
HPLC studies and was concluded to arise from the tautomerism of the benzimidazole 
moiety.  
 
The aim of developing new A1AR selective fluorescent ligands was not achieved in this 
thesis and the biological data indicates that conjugation of a fluorophore to the 
(benzimidazolyl)isoquinolinol scaffold via the C-6 or C-7 position of the isoquinoline is 
unlikely to attain this goal. There remains a possibility of developing an A1AR selective 
fluorescent ligand via exploring other positions of the (benzimidazolyl)isoquinoline 
scaffold (such as the benzimidazole) for linker attachment. However, as the literature 
(benzimidazolyl)isoquinoline 2.6 did not exhibit any significant A1AR affinity, it seems 




Chapter 3 Development of chromenopyrazoles 
as fluorescent ligands for cannabinoid type 1 
receptor 
3.1 Design rationale for chromenopyrazole-based 
fluorescent ligands 
 
The availability of rich SAR data132 for cannabis-derived CBR ligands (for example THC, 
described in chapter 1, section 1.4.3) along with the high affinity and potency for CBRs 
make these ligands attractive leads for development of the fluorescent ligands. However, 
structural variations of cannabis-derived CBR ligands such as THC and CBN have 
generally not been very successful in attaining CBR subtype selectivity.132  
 
Cumella et al.137 reported chromenopyrazole derivatives as CBR agonists, obtained by 
replacing the phenyl ring of CBN (Figure 3.1) with a pyrazole (Table 3.1). Representative 
examples of these chromenopyrazoles,137 including those with N-aryl and N-alkyl 
substituents on which the fluorescent ligand design rationale was based, are shown in 
Table 3.1. Chromenopyrazoles with an n-pentyl side chain (for example 3.6-3.9) showed 
weak or no affinity for CBRs while those with a dimethylheptyl side chain showed high 
affinity for CBRs. These results are consistent with those of Rhee et al.,138 who reported 
derivatives of CBN and THC with a dimethylheptyl side chain that showed higher affinity 
and potency at both CBRs compared to n-pentyl side chain analogues. Prior to the report 
of CBR chromenopyrazoles by Cumella et al.137, chromenopyrazoles were also reported 
by Chiodini et al.202 and Press et al.203 which were inactive in pharmacological tests 








Among the dimethylheptyl chromenopyrazoles reported by Cumella et al.137 was 3.4 
(Table 3.1) with a N1-2,4-dichlorophenyl moiety, which exhibited high affinity for CB1R 
and good selectivity over CB2R. The high affinity of 3.4 at CB1R was in contrast to the 
structurally similar regioisomer 3.3 (Table 3.1) with a N1-3,4-dichlorophenyl moiety, 
which showed moderate affinity for both CBRs. Chromenopyrazoles 3.1, 3.2 and 3.5 
inhibited electrically induced contraction of mouse vas deferens (a tissue commonly used 
to evaluate CB1R function of CBR ligands
204) and therefore behaved as mCB1R agonists. 
It was envisioned that a CB1R selective (over CB2R) fluorescent agonist could be 
developed by maintaining a dimethylheptyl side chain and careful substitution of the 
atoms near N1 pyrazole position.  
 
Table 3.1. Previously reported chromenopyrazole and chromenoisoxazole CBR ligands in literature
137, 202-
203, 205  
 
 R1 R2 Ki hCB1R (nM ± SEM)* Ki hCB2R (nM ± SEM)* Ref 
3.1 H H 28.5 ± 23.7 >40000 137 
3.2 Ethyl H 4.5 ± 0.6 >40000 137 
3.3 3,4-Dichlorophenyl H 514 ± 205 270 137 
3.4 2,4-Dichlorophenyl H 5.2 ± 4.3 >40000 137 
3.5 H Ethyl 18.6 ± 4.1 >40000 137 
3.6 H H 4100 ± 800 2010 ± 500 
137, 
202 
3.7 Ethyl H 9610 >40000 137 
3.8 3,4-Dichlorophenyl H 607 ± 151 >40000 137 
3.9 H Methyl 22100 ± 1410 >40000 
203,13
7 
3.10 - - >40000 12.8 ± 2.4 205 
 
*Binding affinity (Ki) obtained by competition binding assay performed on membranes obtained from HEK-
293 cells expressing either hCB1R or hCB2R with [3H]-CP55,940 as radioligand. 
 
While this PhD thesis was underway, Morales et al.205, part of the same research group 
as Cumella et al.137, reported a revised series of chromenopyrazoles and new 
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chromenoisoxazoles with high affinity and selectivity for CB2R. Some of the N-alkylated 
chromenopyrazoles and chromenoisoxazoles (for example 3.10) described by Morales et 
al.205 behaved as CB2R agonists in a cAMP BRET assay.
205 The same group of 
researchers also reported chromenopyrazolediones as CBR ligands (Figure 3.2), which 
exhibited in vivo antitumor activity against human prostate cancer206 and human triple-
negative breast cancer tumours207 generated in mice. One of these, 
chromenopyrazoledione 3.11 (Ki > 40000 nM at hCB1R; 529 ± 26 nM at hCB2R, Figure 
3.2) was shown to exhibit its antitumor activity by induction of apoptosis through CB2R 
activation and oxidative stress (by formation of reactive oxygen species). Morales et al.208 
also reported chromenopyrazoles lacking phenolic hydroxyl and the dimethylheptyl side 
chain as GPR55 (a GPCR) antagonists and partial agonists (for example 3.12, EC50 = 1.28 
nM at human GPR55 (hGPR55)). 
 
 
Figure 3.2. Chromenopyrazoledione 3.11207 exhibited in vivo antitumor activity against human triple-
negative breast cancer tumours generated in mice. Chromenopyrazole 3.12208 is a selective GPR55 agonist. 
 
As has been discussed in chapter 1 (section 1.2.3.1), small molecule based fluorescent 
ligands consist of a high affinity ligand tethered to a fluorophore via a suitable length 
linker. At the time when this project commenced, the crystal structure of CB1R was not 
reported. SAR data available for the chromenopyrazoles indicated that the best position 
to introduce a linker would likely be around the pyrazole nucleus. Accordingly, the 
primary aim was to identify a robust position around the pyrazole nucleus for the 
conjugation of linkers to the chromenopyrazole scaffold.  
 
It was decided to prepare chromenopyrazole-linker conjugates with aryl or alkyl linkers 
attached to atoms belonging to pyrazole nucleus. Further, an O-alkylated 
chromenopyrazole was also designed as a potential CB1R chromenopyrazole-linker 
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conjugate. Five N-phenyl-chromenopyrazoles with a functional group attached at the 
para, meta and ortho position were designed to determine which position on the phenyl 
ring could tolerate attachment of substituents including that of long linkers (Figure 3.3). 
This was particularly important considering the difference in CBR binding affinity of N-
(meta, para-dichlorophenyl)-chromenopyrazole 3.3 and N-(ortho,para-dichlorophenyl)-
chromenopyrazole 3.4.  
 
 
Figure 3.3. New chromenopyrazoles designed as potential CB1R agonists. 
 
Among the N-phenyl-chromenopyrazoles designed were N-(para-(methylamine)-
phenyl)-chromenopyrazoles and N-(para-carboxyphenyl)-chromenopyrazoles. N-(para-
(methylamine)phenyl)-chromenopyrazoles have an amine-substituent/linker bonded with 
phenyl ring via a methylene sp3 carbon whereas N-(para-carboxyphenyl)-
chromenopyrazoles have an sp2 carbonyl carbon bonded carboxyl-substituent/linker with 
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a phenyl ring. The sp3 carbon in N-(para-(methylamine)phenyl)-chromenopyrazoles 
provides a greater degree of rotational freedom to the amine-substituent (or amine-linker) 
compared to the carboxy-substituent in N-(para-carboxyphenyl)-chromenopyrazoles. It 
was reasoned that this greater flexibility might be important for tolerance to a long linker-
chromenopyrazole in the CB1R binding site. 
 
As the ligand-binding pocket of CBRs is lipophilic, a series of N-(para-(4-
carboxypropyl)phenyl)-chromenopyrazoles with a short lipophilic alkyl chain separating 
the chromenopyrazole pharmacophore from longer linkers (PEG, peptide and alkyl) were 
designed (Figure 3.3). It was thought that this alkyl chain might also minimise any 
detrimental effect of bulky linkers on the CB1R binding affinity of the 
chromenopyrazoles. 
 
Two other N-phenyl-chromenopyrazoles were designed – N-(meta-(methylamine)-
phenyl)-chromenopyrazoles and N-(ortho-carboxyphenyl)-chromenopyrazoles (Figure 
3.3). Comparison of the binding affinity of N-(meta-(methylamine)phenyl)-
chromenopyrazoles and N-(para-(methylamine)phenyl)-chromenopyrazoles would be 
useful in determining the suitability of meta or para position for introduction of the longer 
linkers. 
 
N-(5-Carboxypentyl)-chromenopyrazoles and (C-3)-(6-aminohexyl)-chromenopyrazoles 
(linker attached at the third pyrazole position, Figure 3.3) were also designed. In the case 
of N-(5-carboxypentyl)-chromenopyrazoles, alkyl linkers would be attached from both 
N1 and N2 positions of the chromenopyrazole. (C-3)-Alkyl-chromenopyrazoles were 
designed on the basis of spatial closeness of C-3 carbon to the previously substituted N1 
and N2 of pyrazole (N-substituted 3.2, 3.3, 3.4, and 3.5 are high affinity CB1R agonists 
(Table 3.1)).  
 
It was planned that the final fluorescent ligands would be synthesised using a reliable 
amide coupling reaction between a pharmacophore-linker-amine and a fluorophore (for 
example BODIPY-630/650-SE; Figure 3.4). Initially, fluorescent ligands were only made 
with the BODIPY-630/650 fluorophore due to its previous success in developing other 
class A GPCR ligands,43, 86 high fluorescence quantum yield and emission in the red 
spectral region, thus allowing imaging studies with minimal interference from molecules 
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present in cells. If a high affinity CB1R chromenopyrazole-linker was developed, it could 
then be conjugated with different fluorophores (such as 1-(5-carboxypentyl)-3,3-
dimethyl-2-((1E,3E)-5-((E)-1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-3H-
indol-1-ium (Cy5), 5-(5,5-difluoro-7,9-dimethyl-5H-5λ4,6λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-3-yl)pentanoyl (BODIPY-FL), and TAMRA) to investigate the 
pharmacological and spectral properties of the resulting fluorescent ligands. Considering 
the time available for synthesis and biological evaluation, it was decided to prepare only 
a subset of compounds possible from a combination of different chromenopyrazole 
pharmacophores and linkers described in previous paragraphs, which depending on 
biological results could be refined to prepare a second generation of chromenopyrazoles.  
 
 




3.2 Synthesis and structural characterisation 
3.2.1    Synthesis of N-Phenyl-chromenopyrazoles 
3.2.1.1 Synthesis of N-(para-(methylamine)phenyl)-chromeno-
pyrazoles  
 
Following a literature procedure, condensation of mono-Boc-protected amine 2.12 
(synthesis described in chapter 2, section 2.2.1) with succinic anhydride gave the 
carboxylic acid linker 3.1386  (Scheme 3.1). 
 
  
Scheme 3.1. (i) Succinic anhydride, CHCl3, 65%. 
 
The commercially available diol 3.14 was reacted with 3,3-dimethylacrylic acid, 
methanesulfonic acid, and phosphorous pentoxide as described in a literature procedure137  
to provide 3.15 (Scheme 3.2). The first step of this reaction occurs via Friedel–Crafts 
acylation mechanism to provide an ortho-acylated diol,209 which then undergoes oxa-
Michael addition of the aromatic hydroxyl to acrylate to provide chromene 3.15. 
 
α–Formylation of 3.15 with ethyl formate using excess sodium hydride as a base afforded 
β-ketoaldehyde 3.16. This reaction was carried out according to a literature procedure137 
but used conventional heating instead of the reported microwave irradiation. An excess 
of sodium hydride was used to compensate for some of the base consumed in the 
deprotonation of the aromatic hydroxyl group of 3.15. β-Ketoaldehyde 3.16 is a key 
compound in this thesis and is used in subsequent synthetic schemes in chapters 3 and 4. 
Initial attempts to directly synthesise acid 3.19 by heating a mixture of 3.16 with 
commercially available 4-hydrazinobenzoic acid at 90 °C for 20 h provided a mixture of 
the reaction intermediate enehydrazinone 3.17 and cyclised acid 3.19 as determined by 
low-resolution mass spectrometry (MS). Protic acids such as H2SO4 have been previously 
used in the preparation of pyrazoles.210 Accordingly, it was decided to use H2SO4 to 
facilitate the formation of the pyrazole, that at the same time would esterify the carboxylic 
acid to give methyl ester  3.18, which would be easier to purify than a carboxylic acid. 
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Condensation of 3.16 with 4-hydrazinobenzoic acid in methanol with H2SO4 still gave a 
mixture of the reaction intermediate enehydrazinone 3.17 and cyclised acid 3.19 
(determined by MS) after 4 h of heating at 75 °C, but increasing the reaction time to 8 h 
provided ester 3.18 as the sole product (Scheme 3.2). 
 
 
Scheme 3.2. (i) 3,3-Dimethylacrylic acid, methanesulfonic acid, P2O5, 70 °C, 69%. (ii) Ethyl formate, 
NaH, 45 °C then 65 °C, 70%. (iii) 4-Hydrazinobenzoic acid, H2SO4, MeOH, 75 °C, 61%. (iv) aq. LiOH, 
THF:H2O, quantitative. (v) NH4Cl, HBTU, DIPEA, DMF, 81%. (vi) LiAlH4, THF, 70 °C. (vii) 3.13, 
HBTU, DIPEA, DMF, 34%. (viii) TFA, DCM, quantitative. (ix) BODIPY-630/650-SE, DIPEA, DMF, 
quantitative. 
 
Conversion of 3.16 to give 3.18 is an example of the Knorr pyrazole synthesis, which first 
involved condensation of the primary amine of 4-hydrazinobenzoic acid and the aldehyde 
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of 3.16 to give enehydrazinone 3.17, followed by condensation of the secondary amine 
and ketone to yield 3.18 (Scheme 3.2). Although two regioisomers can be formed via 
condensation of an unsymmetrical hydrazine with β-ketoaldehyde 3.16 (Figure 3.5), only 
the N1 regioisomer was isolated upon condensation of 4-hydrazinobenzoic acid with 3.16. 
Analysis via RP-HPLC of the optimised crude reaction mixture and subsequent analysis 
of RP-HPLC fractions by MS indicated formation of only one compound with a 
molecular weight corresponding to 3.18 (Scheme 3.2), however this does not reveal 
information regarding the identity of regioisomer. 
 
Investigation of the potentially regioisomeric nature of 3.18 by 2D (two dimensional) 
NMR techniques such as gHMBC was inconclusive. Comparison of 1H and 13C NMR 
chemical shifts of 3.18 with reported chromenopyrazoles (3.2, 3.3, 3.4, 3.5, 3.7 and 3.8) 
supported the structure of 3.18 as the N1 regioisomer. In particular, this assignment was 
based on NMR data reported by Cumella et al.137, which revealed that 1H and 13C 
chemical shifts of H-3 and C-3 nuclei of N1 chromenopyrazoles are upfield by at least 
0.2 parts per million (ppm) and 9.0 ppm respectively, as compared to the N2 isomers. 
Chemical shifts of atoms of pyrazole ring (especially H-3 (7.45 ppm) and C-3 (13C = 
134.90 ppm)) of 3.18 were closer to N1 chromenopyrazole regioisomers than N2 isomers 
reported by Cumella et al.137 In subsequent syntheses (Schemes 3.5, 3.7 and 3.8), only 
the N1 regioisomer (assigned using chemical shift comparison with chromenopyrazole 
regioisomers reported by Cumella et al.137) was isolated on condensation of 3.16 with 
aryl hydrazines (for example 3.29 in Scheme 3.5, 3.41 in Scheme 3.7, and 3.48 in Scheme 
3.8) or with 6‐hydrazinylhexanoic acid (6‐hydrazinylhexanoic acid was used in Scheme 
3.11 to prepare 3.51). Later, N2-alkyl-chromenopyrazole 3.59 (Scheme 3.12) was also 
prepared. The structure of 3.51 as the N1 regioisomer and 3.59 as the N2 regioisomer 








Figure 3.5. Two possible regioisomeric pyrazoles that can form from condensation of 3.16 with hydrazine 
derivatives via the Knorr pyrazole synthesis.  
 
Formation of the N1 instead of the N2 regioisomer is likely due to the steric hindrance of 
the secondary amine compared to the primary amine in the case of arylhydrazines and 
long alkyl chain hydrazine 3.51 (synthesis shown in Scheme 3.11). In the case of 
arylhydrazines, the secondary amine is also less nucleophilic compared to the primary 
amine hence disfavouring the formation of the N2 regioisomer. Formation of only the N1 
regioisomer with aryl hydrazines and cyclohexylhydrazine was also reported by Cumella 
et al.137, while they obtained both N1 and N2 regioisomers upon reaction of methyl and 
ethyl hydrazine with 3.16. In this PhD thesis, 6‐hydrazinylhexanoic acid (as used in 
Scheme 3.11 to prepare 3.51) is a bulkier alkyl hydrazine similar to cyclohexylhydrazine 
used by Cumella et al.137 and favoured the formation of only the N1 regioisomer.  
 
The synthesis continued with hydrolysis of the methyl ester 3.18 with aq. LiOH, which 
provided the carboxylic acid 3.19 (Scheme 3.2). This was then reacted with ammonia, 
using HBTU as a coupling reagent and NH4Cl as a source of ammonia in the presence of 
DIPEA to prepare benzamide 3.20. Reduction of 3.20 with LiAlH4 in refluxing THF 
provided benzylamine 3.21, which was not purified and used as such in the next reaction. 
Benzylamine 3.21 was coupled with carboxylic acid linker 3.13 using HBTU as coupling 
reagent and DIPEA as base to provide chromenopyrazole 3.22. The lower yield obtained 
in the synthesis of 3.22 and subsequent linker conjugates (3.32 (Scheme 3.5), 3.45 
(Scheme 3.7), 3.53 (Scheme 3.11)) is likely due to the loss of the polar product during 




Boc-deprotection of 3.22 with TFA, followed by semi-preparative RP-HPLC purification 
of the amino trifluoroacetate salt then reaction with the commercially available 
fluorophore BODIPY-630/650-SE using DIPEA as a base provided the fluorescent ligand 
3.23 in a quantitative yield.  
 
The calculated yield for the reaction of commercially available BODIPY-630/650-SE 
with amine linker conjugates to give fluorescent ligands was more than quantitative in 
some cases. It is believed that this is due to the commercial supply of BODIPY-630/650-
SE in slightly higher amounts than that specified on the container (the amount of 
fluorophore specified on the container was used in the calculation of yield). BODIPY-
630/650-SE is moisture and light sensitive so was not weighed accurately but instead 
DMF was added to the commercial bottle and used directly in the coupling reactions. 
Other members of the Vernall research group have observed greater than quantitative 
yields of the coupling reactions with the same commercially available fluorophore and 
pack size. Lower yield of the coupling reaction observed for the preparation of fluorescent 
ligand 3.46 (Scheme 3.7) and fluorescent ligand 3.54 (Scheme 3.11) is likely due to the 
loss of the compound during semi-preparative RP-HPLC purification. 
 
It was reasoned that pharmacological comparison of a short linker conjugate such as 3.25 
(Scheme 3.3) with long linker conjugate 3.22 (Scheme 3.2) would provide useful 
information regarding the effect of linker length on the affinity of chromenopyrazole-
linker conjugates for CBRs. So, preparation of 3.25 commenced with reaction of 3.21 
with acetic anhydride, which provided N,O-diacetylated product 3.24 and N-acetylated 
product 3.25, as determined by MS and 1H NMR spectroscopy. The ratio of N,O-
diacetylated product 3.24 to N-acetylated product 3.25 was approximately 3:1 
(determined by 1H NMR spectra analysis of the crude mixture). The mixture of 3.24 and 
3.25 was then subjected to alkaline hydrolysis conditions to give 3.25 (Scheme 3.3). 
Chemoselective hydrolysis of the ester functional group in 3.24 and the presence of an 
amide in 3.25 is supported by combined MS and NMR experiments (gHMBC correlation 
between benzylic protons and acetyl carbonyl carbon (Figure 3.6)). Formation of the N-
acetylated product 3.25 and N,O-diacetylated product 3.24 is in contrast to formation of 
only N-acylated product in the case of 3.23 (section 3.2.1.1). This is likely due to lower 
electrophilicity of HBTU-activated carboxylic acid 3.13 compared to acetic anhydride 
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and due to a lower amount of 3.13 (1 equivalent) than acetic anhydride (3 equivalents), 
used in the reaction with amine 3.21. 
 
 





Figure 3.6. Evidence for 3.25 as an N-acetylated product - gHMBC spectrum of 3.25 in CDCl3, correlation between H-32 and C-34 is circled. 
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3.2.1.2 Synthesis of tert‐butyl N‐(2‐{2‐[2‐({4‐[9‐hydroxy‐4,4‐
dimethyl‐7‐(2‐methyloctan‐2‐yl)‐1H,4H‐chromeno[4,3‐c]pyrazol‐1‐yl] 
phenyl}formamido) ethoxy]ethoxy}ethyl) carbamate 
 
As discussed in section 3.1, comparison of CB1R binding affinity of 3.22 and 3.26 will 
provide information about the effect of flexibility at the point of linker attachment. 3.26 
was prepared by coupling 3.19 with linker 2.12 (synthesis described in chapter 2, section 
2.2.1) using HATU as coupling reagent and DIPEA as a base (Scheme 3.4).   
 
 
Scheme 3.4. (i) 2.12, HATU, DIPEA, DMF, 60%. 
 
3.2.1.3 Synthesis of N-(para-(4-carboxypropyl)phenyl)-
chromenopyrazoles  
 
Synthesis of this series began with reaction of commercially available 3.27 with sodium 
nitrite and hydrochloric acid to generate a diazo compound, which was reduced in situ 





Scheme 3.5. (i) HCl aq., NaNO2, SnCl2.2H2O, 120 °C to -5 °C to -20 °C, 50%. (ii) H2SO4, MeOH, 75 °C, 
43%. (iii) LiOH, THF, H2O, 91%. (iv) 2.10 or 2.12, HBTU, DIPEA, DMF, 53-72%. (v) TFA, DCM, 
quantitative. (vi) BODIPY-630/650-SE, DIPEA, DMF, 88%.  
 
Condensation of 3.28 with 3.16 using conditions optimised for the synthesis of 3.18 
(Scheme 3.2) gave chromenopyrazole ester 3.29 as the N1 regioisomer, which on 
hydrolysis with aqueous LiOH provided carboxylic acid 3.30. Reaction of 3.30 with 
mono-Boc-protected 2.10 or 2.12 (synthesis described in chapter 2, section 2.2.1) gave 
PEG or alkyl chromenopyrazole-linker conjugates 3.31 and 3.32 respectively. Boc-
protected 3.32 was treated with TFA to give the Boc-deprotected 3.32, which after semi-
preparative RP-HPLC purification was reacted with BODIPY-630/650-SE to provide 
fluorescent ligand 3.33. 
 
Fmoc solid-phase peptide synthesis was used to synthesise peptide-linked 3.38, which is 
an analogue of 3.31 and 3.32 (Scheme 3.5). Reaction of 1,2-diaminoethane trityl resin 
3.34 with Fmoc-Ala-OH, HBTU and DIPEA gave resin-bound 3.35 (Scheme 3.6). 
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Coupling of Fmoc-Ala-OH with 1,2-diaminoethane trityl resin 3.34 was repeated to 
maximise resin loading. The resin was then capped by reacting any unreacted resin-
primary-amine sites with Ac2O in DMF. The amount of Fmoc-Ala bound to the resin was 
determined by an Fmoc loading test (details in chapter 7, section 7.3.1) and was found to 
be 0.78 mmol/g. Fmoc deprotection of resin-bound 3.35 with a solution of piperidine in 
DMF (20% v/v), followed by reaction with Fmoc-Ala-OH, HBTU and DIPEA gave resin-
bound 3.36. Resin-bound 3.36 was again subjected to Fmoc deprotection using a solution 
of piperidine in DMF (20% v/v) and then the free primary amine was coupled with 
carboxylic acid 3.30 (Scheme 3.5) using HATU and DIPEA to give resin bound 3.37. 
Cleavage from the trityl resin was performed by treating resin-bound 3.37 with TFA. 
Peptide linker conjugate 3.38 thus obtained was purified using semi-preparative RP-
HPLC and then reacted with acetic anhydride or BODIPY-630/650-SE in separate 






Scheme 3.6. (i) Fmoc-Ala-OH, HBTU, DIPEA, DMF. (ii) Fmoc-Ala-OH, HBTU, DIPEA, DMF (double 
coupling). (iii) Ac2O, DIPEA DMF. (iv) Piperidine, DMF. (v) 3.30, HATU, DIPEA, DMF. (vi) TFA, DCM. 




3.2.1.4 Synthesis of N-(meta-(methylamine)phenyl)-chromeno-
pyrazoles  
 
Synthesis of this series of compounds, including 3.47 and fluorescent ligand 3.46 
(Scheme 3.7), was carried out using similar methodology as described in section 3.2.1.1. 
Condensation of 3.16 with 3-hydrazinobenzoic acid hydrochloride provided 3.41 as the 
N1 regioisomer. Hydrolysis of 3.41 with aqueous LiOH gave carboxylic acid 3.42, which 
was reacted with NH4Cl to give benzamide 3.43. Reduction of benzamide 3.43 with 
LiAlH4 gave benzylamine 3.44 (compound not purified), which on coupling with 
carboxylic acid 3.13 gave chromenopyrazole 3.45. Boc-deprotection of 3.45 with TFA, 
followed by reaction of the semi-preparative RP-HPLC purified amino trifluoroacetate 
salt with BODIPY-630/650-SE gave fluorescent ligand 3.46. As observed for 3.21 
(Scheme 3.3), acetylation of benzylamine 3.44 with Ac2O gave a mixture of N,O-
diacetylated product and N-acetylated product, which on alkaline hydrolysis with aqueous 




Scheme 3.7. (i) 3-Hydrazinobenzoic acid hydrochloride, H2SO4, MeOH, 75 °C, 49%. (ii) LiOH, THF:H2O, 
93%. (iii) NH4Cl, HBTU, DIPEA, DMF, 78%. (iv) LiAlH4, THF, 70 °C. (v) 3.13, HBTU, DIPEA, DMF, 
37%. (vi) TFA, DCM, quantitative. (vii) BODIPY-630/650-SE, DIPEA, DMF, 14%. (viii) Ac2O, Et3N, 
DCM. (ix) NaOH, MeOH, 36% over two steps. 
 
3.2.1.5 Synthesis of N-(ortho-carboxyphenyl)-chromenopyrazoles  
 
It was decided that only one compound (3.48, Scheme 3.8) would be made for this series 
and depending on the biological results, further 3.48-linker conjugates could be prepared 
as a second generation of compounds. The N-(ortho-carboxyphenyl)-chromenopyrazole 
3.48 was prepared by condensation of β-ketoaldehyde 3.16 with commercially available 
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2-hydrazinobenzoic acid. This reaction was carried out according to the optimised 
procedure for 3.18 (Scheme 3.2). As in the case of 3.18 (Scheme 3.2), chromenopyrazole 
3.48 was obtained as an N1 regioisomer. 
 
 
Scheme 3.8. (i) 2-Hydrazinobenzoic acid, H2SO4, MeOH, 75 °C, 41%. 
 
3.2.1.6 Synthesis of 1-(2,4-dichlorophenyl)-4,4-dimethyl-7-(2-
methyloctan-2-yl)-1,4-dihydrochromeno[4,3-c]pyrazol-9-ol (3.4) 
 
Chromenopyrazole 3.4 is a high affinity chromenopyrazole CB1R agonist previously 
reported in the literature by Cumella et. al.137 Chromenopyrazole 3.4 was synthesised to 
use as a literature control in pharmacological experiments (section 3.3.1). It was 
synthesised by condensing 3.16 with commercially available (3,4-










3.2.2 Synthesis of N- and O- alkyl-chromenopyrazoles 
3.2.2.1 Synthesis of N-(5-carboxypentyl)-chromenopyrazoles 
 
Synthesis of these compounds began with preparation of hydrazine acid 3.50 (Scheme 
3.10). Initially, Et3N or Ba(OH)2.8H2O were used as bases in the substitution reaction of 
bromo carboxylic acid 3.49 with hydrazine hydrochloride due to the ease of removal from 
the reaction mixture. However, the reaction was likely unsuccessful due to the weak 
basicity of Et3N or low solubility of Ba(OH)2.8H2O in water. Compound 3.50 was instead 
synthesised from reaction of 3.49 and hydrazine hydrochloride using NaOH as the base. 
Hydrazine acid 3.50 is an amphoteric compound with high water solubility and low 
solubility in non-polar solvents. Removal of excess hydrazine hydrochloride from crude 
3.50 present in the reaction mixture proved difficult and attempts to use crude 3.50 
contaminated with hydrazine hydrochloride in the condensation reaction with 3.16 
resulted in the formation of 3.57 (condensation product of 3.16 and hydrazine, synthesis 
shown in Scheme 3.12) as the sole product. Finally, hydrazine was removed from crude 
3.50 by repeated co-evaporation of the alkaline reaction mixture with water, acidification 
of the residual mixture to pH 2.0-3.0 and extraction of 3.50 with a mixture of 
EtOH:EtOAc (25% v/v).  
 
 
Scheme 3.10. (i) NH2NH2.HCl, Et3N, dioxane, H2O, 90 °C or NH2NH2.HCl, Ba(OH)2.8H2O, THF, H2O, 
90 °C. (ii) NH2NH2.HCl, NaOH, dioxane, water, 90 °C, HCl(aq.), 61%. 
 
Condensation of hydrazine acid 3.50 with 3.16 provided hydrazine ester 3.51 (Scheme 
3.11). Although a compound corresponding to molecular weight of 3.51 was the only 
major compound isolated, as discussed previously for 3.18 (section 3.2.1.1), it could be 
either the N1 or N2 regioisomer. Consequently, the structure of hydrazine ester 3.51 was 
investigated by 2D-NMR spectroscopy. gHMBC spectrum showed a correlation between 
H-17 and C-10 of 3.51 thus supporting that 3.51 was the N1 regioisomer (Figure 3.7). In 
addition, a gHMBC correlation was not observed between H-17 and C-13, which would 
have supported the structure of 3.51 as N2 regioisomer. The N2 regioisomer of 3.51 was 





Scheme 3.11. (ii) 3.50, H2SO4, MeOH, 75 °C, 42%. (ii) LiOH, THF:H2O, 81%. (iii) 2.12, HATU, DIPEA, 
DMF, 39%. (iv) TFA, DCM, quantitative. (v) BODIPY-630/650-SE, DIPEA, DMF, 37%. 
 
Basic hydrolysis of hydrazine ester 3.51 with aq. LiOH provided carboxylic acid 3.52. 
An amide coupling of 3.52 with 2.12 using HATU as coupling reagent yielded linker 
conjugate 3.53. Boc-deprotection of 3.53 with TFA and coupling reaction of the resulting 
semi-preparative RP-HPLC purified amine trifluoroacetate salt with BODIPY-630/650-




Figure 3.7. Evidence of N1-alkylation alkyl product 3.51 - gHMBC spectrum of 3.51 in CDCl3, correlation between H-17 and C-10 is circled. 
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3.2.2.2 Synthesis of O-(5-carboxypentyl)-chromenopyrazoles  
 
It was planned that alkylation of the aromatic hydroxyl of 3.57 (Scheme 3.12) with bromo 
ester 3.56 would provide O-alkyl-chromenopyrazoles 3.58. It was decided to initially just 
synthesise and test O-linked chromenopyrazole 3.58 and depending on the biological data 
a fluorescent derivative could then be made. Some issues of chemoselectivity were 
expected from this strategy as chromenopyrazole 3.57 can undergo either N- or O- 
alkylation by substitution of bromide or react with the ester of 3.56. Nevertheless, 
alkylated products can be easily identified from ester reacted products by MS owing to 
different molecular masses.  
 
Bromo ester linker 3.56 was prepared by esterification of commercially available 3.55. 
Condensation of 3.16 with hydrazine hydrochloride gave chromenopyrazole 3.57. An 
initial attempt to alkylate 3.57 with linker 3.56 using NaH as a base proved fruitless as 
thin-layer chromatography (TLC) and MS indicated the presence of mostly unreacted 
3.57 along with formation of a small amount of new compound with molecular mass 
corresponding to hydrolysed esters of 3.58 or 3.59. This is most likely due to basic 
hydrolysis of 3.58 or 3.59 by reaction with NaOH, formed by reaction of NaH with trace 
moisture or during the aq. work up. 
 
Next, alkylation of 3.57 with methyl 6-bromohexanoate 3.56 using caesium carbonate 
was attempted. TLC analysis of the reaction mixture showed formation of a higher TLC 
retention factor (Rf) spot and a lower TLC Rf spot compared to TLC Rf of starting material 
3.16. Column purification to isolate each spot, followed by MS indicated both compounds 
possessed a mass corresponding to an alkylated product. NMR experiments were carried 
out to determine the structure of these compounds, which indicated the higher TLC Rf 
compound to be N2-alkylated 3.59 and the lower TLC Rf compound to be O-alkylated 
3.58. This conclusion was based on the gHMBC correlation of H-17 and C-13 of N2-
alkylated 3.59 (Figure 3.8), versus the gHMBC correlation between H-17 and C-1 in case 




Scheme 3.12. (i) H2SO4, MeOH, 70 °C, 63%. (ii) NH2NH2.HCl, H2SO4, MeOH, 75 °C, 83%. (iii) 3.56, 








Figure 3.9. Evidence for O- alkylation gHMBC spectrum of 3.58, correlation between H-17 and C-1 is circled.   
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3.2.2.3 Attempted synthesis of (C-3)-(6-aminohexyl)-
chromenopyrazoles  
 
It was envisaged that α-acylation of ketone 3.15 with an acylating reagent (for example 
Weinreb amide 3.62) would provide diketone chromenopyrazole 3.63, which could be 
reacted with hydrazine to provide (C-3)-(6-aminohexyl)-chromenopyrazole 3.64 
(Scheme 3.13). Although the aromatic hydroxyl of 3.15 might react with acylating agents, 
previously successful formylation of 3.15 despite an unprotected hydroxyl (Scheme 3.2) 
indicated that acylation without protecting the hydroxyl of 3.15 might be possible. 
 
Hence, Boc-protection of amino heptanoic acid 3.60 gave 3.61, which was reacted with 
N,O-dimethylhydroxylamine hydrochloride using HBTU to provide the Weinreb amide 
3.62 (Scheme 3.13). Attempts to acylate 3.15 with 3.62 using NaH or n-BuLi as the base 
were unsuccessful and starting compound 3.15 was recovered. It was thought that failure 
of this reaction might be due to low reactivity of Weinreb amide 3.62. Therefore, alternate 
acylating reagent succinimidyl ester 3.65 was prepared by reaction of 3.61 with N-
hydroxysuccinimide. Unfortunately, acylation of 3.15 with 3.65 using NaH or n-BuLi as 
base didn’t succeed either and starting compound 3.15 was recovered. Another alternative 
acylating reagent was synthesised by reaction of 3.61 with TFFH and Et3N to provide the 
in situ generated acid fluoride of 3.61 (not shown in Scheme 3.13), which was neither 
purified nor characterized by spectroscopic techniques. However, reaction of 3.15 with 
the acid fluoride of 3.61 using NaH as base (not shown in Scheme 3.13) provided a new 
compound which was determined by 1H NMR spectroscopy and MS to be a compound 
other than the desired product 3.63. The structure of this new compound could not be 
determined. Failure of the acylation reaction of 3.15 with 3.62, 3.65, and the acid fluoride 
of 3.61 might be due to the low electrophilicity of the acylating reagents, or due to side 
reactions of these acylating reagents with the hydroxyl of 3.15 or with the bases 
employed. O-Protection of 3.15 (for example by a benzyl group) might be more 




Scheme 3.13. (i) (Boc)2O, NaOH, Dioxane, water, 98%. (ii) N,O-Dimethylhydroxylamine hydrochloride, 
HBTU, DIPEA, THF, 85%. (iii) N-Hydroxysuccinimide, HBTU, DIPEA, DMF, 91%. (iv) NaH, THF, 60 
°C (v) n-BuLi, THF, -78 °C.  
 
Another approach to synthesise C-3-linker-chromenopyrazoles could involve coupling of 
linkers with a 3-amino-chromenopyrazole (likely obtainable by reaction of α-cyano 
derivative of ketone 3.15 with hydrazine; a similar method was reported for the synthesis 
of some aminothiazoles211). However, based on the biological results of newly 
synthesised chromenopyrazoles (section 3.3.1), synthesis of this series of compounds was 







3.3 Biological studies 
3.3.1 Radioligand binding assays 
 
Due to the time constraint of being able to visit the collaborator’s laboratory for only a 
few weeks over summer, it was decided to evaluate a planned subset of the 
chromenopyrazoles described in section 3.2 for determining the binding affinity and 
functional activity at CBRs. Selection of these chromenopyrazoles was done with the aim 
of obtaining meaningful SAR data which could be used in the design of a second 
generation of high affinity chromenopyrazoles.  
 
A commonly used CBR radioligand, [3H]-CP55,940 (described in chapter 1, section 
1.2.1), was used to determine the affinity of synthesised chromenopyrazoles at membrane 
preparations derived from HEK-293 cells transfected with either CB1R or 
CB2R according to a previously described method.
169, 212 An initial screen of 
chromenopyrazoles (3.4, 3.18, 3.19, 3.22, 3.23, 3.25, 3.26, 3.29, 3.31, 3.32, 3.33, 3.39, 
3.40, 3.41, 3.45, 3.46, 3.47, 3.48, 3.51, 3.53, 3.54, 3.58 and 3.59) at 10 µM was carried 
out to determine the percentage displacement of [3H]-CP55,940 from CBRs (Figure 3.10, 
panels A and B) in a competition radioligand binding assay. Compounds that displaced 
[3H]-CP55,940 from both CBRs by more than 50% at a 10 µM concentration were then 
analysed in a concentration-dependent way to determine concentration response curves 
and calculate binding affinity (Ki). When there was no significant difference between 
displacement of [3H]-CP55,940 by a test compound (at concentration of 10 µM) 
compared to vehicle, a compound Ki was reported as no binding (Table 3.2, Figure 3.10, 
panel A and B). Some compounds exhibiting weak affinity for CBRs were reported as 
having Ki >5000 nM, which was calculated as described in the following paragraph. 
 
The radioligand [3H]-CP55,940 with a Kd (equilibrium dissociation constant) of 3 nM at 
CB1R was used at 2.5 nM concentration in the radioligand assay carried out for CB1R. 
The Ki of the test compounds (with IC50 of 10 µM for the compounds displacing 50% of 








= 5.45 µM 
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So, for the test compounds which displaced less than 50% of total [3H]-CP55,940 at 10 
µM at CB1R, Ki was reported as >5000 nM (Ki value rounded off to account for the 
experimental errors) (Table 3.2). Similarly, for the test compounds which displaced less 
than 50% of total [3H]-CP55,940 at 10 µM at CB2R, Ki was reported as >5000 nM 
(calculated for [3H]-CP55,940 used at a concentration of 1 nM and with Kd  of 1.7 nM for 
CB2R). 
 
It was unexpected that the high reported affinity of CB1R selective literature compound 
3.4 (Ki = 5.2 ± 6 nM at hCB1R; >40000 nM at hCB2R)
137 could not be reproduced in this 
study (Table 3.2, last entry). In this PhD thesis, 3.4 (Ki = 499.9 ± 40 nM at hCB1R; 162.5 
± 68 nM at hCB2R) exhibited higher affinity for CB2R over CB1R. As membrane 
preparations obtained from HEK-293 cells expressing CB1R or CB2R and [
3H]-CP55,940 
was used as radioligand both in this thesis and by Cumella et al.137, the reason for this 





Figure 3.10. Radioligand binding assay: Screen of synthesised chromenopyrazoles at 10 µM at HEK-293 cells expressing hCB1R (panel A) or hCB2R (panel B), with [3H]-
CP55,940 as the radioligand. Data represented is from a single experiment carried out in triplicate and is expressed as mean ± SEM. V (vehicle), CP (CP55,940). 
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Table 3.2 continued 
Compound Structure 
hCB1R Ki (nM ± 
SEM)* 






> 5000 1434 ± 370.2 >3 
3.59 
 
4200 ± 594 1016 ± 173 4 
3.58 
 
1371 ± 309 2031 ± 582 0.6 
3.18 
 
> 5000 435.6 ± 63.1 >11 
3.19 
 
> 5000 > 5000 - 
3.41 
 
> 5000 274.5 ± 42.7 >18 
3.48 
 
2343 ± 906 304.5 ± 44.8 7 
3.4 
 
499 ± 40 162.5 ± 68 3 
 
*Binding affinity (Ki) obtained by competition binding assay performed on membranes obtained from HEK-
293 cells expressing either hCB2R or hCB1R with [3H]-CP55,940 (Kd = 1.7 nM for hCB2R and 3.0 nM for 
hCB1R). All data is from at least three individual experiments performed in triplicate, except a which is two 
individual experiments performed in triplicate. 
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3.3.2 SAR discussion of cannabinoid type 2 receptor binding 
affinity data of chromenopyrazoles 
 
None of the chromenopyrazoles other than the literature chromenopyrazole 3.4 (Ki = 499 
± 40 nM at hCB1R) tested in this chapter exhibited appreciable affinity for CB1R (Table 
3.2). Widely used CBR ligand CP55,940 (Ki = 4.53 ± 0.22 nM at hCB1R; Ki = 1.66 ± 0.31 
nM at hCB2R) was used as a positive control in this study. CP55,940 exhibited affinity 
for CBR  in agreement with a recent literature report (pKi = 9.26 ± 0.12 nM at hCB1R, 
(Ki = 0.55 nM)) and (pKi = 8.44 ± 0.18 nM at hCB2R (Ki = 3.63 nM)).
119 As the majority 
of these chromenopyrazoles revealed high affinity and selectivity for CB2R over CB1R, 
the following SAR discussion will primarily be derived from the comparison of the CB2R 
affinities.  
 
N-(para-(Methylamine)phenyl)-chromenopyrazole 3.25 (Ki = 13.2 ± 3.4 nM at hCB2R; > 
1000 nM at hCB1R) exhibited the highest affinity and selectivity for CB2R over CB1R 
among all the tested chromenopyrazoles (Table 3.2; competition binding curve for 3.25 
shown in Figure 3.11). The analogue of 3.25 with a PEG linker, 3.22 (Ki = 71.1 ± 6.7 nM 
at hCB2R; >5000 nM at hCB1R; competition binding curve for 3.22 shown in Figure 3.11) 
exhibited the highest affinity and selectivity (CB2R:CB1R selectivity of 70) for CB2R 
among the chromenopyrazole-linker conjugates tested in this chapter. This tolerance of 
the long PEG linker in 3.22 was an exciting result and provided a promising lead 
compound to prepare high affinity CB2R fluorescent ligands. However disappointingly, 
the BODIPY-630/650 analogue 3.23 (Ki = 2312 ± 298 nM at hCB2R) provided only a 
moderate affinity fluorescent ligand, which showed approximately 32-fold reduced CB2R 
binding affinity compared to 3.22. Although the reasons for this reduction in the CB2R 
binding affinity are not known, it is likely due to the steric clashes of the bulky BODIPY-
630/650 of 3.23 with the CB2R amino acid residues. The fluorescent ligand 3.23 did not 




Figure 3.11. Competition binding curves for the highest affinity CB2R chromenopyrazole 3.25, the highest 
affinity CB2R chromenopyrazole-linker conjugate 3.22 and CP (CP55,940) using radioligand [3H]-
CP55,940 (Kd = 1.7 nM for hCB2R) at HEK-293 cells expressing hCB2R. Data represented is from a single 
experiment carried in triplicate and is expressed as mean ± SEM. 
 
N-(para-(4-Carboxypropyl)phenyl)-chromenopyrazole 3.29 (Ki = 251.5 ± 21 nM at 
hCB2R; 2220 ± 316 nM at hCB1R) exhibited high affinity for CB2R  and moderate affinity 
for CB1R. The three different linker (alkyl, PEG and Ala-Ala peptide) conjugates of 3.29 
provided high affinity and selective CB2R ligands 3.31 (Ki = 148.9 ± 15.5 nM at hCB2R; 
>5000 nM at hCB1R), 3.32 (Ki = 104.6 ± 39.9 nM at hCB2R; 3716 ± 1202 nM at hCB1R) 
and 3.39 (Ki = 138.4 ± 6.75 nM at hCB2R; >5000 nM at hCB1R) respectively. 
Remarkably, 3.31, 3.32 and 3.39 contain three different types of linkers but still exhibited 
similar high affinities at CB2R. Although the specific reasons for this similar high affinity 
for CB2R of the 3.29-linker conjugates (3.31, 3.32 and 3.39) are not known, it might be 
due to the presence of the long linkers extended from 3.29 in the extracellular space, out 
of the ligand-binding pocket of CB2R (refer to section 3.4 for computational studies). The 
high affinities at CB2R of 3.29-linker conjugates (3.31, 3.32 and 3.39) and the tolerance 
of the linker to change make these ligands highly promising leads for developing the 
CB2R fluorescent ligands. The BODIPY-630/650 conjugates of 3.39 and 3.32 gave 
moderate affinity fluorescent ligands 3.40 (Ki = 2693 ± 302 nM at hCB2R) and 3.33 (Ki 
= 3996 ± 612 nM at hCB2R) respectively. Similar to 3.23, decreased binding affinity of 
3.39 and 3.32 is likely due to steric clashes of BODIPY-630/650 with CB2R amino acid 




N-(meta-(Methylamine)phenyl)-chromenopyrazole 3.47 (Ki = 397.3 ± 40.5 nM at 
hCB2R) exhibited moderate to high affinity for CB2R. Extension of PEG linker from 3.47 
provided 3.45 (Ki = 1277 ± 94.3 nM at hCB2R), a moderate affinity CB2R ligand with 
three times reduced CB2R affinity compared to 3.47. This decrease in CB2R affinity upon 
attachment of PEG linker to parent chromenopyrazole was also observed in case of 3.22. 
Fluorescent ligand 3.46, a BODIPY-630/650 conjugate of 3.45, did not exhibit any 
significant binding at either CBR.  
 
N1-Alkyl-chromenopyrazole 3.51 (Ki = 101 ± 13 nM at hCB2R; 964 ± 372 nM at hCB1R) 
exhibited high affinity for CB2R and moderate affinity for CB1R. The 3.51 PEG linker 
conjugate 3.53 (Ki = 1291 ± 303.6 nM at hCB2R) exhibited reduced binding affinity for 
CB2R by approximately 12-fold compared to 3.51. This decrease in CB2R affinity upon 
attachment of long linker was also observed in case of 3.22 and 3.45. The 3.53 BODIPY-
630/650 conjugate 3.54 did not exhibit any significant binding at CBRs likely due to steric 
clashes of BODIPY-630/650 with CB2R amino acid residues in line with other fluorescent 
ligand trends.  
 
N-(para-Carboxyphenyl)-chromenopyrazole 3.26 (Ki = 1434 ± 370.2 nM at hCB2R) 
showed moderate affinity for CB2R, which was 20-fold less than the binding affinity of 
the highest overall chromenopyrazole-linker conjugate 3.22. Reasons for this difference 
could be that the linker of 3.26 is bonded to the chromenopyrazole pharmacophore by a 
sp2 carbon atom whereas 3.22 contains a sp3 carbon atom linking directly to the 
pharmacophore. This difference in attachment by different carbon types provides a higher 
flexibility to the attached linker in case of 3.22 compared to 3.26. Another difference is 
the linker length and chemical functionality – the PEG linker of 3.26 is five atoms shorter 
and contains one less amide functional group than 3.22. These differences provide a 
longer linker and additional hydrogen bonding atoms in case of 3.22 which might also be 
responsible for the higher binding affinity of 3.22 compared to 3.26.  
 
N2-Alkyl-chromenopyrazole 3.59 (Ki = 1016 ± 173 nM at hCB2R) exhibited 10-fold 
reduced affinity for CB2R compared to N1-alkyl-chromenopyrazole 3.51 (Ki = 101 ± 13 
nM at hCB2R). Reasons for this difference in the CB2R affinity is not known but might 
be due to the steric clashes of linker attached in 3.59 with the CB2R amino acid residues. 
O-Alkyl chromenopyrazole 3.58 (Ki = 1371 ± 309 nM at hCB1R; 2031 ± 582 nM at 
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hCB2R) displayed moderate affinity for CB1R and CB2R. Although N- and O- alkyl 
chromenopyrazole–linker conjugates (such as 3.2, 3.5, 3.9, and 3.10; Table 3.1) with short 
linkers have been reported in literature,137, 205 none of the reported compounds contain 
linkers of six atoms or longer as described in this chapter. These CB2R affinity data 
indicated that N- and O-  alkyl chromenopyrazole–linker conjugates are not suitable leads 
for developing CB2R fluorescent ligands. 
 
Among the N-(methoxycarbonylphenyl)-chromenopyrazoles (3.18, 3.41 and 3.48), 3.41 
(Ki = 274.5 ± 42.7 nM at hCB2R) exhibited the highest affinity for CB2R, and none of the 
three compounds exhibited high affinity for CB1R. Chromenopyrazole 3.19, a carboxylic 
acid derivative of 3.18, did not exhibit any significant binding at CB1R or CB2R. 
Chromenopyrazole 3.19 would exist predominantly in an ionised form (RCO2
-) at 
physiological pH and thus this charge would likely disrupt binding at the lipophilic 
binding pocket of CBRs, which might explain low affinity of 3.19 compared to 3.18.  
 
 
Figure 3.12. Competition binding curve for fluorescent ligands 3.40, 3.33, 3.23, and literature CBR 
agonist CP (CP55,940) using [3H]-CP55,940 (Kd = 1.7 nM for hCB2R) at HEK-293 cells expressing 
hCB2R. Data represented is from a single experiment carried in triplicate and is expressed as mean ± 
SEM. 
 
Chromenopyrazole 3.51 showed the highest affinity for CB1R whereas 3.25 exhibited 
highest affinity for CB2R among all the novel chromenopyrazoles synthesised. None of 
the fluorescent ligands synthesised by conjugation of chromenopyraozle-linker-
conjugates with BODIPY-630/650 exhibited any significant binding at CB1R however 
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3.23, 3.33, and 3.40 exhibited moderate affinity for CB2R (Figure 3.12). Among the 
moderate affinity fluorescent ligands, 3.23, a 3.22-BODIPY-630/650 conjugate displayed 
the highest affinity (although still only moderate). 
 
Comparison of 3.25 with 3.18, 3.22 with 3.26 and 3.47 with 3.41 indicated that atoms 
near the pyrazole-N-phenyl substituent play an essential role in determining the binding 
affinity of the ligand. Among the N-(methoxycarbonylphenyl)-chromenopyrazoles, meta-
substituted 3.41 displayed higher binding affinity than para-substituted 3.18. 
Notwithstanding this result, the binding affinity comparison of 3.25 with 3.47, 3.22 with 
3.45 and 3.23 with 3.46 showed that the N-(para-(methylamine)phenyl)-
chromenopyrazole series exhibited greater tolerance to bulky substituents than N-(meta-
(methylamine)phenyl)-chromenopyrazole series at CB2R binding site. 
 
3.3.3 cAMP Functional assays  
 
Due to the time constraints as mentioned previously, the functional activity of only 
selected high affinity CB2R N-phenyl-chromenopyrazoles (3.22, 3.25, 3.29, 3.31, 3.39, 
and 3.47) that exhibited robust tolerance of substituents/linkers was determined. 
Functional activity of these chromenopyrazoles was determined by a cAMP BRET 
assay169 (described in chapter 1, section 1.5.2). Despite the fact that these 
chromenopyrazoles were designed as CB1R agonists, their functional nature at CB1R was 
not determined due to their poor binding affinity for CB1R.  
 
As described in chapter 1 (section 1.5.2), CBR agonists decrease the ‘inverse BRET ratio’ 
(obtained from cAMP BRET assay), inverse agonists increase it and neutral antagonists 
don’t produce a change. For example, the high affinity CB2R chromenopyrazole 3.25 
behaved as an agonist at CB2R since in the initial screen at 10 µM, 3.25 decreased the 
inverse BRET ratio compared to forskolin alone (Figure 3.13). The literature CBR agonist 
CP55,940 was used as a positive control in the 10 µM screen and also decreased the 
inverse BRET ratio compared to forskolin alone (Figure 3.13). None of the 
chromenopyrazoles tested in the cAMP assay in this chapter showed any activity at 10 
µM concentration in the cAMP BRET assay at WT HEK-293 cells and thus did not 
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exhibit CB2R independent effects on cAMP levels (Table 3.4; Figure 3.14 shows cAMP 
screen of the highest affinity chromenopyrazole 3.25 at WT HEK-293 cells).  
 
 
Figure 3.13. The highest CB2R binding affinity chromenopyrazole 3.25 (10 µM) screened in a cAMP 
BRET assay using HEK-293 cells expressing hCB2R. Data is representative of a single experiment carried 
in duplicate and is expressed as mean ± SEM. Literature agonist CP (CP55, 940), FSK (Forskolin), V 
(vehicle). 
 
Area under the curve analysis was used to calculate the potency (EC50) and efficacy (Emax) 
of the chromenopyrazoles (Table 3.3) from raw cAMP functional assay data. Literature 
control CP55, 940 (EC50 = 1.7 ± 0.23 nM at hCB2R; Emax = 43 ± 0.75 % of forskolin 
response at hCB2R) exhibited potency  and efficacy in agreement with those reported in 







Figure 3.14. Screen of the highest affinity chromenopyrazole 3.25 tested at 10 µM at WT HEK-293 cells 
by a cAMP BRET assay. Data is representative of a single experiment carried in duplicate and is expressed 
as mean ± SEM. Literature agonist CP (CP55, 940), FSK (Forskolin), V (vehicle). 
 
Table 3.3. Functional data for selected chromenopyrazoles obtained from cAMP BRET assay. 
Compound EC50 (nM± SEM) * Emax (%FSK response ± SEM)# Functional activity 
3.25 12.5 ± 2.3 59.9 ± 2.04 Agonist 
3.22 338.2 ± 20.2 49.91 ± 3.94 Agonist 
3.29 152.5 ± 21.6 54.31 ± 3.09 Agonist 
3.31 511.2 ± 56.0 53.75 ± 2.32 Agonist 
3.39 17.3 ± 5.3 61.2 ± 1.53 Agonist 
3.47 181.3 ± 13.3 70.36 ± 2.67 Agonist 
CP 1.7 ± 0.23 43.33 ± 0.75 Agonist 
*Potency (EC50) and 
#
efficacy (Emax) data for selected chromenopyrazoles, CP (CP55,940) obtained from 
cAMP BRET assay using HEK-293 cells expressing hCB2R. All data is from at least three individual 
experiments performed, raw data is normalised to forskolin (100 %) and vehicle (0 %).  
 
The highest CB2R affinity (highest affinity among the novel chromenopyrazoles tested) 
chromenopyrazole 3.25 (EC50 = 12.5 ± 2.3 nM at hCB2R) also displayed the highest 
potency for CB2R out of the novel chromenopyrazoles tested (Table 3.3 and Figure 3.15). 
Chromenopyrazole-linker conjugate 3.22 (Emax = 49.91 ± 3.94 % of forskolin response at 
hCB2R) showed the highest efficacy and was only slightly less efficacious than the 
literature control CP55,940 (Emax = 43.33 ± 0.75 % of forskolin response at hCB2R; Table 
3.3; Figure 3.15). It was a good result as it indicated that the linker in 3.22 improved the 
efficacy of 3.22 compared to 3.25 and revealed 3.22 as a promising lead in developing 
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agonist-based CB2R fluorescent ligands. Remarkably, all of the chromenopyrazoles 
tested in the cAMP assay including linker conjugates of 3.25 and 3.29 behaved as agonists 
(Table 3.3). Previously, Cumella et al.137 had also shown chromenopyrazoles 3.1, 3.2 and 
3.5 (Table 3.1) as mCB1R agonists by inhibition of contraction of mouse vas deferens.
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Another important result was the agonist functional nature and high potency of a 
chromenopyrazole-peptide linker conjugate 3.39 (EC50 = 17.3 ± 5.3 nM at hCB2R). Most 
of the reported cannabinoid receptor agonists are highly lipophilic in nature, and hence 
peptide linker conjugates such as 3.39 provide a crucial lead for the development of polar 
cannabinoid receptor agonists. These polar cannabinoid receptor agonists would be useful 
as chemical tools to investigate CB2R trafficking studies (GPCRs are known to signal 
from intracellular vesicles, also discussed in chapter 1, section 1.1). A cAMP BRET assay 
was used to determine the functional nature of the novel chromenopyrazoles (3.22, 3.25, 
3.29, 3.31, 3.39 and 3.47) in this chapter; it would be interesting to investigate the 
functional nature of these ligands in other CBR signalling pathways such as activation of 
ERK, GIRKs, and recruitment of β-arrestin. 
 
 
Figure 3.15. Concentration-response curve for highest affinity CB2R chromenopyrazole 3.25, highest 
affinity CB2R chromenopyrazole-linker conjugate 3.22 (highest affinity among chromenopyrazoles tested 
in this chapter) and literature CBR agonist CP (CP55,940) using cAMP BRET assay with HEK-293 cells 
expressing hCB2R. All data is from at least three individual experiments performed and is expressed as 




Table 3.4 % Response in cAMP BRET assay at wild type HEK-293 cells. 
Compound %FSK Response ± SEM* 
3.39 104.51 ± 1.068 
3.25 100.15 ± 2.76 
3.47 106.46 ± 1.92 
3.31 98.28 ± 1.64 
3.22 100.89 ± 4.71 
3.29 102.40 ± 4.05 
*cAMP BRET assay for the test compounds (10 μM) was carried out at WT HEK-293 cells. All data is 
from at least two individual experiments performed in duplicate, raw data is normalised to forskolin 
response (100 %) and vehicle response (0 %). A one-sample t-test was used to determine whether the % 
cAMP response of test compounds was significantly different from the forskolin only response. 
 
3.4 Molecular modelling and docking studies 
 
Computational studies were carried out to rationalise some key SAR results obtained from 
biological evaluation of the chromenopyrazoles (section 3.3). These key SARs included 
the greater tolerance of the long linkers in the N-(para-(methylamine)phenyl)-
chromenopyrazoles compared to the N-(meta-(methylamine)phenyl)-chromeno-
pyrazoles and similar high affinities at CB2R of 3.29-long linker conjugates (3.31, 3.32, 
and 3.39). 
 
At the time of writing this thesis the crystal structure of CB2R was not published, however 
three crystal structures of CB1R (two with inverse agonists
111-112 and one with an 
agonist113) were published. As all of the novel chromenopyrazoles tested in the cAMP 
functional assay in this chapter behaved as agonists, it was decided to build a homology 
model of CB2R based on the higher resolution active state structure of CB1R (PDB ID: 
5XRA) published by Hua et al.113 The CB1R structure (PDB ID: 5XRA) (CB1R structure 
described in chapter 1, section 1.4.1) was crystallised with ligand AM11542 (shown in 
Figure 3.16), which shares good structural similarity with the novel chromenopyrazoles 
synthesised in this thesis.  
 
Previously, computational studies for the literature chromenopyrazoles and the 
chromenoisoxazoles (Table 3.1) was carried out by Hurst et al.137 with a homology model 
of CB2R built using the bovine rhodopsin as the template. Results obtained from the 
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computational studies carried out by Hurst et al.137 will not be compared with those 
obtained in this chapter due to the use of different homology models obtained from 
different template structures. 
 
Figure 3.16. The scaffold constraint was applied in docking studies to match the location of the 
chromenopyrazolol moiety (structure fragment with bold bonds of 3.25, 3.47, and 3.29) in the CB2R 
homology model-binding site to the dibenzopyranol moiety (structure fragment with bold bonds) of 
AM11542. 
 
The alignment of the CB1R sequence (Uniprot id – P21554) against the CB2R sequence 
(Uniprot id - P34972) was carried out using a multiple sequence alignment web server T-
coffee213 (Figure 3.17). Modeller214 was used for building the active state homology 
model of CB2R using the CB1R active state crystal structure (PDB ID: 5XRA) published 
by  Hua et al.113 In total, 25 models were built and the model with the lowest DOPE 




sp|P34972|CNR2_   --------------------------------------------------------------- 
sp|P21554|CNR1_   MKSILDGLADTTFRTITTDLLYVGSNDIQYEDIKGDMASKLGYFPQKFPLTSFRGSPFQEKMT 
cons                                                                              
 
            / TM1 
sp|P34972|CNR2_   ---------MEECWVTEIANGSKDGLDSN-----------PMKDYMILSGPQKTAVAVLCTLL 
sp|P21554|CNR1_   AGDNPQLVPADQVNITEFYNKSLSSFKENEENIQCGENFMDIECFMVLNPSQQLAIAVLSLTL 
cons                                                       :: :*:*. .*: *:***.  * 
 
         \   ICL1  /      TM2         \   ECL1   / 
sp|P34972|CNR2_   GLLSALENVAVLYLILSSHQLRRKPSYLFIGSLAGADFLASVVFACSFVNFHVFHGVDSKAVF 
sp|P21554|CNR1_   GTFTVLENLLVLCVILHSRSLRCRPSYHFIGSLAVADLLGSVIFVYSFIDFHVFHRKDSRNVF 
cons              * ::.***: ** :** *:.** :*** ****** **:*.**:*. **::*****  **: ** 
 
     TM3              \      ICL2     /                 TM4 
sp|P34972|CNR2_   LLKIGSVTMTFTASVGSLLLTAIDRYLCLRYPPSYKALLTRGRALVTLGIMWVLSALVSYLPL 
sp|P21554|CNR1_   LFKLGGVTASFTASVGSLFLTAIDRYISIHRPLAYKRIVTRPKAVVAFCLMWTIAIVIAVLPL 
cons              *:*:*.** :********:*:*****:.:: * :** ::** :*:*:: :**.:: ::: *** 
 
         \       ECL2  /  TM5         \      ICL3 
sp|P34972|CNR2_   MGWTC--CPRPCSELFPLIPNDYLLSWLLFIAFLFSGIIYTYGHVLWKAHQHVASLSGH---- 
sp|P21554|CNR1_   LGWNCEKLQSVCSDIFPHIDETYLMFWIGVTSVLLLFIVYAYMYILWKAHSHAVRMIQRGTQK 
cons              :**.*      **::** * : **: *: . :.*:  *:*:* ::*****.*..          
 
               /  TM6         \ ECL3 / 
sp|P34972|CNR2_   ---------QDRQVPGMARMRLDVRLAKTLGLVLAVLLICWFPVLALMAHSLATTLSDQVKKA 
sp|P21554|CNR1_   SIIIHTSEDGKVQVTRPDQARMDIRLAKTLVLILVVLIICWGPLLAIMVYDVFGKMNKLIKTV 
cons                                   :*:.***** *:*.**:*** *:**:*.:.:  .:.. :*.. 
 
            TM7    \ 
sp|P34972|CNR2_   FAFCSMLCLINSMVNPVIYALRSGEIRSSAHHCLAHWKKCVRGLGSEAKEE------------ 
sp|P21554|CNR1_   FAFCSMLCLLNSTVNPIIYALRSKDLRHAFRSMFPSCEGTAQPLDNSMGDSDCLHKHANNAAS 
cons              *********:** ***:****** ::* : :  :.                             
 
 
sp|P34972|CNR2_   APRSS---VTETEADGKITPWPDSRDLDLSD 
sp|P21554|CNR1_   VHRAAESCIKSTVKIAKVTMSVSTDTSAEAL 
cons                                             
Figure 3.17. Sequence alignment of hCB1R sequence (Uniprot id – P21554) against the hCB2R sequence 
(Uniprot id - P34972) was carried out with web server T-coffee213 and manually improved. The alignment 
is colour coded for agreement with the library used by T-coffee – pink colour (good), yellow (average), and 
green (bad). 
 
The ligands were drawn in Avogadro216 and the structures optimised by energy 
minimisation using the Merck Molecular ForceField (MMFF94). GOLD217, a docking 
programme, was used for docking studies with the CB2R binding site of the ligands 
defined as 20 Å region around the CB1R co-crystallised ligand AM11542 (PDB ID: 
5XRA). The scaffold constraint was applied to match the location of the 
chromenopyrazolol moiety of the ligands (3.25, 3.47, and 3.29; Figure 3.16) to the 
dibenzopyranol moiety of AM11542 in the CB2R homology model-binding site. The 
docking studies were carried out only with three small-linker/substituent N-phenyl-
chromenopyrazole conjugates – 3.25 (N-(para-(methylamine)phenyl)-
chromenopyrazole), 3.47 (N-(meta-(methyl-amine)phenyl)-chromenopyrazole, and 3.29 
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(N-(5-carboxypentyl)-chromenopyrazoles) that showed high CB2R affinity. The docking 
studies of the chromenopyrazole-long linker or (long linker-fluorophore) conjugates were 
not carried out due to the large degree of freedom of the linker atoms, which usually 
produces varied binding poses. Docking poses of the ligands were visualised with 
PyMOL. 
 
The docking studies indicated a hydrogen bond between aromatic hydroxyl of 3.25 and 
S285 (Figure 3.18). In a previous study, S285 was shown to play an essential role in the 
binding of CB2R agonists such as HU243.
218 A hydrogen bond was also observed between 
the amine of 3.25 and the carboxyl group of K278. In this docking pose, the methylamine 
linker exits out of the binding pocket from the cavity located between TM1 and TM7. 
Thus, the long PEG linker extended from 3.25 (PEG linker in 3.22) will likely reside in 
the extracellular environment and might explain the high CB2R binding affinity of 3.22 
(section 3.3.2). In a previous literature report, it has been suggested using molecular 
dynamics simulations, that cannabinoid ligands enter the CBR via the lipid membrane219 
and THC enters CB1R via the cavity located between helices TM1 and TM7
220. Shao et 
al.111, who reported the CB1R crystal structure with inverse agonist taranabant, have also 
suggested that lipophilic ligands enter CB1R orthosteric binding site via the cavity 
between helices TM1 and TM7. Aromatic interactions were observed between the 
aromatic rings of 3.25 and F106, F183, F281, F87, F94, F91 and H95. van der Waals 
interactions were observed between dimethyl side chain of 3.25 and residues M265, 




Figure 3.18. Docking pose of 3.25 (cyan carbons, red oxygens, blue nitrogens, white hydrogens) in CB2R 
homology model (forest green ribbon). Side chain residues forming hydrogen bonds or hydrophobic 
interaction with 3.25 are shown as sticks (leaf green). Hydrogen bonds are shown as yellow lines. 
 
The docking studies of 3.47 (Figure 3.19) showed a hydrogen bond between the aromatic 
hydroxyl of 3.47 and S285, and between the carboxyl group of Y25 and the amine of 
3.47. Although 3.47 bound in a similar docking pose to 3.25, extension of a longer linker 
from 3.47 likely introduces steric clashes leading to decreased CB2R binding affinity of 
3.47-linker conjugate 3.45 (section 3.3.2). Similar to 3.25, aromatic interactions between 
aromatic rings of 3.47 with F106, F183, F281, F87, F94, F91, H95 and van der Waals 
interactions between the dimethyl side chain of 3.47 with M265, V113, T114, F117, 




Figure 3.19. Docking pose of 3.47 (cyan carbons, red oxygens, blue nitrogens, white hydrogens) in CB2R 
homology model (forest green ribbon). Side chain residues forming hydrogen bonds or hydrophobic 
interaction with 3.47 are shown as sticks (leaf green). Hydrogen bonds are shown as yellow lines. 
 
Similar to 3.25 and 3.47, docking studies of 3.29 showed a hydrogen bond between 
aromatic hydroxyl of 3.29 and S285 (Figure 3.20). The long linkers (alkyl, PEG and 
peptide) extended from 3.29 likely exit the CB2R binding pocket through the cavity 
located between TM1, TM7 and resides in the extracellular cavity, which might explain 
the similar high binding affinity of 3.29-linker conjugates (3.31, 3.32 and 3.39) (section 
3.3.2). Similar to 3.25 and 3.47, aromatic interactions between aromatic rings of 3.29 with 
M265, V261, T114, F117, W194 and van der Waals interactions between the dimethyl 




Figure 3.20. Docking pose of 3.29 (cyan carbons, red oxygens, blue nitrogens, white hydrogens) in CB2R 
homology model (forest green ribbon). Side chain residues forming hydrogen bond or hydrophobic 
interaction with 3.25 are shown as sticks (leaf green). Hydrogen bonds are shown as yellow lines.  
 
The docking studies of chromenopyrazole-long linker plus fluorophore conjugates were 
not carried out due to the difficulty in obtaining accurate binding poses of these 
compounds containing a number of rotatable bonds with a CB2R homology model. It is 
likely that the decrease in CB2R binding affinity upon attachment of fluorophore to the 
linker conjugates could be due to steric clashes of the fluorophore with the CB2R amino 
acid residues present in the TM helices or EL(s).  
 
A previous report suggests that the CBR ligands enter the CBR ligand binding site via the 
lipid membrane.219 It is therefore likely that polarity, charge and molecular size of the 
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chromenopyrazoles (listed in Table 3.2) might affect the ability of these ligands to enter 
via the lipid membrane and hence influence CBR affinity through this mechanism too. 
3.5 Summary and conclusions 
 
With the aim of developing a high affinity CB1R fluorescent agonist, chromenopyrazole 
derivatives with the linkers conjugated at six different positions of the chromenopyrazole 
core (section 3.2) were prepared. These derivatives were synthesised from reaction of the 
β-ketoaldehyde 3.16 with different hydrazines. The steric/electronic factors led to the 
formation of only the N1 isomer from the reactions of aryl hydrazines and long chain 
alkyl hydrazine with 3.16. Three different types of linkers (alkyl, PEG and peptide) were 
conjugated to the synthesised chromenopyrazoles. The fluorophore BODIPY-630/650 
was also conjugated to a set of the chromenopyrazole-linker derivatives to provide the 
fluorescent ligands 3.23, 3.33, 3.40, 3.46, and 3.54.  
 
Disappointingly, most of the synthesised chromenopyrazoles, including fluorescent 
ligands, did not exhibit high binding affinity for CB1R in the radioligand binding assay 
(Table 3.2). Nonetheless, the majority of the chromenopyrazoles showed higher affinity 
for CB2R as well selectivity over CB1R. The chromenopyrazole 3.25 (Ki = 13.2 ± 3.4 nM 
at hCB2R) displayed the highest overall affinity and also the best selectivity (greater than 
75 fold) for CB2R over CB1R. The long linkers were best tolerated at the para-substituted 
N-phenyl-chromenopyrazoles than the meta-substituted N-phenyl-chromenopyrazoles. 
Among chromenopyrazole-linker conjugates, 3.22 (Ki = 71.1 ± 6.7 nM at hCB2R) 
exhibited highest affinity for CB2R and selectivity (greater than 70 fold) over CB1R. 
Three moderate affinity CB2R fluorescent ligands 3.23, 3.33 and 3.40 were also obtained.  
 
The highest affinity CB2R chromenopyrazoles (3.29, 3.31, 3.22, 3.25, 3.39, and 3.47) 
were tested in a cAMP functional assay to investigate the functional activity of these 
chromenopyrazoles (Table 3.3). The chromenopyrazole-linker conjugate 3.22 (Emax = 
49.91 ± 3.94 % of forskolin response at hCB2R) exhibited the highest efficacy and 3.25 
(EC50 = 12.5 ± 2.3 nM at hCB2R) exhibited highest potency. 
 
The CB2R binding affinity of 3.25 and 3.29 (Table 3.2) were also preserved/improved in 
their linker conjugates (3.22, 3.31, 3.32, and 3.39). Taken together, these functional and 
124 
 
binding affinity results indicated that the linker conjugates of 3.25 and 3.29 would be 
promising leads for the development of CB2R fluorescent ligands.  
 
Docking studies of 3.25, 3.47, and 3.29 using the homology model of CB2R revealed that 
the short linkers exit the CB2R binding pocket through cavity located between TM1 and 
TM7 (section 3.4). Although the initial aim of developing a high affinity CB1R 
fluorescent ligand was not achieved, several chromenopyrazoles exhibiting high affinity 
for CB2R and selectivity over CB1R were obtained. Importantly, in contrast to the 
typically lipophilic cannabinoids, a high affinity polar peptide linker containing conjugate 
3.39 along with several other high affinity chromenopyrazole-linker conjugates (3.22, 
3.31, 3.32 and, 3.39) were successfully developed. With these lead CB2R 
chromenopyrazoles in hand, efforts were then directed towards development of selective 
CB2R fluorescent ligands (described in chapter 4). A new series of pyridyl-based ligands 





Chapter 4 Optimisation of chromenopyrazoles 
as high affinity fluorescent ligands for 
cannabinoid type 2 receptor 
4.1 Design rationale for optimisation of 
chromenopyrazole-based fluorescent ligands 
 
The chromenopyrazoles 3.22 (linker analogue of 3.25) and 3.31, 3.32, 3.39 (linker 
analogues of 3.29, Figure 4.1) described in chapter 3, showed high affinity and selectivity 
for CB2R over CB1R. Disappointingly, the BODIPY-630/650 analogues of 3.22, 3.32, 
and 3.39 provided only moderate affinity CB2R ligands. High affinity for the target 
receptor along with favourable polarity (to reduce non-specific membrane binding) are 
two essential criteria a fluorescent ligand should possess for being used as an imaging 
tool (refer to chapter 1, section 1.2.3.1). So, the second-generation of chromenopyrazole-
based fluorescent ligands was developed with the aim of improving the CB2R affinity by 
refining fluorophore and linkers around the chromenopyrazole ligand core. A second-
generation of chromenopyrazole peptide-linker conjugates were also developed in an 
effort to make more polar compounds while maintaining high affinity for CB2R. 
 
The BODIPY-630/650 derivatives (3.40, 3.33, and 3.23) of high affinity 
chromenopyrazole-linker conjugates (3.39, 3.32, and 3.22) showed poor CB2R affinity. 
One way to test the effect the fluorophore has on CB2R affinity would be to substitute 
BODIPY-630/650 with a range of different fluorophores such as BODIPY-FL, TAMRA 
and Cy5. As the chromenopyrazole-linker conjugate 3.22 (Figure 4.1; Ki = 71.1 ± 6.7 nM 
at hCB2R; Table 3.2, chapter 3) displayed the highest affinity for CB2R, it was decided to 
append the fluorophores (BODIPY-FL, TAMRA and Cy5) to 3.22 (4.01 - 4.03; Figure 
4.2). All of these fluorescent ligands (4.01 – 4.03) were designed with PEG linkers of 








Figure 4.1. The high affinity CB2R chromenopyrazoles 3.25, 3.29 and the linker conjugates 3.22, 3.31, 
3.32 and 3.39 prepared in chapter 3. 
 
The fluorophore BODIPY-FL (excitation 505 nM, emission 513 nM) was selected, as it 
is structurally similar but smaller compared to BODIPY-630/650. It was hoped that the 
smaller-sized BODIPY-FL-based fluorescent ligand 4.01 (Figure 4.2) might exhibit 
higher affinity for CB2R compared to the BODIPY-630/650 based fluorescent ligand 3.23 
(Ki = 2312 ± 298nM at hCB2R, Table 3.2, chapter 3) due to the reduced steric clashes 
with the CB2R amino acid residues. The red-emitting fluorophore Cy5 (excitation 646 
nM, emission 662 nM) consists of two indoline moieties separated by a pentamethine 
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spacer. Replacement of the BODIPY-630/650 of fluorescent ligand 3.23 with Cy5 to give 
fluorescent ligand 4.02 will preserve the red fluorescence but the variation in structure 
might improve the CB2R affinity. The rhodamine-based fluorophore TAMRA (excitation 
565 nM, emission 580 nM) lacks a short linker present in other fluorophores (BODIPY-
630/650, BODIPY-FL and Cy5). As the aim was to maintain the similar linker length of 
3.23 while changing the fluorophore, it was decided to prepare a new chromenopyrazole-
based linker conjugate 4.13 (synthesis described in section 4.2.1.3) for preparing 





Figure 4.2. Lead chromenopyrazole CB2R fluorescent ligand 3.23 (developed in chapter 3) and second-
generation fluorescent ligands (4.01 – 4.05) designed as potential CB2R ligands. 
 
Fluorescent ligands 4.04 (a long linker analogue of 3.23) and 4.05 (a short linker analogue 
of 4.01) were also designed to assess the influence of PEG linker length on the CB2R 
affinity (Figure 4.2). It was hoped that fluorophore BODIPY-630/650 of 4.04 might suffer 
reduced steric clashes with the CB2R amino acid residues compared to BODIPY-630/650 
of 3.23 due to the greater separation of fluorophore and pharmacophore by a longer PEG 
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linker. The fluorescent ligand 4.05 was designed to investigate whether the fluorophore 
BODIPY-FL could be tolerated in close proximity to the pharmacophore to make a high 
affinity CB2R fluorescent ligand. 
  
A polar, high affinity fluorescent ligand is desired as it usually displays lower non-
specific membrane binding compared to a non-polar fluorescent ligand and is especially 
challenging to make for a lipid receptor such as CB2R (chapter 1, section 1.2.3.1). Among 
the chromenopyrazole-linker conjugates described in chapter 3, 3.39 (Figure 4.3, Ki = 
138.4 ± 6.75 at hCB2R; Table 3.2, chapter 3) was particularly promising as despite 
containing a peptide linker (Ala-Ala), it displayed high affinity and functional activity 
(agonist, EC50 = 17.3 ± 5.3 nM; Emax = 61.2 ± 1.53% of forskolin response at hCB2R) 
at CB2R. A second-generation of polar peptide linker-chromenopyrazole conjugates (4.06 
- 4.08) containing serine and asparagine amino acids was designed (Figure 4.3). The 
amino acids serine and asparagine were selected as these contain more hydrophilic (but 
non-ionised at physiological pH) side chain residues compared to Ala, which might make 
hydrogen bonds with the CB2R amino acid residues.  
 
 
Figure 4.3. Lead chromenopyrazole CB2R peptide-linker conjugate 3.39 (developed in chapter 3) and 
second-generation peptide linker-conjugates (4.06 – 4.08) designed as potential CB2R polar ligands. 
 
Based on the comparison of CB2R affinity of chromenopyrazoles (3.25, 3.18), (3.22 
(Figure 4.3), 3.26) and (3.41, 3.47), it was concluded in chapter 3 (section 3.3.2) that the 
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atoms near the pyrazole-N-phenyl substituent of the chromenopyrazole might play a 
crucial role in CB2R binding. It was thought that a modification near the benzylic position 
might improve the CB2R affinity of chromenopyrazole-linker conjugates. Accordingly, a 
new heterocyclic analogue 4.09 of 3.22 was designed by substituting the phenyl ring of 
3.22 with a pyridyl ring (Figure 4.4). The presence of a pyridine in 4.09 would also 
increase the polarity of the linker conjugate and may reduce the non-specific membrane 
interactions of the 4.09-based fluorescent ligands. Due to the time constraints of 
pharmacological testing, only one compound 4.09 was to be tested for pharmacological 
activities and depending on the pharmacological results additional derivatives of 4.09 
including fluorescent ligands would be prepared. 
 
 
Figure 4.4. Pyridyl chromenopyrazole 4.09 designed by substitution of phenyl carbon atom (circled) of 
3.22 with a nitrogen atom (circled).  
 
4.2 Synthesis and structural characterisation 
4.2.1 Synthesis of second-generation fluorescent conjugates of 
chromenopyrazole (3.22) 
4.2.1.1 Synthesis of BODIPY-FL-based fluorescent ligands 
 
The benzylamine 3.21 (synthesis described in chapter 3, section 3.2.1.1) was used in 
crude form in the amide coupling reactions to prepare chromenopyrazole linker 
conjugates in chapter 3. However, it was decided to purify the crude benzylamine 3.21 
before reacting with the commercially available fluorophore BODIPY-FL-SE. For the 
ease of purification on suitable scale, benzylamine 3.21 was reacted with Boc anhydride 
to give 4.10, which was then purified by silica gel column chromatography (Scheme 4.1). 




Scheme 4.1. (i) (Boc)2O, Et3N, DCM, 35%. 
 
Boc deprotection of 4.10 with TFA and reaction of the semi-preparative RP-HPLC 
purified trifluoroacetate salt with BODIPY-FL-SE using DIPEA as a base provided 
fluorescent ligand 4.05 (Scheme 4.2). Similarly, fluorescent ligand 4.01 was prepared by 
reaction of Boc-deprotected 3.22 (synthesis described in chapter 3, section 3.2.1.1) with 
BODIPY-FL-SE.  
 
As also noted in chapter 3 (section 3.2.1.1), calculated yields of reactions of commercially 
available fluorophore succinimidyl esters to give fluorescent ligands (4.01-4.05) (Scheme 
4.2, 4.3, 4.4 and 4.5) with chromenopyrazoles were greater than quantitative. This was 
assumed to be because the commercially available fluorophore succinimidyl esters are 
supplied in higher amounts than that specified on the container. The amount of 
fluorophore specified on the container was used in the calculation of yield. 
 
 







4.2.1.2 Synthesis of a Cy5-based fluorescent ligand 
 
The fluorescent ligand 4.02, which is the Cy5 analogue of 3.23, was synthesised by 
reaction of Boc-deprotected chromenopyrazole 3.22 (RP-HPLC purified) with 
commercially available fluorophore Cy5-SE using DIPEA as a base.   
 
 
Scheme 4.3. (i) TFA, DCM, quantitative. (ii) Cy5-SE, DIPEA, DMF, quantitative. 
 
4.2.1.3 Synthesis of a TAMRA-based fluorescent ligand 
 
A new chromenopyrazole-based linker conjugate 4.13 was prepared for reaction with 
TAMRA-SE so that the resulting TAMRA fluorescent ligand 4.03 would have a linker 
length similar to other fluorescent ligands (3.23, 4.01, 4.02, and 4.04). Synthesis of 
fluorescent ligand 4.03 began with Boc protection of commercially available 6-
aminohexanoic acid 4.11 according to a previously reported literature synthesis221 to give 
4.12 (Scheme 4.4). The reaction of 4.12 with Boc-deprotected 3.22 using TFFH as a 
coupling reagent and Et3N as a base gave 4.13. The low yield obtained for 4.13 is 
attributed to the loss of the polar compound during silica gel column purification. 
Chromenopyrazole-linker conjugate 4.13 was reacted with TFA and the resulting Boc-
deprotected 4.13 was then reacted with commercially available TAMRA-SE using 





Scheme 4.4. (i) (Boc)2O, NaOH, 1,4-dioxane, H2O, 71%. (ii) TFA, DCM, quantitative. (iii) 4.12, TFFH, 
Et3N, DCM, 34%. (iv) TFA, DCM, quantitative. (v) TAMRA-SE, DIPEA, DMF, quantitative. 
 
4.2.1.4 Synthesis of chromenopyrazole-long linker-BODIPY-
630/650 fluorescent ligand analogue of 3.23 
 
Preparation of the fluorescent ligand 4.04 commenced with the reaction of commercially 
available PEG linker 4.14 with succinic anhydride to yield carboxylic acid 4.15. The 
coupling of 4.15 with Boc-deprotected 4.10 using TFFH as a coupling reagent gave 4.16. 
As in the case of 4.13, the low yield obtained for 4.16 is likely due to the loss of polar 
compound during silica gel column purification. Chromenopyrazole linker conjugate 4.16 
was then reacted with TFA and the resulting Boc-deprotected 4.16 was subsequently 






Scheme 4.5. (i) Succinic anhydride, CHCl3. (ii) TFA, DCM, quantitative. (iii) 4.15, TFFH, Et3N, DCM. 
25%. (iv) TFA, DCM, quantitative. (v) BODIPY-630/650-SE, DIPEA, DMF, quantitative. 
 
4.2.2 Synthesis of second-generation chromenopyrazole 
peptide linker conjugates  
 
Fmoc solid-phase peptide synthesis was used for the preparation of new 
chromenopyrazole peptide linker conjugates (4.25-4.27; Scheme 4.6). Coupling of 1,2-
diaminoethane trityl resin 3.35 with Fmoc-Ser(tBu)-OH or Fmoc-Ala-OH using HBTU 
and DIPEA gave 4.17 and 4.18. The resins were then capped by reacting any unreacted 
resin-amine sites with Ac2O in DMF. The Fmoc deprotection of resin-bound (4.17-4.18) 
with a solution of piperidine in DMF (20% v/v), followed by reaction with Fmoc-Ala-OH 
or Fmoc-Ser(tBu)-OH or Fmoc-Asn(Trt)-OH, HBTU, and DIPEA gave resin-bound 
4.19-4.21 respectively. Fmoc deprotection of resin-bound 4.19-4.21 with a solution of 
piperidine in DMF (20% v/v) and then coupling of the free primary amines with 
carboxylic acid 3.30 (synthesis described in chapter 3, section 3.2.1.3) using HATU and 
DIPEA gave resin-bound 4.22-4.24 respectively. Compounds were cleaved from the trityl 
resins by treating resin-bound 4.22-4.24 with TFA. Peptide linker conjugates 4.25-4.27 
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thus obtained were purified using semi-preparative RP-HPLC and then reacted with 
acetic anhydride in separate reactions to give, Ala-Ser conjugate 4.06, Ser-Ala conjugate 






Scheme 4.6. (i) Fmoc-Ser(tBu)-OH or Fmoc-Ala-OH, HBTU, DIPEA, DMF (ii) Piperidine, DMF (iii) 
Fmoc-Ala-OH or Fmoc-Ser(tBu)-OH or Fmoc-Asn(Trt)-OH, HBTU, DIPEA, DMF (iv) 3.29, HATU, 
DIPEA, DMF (v) TFA, DCM (vi) Ac2O, Et3N, CHCl3, 30 - 67%. 
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4.2.3 Synthesis of pyridyl analogue of (3.22) 
 
Synthesis of chromenopyrazole-linker conjugate 4.09 commenced with the preparation 
of hydrazine 4.29, by reaction of commercially available aminopyridine 4.28 with 
NaNO2, HCl (6 M aqueous solution) and SnCl2.2H2O according to a previously reported 
literature synthesis222 to give 4.29 (Scheme 4.7). Attempts to purify 4.29 from the crude 
reaction mixture (identified as present in the crude reaction mixture by 1H NMR 
spectroscopy and HRMS) by acid-base work up or crystallisation proved futile. It was 
soon learnt that hydrazine 4.29 slowly degraded to a less polar compound (observed as a 
higher TLC Rf spot relative to 4.28). The structure of this non-polar impurity could not 
be determined from the 1H NMR spectrum and MS of the crude mixture also containing 
4.29 and 4.28. Therefore, the crude reaction mixture of 4.29 was condensed with β-
ketoaldehyde 3.16 (synthesis described in chapter 3, section 3.2.1.1) to give nitrile 4.30, 
which was reduced by LiAlH4 to give benzylamine 4.31. Reaction of 4.31 with carboxylic 
acid 3.13 (synthesis described in chapter 3, section 3.2.1.1) using HBTU as a coupling 




Scheme 4.7. (i) HCl, NaNO2, SnCl2.2H2O, -10 °C to rt. (ii) 4.29, MeOH, H2SO4, 70 °C, 86%. (iii) LiAlH4, 
THF, 0°C to rt. (iv) 3.13, 4.31, HBTU, DIPEA, DMF, 46%. 
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4.3 Biological studies 
4.3.1 Radioligand binding assays 
 
The CB2R affinity of second-generation chromenopyrazoles was determined using 
radioligand binding assays (as described in chapter 3, section 3.3.1) with the commonly 
used CBR radioligand [3H]-CP55,940 and membrane preparations derived from HEK-
293 cells transfected with either CB1R or CB2R according to a previously described 
method.169, 212 Chromenopyrazoles (4.01-4.09) were initially screened in the competition 
radioligand binding assay at 10 µM to determine the percentage displacement of [3H]-
CP55,940 from CBRs (Figure 4.5, panels A and B). The chromenopyrazoles (4.01-4.09) 
which displaced [3H]-CP55,940 from CBRs by more than 50% were then analysed in a 


















Figure 4.5. Radioligand binding assay: Screen of novel chromenopyrazoles at 10 µM at HEK-293 cells 
expressing hCB2R (panel A) or hCB1R (panel B), with [3H]-CP55,940 as the radioligand. Data represented 
is from a single experiment carried out in triplicate and is expressed as mean ± SEM. V (vehicle), CP 
(CP55,940).  
 
Pleasingly, BODIPY-FL-based fluorescent ligand 4.01 (Ki = 145.5 ± 11.8 nM at hCB2R; 
Table 4.1) exhibited high affinity for CB2R, which was fifteen-fold higher than analogous 
BODIPY-630/650 based fluorescent ligand 3.23 (Ki = 2312 ± 298nM at hCB2R; Table 
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*Binding affinity (Ki) obtained by competition binding assay performed on membranes obtained from HEK-
293 cells expressing hCB2R or hCB1R with [3H]-CP55,940 as radioligand (Kd = 1.7 nM for hCB2R and 3.0 
nM for hCB1R). All data is from at least three individual experiments performed in triplicate. 
 
As both fluorescent ligands 4.01 and 3.23 contain similar chromenopyrazole-linker 
structures, the observed difference in the CB2R affinities is likely due to the presence of 
different fluorophores. One possible reason for the higher CB2R affinity of 4.01 compared 
to 3.23 might be the relatively smaller size of 4.01. The fluorescent ligand 4.01, owing to 
its smaller size, might be free from the steric clashes suffered by 3.23 with the CB2R 
amino acid residues. Other possible reasons for the difference in the CB2R affinities might 
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include the different CB2R binding conformation of 4.01 compared to 3.23 or due to some 
favourable interactions of BODIPY-FL fluorophore with the CB2R amino acids. 
 
The Cy5 conjugate 4.02 (Ki = 41.8 ± 4.5 nM at hCB2R; 5856 ± 1264 nM at hCB1R) 
exhibited the highest affinity and selectivity for CB2R over CB1R among all the second-
generation chromenopyrazoles (Figure 4.6, Table 4.1). This was an excellent result as 
4.02, despite containing a bulky fluorophore as in analogous BODIPY-630/650-based 
fluorescent ligand 3.23, exhibited fifty-five fold higher affinity for CB2R than 3.23. The 
fluorescent ligand 4.02 also exhibited higher affinity and selectivity at CB2R than any 
reported CB2R fluorescent ligand (as of July 2018).
25, 155 Although both fluorescent 
ligands 4.02 and 3.23 contain bulky fluorophores, the higher affinity for CB2R of 4.02 
might be due to the different CB2R binding conformation of Cy5-based fluorescent ligand 
4.02, free from steric clashes suffered by 3.23 conformation. However, similar to 4.01, 
the high CB2R affinity of 4.02 could also be a result of other possibilities such as 
favourable interactions of the Cy5 fluorophore with the CB2R amino acid residues. 
 
 
Figure 4.6. Competition binding curves for the highest affinity CB2R fluorescent ligand 4.01, 4.02, and CP 
using radioligand [3H]-CP55,940 (Kd = 1.7 nM for hCB2R) at HEK-293 cells expressing hCB2R. Data 
represented is from a single experiment carried in triplicate and is expressed as mean ± SEM. 
 
The fluorophore Cy5 carries a net positive charge. The positive nitrogen could engage in 
specific ionic interactions with the acidic/anionic CB2R amino acids (such as E2, E3, E8, 
D18, D24) likely to be present in the vicinity of methylamine linker as indicated by the 
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docking pose of structurally related chromenopyrazole 3.25 (chapter 3, section 3.4), 
which might contribute to the high affinity for CB2R of 4.02. 
 
TAMRA-based fluorescent ligand 4.03 (Ki = 938.7 ± 127.9 nM at hCB2R; Table 4.1) had 
moderate affinity for CB2R, which was two times better than BODIPY-630/650-
derivative 3.23. This improvement in CB2R affinity might be ascribed to the similar 
reasons described for 4.02 and 4.01, that is due to the difference in the CB2R binding 
conformation of 4.03 compared to 3.23 or due to some favourable interactions of TAMRA 
fluorophore with the CB2R amino acid residues.  
 
The fluorescent ligands, 4.04 and 4.05, were prepared to evaluate the effect of the linker 
length (or more broadly the distance between fluorophore and ligand) on the CB2R 
affinity of 3.23. The BODIPY-630/650 derivative 4.04 (Ki = 1730 ± 377.3 nM at hCB2R), 
a long linker analogue of 3.23, exhibited a similar CB2R affinity to 3.23, revealing that 
increasing the 3.23 linker length did not improve CB2R affinity.The short linker 
BODIPY-FL derivative 4.05 (Ki = 661.7 ± 59.1 nM at hCB2R; Table 4.1) exhibited 
moderate affinity for CB2R. The reduced CB2R affinity of 4.05 compared to the longer-
linker BODIPY-FL derivative 4.01 is likely due to the steric clashes of the 4.05-BODIPY-
FL fluorophore with the CB2R amino acid residues. This result revealed that the linker 
present in 4.05 is not of sufficient length to provide enough separation between the 
BODIPY-FL fluorophore and the chromenopyrazole pharmacophore. 
 
The new polar peptide linker conjugates (4.06, 4.07, and 4.08) exhibited high to moderate 
affinity for CB2R (Table 4.1). The Ala-Ser linker conjugate 4.06 (Ki = 184 ± 37.8 nM at 
hCB2R) exhibited higher affinity for CB2R than Ser-Ala linker conjugate 4.07 (Ki = 
317.06 ± 55.9 nM at hCB2R) and Asn-Ser linker conjugate 4.08 (Ki = 461.8 ± 18.5 nM at 
hCB2R). The lower affinity for CB2R of the new peptide linker conjugates (4.06, 4.07 
and 4.08) compared to lead Ala-Ala peptide linker conjugate 3.39 (Ki = 138.4 ± 6.75 nM 
at hCB2R, Table 3.2, chapter 3) might be due to the presence of bulkier amino acid side 
chain residues on the ligand which may suffer from steric clashes with the CB2R amino 
acid residues. These polar peptide linker conjugates (4.06 (calculated logP (clogP) = 
3.42)‡, 4.07 (clogP = 3.42), and 4.08 (clogP = 1.94)) exhibit significantly higher polarity 
                                                 




compared to the commonly used literature CBR ligands, which are highly lipophilic, for 
example CP55,940 (clogP = 5.57), and therefore would be useful as chemical tools in 
CB2R studies requiring a polar ligand. 
 
The pyridyl chromenopyrazole 4.09 (Ki = 1600 ± 466.6 nM at hCB2R, Table 4.1), 
designed to access the effect of a heteroatom near the pyrazole-N-phenyl substituent on 
CB2R affinity, displayed twenty-two fold reduced affinity for CB2R compared to the 
benzene analogue 3.22 (Ki = 71.1 ± 6.7 nM at hCB2R, Table 3.2, chapter 3). This result 
showed that atoms near the pyrazole-N-phenyl substituent likely participate in important 
interactions with the CB2R amino acid residues. 
  
The docking studies of the second-generation fluorescent ligands (4.01-4.05) and the 
chromenopyrazole-linker conjugates (4.06-4.09) at CB2R were not carried out. The 
presence of long linkers having multiple rotatable bonds coupled with difficulty in 
homology modelling of loop region amino acids (which likely play an extensive role in 
CB2R binding with a large molecule such as a fluorescent ligand) make prediction of the 
CB2R binding poses of these ligands challenging and not particularly accurate. It is likely 
that these fluorescent ligands and linker conjugates would occupy similar CB2R binding 
pockets and bind in similar docking-poses as the ligand docking poses generated for 
chromenopyrazoles 3.25 and 3.29 respectively (chapter 3, section 3.4).  
 
It was suggested in a previous literature report that the cannabinoid receptor ligands enter 
CBR via the lipid membrane.219 It is likely that the ability of these chromenopyrazoles 
(shown in Table 4.1) to enter the lipid membrane would be affected by their polarity, 
charge, and molecular size and hence, these factors might also be important determinants 
of the chromenopyrazoles’ CB2R affinity of the. 
 
4.3.2 cAMP Functional assays  
 
The functional nature of second-generation chromenopyrazoles (4.01-4.08) at CB2R was 
determined by cAMP BRET assay as described in chapter 1 (section 1.5.2) and chapter 3 
(section 3.3.3), where the change in intracellular cAMP concentration was determined 
indirectly by a change in inverse BRET ratio (ratio of Rluc signal at 460 nm to YFP signal 
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at 535 nm). The functional nature of these chromenopyrazoles (4.01-4.08) was not 
determined at CB1R due to the low affinity for CB1R (Table 4.1).  
 
Functional determination of the fluorescent ligands (4.01-4.05) proved challenging as the 
fluorescence of these ligands changed the inverse BRET ratio of the cAMP BRET assay 
components including that of the vehicle (used as a negative control) (fluorescence 
interference in the cAMP assay conduced at WT HEK-293 cells shown in Appendix, 
Figure A.11). The initial screen of (4.01-4.05) was carried out at 10 µM concentration at 
CB2R expressing HEK-293 cells or at WT HEK-293 cells. It was hoped that for the high 
affinity CB2R fluorescent ligands (4.01 and 4.02), a lower concentration (1 or 3 µM) 
would not interfere with the inverse BRET ratio but would be sufficient to produce a 





Figure 4.7. The highest affinity CB2R fluorescent ligand 4.02 (1 μM) screened in a cAMP BRET assay: 
(A) cAMP BRET assay of 4.02 at HEK-293 cells stably expressing hCB2R. (B) cAMP BRET assay of 4.02 
at WT HEK-293 cells. Data is representative of a single experiment carried in duplicate and is expressed 
as mean ± SEM. Literature agonist CP (CP55,940), FSK (Forskolin), V (vehicle). 
 
The fluorescent ligand 4.02 at 1 µM (Figure 4.7, panel A and B, Table 4.3) did not change 
the inverse BRET ratio of either the vehicle controls or any other cAMP BRET assay 
reaction components while a minimal change was observed when 4.02 was tested at 3 
µM concentration (Figure 4.8 panel, A and B). The fluorescent ligand 4.02 (1 µM or 3 
µM) increased the intracellular cAMP concentration at CB2R expressing HEK-293 cells 
thus showing that 4.02 behaves as an inverse agonist (Figures 4.7 and Figure 4.8). The 
fluorescent inverse agonist 4.02 exhibited higher potency and efficacy (IC50 = 142.0 ± 
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13.1 nM; Emax = 196.7 ± 9.11 % of forskolin response at hCB2R, Table 4.2) than the 
commonly used selective CB2R inverse agonist SR144528 (IC50 = 536.1 ± 72.4 nM; 
Emax = 148.3 ± 14.17 % of forskolin response at hCB2R - values obtained in this thesis 
and in agreement with a recent literature report155). The fluorescent ligand 4.02 is the first 
high affinity CB2R fluorescent ligand for which functional data has been reported (as of 




Figure 4.8. The highest affinity CB2R fluorescent ligand 4.02 (3 μM) screened in a cAMP BRET assay: 
(A) cAMP BRET assay of 4.02 at HEK-293 cells stably expressing hCB2R. (B) cAMP BRET assay of 4.02 
at WT HEK-293 cells. Data is representative of a single experiment carried in duplicate and is expressed 
as mean ± SEM. A minimal change was observed in the inverse BRET ratio of the cAMP BRET assay 




Figure 4.9. Concentration-response curve for the highest affinity CB2R fluorescent ligand 4.02 and 
literature CBR inverse agonist SR (SR144528) using HEK-293 cells stably expressing hCB2R. All data is 
from at least three individual experiments performed and is expressed as mean ± SEM. Raw data is 
normalised to forskolin response (100 %) and vehicle response (0 %). 
 
Unfortunately, the fluorescent ligand 4.01 at 1 µM did not produce any significant 
response in the cAMP BRET assay and at 3 µM, a significant change in the inverse BRET 
ratio of the cAMP BRET assay reaction components due to the fluorescence of 4.01 was 
observed (data for cAMP BERT assay carried out for 4.01 (1 µM and 3 µM) shown in 
Appendix, Figure A.12). Consequently, the functional nature of 4.01 could not be 
determined by this cAMP BRET assay. The fluorescent ligand 4.01 produces a large 
change in the inverse BRET ratio in the cAMP BRET assay as BODIPY-FL excitation 
and emission (excitation 460 nM, emission 535 nM) falls in the same range as the BRET 
signal (Rluc signal at 460 nm and YFP signal at 535 nm) in the cAMP assay. Interestingly, 
the BRET assay data for another BODIPY-FL fluorescent ligand 4.05 does not show 
significant change in the BRET ratio of cAMP BRET assay reaction components (shown 
in Appendix, Figure A.11, panel E). However, considering the large interference observed 
for 4.01 and the fact that BODIPY-FL fluorescence spectra falls in the cAMP BRET assay 
signal range, it is likely that the magnitude of the fluorescence interference produced by 
4.05 is reduced by some unclear mechanisms. 
 
Fluorescent ligand 4.03 (excitation 565 nM, emission 580 nM) also has excitation and 
emission in a similar range as to cAMP assay signal, and again interference was observed 
in the cAMP BRET assay. In contrast, fluorescent ligands 4.02 (excitation 646 nM, 
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emission 662 nM) and 4.04 (excitation 630 nM, emission 650 nM) do not exhibit 
excitation and emission in the cAMP BRET assay signal range (Figure A.11, panel C). 
Nevertheless, a significant fluorescence interference was observed in the cAMP assay 
with 4.02 and 4.04 at 10 µM (shown in Appendix, Figure A.11, panel B and panel D). In 
future studies, the functional nature of 4.01 and 4.03 - 4.05 could be determined by non-
fluorescence based functional assays such as a [35S]GTPγS assay. 
 
All of the newly synthesised polar peptide chromenopyrazole conjugates (4.06-4.08) 
behaved as agonists at CB2R. None of the peptide conjugates (4.06-4.08, at 10 μM) 
showed a response significantly different from forskolin in the cAMP BRET assay at WT 
HEK-293 cells (Table 4.3) and thus did not exhibit CB2R independent cAMP effects. The 
Asn-Ser peptide linker conjugate 4.08 (EC50 = 44.1 ± 5.0 nM; Emax = 73.27 ± 1.21 % of 
forskolin response at hCB2R) exhibited lower potency and efficacy than Ala-Ser peptide 
linker conjugate 4.06 (EC50 = 32.7 ± 2.9 nM; Emax = 55.96 ± 1.07 % of forskolin response 
at hCB2R) and Ser-Ala peptide linker conjugate 4.07 (EC50 = 23.7 ± 3.2 nM; Emax = 61.55 
± 3.51 % of forskolin response at hCB2R; Table 4.2). Although all three new peptide 
linker conjugates (4.06-4.08) were less potent than Ala-Ala-conjugate 3.39 (EC50 = 17.3 
± 5.3 nM at hCB2R; chapter 3, Table 3.3), the Ala-Ser peptide linker conjugate 4.06 (Emax 
= 55.96 ± 1.07 % of forskolin response at hCB2R) showed higher efficacy than 3.39 (Emax 
= 61.2 ± 1.53 nM % of forskolin response at hCB2R; chapter 3, Table 3.3).  
 
It is difficult to rationalise the complex role of conformational changes, lipophilicity, 
steric bulk, and hydrogen bonding to explain the trends in the CB2R potency and efficacy 
of the peptide linker conjugates (3.39, 4.06-4.08). In the cAMP BRET assay carried out 
in this thesis, all of the tested novel chromenopyrazoles (3.22, 3.25, 3.29, 3.31, 3.47 
including peptide conjugates 3.39, 4.06-4.08) described in this chapter or chapter 3 
behaved as CB2R agonists, however, the highest affinity CB2R fluorescent ligand 4.02 
behaved as an inverse agonist. Perhaps an appreciable increase in the molecular size of a 
small sized agonist (for example 3.25 to 4.02) might be partly responsible for the change 







Table 4.2. CB2R functional data of the second-generation chromenopyrazoles 
Compound EC50 (nM± SEM)* Emax (%FSK response ± SEM)# Functional activity 
4.02 142.0 ± 13.1b 196.7 ± 9.11 Inverse Agonist 
4.06 32.7 ± 2.9a 55.96 ± 1.07 Agonist 
4.07 23.7 ± 3.2a 61.55 ± 3.51 Agonist 
4.08 44.1 ± 5.0a 73.27 ± 1.21 Agonist 
*Potency (EC50) and 
#
efficacy (Emax) data for the chromenopyrazoles, obtained from cAMP BRET assay 
using HEK-293 cells expressing hCB2R. All data is from at least three individual experiments performed, 
raw data is normalised to forskolin response (100 %) and vehicle response (0 %). a EC50 for agonists. b IC50 
for inverse agonists. 
 
The functional nature of novel chromenopyrazoles (3.25, 3.22, 3.29, 3.31, 3.39, 3.47, 
4.02, 4.06-4.08) in this thesis was determined by a cAMP BRET assay, other CBR 
signalling pathways such as activation of ERK, GIRK and recruitment of β-arrestin are 
yet to be investigated. 
 
Table 4.3. % Response in cAMP BRET assay at wild type HEK-293 cells. 
Compound % FSK Response ± SEM* 
4.02 102.99 ± 3.56 
4.06 101.70 ± 1.77 
4.07 105.86 ± 7.29 
4.08 98.33 ± 3.73 
*All compounds tested at (10 μM) in the cAMP BRET assay at WT HEK-293 cells except for 4.02 (tested 
at 1 μM). All data is from at least two individual experiments performed in duplicate, raw data is normalised 
to forskolin response (100 %) and vehicle response (0 %). A one-sample t-test was used to determine 
whether the % cAMP response of test compounds was significantly different from the forskolin only 
response. 
 
4.3.3 Imaging studies 
 
Widefield imaging experiments were carried out by collaborators at the University of 
Auckland to determine the suitability of highest affinity CB2R fluorescent ligand 4.02 to 
visualise CB2R at a single cell level in the CB2R expressing HEK-293 cells. Pleasingly, 
the fluorescent ligand 4.02 exhibited clear cell surface labelling with no intracellular 
accumulation (Figure 4.10 – panel (A) and panel (D)). Yellow colour at the cell surface 
seen in panel (A) arises from colocalisation of 4.02 (red) and mouse anti-HA primary 
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antibody, Alexa 488-conjugated goat anti-mouse secondary antibody (green). CB2R 
specific binding was evident since there was only a very low amount of 4.02 binding 
when the cells were co-incubated with SR144528 (30 µM, a selective CB2R inverse 
agonist) (Figure 4.10 – panel (B) and panel (E)). Further CB2R specific binding was 
shown by the very low 4.02 binding on incubation with HEK-293 cells transfected with 
an empty vector (Figure 4.10 – panel (C) and panel (F)). These studies show that 4.02 
possess suitable properties for the imaging of CB2R at the single cell level.  
 
 
Figure 4.10. Widefield fluorescence microscopy imaging of 4.02 at HEK-293 cells expressing hCB2R. (A) 
HEK-Flp cells transfected with pplss-HA-hCB2R incubated for 2 min at rt with 1 µM of 4.02 (red). Mouse 
anti-HA primary antibody and Alexa 488-conjugated goat anti-mouse secondary antibody (green) were 
used to visualise hCB2R, and Hoechst 33258 (blue) was used to visualise nucleus respectively. (B) – similar 
experiment as (A) except that cells were also co-incubated with 30 µM of SR144528 (a non-fluorescent, 
selective CB2R inverse agonist. (C) – similar experiment as in (A) except that HEK-Flp WT cells 
transfected with an empty vector. (D), (E) and (F) are similar experiments as shown in (A), (B) and (C) 
respectively except that cells were incubated for 2 min at rt with 1 µM of 4.02 and no Hoechst 33258 stain 
or antibodies were used and images shown in black/white colour. Data was generated by the collaborators 






4.4 Summary and conclusions 
 
The second-generation fluorescent ligands (4.01-4.05, Table 4.1), based on the previously 
developed lead fluorescent ligand 3.23 (Table 3.2, chapter 3), were prepared with the aim 
of improving CB2R affinity. The new fluorescent ligands were designed to contain similar 
chromenopyrazole-linker structures so that the CB2R affinity of different fluorescent 
ligands could be directly correlated with the different fluorophores. Three new polar 
peptide linker analogues containing polar amino acids serine and asparagine (4.06-4.08, 
Table 4.1), following on from peptide linker conjugate 3.39 (Table 3.2, chapter 3), were 
also prepared. A pyridyl derivative 4.09 (Table 4.1) of 3.22 was also prepared with the 
aim of interrogating the importance of atoms near the pyrazole-N-phenyl substituent in 
CB2R binding. 
 
All of the new chromenopyrazoles were then evaluated for CBR affinity using a 
radioligand competition-binding assay. Similar to the CBR affinity trends observed in 
chapter 3 (section 3.3.2, chapter 3), most of the chromenopyrazoles (4.01-4.09, Table 4.1) 
displayed higher affinity for CB2R and selectivity over CB1R (Table 4.1). Delightfully, 
the Cy5-based fluorescent ligand 4.02 (Ki = 41.8 ± 4.5 nM at hCB2R; 5856 ± 1264 nM at 
hCB1R, Table 4.1) and BODIPY-FL-based fluorescent ligand 4.01 (Ki = 145.5 ± 11.8 nM 
at hCB2R; > 1000 nM at hCB1R, Table 4.1) displayed high affinity for CB2R and 
selectivity over CB1R. Three moderate affinity CB2R fluorescent ligands (4.03, 4.04, 
4.05; Table 4.1) were also prepared. New polar peptide linker conjugates (4.06-4.08, 
Table 4.1) showed high to moderate affinity for CB2R and selectivity over CB1R. 
Chromenopyrazole 4.09 (Table 4.1), pyridyl analogue of 3.22, showed twenty two-fold 
reduced CB2R affinity compared to 3.22. 
 
The highest affinity CB2R fluorescent ligand 4.02 (EC50 = 142.0 ± 13.1 nM; Emax = 196.7 
± 9.11 % of forskolin response at hCB2R) behaved as an inverse agonist in the cAMP 
functional assay (Table 4.2). Importantly, all of the new polar peptide linker conjugates 
(4.06, 4.07, and 4.08; Table 4.1) behaved as agonists in the cAMP BRET assay. These 
polar peptide linker agonists would be useful in CB2R studies requiring a polar ligand, 
for example in receptor trafficking studies. The peptide linker conjugate 4.06 (Emax = 
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55.96 ± 1.07) exhibited the highest efficacy and peptide linker conjugate 4.07 (EC50 = 
23.7 ± 3.2 nM) exhibited the highest potency. 
 
The highest affinity CB2R fluorescent ligand 4.02 (Table 4.1) was evaluated in widefield 
imaging experiments by collaborators and showed CB2R specific binding (Figure 4.10). 
The aim of developing a high affinity CB2R fluorescent ligand with suitable properties 
for imaging CB2R was therefore achieved. 
 
4.5 Future directions 
 
The highest affinity CB2R fluorescent ligand 4.02 is currently being used for studying 
CB2R pharmacology via widefield imaging experiments. Another high affinity CB2R 
fluorescent ligand 4.01 containing different fluorophore and with different molecular 
charge compared to 4.02 will be evaluated in various imaging and pharmacological 
assays. 
 
Fluorescent ligand 4.02 behaved as an inverse agonist at CB2R in the cAMP assay, 
however, the functional nature of the other fluorescent ligands (4.01, 4.03-4.05) could not 
be determined due to the fluorescence interference. Determination of the functional nature 
of the fluorescent ligands (4.01-4.05) ideally via a non-fluorescence based assay and in 
various CB2R signalling pathways (for example activation of ERK, GIRK, and 
recruitment of β-arrestin) could be carried out. CB2R chromenopyrazole agonists (3.22, 
3.25, 3.29, 3.31, 3.39, 3.47) are promising leads for developing a fluorescent CB2R 
agonist.  
 
As can be seen from the CB2R affinities of the fluorescent ligands reported in this chapter 
(Table 4.1), fluorophores exert a huge influence on the CB2R affinity. Hence, preparation 
of new fluorophore conjugates including a sulphonic acid derivative of Cy5 would be an 
attractive strategy to improve the polarity of the fluorescent ligand.  
 
Synthesis of the chromenopyrazole-linker conjugates containing linkers of different 
length and new peptide-linker conjugates can be made to improve the polarity and CB2R 
affinity. The peptide linker analogues of only high CB2R affinity chromenopyrazole 3.29 
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(chapter 3, Table 3.2) were prepared in this thesis, however, the peptide analogues of the 
highest CB2R affinity chromenopyrazole-linker conjugate 3.22 (chapter 3, Table 3.2) 
remain to be explored. A polar peptide chromenopyrazole-linker conjugate would be 
useful tool to study CB2R trafficking. The polar peptide chromenopyrazoles could also 





Chapter 5 Development of pyridyl derivatives 
as fluorescent ligands for cannabinoid type 1 
receptor 
5.1 Design rationale for pyridyl-2-carboxamide-based 
fluorescent ligands 
 
Most of the chromenopyrazoles designed as CB1R agonists in chapter 3 of this thesis did 
not exhibit high affinity for CB1R. In this chapter, pyridyl derivatives were investigated 
as a new series for development into CB1R fluorescent agonists.  
 
Researchers at AstraZeneca reported pyridyl derivatives as high affinity CB1R 
agonists.223-224 Representative examples of these pyridyl derivatives, including those on 
which the design rationale was based, are shown in Table 5.1. The lead compound 5.1 of 
this pyridyl series was identified by screening a GPCR compound library. Efforts to 
improve the CB1R affinity by substitution of the ‘core’ phenyl ring of 5.1 with a pyridyl 
ring led to pyridyl-2-carboxamide 5.2 with high affinity for CB1R and reduced 
lipophilicity.  
 
Further optimisation of 5.2 was carried out by the researchers at AstraZeneca to identify 
a number of high affinity CB1R agonists.
223-224 The SAR studies of these pyridyl-2-
carboxamides (including 5.3-5.7) revealed that aromatic moieties including naphthalene 
with a polar triazoline group or quinoline at the C-3 position of the pyridine were well 
tolerated at CB1R (Table 5.1). These pyridyl-2-carboxamides (5.3-5.7) with cyclic 
aliphatic moieties such as cyclobutylmethyl at the C-2 position of the pyridine exhibited 
high affinity for CB1R (Table 5.1). Importantly, these pyridyl-2-carboxamides tolerated 
bulky/long substituents at the C-6 position of the pyridine, for example compound 5.4 
and 5.7, indicating potential for the tolerance of a bulky/long linker in this position (Table 
5.1). The high affinity for CB1R (and selectivity over CB2R) of these pyridyl-2-
carboxamides, tolerance of the bulky/long substituents, favourable polarity, and presence 
of aromatic hydroxyl, amide functional groups (for the introduction of linkers) made these 









IC50 or Ki hCB1R 
(nM)* 
IC50 or Ki hCB2R 
(nM)* 
Ref 
5.1 - 160a  1800a 223 
5.2 - 10a  110a 223 




3.2b Not reported 224 
5.5 H 28a 82a 223 
5.6 CH3 15a 100a 
223 
5.7  10
a 1200a 223 
*Binding affinity (Ki or IC50) obtained by competition binding assay performed on membranes obtained 
from HEK-293 cells expressing hCB1R or Sf9 cells expressing hCB2R with [3H]-CP55,940 as radioligand. 
aIC50, bKi 
 
Computational studies were used to further evaluate the suitability of the C-6 position for 
the introduction of long linkers to the pyridyl-2-carboxamides in this thesis. As the 
pyridyl-2-carboxamides (5.2-5.7) were reported as CB1R agonists (determined by a 
[35S]GTPγS assay at HEK-293 cells expressing canine cannabinoid type 1 receptor 
(cCB1R)
223), the active state structure of CB1R (PDB ID: 5XRA) published by Hua et 
al.113 was used for the ligand docking studies.  
 
The pyridyl-2-carboxamides (including 5.2-5.7) contain a flexible ‘core’ of pyridine with 
2-carboxamide and 3-aminocarbonyl substituents. It was reported previously that these 
pyridyl-2-carboxamides (including 5.2-5.7 in Table 5.1) likely bind to CB1R in a planar 
conformation, which exists due to the presence of an intramolecular hydrogen bond 
between NH of the 2-carboxamide moiety and nitrogen of the pyridine.223 This 
assumption was based on a marked higher affinity for CB1R of 5.2-5.7 relative to 5.1 and 
other pyridyl or pyrazinyl isomers223 (structures not shown) which lacked the 
heteroaromatic nitrogen α to the 2-carboxamide moiety (necessary for the formation of 
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the intramolecular hydrogen bond to obtain the planar conformation). A hydrogen bond 
was observed in this thesis (discussed in section 5.2.2) between NH of 3-aminocarbonyl 
moiety and oxygen of 2-carboxamide moiety in the new pyridyl-2-carboxamides (5.3, 
5.30-5.35, 5.37-5.39, 5.49-5.52 and 5.54; synthesis described in section 5.2.2, 5.2.3, 5.2.4, 
5.2.5 and 5.2.6). 
 
So, before commencing CB1R docking studies, a conformational search for the highest 
affinity CB1R literature pyridyl-2-carboxamide 5.3 (used as a model compound for the 
CB1R docking studies of pyridyl-2-carboxamides) was performed in MarvinSketch.
 225 
224 224 224 The lowest energy conformation of 5.3 (a planar conformation) showed 
intramolecular hydrogen bonds between the pyridine nitrogen and NH of 2-carboxamide 
moiety and another between NH of 3-aminocarbonyl moiety, oxygen of the 2-
carboxamide moiety (Figure 5.1 (A)). 
 
Further, a search of three-dimensional structures similar to 5.3 with a pyridine 
substructure query (shown in Figure 5.2 (A)) was carried out using the Cambridge 
Structural Database173 (searched using ConQuest), but did not provide any results. 
Another search with a benzene substructure query (shown in Figure 5.2 (B)) provided 
three compounds (CSD ID – ALUCAN,226 CUCYAC,227 and MUDKUT228), all of which 
showed an intramolecular hydrogen bond between NH of aminocarbonyl and oxygen of 
carboxamide moieties. However, in contrast to the lowest energy conformation obtained 
from MarvinSketch (Figure 5.1 (A)), the carboxamide and aminocarbonyl moieties were 
not planar in these known compounds. These differences might be because the 
compounds were benzene derivatives and not pyridine derivatives, as was 5.3 (there is a 
hydrogen present in the benzene ring where the pyridyl nitrogen would be and thus 
causing a potential clash with the carboxamide NH). Based on the results obtained from 
MarvinSketch, CSD, and the previous report223 of the pyridyl-2-carboxamides, it was 
decided to use the lowest energy conformation of 5.3 with selected rotatable bonds (bold 





Figure 5.1. (A) The lowest energy conformation of 5.3 (obtained by a conformational search using 
MarvinSketch, 225 224 224 224 (cyan carbons, red oxygens, blue nitrogens, white hydrogens)). Hydrogen bonds 
are shown as yellow lines. (B) The selected bonds (bold) of 5.3 were fixed from the rotation in one of the 
CB1R docking studies – shown in Figure 5.3. (C) Only amide bonds (bold) of 5.3 were fixed from the 
rotation in a second CB1R docking study – shown in Figure 5.5. 
 
GOLD217 was used for the docking studies with the CB1R binding site of the 5.3 defined 
as a 15 Å region around the CB1R co-crystallised ligand AM11542 (PDB ID: 5XRA). 
The docking studies were carried out only with 5.3 as other designed analogous pyridyl-
2-carboxamides (shown in Figure 5.6) were believed to bind CB1R in similar docking 




Figure 5.2. (A) Pyridine and (B) benzene – substructures queries used for search of compounds similar to 
pyridyl-2-carboxamide 5.3 in CSD with ConQuest.  
 
The docking studies (carried out with rotation-restricted bonds of the lowest energy 
conformation of 5.3; Figure 5.1 (B)) showed 5.3 to occupy a similar region in the CB1R 
binding pocket (Figure 5.3) as was previously observed for AM11542 in the CB1R crystal 
structure (PDB ID: 5XRA). A hydrogen bond was observed between AM11542 and S383 
in the CB1R crystal structure (PDB ID: 5XRA), however, no hydrogen bond(s) was 
observed between 5.3 and CB1R amino acids in the docking studies carried out in this 
thesis. Previously, another CB1R ligand AM6538 (PDB ID: 5TGZ) was observed to 
interact with CB1R amino acids primarily by a number of aromatic and van der Waals 
interactions and a hydrogen bond interaction was not observed. In the docking studies of 
5.3, the aromatic interactions were observed between aromatic rings of 5.3 and F268, 
F379, W279, Y275, F200, F170, F174, F177, H178. van der Waals interactions were also 
observed between 5.3 and residues S173, K192, I267, I271, P269, L193, L359, M363, 
T275, L276, and V196 (Figure 5.3). The docking pose of 5.3 showed that the methoxy 
moiety was pointing towards a small cavity located between TM1 and TM7, near the 
extracellular N-terminal of CB1R (Figure 5.3). The cyclobutylmethanamine moiety and 
triazoloylmethylnaphthalene moiety were buried in the TM region and appeared 





Figure 5.3. Docking pose of 5.3 (cyan carbons, red oxygens, blue nitrogens) in the CB1R crystal structure 
(PDB ID: 5XRA; forest green ribbon). Side chain residues forming hydrophobic interactions with 5.3 are 
shown as sticks (leaf green). Docking carried out with restricting rotation of the selected bonds of the lowest 
energy conformation of 5.3 (bold bonds in structure shown in rectangle) 
 
Docking studies were also carried out without restricting rotation of the bonds of 5.3 
(lowest energy conformation; Figure 5.1 (A)) and showed the 
triazoloylmethylnaphthalene moiety (particularly the unsubstituted naphthyl ring atoms) 
as the most promising position for the introduction of linkers (Figure 5.4). In these 
docking studies carried out without rotation-restricting the bonds of 5.3 (lowest energy 
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conformation; Figure 5.1 (A)), GOLD changed the conformation of the amide bond (the 
amide bond between naphthyl moiety and C-3 pyridine; Figure 5.1(A)) of 5.3 from cis to 
trans during the ligand initialisation stage, before commencing the actual docking run.  
 
 
Figure 5.4. Docking pose of 5.3 (cyan carbons, red oxygens, blue nitrogens) in the CB1R crystal structure 
(PDB ID: 5XRA; forest green ribbon). Side chain residues forming hydrophobic interactions with 5.3 are 
shown as sticks (leaf green). Docking study was carried out without restricting rotation of the amide bonds 
of the lowest energy conformation of 5.3 (structure shown in Figure 5.1 (A); structure also shown in 
rectangle). The amide bond between naphthyl moiety and C-3 pyridine of 5.3 was flipped from cis to trans 




It was decided to carry out another docking study with the conformation of amide bonds 
preserved (by restricting rotation of only amide bonds (bold bonds) shown in Figure 5.1 
(C)) (docking pose shown in Figure 5.5). Docking studies carried out with restricted-
rotation of only amide bonds, rotation of the single bond connecting C-2 and the 2-
carboxamide carbon caused the movement of 2-carboxamide moiety such that the 
intramolecular hydrogen bonds observed in the lowest energy conformation of 5.3 (Figure 
5.1 (A)) were not feasible. These docking studies with restricted-rotation of only amide 
bonds showed the methoxy moiety as the most promising position for the introduction of 
linkers (Figure 5.5; as was also observed for docking studies shown in Figure 5.3).  
 
 
Figure 5.5. Docking pose of 5.3 (cyan carbons, red oxygens, blue nitrogens) in the CB1R crystal structure 
(PDB ID: 5XRA; forest green ribbon). Side chain residues forming hydrophobic interactions with 5.3 are 
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shown as sticks (leaf green). Docking study carried out with restricting only amide bonds from rotation of 
the lowest energy conformation of 5.3 (bold bonds in structure shown in rectangle). 
 
Overall, the docking studies (carried out with or without rotation restricting the bonds of 
lowest energy conformation of 5.3) showed that the most suitable positions for 
conjugation of long linkers would be either the triazoloylmethylnaphthalene moiety or 
the methoxy moiety (bonded to the C-6 atom). 
 
Based on the docking studies but with emphasis on the previously reported pyridyl-2-
carboxamides SAR223-224 (for example 5.4 and 5.7 in Table 5.1), it was concluded that the 
C-6 position of the pyridyl-2-carboxamides would be most suitable for the conjugation 
of bulky/long linkers. It was decided to prepare two series of (C-6)-linkers-pyridyl-2-
carboxamides – one with triazoloylmethylnaphthalene moiety and another with a 
quinoline moiety at the C-3 position of the pyridyl-2-carboxamides.  
 
New triazoloylmethylnaphthalene-pyridyl-2-carboxamides containing PEG linkers, 
alkyl-PEG linkers, and peptide linkers were designed (Figure 5.6) to build knowledge 
regarding the influence of different linkers on CB1R affinity. The alkyl-PEG linker 
derivative with a short lipophilic alkyl chain separating the pharmacophore from the 
hydrophilic PEG linker was designed. The short alkyl chain would hopefully contribute 
to the tolerance of the hydrophilic linker in the lipophilic CB1R binding pocket. Further, 
a pyridyl-PEG-linker derivative of triazoloylmethylnaphthalene-pyridyl-2-carboxamides 
was designed as a similar pyridyl moiety was previously well tolerated, for example 5.4 
(Table 5.1). It was envisioned that if an extended linker derivative of 5.4 with moderate 
affinity for CB1R was identified, linker-regioisomers of 5.4 could be synthesised to probe 
the chemical space around the short pyridyl linker. 
 
It was decided to prepare only PEG linker conjugates of quinoline-pyridyl-2-
carboxamides series, which could be compared with analogous triazoloylmethyl-
naphthalene-pyridyl-2-carboxamides (Figure 5.6). It was hoped that PEG linker 
derivatives of the quinoline-pyridyl-2-carboxamide series would retain high affinity for 






Figure 5.6. New pyridyl-2-carboxamides designed as potential CB1R agonists. 
 
The new pyridyl-2-carboxamide-based fluorescent ligands would be prepared by facile 
reaction of pyridyl-2-carboxamide-linker conjugates with a fluorophore (BODIPY-
630/650-SE; Figure 5.7). The pyridyl-2-carboxamide-linker conjugates would be 
synthesised by reaction of corresponding hydroxypyridines with the linker derivatives. 
The hydroxypyridines would be prepared from the key intermediate 5.8 using an 
analogous synthetic route as reported previously for the synthesis of pyridyl-2-
carboxamides by researchers at AstraZeneca.223  It was thought that the key intermediate 
5.8 could be prepared from the commercially available pyridine 5.9 by the nucleophilic 





Figure 5.7. Retrosynthesis of fluorescent pyridyl-2-carboxamides designed in this chapter. 
 
Only a subset of the designed pyridyl-2-carboxamides were synthesised (described in 
Figure 5.6) due to the limited number of compounds that could be pharmacologically 
evaluated during this PhD timeframe in the collaborator’s laboratory. The fluorophore 
BODIPY-630/650 was selected because of the superior spectroscopic properties 
including high quantum yield and emission in the red spectral region and previous use in 
developing GPCR fluorescent ligands. 43, 86 Depending on the initial biological results, a 
revised series of high affinity pyridyl-2-carboxamide-based linker and fluorophore 




5.2 Synthesis and structural characterisation 
5.2.1 Synthesis of linkers 
 
Four types of linkers were used in the synthesis of pyridyl-2-carboxamide-linker-
conjugates described in this chapter. Synthesis of the PEG linker 5.12, pyridyl-PEG linker 
5.17, and alkyl-PEG linker 5.18 are described in this section and synthesis of pyridyl-2-
carboxamide peptide linker conjugates (5.45 and 5.46) are described in section 5.2.5. 
 
Boc-protection of the commercially available amine 5.10 gave 5.11, which was reacted 
with methanesulfonyl chloride to give the PEG linker mesylate 5.12 (Scheme 5.1). 
 
 
Scheme 5.1. (i) (Boc)2O, EtOH. (ii) MeSO2Cl, Et3N, DCM, 0 °C to rt, 96% over two steps from 5.10. 
 
Synthesis of the pyridyl-PEG linker 5.17 began with esterification of the commercially 
available carboxylic acid 5.13 to give 5.14 (compound not purified). Alkylation of the 
hydroxypyridine 5.14 with the PEG linker 5.12 using K2CO3 as a base gave ester 5.15, 
which was reduced with LiAlH4 to give 5.16 (compound not purified). The pyridyl 
alcohol 5.16 was reacted with methanesulfonyl chloride to afford mesylate 5.17 
(compound not purified). 
 
 
Scheme 5.2. (i) SOCl2, MeOH, 75 °C. (ii) 5.12, K2CO3, DMF, 60 °C, 64% over two steps from 5.14. (iii) 




The alkyl-PEG linker 5.18 was prepared by coupling the commercially available bromo 
acid 3.49 with the commercially available alcohol 4.16 using TFFH as a coupling reagent 
and Et3N as a base. 
 
 
Scheme 5.3. (i) TFFH, Et3N, DCM, 84%. 
 




Wohl–Ziegler bromination of the commercially available carboxylic acid 5.19 with N-
Bromosuccinimide (NBS) and 2,2′-Azobis(2-methylpropionitrile) (AIBN) following a 
literature procedure229 gave 5.20 (compound not purified; Scheme 5.4). The 
naphthylmethyl bromide 5.20 was reacted with 1,2,3-triazoline according to a reported 
synthesis230 to provide 5.21. The carboxylic acid 5.21 was reacted with SOCl2 to provide 
acid chloride 5.22 (compound not purified). 
 
 
Scheme 5.4. (i) NBS, AIBN, CCl4, 80 °C. (ii) 1,2,3-Triazoline, DMF, 50 °C, 91% over two steps from 
5.19. (iii) SOCl2, 80 °C. 
 
Synthesis of pyridine 5.8 (a key intermediate in the synthesis of pyridyl-2-carboxamides, 
Figure 5.7) commenced with the nucleophilic aromatic substitution of the commercially 
available pyridine 5.9 with NaOMe in an attempt to obtain 5.23 (Scheme 5.5). 
Disappointingly, initial reactions of the pyridine 5.9 with NaOMe provided 5.24 or a 
mixture of 5.23 and 5.25. After several experiments, it was observed that predominantly 
one product (5.23 or 5.24 or 5.25) could be obtained by amending the equivalents of 
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NaOMe used and the time interval between addition of each equivalent in the substitution 
reaction (optimised reaction conditions summarised in Table 5.2).  
 
The desired pyridine 5.23 was obtained as the major product upon the reaction of only 
one equivalent of NaOMe (<15 % w/v NaOMe solution in MeOH) with 5.9 (Table 5.2). 
This was not obvious from the outset since 5.23 and starting pyridine 5.9 had a very 
similar TLC Rf (TLC was used for monitoring the progress of the substitution reaction, 
the structure of 5.23 was confirmed by NMR spectroscopy and HRMS experiments). 
Therefore, a TLC spot at the same Rf was incorrectly interpreted as an incomplete reaction 
and more equivalents of NaOMe were added, leading to the formation of 5.25.  
 
 
Scheme 5.5. (i) NaOMe, MeOH, 0 °C. Attempts to prepare pyridine 5.23 resulted in the formation of 5.24 
and 5.25. Reaction conditions for the preparation of a particularly substituted pyridine (5.23 or 5.24 or 5.25) 
are summarised in Table 5.2. 
 








<15 % w/v NaOMe solution in MeOH added to the reaction 
mixture; <5 % w/v concentration of NaOMe in the reaction 
mixture. 
5.23 
2.0 or more 
20 % w/v NaOMe solution in MeOH added to the reaction 
mixture. 
5.24 
2.0 or more 
Reaction with one equivalent of NaOMe, followed by 
reaction with another equivalent of NaOMe after a delay of 
10 min. NaOMe used as <15 % w/v solution in MeOH. 
5.25 
 
The pyridine 5.24 was obtained as the sole product upon reaction of two or more 
equivalents of NaOMe (20 % w/v NaOMe solution in MeOH) with the pyridine 5.9 (Table 
5.2). On the other hand, pyridine 5.25 was obtained as the major product from the reaction 
of 5.9 with one equivalent of NaOMe (<15 % w/v NaOMe solution in MeOH), followed 
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by a time interval of 10 minutes and then reaction with another equivalent of NaOMe 
(Table 5.2). 
 
These observations could be explained by the fact that reaction of 5.9 with one equivalent 
of NaOMe forms 5.23, in which the influence of the +R (resonance) electron donating 
OMe group decreases the reactivity of the pyridine ring towards further nucleophilic 
substitution and so additional equivalents of NaOMe results in additional reaction at the 
electrophilic nitrile carbon to form 5.25. The reasons for the formation of the dimethoxy 
pyridine 5.24 are less clear but likely involve nucleophilic aromatic substitution at C-2 of 
5.9, followed by substitution at C-6 of 5.9 with NaOMe. The dimethoxy pyridine 5.24 
does not form via 5.23 as an intermediate because pyridine 5.25 was the only major 
product isolated (yield 95%) upon reaction of additional equivalents (two or more) of 
NaOMe with 5.23. 
 
Efforts were then focused on synthesising pyridyl-2-carboxamide 5.3 (Scheme 5.6). The 
nitropyridine 5.23 was reduced with SnCl2.2H2O to provide 5.26. The cyanopyridine 
5.26, upon alkaline hydrolysis using aqueous KOH, gave 5.8. Reaction of carboxylic acid 
5.8 with cyclobutylmethanamine using HATU as a coupling reagent provided 5.27 and 
cyclobutylmethanamine to give 5.27  
 
Coupling was then attempted between 5.27 and carboxylic acid 5.21 (synthesis shown in 
Scheme 5.4) using HATU or TFFH as the coupling reagent, however both attempts were 
unsuccessful. This failure of the coupling reaction is attributed to the low nucleophilicity 
of the amino group of 5.27 due to the presence of the electron withdrawing α-carboxamide 
moiety and the pyridine ring. Instead, following a literature procedure for the synthesis 
of analogous pyridyl-2-carboxamides,223 5.3 was successfully obtained by the reaction of 
5.27 with acid chloride 5.22 (synthesis shown in Scheme 5.4) (Scheme 5.6).  
 
The 1H NMR spectrum of pyridyl-2-carboxamide 5.3 indicated that the NH of 3-
aminocarbonyl participates in a hydrogen bond. The participation of 3-aminocarbonyl 
NH in hydrogen bonding was suggested by the upfield chemical shift of 3-aminocarbonyl 
NH (12.64 ppm) and presence of 3-aminocarbonyl NH as a sharp peak (likely due to the 
slow chemical exchange). It is likely that NH of the 3-aminocarbonyl participates in an 
intramolecular hydrogen bond with the oxygen of the neighbouring 2-carboxamide, as 
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observed in the lowest energy conformation of 5.3 (section 5.1, Figure 5.1 (A) and the 
compounds (CSD ID – ALUCAN,226 CUCYAC,227 and MUDKUT228) obtained from the 
CSD search, section 5.1). Subsequently synthesised pyridyl-2-carboxamides (5.3, 5.30-
5.35, 5.37-5.39, 5.49-5.52 and 5.54; synthesis described in section 5.2.2, 5.2.3, 5.2.4, 
5.2.5 and 5.2.6) also indicated the presence of 3-aminocarbonyl NH hydrogen bond. 
These observations support the assumption that 5.3 and other pyridyl-2-carboxamides 
likely exist in a conformation with intramolecular hydrogen bond(s) (section 5.1). 
 
 
Scheme 5.6. (i) SnCl2.2H2O, EtOH, 62%. (ii) Aqueous KOH, MeOH, 80 °C, 59%. (iii) 1-
Cyclobutylmethanamine hydrochloride, HATU, DIPEA, DMF, 68%. (iv) 5.22, DIPEA, CHCl3, 80 °C, 
92%. 
 
Although pyridyl-2-carboxamide 5.3 was first obtained by following the synthetic route 
shown in Scheme 5.6, attempts to prepare pyridine 5.23 in larger scale (>500 mg) for 
preparing other analogues in accordance with conditions optimised in Table 5.2 resulted 
in the significant formation of 5.25 along with 5.23 (for example reaction of 5.9 (4.0 g) 
with NaOMe provided 5.23 (62%) and 5.25 (33%)). In addition, the carboxylic acid 5.8 
in Scheme 5.6 was difficult to purify. Therefore, a revised synthetic scheme for the 
preparation of pyridyl-2-carboxamide 5.3 was developed (Scheme 5.7).  
 
In the revised synthesis (Scheme 5.7), commercially available pyridine 5.9 was converted 
to imidate 5.25 (using optimised reaction conditions shown in Table 5.2), which was not 
isolated and reacted with methanol under acidic conditions to give 5.28 in a one pot 
reaction. Conversion of the nitrile of 5.9 to the ester of 5.28 is an example of the Pinner 
reaction. The nitropyridine 5.28 was then reduced with SnCl2.2H2O to give 5.29. 
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Aminopyridine 5.29 was reacted with acid chloride 5.22 (Scheme 5.4) using DIPEA as a 
base to give 5.30. Hydrolysis of the ester 5.30 with aqueous KOH gave 5.31, which was 
coupled with cyclobutylmethanamine using HATU as a coupling reagent and DIPEA as 
a base to give the pyridyl-2-carboxamide 5.3 (Scheme 5.7).  
 
Scheme 5.7. (i) NaOMe, MeOH, 0 °C. (ii) H2SO4, H2O, MeOH, 70%. (iii) SnCl2.2H2O, MeOH, 72%. (iv) 
5.22, DIPEA, CHCl3, 80 °C, 69%. (v) aq. KOH, THF:H2O, 87% (vi) 1-Cyclobutylmethanamine 
hydrochloride, HATU, DIPEA, DMF, 85%. (vii) Pyridine hydrochloride, 180 °C, 51%. (viii) NaI, Ag2CO3, 
DMF, 90 °C, 25%. 
 
Following a reported synthesis223 of 5.32, demethylation of 5.3 with pyridine 
hydrochloride provided 5.32 (Scheme 5.7). Pyridine 5.32 can exist in two tautomeric 
forms – 2-hydroxypyridine and 2-pyridone. A literature reported stated 5.32 as the 2-
hydroxypyridine tautomer.223 NMR spectra of 5.32 in this study revealed only one isomer 
therefore it was assumed to be the 2-hydroxypyridine. Pyridine 5.32 is a key intermediate 
in the triazoloylmethylnaphthalene-pyridyl-2-carboxamide series and will be used in the 
subsequent synthetic schemes (Scheme 5.8, 5.9, 5.10) to obtain various O-alkylated 
pyridyl-2-carboxamides. It is important to note here that base deprotonated 2-
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hydroxypyridine 5.32 is an ambident anion and can undergo alkylation at either N-1 or 
OH of 5.32. It is well known that silver salts of 2-hydroxypyridines undergo 
regioselective O-alkylation231 and indeed Ag2CO3 was used for the preparation of O-
alkylated pyridyl-2-carboxamides by the researchers at AstraZeneca.223  
 
Initial attempts to alkylate 5.32 with PEG methanesulphonate 5.12 (synthesis shown in 
Scheme 5.1) using Ag2CO3 as a base proved unsuccessful. The failure of these alkylation 
reactions were attributed to the use of alkyl methanesulphonate instead of alkyl halides 
as reported previously for the preparation of O-alkylated pyridyl-2-carboxamides.223 
Therefore, it was decided to carry out alkylation of 5.32 with a halide analogue of 5.12. 
Pleasingly, the reaction of 5.32 with NaI, Ag2CO3 and 5.12 successfully provided pyridyl-
2-carboxamide 5.33. It is thought that 5.12 reacts with NaI to generate tert‐butyl N‐(2‐{2‐
[2‐(2‐iodoethoxy)ethoxy]ethoxy}ethyl) carbamate,232 which then undergoes an 
alkylation reaction with 5.32. The success of Ag2CO3 mediated alkylation reaction of 5.32 
with alkyl halides but not with alkyl methanesulphonate is attributed to the halophilic 
nature of silver. The low yield of the reaction obtained for the preparation of 5.33 is due 
to the difficult separation of 5.33 from 5.12 in the column purification. 
 




The pyridyl-PEG linker conjugate 5.34 was synthesised by alkylation of the 
hydroxypyridine 5.32 with mesylate 5.17 (synthesis shown in Scheme 5.2) (Scheme 5.8). 
The alkylation reaction was carried out with NaI and Ag2CO3, using the optimised 







Scheme 5.8. (i) 5.17, NaI, Ag2CO3, DMF, 90 °C, 64%. 
 
5.2.4 Synthesis of alkyl-PEG derivatives of N‐(cyclobutylmethyl)‐
6‐hydroxy‐3‐{4‐[(1H‐1,2,3‐triazol‐1‐yl)methyl]naphthalene‐1‐
amido}- pyridine‐2‐carboxamide (5.32) 
 
Synthesis of the fluorescent ligand 5.36 began with alkylation of the hydroxypyridine 
5.32 with 5.18 (synthesis shown in Scheme 5.3, section 5.2.1) using Ag2CO3 as a base to 
provide 5.35. Boc-deprotection of 5.35 with TFA gave a primary amine (TFA salt), which 
was purified by semi-preparative RP-HPLC and then reacted with BODIPY-630/650-SE 





Scheme 5.9. (i) 5.18, NaI, Ag2CO3, DMF, 90 °C, 56%. (ii) TFA, DCM, quantitative. (iii) BODIPY-
630/650-SE, DIPEA, DMF, 58%.  
 
5.2.5 Synthesis of PEG or peptide linker derivatives of 2‐({6‐
[(cyclobutylmethyl)carbamoyl]‐5‐{4‐[(1H‐1,2,3‐triazol‐1‐
yl)methyl] naphthalene‐1‐amido}pyridin‐2‐yl}oxy)acetic acid 
(5.38) 
 
The hydroxypyridine 5.32 was alkylated with tert-butyl bromoacetate to give 5.37, which 
on reaction with TFA gave carboxylic acid 5.38 (Scheme 5.10). The coupling reaction of 
the carboxylic acid 5.38 with linker 2.12 (synthesis described in chapter 2, section 2.2.1) 
using HBTU and DIPEA gave 5.39. The PEG linker conjugate 5.39 was reacted with 
TFA to give the Boc-deprotected 5.39, which after semi-preparative RP-HPLC 






Scheme 5.10. (i) tert-Butyl bromoacetate, Ag2CO3, DMF, 90 °C, 94%. (ii) TFA, DCM, 95%. (iii) 2.12, 
HBTU, DIPEA, DMF, 59%. (iv) TFA, DCM, quantitative. (v) BODIPY-630/650-SE, DIPEA, DMF, 98%.  
 
The peptide linker analogues of pyridyl-2-carboxamides were synthesised by Fmoc solid-
phase peptide synthesis (Scheme 5.11). The amino acid Fmoc-Ala-OH was double 
coupled with 1,2-diaminoethane trityl resin 3.34 using HBTU and DIPEA to give resin-
bound 5.41. Capping of any unreacted resin-primary-amine sites on 5.41 with Ac2O was 
carried out. The resin-bound 5.41 was reacted with a solution of piperidine in DMF (20% 
v/v) and the resulting Fmoc—deprotected resin-bound 5.41 was reacted with Fmoc-Ala-
OH, HBTU, and DIPEA to give resin-bound 5.42. Fmoc deprotection of resin-bound 5.42 
was repeated and the Fmoc-deprotected resin-bound 5.42 was reacted with carboxylic 
acid 5.38 (synthesis shown in Scheme 5.10, section 5.2.5) using HATU and DIPEA to 
provide resin bound 5.43. The resin-bound 5.43 was treated with TFA to undergo resin 
cleavage and give peptide linker conjugate 5.44. The peptide-conjugate 5.44 was purified 
using semi-preparative RP-HPLC and subsequently reacted with Boc anhydride or 
BODIPY-630/650-SE in separate reactions to give 5.45 or 5.46 respectively. The low 
yield obtained for 5.46 is due to the poor solubility of 5.46 in a DMSO-water solution, 




Scheme 5.11. (i) Fmoc-Ala-OH, HBTU, DIPEA, DMF. (ii) Fmoc-Ala-OH, HBTU, DIPEA, DMF (double 
coupling was done). (iii) Ac2O, DIPEA DMF. (iv) Piperidine, DMF. (v) 5.38, HATU, DIPEA, DMF (vi) 
TFA, DCM. (vii) (Boc)2O, Et3N, DMF, 38%. (viii) BODIPY-630/650-SE, DIPEA, DMF, 13%. 
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5.2.6 Synthesis of PEG linker derivatives of 2‐({6‐
[(cyclobutylmethyl)carbamoyl]‐5‐(quinoline‐4‐amido)pyridin‐2‐
yl} oxy)acetic acid (5.53) 
 
Synthesis of quinoline-pyridyl-2-carboxamides commenced with reaction of quinoline‐




Scheme 5.12. (i) SOCl2, 80 °C. 
 
Pyridyl-2-carboxamides of this series were synthesised (Scheme 5.13) using a similar 
synthetic strategy as described in Scheme 5.7. The coupling reaction of aminopyridine 
5.29 (synthesis shown in Scheme 5.7, section 5.2.2) with 5.48 provided 5.49. Hydrolysis 
of 5.49 with aqueous KOH gave carboxylic acid 5.50, which on coupling with 
cyclobutylmethanamine gave 5.6. Demethylation of 5.6 with pyridine hydrochloride gave 
5.51. Alkylation of the hydroxypyridine 5.51 with tert-butyl bromoacetate using 
conditions optimised for the preparation of 5.33 (synthesis shown in Scheme 5.7) 
provided 5.52, which was reacted with TFA to give 5.53. Coupling of the carboxylic acid 
5.53 with 2.12 gave linker conjugate 5.54. Boc-protected 5.54 was reacted with TFA, 
purified using semi-preparative RP-HPLC to give Boc-deprotected 5.54 and subsequently 




Scheme 5.13. (i) 5.48, DIPEA, CHCl3, 80 °C, 82%. (ii) KOH, THF:H2O, quantitative (iii) 1-
Cyclobutylmethanamine hydrochloride, HATU, DIPEA, DMF, 93%. (iv) Pyridine hydrochloride, 180 °C, 
63%. (v) tert-Butyl bromoacetate, NaI, Ag2CO3, DMF, 90 °C, 94%. (vi) TFA, DCM (vii) 2.12, HBTU, 
DIPEA, DMF, 62%. (viii) TFA, DCM, quantitative. (ix) BODIPY-630/650-SE, DIPEA, DMF, quantitative. 
 
5.3 Biological studies 
5.3.1 Radioligand binding assays 
 
A subset of pyridyl-2-carboxamides (synthesised in section 5.2) were analysed for affinity 
at CBR, due to the availability of only limited time for carrying out biological studies in 
the collaborator’s laboratory. Pharmacological evaluation of these compounds would 
build knowledge of the effect of different O-substituents on CBR affinity and help design 
a revised series of high affinity CB1R pyridyl-2-carboxamides. 
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A radioligand binding assay was used to determine CBR affinity of synthesised pyridyl-
2-carboxamides using CBR radioligand [3H]-CP55,940 and membrane preparations 
derived from HEK-293 cells transfected with either CB1R or CB2R according to a 
previously described method169, 212 (assay described previously in chapter 3, section 3.3.1;  
experiments details described in the chapter 7, section 7.1.2). Pyridyl-2-carboxamides 
(5.3, 5.6, 5.33, 5.34, 5.35, 5.37, and 5.39) displaced [3H]-CP55,940 from CB1R or CB2R 
by more than 50% in the initial screen at 10 μM (displacement of [3H]-CP55,940 in initial 
screen shown in Figure 5.8). Accordingly, these compounds were then analysed in a 
concentration-dependent way to determine the concentration binding curves and calculate 




Figure 5.8. Radioligand binding assay: Screen of synthesised chromenopyrazoles at 10 µM at HEK-293 cells expressing hCB1R (panel A) or hCB2R (panel B) with [3H]-
CP55,940 as the radioligand. Data represented are from a single experiment carried out in triplicate and is expressed as mean ± SEM. V (vehicle), CP (CP55,940). 
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The literature compound 5.3 (Ki = 0.81 ± 0.16 nM at hCB1R; 108.6 ± 1.46 nM at hCB2R; 
Table 5.3, Figure 5.9) showed high affinity for CB1R and selectivity over CB2R, 
consistent with previous literature reports (5.3 IC50 = 0.97 nM at hCB1R; Ki at CB1R or 
CB2R not reported)
223-224. The other literature compound 5.6 also showed high affinity 
for CB1R (Ki = 77.1 ± 10.4 nM at hCB1R; 559.8 ± 40.4 nM at hCB2R; Table 5.3) and 
moderate affinity for CB2R, which is similar to the previously reported CBR affinities 
(5.6 IC50 = 15 nM at hCB1R; IC50 = 100 nM at hCB1R)
223. The positive control CP55,940 
(Ki = 4.53 ± 0.22 nM at hCB1R; Ki = 1.66 ± 0.31 nM at hCB2R) showed the CBR affinities 
consistent with those reported recently – (CP55,940 pKi = 9.26 ± 0.12 nM at hCB1R, (Ki 
= 0.55 nM) and (CP55,940 pKi = 8.44 ± 0.18 nM at hCB2R (Ki = 3.63 nM))
119. None of 
the newly synthesised pyridyl-2-carboxamides exhibited significant CB2R affinity, 




Figure 5.9. Competition binding curves for CB1R pyridyl-2-carboxamide 5.37, 5.33, literature compound 
5.3, and CP (CP55,940) using radioligand [3H]-CP55,940 (Kd = 3.0 nM for hCB1R) at HEK-293 cells 
expressing hCB1R. Data represented are from a single experiment carried in triplicate and is expressed as 
mean ± SEM. 
 
The short linker conjugate 5.37 (Ki = 245.6 ± 36.4 nM at hCB1R; > 5000 nM at hCB2R; 
Table 5.3; Figure 5.9) exhibited the highest affinity for CB1R and selectivity over CB2R 
of the novel compounds tested. Nonetheless, the CB1R affinity of short linker-conjugate 
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*Binding affinity (Ki) obtained by competition binding assay performed on membranes obtained from HEK-
293 cells expressing either hCB2R or hCB1R with [3H]-CP55,940 as radioligand (Kd = 1.7 nM for hCB2R 
and 3.0 nM for hCB1R). All data is from at least three individual experiments performed in triplicate, except 
a which is two individual experiments performed in triplicate.  
 
The triazoloylmethylnaphthalene-pyridyl-2-carboxamide linker conjugates 5.33, 5.34, 
and 5.35 exhibited moderate affinity for CB1R. The CB1R affinity of 5.33 (Ki = 1217 ± 
253.6 nM at hCB1R; Figure 5.9) was noticeably reduced compared to the previously 
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reported short PEG-linker conjugate 5.7 (IC50 = 10 nM at hCB1R, Table 5.1)
223-224. 
Similarly, the pyridyl-PEG linker 5.34 (Ki = 2728 ± 625.2 nM at hCB1R) exhibited 
markedly reduced CB1R affinity compared to the previously reported pyridyl moiety 
containing 5.4 (IC50 = 3.2 nM at hCB1R)
223. The fluorescent ligand 5.36, a BODIPY-
630/650 analogue of 5.35 did not exhibit any significant affinity for CB1R. The moderate 
affinity for CB1R of 29 atoms long linker conjugate 5.35 indicates tolerance of O-long 
linkers in the triazoloylmethylnaphthalene-pyridyl-2-carboxamide series. 
 
The PEG-linker conjugate 5.39 (Ki = 4099 ± 752.2 nM at hCB1R, which contains a 
carboxamide moiety in the linker) exhibited decreased CB1R affinity compared to the 
PEG-linker conjugate 5.33 (Table 5.3). The fluorescent ligand 5.40 (BODIPY-630/650 
analogue of 5.39), the peptide-linker conjugate 5.45 and fluorescent ligand 5.46 
(BODIPY-630/650 analogue of 5.45) did not exhibit any significant CB1R affinity (Table 
5.3).  
 
In the quinoline-pyridyl-2-carboxamide series, linker conjugates 5.54 and 5.55 
(BODIPY-630/650 analogue of 5.54) did not exhibit any significant CB1R affinity (Table 
5.3). The lack of CB1R affinity of 5.54 was slightly surprising considering it is a 
carboxamide-PEG linker analogue of literature pyridyl-2-carboxamide 5.7 (IC50 = 10 nM 
at hCB1R; Table 5.1), that was reported as a high affinity CB1R ligand
223. 
 
In summary, the newly synthesised pyridyl-2-carboxamide 5.37 showed the highest 
affinity for CB1R of all the novel compounds tested (Table 5.3). The PEG-linker 
conjugate 5.33 exhibited the best affinity for CB1R among the newly synthesised pyridyl-
2-carboxamide-linker conjugates. None of the BODIPY-630/650 derivatives of pyridyl-
2-carboxamide exhibited any significant affinity for CB1R. A reason for the reduced 
affinity at CB1R of the pyridyl-2-carboxamides might be the steric clashes of the linkers 
with the CB1R amino acid residues. In the docking studies (section 5.1, Figure 5.3 and 
5.5), the methoxy moiety of pyridyl-2-carboxamide 5.3 was pointing towards the 
extracellular N-terminal of CB1R, indicating linker attachment in this position may be 
tolerated. However, the reduced CB1R binding affinities of linker conjugates (Table 5.3) 
indicate that there might not be a large enough cavity in the N-terminal of CB1R (between 
TM1 and TM7) for the long O-linkers to exit through, or alternatively the O-linker 




5.3.2 cAMP Functional assays  
 
The newly synthesised pyridyl-2-carboxamides (5.33, 5.34, 5.35, and 5.37) that exhibited 
appreciable affinity for CB1R were evaluated using the cAMP BRET assay as previously 
described in chapter 3 (section 3.3.3). Due to the low affinity for CB2R, the functional 
activities of pyridyl-2-carboxamides (5.33, 5.34, 5.35, and 5.37) at CB2R were not 
determined.  
 
The newly synthesised pyridyl-2-carboxamides (5.33, 5.34, 5.35, and 5.37) were tested 
at 10 µM at CB1R expressing HEK-293 cells and at WT HEK-293 cells. All of the 
pyridyl-2-carboxamides (5.33, 5.34, 5.35, and 5.37) behaved as agonists at 10 µM. 
Incubation of the pyridyl-2-carboxamide (5.33 or 5.34 or 5.35, at 10 µM) with WT HEK-
293 cells and forskolin increased the inverse BRET ratio compared to forskolin alone 
(Appendix, Figure A.13 panel B, D, and C), indicating an effect independent of CB1R 
cAMP signalling. The observation of a CB1R independent effect by pyridyl-2-
carboxamides 5.33, 5.34, and 5.35 led to evaluation of the literature pyridyl-2-
carboxamide 5.3 (10 µM) at WT HEK-293 cells and indeed a similar effect independent 
of CB1R cAMP signalling was observed (Appendix, Figure A.13 panel A). It should be 
emphasised here that a CB1R independent effect of the pyridyl-2-carboxamides (5.3, 5.33, 
5.34, and 5.35) in the cAMP BRET assay at WT HEK-293 cells does not necessarily 
translate to the promiscuous nature of these ligands, provided these can be used at a 
concentration lower than 10 µM (and that this lower concentration does not mediate CB1R 
cAMP independent effects). In contrast to the observations for the pyridyl-2-
carboxamides (5.3, 5.33, 5.34, and 5.35), high affinity CB1R ligand 5.37 (Ki = 245.6 ± 
36.4 nM at hCB1R) at 10 µM exhibited a cAMP response, which was not significantly 
different from forskolin alone in the cAMP assay at the WT HEK-293 cells, and hence 
did not show a CB1R cAMP independent effect (Table 5.5) (Appendix, Figure A.13 panel 
E).  
 
The moderate affinity CB1R pyridyl-2-carboxamide 5.33 (Ki = 1217 ± 253.6 nM at 
hCB1R) was then evaluated at 1 µM to determine function at CB1R (only the highest 
affinity pyridyl-2-carboxamide-linker conjugate 5.33 was further evaluated due to the 
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time constraints). It was hoped that at 1 µM, pyridyl-2-carboxamide 5.33 would produce 
a response in the cAMP BRET assay (at HEK-293 cells expressing CB1R) sufficient 
enough to determine function without producing any significant effects in the WT HEK-
293 cells (in an independent experiment). 
 
 
Figure 5.10. The moderate affinity CB1R linker conjugate 5.33 (1 μM) screened in a cAMP BRET assay: 
(A) cAMP BRET assay of 5.33 at WT HEK-293 cells. (B) cAMP BRET assay of 5.33 at HEK-293 cells 
stably expressing hCB1R. Data is representative of a single experiment carried in duplicate and is 




The pyridyl-2-carboxamide 5.33 (at 1 µM) and forskolin, when incubated with WT HEK-
293 cells, did not increase the inverse BRET ratio compared to forskolin alone (Figure 
5.10 panel A; Table 5.5), thus did not show a CB1R independent effect in the cAMP 
BRET assay. Incubation of the pyridyl-2-carboxamide 5.33 (at 1 µM) and forskolin with 
CB1R expressing HEK-293 cells decreased the intracellular cAMP concentration 
compared to forskolin alone, therefore showing that 5.33 behaved as an agonist (Figure 
5.10 panel B). 
 
Table 5.4. CB2R functional data of the pyridyl-2-carboxamides 5.37 and 5.33. 
Compound EC50 (nM± SEM)* Emax (%FSK response ± SEM)# Functional activity 
5.37 135.5 ± 7.6 52.21 ± 0.10 Agonist 
5.33 222.7 ± 40.4 66.35 ± 3.21 Agonist 
*Potency and #efficacy data for the chromenopyrazoles, obtained from cAMP BRET assay using HEK-
293 cells expressing hCB1R. All data is from at least three individual experiments performed, raw data is 
normalised to forskolin (100 %) and vehicle (0 %). 
 
Due to time constraints, only newly synthesised pyridyl-2-carboxamides (5.37 (Ki = 245.6 
± 36.4 nM) and 5.33 (Ki = 1217 ± 253.6 nM at hCB1R)), which exhibited high to moderate 
affinity for CB1R were further evaluated in a concentration-dependent manner to 
determine the EC50 at CB1R (Figure 5.11, Table 5.4). 
 
 
Figure 5.11. Concentration-response curves for pyridyl-2-carboxamides 5.37 and 5.33 using HEK-293 
cells stably expressing hCB1R. All data is from at least three individual experiments performed and is 




Pyridyl-2-carboxamide 5.37 (EC50 = 135.5 ± 7.6 nM, Emax = 52.21 ± 0.10 % of forskolin 
response at hCB1R) exhibited higher potency and efficacy than 5.33 (EC50 = 222.7 ± 40.4 
nM; Emax = 66.35 ± 3.21 % of forskolin response at hCB1R). Previously, literature 
pyridyl-2-carboxamides (5.2-5.7, Table 5.1) were also reported as CB1R agonists in a 
[35S]GTPγS assay using HEK-293 cells expressing cCB1R.
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Table 5.5. % Response of the pyridyl-2-carboxamide 5.37 or 5.33 in the cAMP BRET assay at wild type 
HEK-293 cells. 
Compound %FSK response ± SEM* 
5.37 114.48 ± 4.0 
5.33 106.098 ± 4.55 
 
*cAMP BRET carried out at WT HEK-293 cells. 5.37 tested at (10 μM) and 5.33 tested at (1 μM). All data 
is from at least two individual experiments performed in duplicate, raw data is normalised to forskolin 
response (100 %) and vehicle response (0 %). A one-sample t-test was used to determine whether the % 




5.4 Summary and conclusions 
 
Two series (triazoloylmethylnaphthalene-pyridyl-2-carboxamide and quinoline-pyridyl-
2-carboxamide) of O-linker conjugates of pyridyl-2-carboxamides were prepared with the 
aim of developing high affinity CB1R fluorescent agonists (section 5.2). An efficient 
synthetic route for the preparation of pyridyl-2-carboxamides from the readily available 
pyridine derivative 5.9 was developed. A set of alkyl, PEG, peptide linker derivatives and 
BODIPY-630/650 derivatives of pyridyl-2-carboxamides were also prepared. 
 
The BODIPY-630/650-containing pyridyl-2-carboxamides (5.36, 5.40, 5.46, and 5.55) 
did not exhibit any significant affinity for either CB1R or CB2R. The novel pyridyl-2-
carboxamide linker conjugates (5.33 (Ki = 1217 ± 253.6 nM at hCB1R), 5.34 (Ki = 2728 
± 625.2 nM at hCB1R), 5.35 (Ki = 1959 ± 740.4 nM at hCB1R), and 5.39 (Ki = 4099 ± 
752.2 nM at hCB1R)) exhibited moderate to low affinity for CB1R and selectivity over 
CB2R (Table 5.3). The short linker conjugate 5.37 (Ki = 245 ± 36.4 nM at hCB1R) 
exhibited high affinity for CB1R and selectivity over CB2R. The pyridyl-2-carboxamides 
5.37 (EC50 = 135.5 ± 7.6 nM; Emax = 52.21 ± 0.10 % of forskolin response at hCB1R) 
and 5.33 (EC50 = 222.7 ± 40.4 nM; Emax = 66.35 ± 3.21 % of forskolin response at 
hCB2R) behaved as CB1R agonists at hCB1R, consistent with the agonist behaviour 
previously reported at cCB1R.
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In this chapter, a high affinity CB1R pyridyl-2-carboxamide based linker conjugate was 
not obtained. Nevertheless, the literature compound 5.3 exhibited subnanomolar CB1R 
affinity; also, the new linker conjugates (5.37, 5.33, 5.34 and 5.35) displayed high CB1R 
selectivity as well as high to moderate CB1R affinity. Therefore, the optimised pyridyl-
2-carboxamide derivatives could be developed into high affinity CB1R fluorescent 
ligands. 
 
5.5 Future directions 
Introduction of the long O-linkers to subnanomolar CB1R affinity pyridyl-2-carboxamide 
5.3 was tolerated albeit with a reduction in the CB1R affinity. Accordingly, efforts might 
be directed to prepare derivatives of 5.3 with different O-linkers or with linkers 
conjugated at different positions of the 5.3 core. To this end, synthesis and biological 
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evaluation of the pyridyl-2-carboxamides with linkers introduced at C-3 naphthyl moiety 
could be an attractive strategy to develop CB1R fluorescent ligands.  
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Chapter 6 Executive conclusions 
 
The primary aims of this thesis were the development of fluorescent ligands for A1AR 
and CBRs. Chapter 2 of this thesis described the development of 
(benzimidazolyl)isoquinolinols as potential A1AR  fluorescent ligands. A multistep 
synthesis for the preparation of (benzimidazolyl)isoquinolinols along with a procedure 
for the DDQ and air mediated aromatisation of (benzimidazolyl)tetrahydroisoquinolinols 
was developed. Investigation for the conformational isomerism of 
(benzimidazolyl)isoquinolinols by NMR spectroscopy and RP-HPLC studies indicated 
tautomerism. Unfortunately, none of the fluorescent (benzimidazolyl)isoquinolinols 
exhibited any significant binding at the A1AR and it was concluded that 
(benzimidazolyl)isoquinolinols might not be a suitable pharmacophore for developing 
A1AR fluorescent ligands. 
 
In chapter 3, the chromenopyrazole-based ligands with linkers introduced at six different 
positions were explored for the development of CB1R fluorescent agonists. 
Unfortunately, these chromenopyrazoles only had low affinity for CB1R however did 
have high affinity for CB2R. The chromenopyrazole-linker-conjugate with the highest 
CB2R affinity was 3.22 (Figure 6.1, Ki = 71.1 ± 6.7 nM at hCB2R; >5000 nM at hCB1R). 
Three moderate CB2R affinity BODIPY-630/650 conjugates (3.23, 3.33 and 3.40) and a 
high-affinity CB2R peptide linker conjugate 3.39 were also obtained. The high affinity 
chromenopyrazoles behaved as agonists at CB2R in a cAMP functional assay. Docking 
studies with a homology model of CB2R showed that linkers conjugated to the high CB2R 
affinity chromenopyrazoles likely exit through a cavity located between TM1 and TM7.  
 
Chapter 4 described new peptide-linker analogues of 3.39 and derivatives of the highest 
CB2R affinity linker conjugate 3.22 with three different fluorophores (BODIPY-FL, Cy5, 
TAMRA, BODIPY-630/650). The newly synthesised polar peptide linker conjugates 
(4.06-4.08) also exhibited high to moderate CB2R affinity. Two high affinity, selective 
CB2R fluorescent ligands were obtained, the best being 4.02 (Figure 6.1, Ki = 41.8 ± 4.5 
nM at hCB2R; 5856 ± 1264 nM at CB1R). Fluorescent ligand 4.02 behaved as an inverse 
agonist in the cAMP BRET assay and was successfully used to visualise CB2R in HEK-
293 cells stably expressing CB2R in widefield imaging experiments. Fluorescent ligand 
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4.02 exhibited the higher CB2R affinity than any reported CB2R fluorescent ligands in the 
literature and is also the only reported high affinity CB2R fluorescent ligand for which 
functional data has been reported (as of July 2018). Fluorescent ligand 4.02 possesses 
suitable properties for imaging CB2R in live cells and can be used as a fluorescent tool 
by other researchers, for example in fluorescence-based assays, confocal microscopy, 
flow-cytometry and in resonance energy transfer experiments with other fluorescent 
partners for studying CB2R biology.  
 
 
Figure 6.1. Chromenopyrazole-linker conjugate 3.22, chromenopyrazole-based-Cy5 conjugate 4.02 and 




In Chapter 5 previously reported pyridyl derivatives were investigated for the 
development of CB1R fluorescent ligands. A multistep synthesis for the preparation of O-
linker pyridyl-2-carboxamides was developed. Two series of naphthyl and isoquinoline 
derivatives based on the pyridyl-2-carboxamide scaffold and conjugated to different 
linkers and BODIY-630/650 were prepared. Although a high CB1R affinity fluorescent 
ligand was not obtained, moderate affinity O-linker pyridyl-2-carboxamides (for example 
5.33, Figure 6.1, Ki = 1217 ± 253.6 nM at hCB1R; >5000 nM at hCB2R) were obtained. 
It was concluded that pyridyl-2-carboxamide remains a potential scaffold for the 
development of CB1R fluorescent ligands and a new series with different O-linker-
fluorophore or linker-fluorophore introduced at a different position, for example 
naphthyl, could be explored.  
 
Availability of a high affinity, selective fluorescent ligand with suitable imaging 
properties will advance the understanding of GPCR biology by enabling use of many 
fluorescent techniques. These techniques such as confocal microscopy would enable 
investigation of these receptors in spatiotemporal manner at a single cell level, which has 
previously not been possible with traditional radioligand assays. One particular 
application of fluorescent ligand such as 4.02 developed in this thesis could be in 
determining the expression level of CB2R in CNS tissue samples using ex vivo 
experiments, which could provide valuable information regarding the role of CB2R in 
various neurological disorders and thus guide the development of CB2R ligands targeted 
towards CNS disorders. Another important application of 4.02 could be in improving our 
understanding of the role of CB2R in various disease conditions such as cancer, a lack of 
which has likely contributed in the failure of many CB2R ligands in the clinical trials. 
 
As was described earlier in section 1.2.3.2 of chapter 1, selective fluorescent ligand such 
as 4.02 could be potentiallly useful as a partner in resonance energy transfer techniques 
(FRET and BRET) for use in in vitro imaging. A derivative of 4.02 containing NIR 
fluorophore would be potentially useful as an in vivo imaging tool in the animal model of 
disorders implicating CB2R. Fluorescent ligand 4.02 could also serve as a lead compound 
for the development of CB2R selective magnetic resonance active ligands, multivalent 




Chapter 7 Experimental 
7.1 General methods and experimental procedures 
7.1.1 Chemical studies 
 
All chemicals were purchased from Sigma Aldrich, Merck, A K Scientific, or Ark Pharm 
Inc. BODIPY-630/650-SE and BODIPY-FL-SE were purchased from Life Technologies. 
Cy5-SE and TAMRA-SE were purchased from Abcam. Reactions were carried out at 
room temperature (rt) unless otherwise stated. Thin layer chromatography (TLC) for 
monitoring reactions was performed on commercially available Merck 0.2 mm 
aluminium-backed silica gel plates 60 F254 and visualised under UV light at λ = 254 and 
365 nM, and with ninhydrin, and/or KMnO4 dip. Flash silica gel column chromatography 
was performed using 40-63 µm silica. An Agilent 1260 Infinity system was used for 
reverse phase high-performance liquid chromatography (RP-HPLC), with a YMC C8 5 
µm (150 × 10 mm) semi-preparative or YMC C8 5 µm (150 × 4.6 mm) analytical column. 
RP-HPLC solvents were A: H2O (0.05% TFA) and B: 9:1 MeCN:H2O (0.05% TFA). For 
compounds synthesised in chapter 2 (section 7.2.1) analytical RP-HPLC retention times 
for biologically tested compounds are reported using the method A - 5% solvent B 1 min, 
gradient of 5-95% solvent B 1-27 min, 95% solvent B 27-28 min, gradient of 95-5% 
solvent B 28-30 min, 5% solvent B 30-34 min. For compounds synthesised in chapter 3, 
4, and 5 (section 7.3.1, 7.4.1, and 7.5.1) analytical RP-HPLC retention times for 
biologically tested compounds are reported using the method B - 5% solvent B 1 min, 
gradient of 5-95% solvent B 1-22 min, 95% solvent B 22-28 min, gradient of 95-5% 
solvent B 28-30 min, 5% solvent B 30-34 min. TFA salts of RP-HPLC purified 
compounds described in chapter 2 (section 7.2.1) were neutralised using an Amberlyst 
A21 ion exchange resin before biological testing. Analytical RP-HPLC was used to 
confirm purity (> 95%) at 254 and 380 nm for all compounds biologically tested. All of 
the fluorescent ligands were purified by semi-preparative RP-HPLC. High-resolution 
electrospray ionisation mass spectra (HRMS) was recorded on a Bruker microTOF mass 
spectrometer. Low-resolution mass spectrometry (MS) was carried out on a Sciex API 
3200 quadrupole mass spectrometer. NMR spectroscopy was carried out on a Varian 400-
MR or Varian 500 MHz AR Premium Shielded spectrometer. Chemical shifts are listed 
in ppm (δ), calibrated using residual non-deuterated solvent as the internal standard, and 
coupling constants (J) are recorded in hertz (Hz). Note - not all magnetically non-
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equivalent carbons were observed in 13C NMR spectrum for all compounds. In some 
cases, the calculated yield of the coupling reaction of commercially available fluorophore 
succinimidyl esters with amine linker conjugates to give fluorescent ligands (obtained in 
chapters 2, 3, 4, and 5) was greater than quantitative. The proposed reason for this is that 
the commercially available fluorophore succinimidyl esters are supplied in a higher 
amount than that specified on the container (usually 1 or 5 mg pack size; the amount of 
fluorophore specified on the container was used in the calculation of yield). These 
fluorophores are moisture, light sensitive and were not weighed accurately but instead 
DMF was added to the whole contents of the container and this DMF solution of the 
fluorophore was used for the coupling reaction. Other members of the Vernall research 
group have observed similar high calculated yields of coupling reactions with 
commercially available fluorophores. 1H and 13C NMR spectra were not obtained for 
some of the compounds prepared at or near the end of a multistep synthesis (including 
fluorescent ligands). This was because these compounds were prepared in very small 
quantities and/or had poor solubility (thereby requiring the use of DMSO-d6). HRMS was 
obtained for all of these compounds and these were >95% pure as determined by 
analytical RP-HPLC. Precursors to these compounds were thoroughly characterised by 
NMR spectroscopy.  
 
7.1.2 Pharmacological studies  
Radioligand binding assays 
 
Competition binding assays were performed with radioligand [3H]-CP55,940 at 
membrane preparations derived from HEK-293 cells. Preparation of HEK-293 cells 
stably transfected with either CB1R or CB2R was carried out according to a previously 
described method169, 212 and protein concentrations determined using the DC Protein 
Assay Kit (Bio-Rad, Hercules, CA) as previously described.233 Different concentrations 
of test compounds and dilutions of [3H]-CP55,940 (PerkinElmer), HEK-293 membrane 
preparations were prepared in binding buffer (50 mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid)), 1 mM MgCl2, 1 mM CaCl2, 0.2% [w/v] fatty acid 
free bovine serum albumin [FAF BSA; MP Biomedicals, Auckland, New Zealand], pH 
7.4). All compounds (including radioligand [3H]-CP55,940 and positive control 
CP55,940) were prepared four times the required concentration in assay. 1 μL of test 
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compounds (10 mM stock in DMSO) were diluted with binding buffer containing EtOH 
(249 μL) to give 250 μL solutions,  50 μL of these solutions were added to designated 
wells of a v-bottom 96-well plate. The concentration of [3H]-CP55,940 used in the 
radioligand binding assay carried out for chromenopyrazoles and pyridyl-2-carboxamides 
is described in section 7.3.3, section 7.4.2, and section 7.5.3. CP55,940 was diluted with 
binding buffer containing DMSO and 50 μL added to a specific well of a v-bottom 96-
well plate. HEK-293 membrane preparations were resuspended in binding buffer to give 
the final assay concentration (protein concentration for determining CBR affinity of 
chromenopyrazoles and pyridyl-2-carboxamides is described in section 7.3.3, section 
7.4.2, and section 7.5.3). The amount of EtOH and DMSO in the vehicle control, test 
compound dilution, [3H]-CP55,940 dilution and CP55,940 dilution was added such as to 
maintain consistent solvent levels throughout the dilution series. The final reaction 
volume of each well was 200 μL including [3H]-CP55,940 and membrane. A solution (50 
μL) of binding buffer containing EtOH and DMSO was used in place of test compound 
or CP55,940 as vehicle controls. The v-bottom 96-well plates containing HEK-293 
membrane preparations expressing CB1R or CB2R, radioligand [
3H]-CP55,940 and test 
compound (or positive control CP55,940 or vehicle control) were sealed and incubated at 
30 °C for 1 h. 
 
During the incubation the GF/C 96-well harvest plate (PerkinElmer) was soaked in 50 
μL/well of 0.1% polyethylenimine for 1 h to block the 1.2 μm pore fibreglass filters. At 
the end of incubation, the harvest plates were washed with 200 μL of ice-cold wash buffer 
solution (50 mM HEPES pH 7.4, 500 mM NaCl, 0.1% FAF BSA). The 200 μL reaction 
mixture of the v-bottom plates was transferred into the harvest plates (under vacuum). 
The v-bottom plates were washed once more with ice-cold wash buffer (200 μL/well) and 
the contents transferred into the harvest plates. The harvest plates were immediately 
washed three more times with 200 μL/well of ice-cold wash buffer. The harvest plates 
were dried overnight at 24 °C, the underside was sealed, and scintillation fluid (50 
μL/well) (IRGASAFE PLUS, PerkinElmer) was dispensed. The harvest plates were 
incubated for 30 min in darkness and scintillation count was read for 2 min/well in a 
MicroBeta TriLux (PerkinElmer). All of the binding experiments were performed at least 
three times in triplicate. Data was analysed by nonlinear regression as provided in 




cAMP functional assays 
 
The functional nature of the test compounds was determined by a commercially available 
cAMP BRET assay as described previously by Cawson et al.169 and Jiang et al.170 HEK 
3HA-CB1 pEF4A or HEK-Flp pcDNA5/FRT HA-3TCS-CB2 63Q (preparation 
described previously169, 212) were seeded in 10 cm tissue culture dishes, one or two days 
prior to transfection. The next day, 5 μg of pcDNA3L-HIS-CAMYEL plasmid (ATCC, 
Manassas, VA, USA) that encodes for a cAMP sensor consisting of YFP-Epac-RLuc was 
transfected into HEK-293 cells using 30 μg of linear PEI (polyethylenimine, molecular 
weight 25 kDa; Polysciences, Warrington, PA, USA) in 150 mM NaCl. After 
approximately 24 h, cells were plated in poly‐D‐lysine (Sigma Aldrich) coated white 96‐
well Solid White Flat Bottom Polystyrene TC-Treated Microplates (Corning) at a density 
of 88,000–1,120,000 cells/well in Dulbecco's Modified Eagle's medium (DMEM) 
containing 10% fetal bovine serum (FBS). After another 24 h, cells were serum-starved 
for 30 min in Hank's balanced salt solution (pH 7.4) supplemented with 1.0 mg/mL fatty 
acid free BSA. Cells were treated with luciferase substrate coelenterazine-h (5.0 μM, 
Nanolight Technology) for 5 min and test compound or vehicle in Hank's balanced salt 
solution containing 1.0 mg/mL FAF BSA and forskolin (5.0 μM, Tocris, Bristol, UK). 
Fluorescence emission was immediately measured at 460/25 nM (Renilla luciferase, 
RLuc) and 535/25 nM (yellow fluorescent protein, YFP) following test compound 
addition at 37 °C. HEK-293 WT cells matched to the background of the CB1R or CB2R 
expressing cell lines were used as negative controls. Raw data is presented as ratio of 
fluorescence emission at 460/535 nm (inverse BRET ratio) such that an increase in ratio 
correlates to an increase in intracellular cAMP concentration. All of the assays were 
carried out at least three times in duplicate unless stated otherwise. 
 
Data was analysed by nonlinear regression as provided in GraphPad Prism (GraphPad 
Software, Inc., San Diego, CA, USA). For the area under the curve analysis, raw data 
(inverse BRET ratio) was normalised to forskolin (100 %) and vehicle (0 %) were 
normalised to the vehicle (0%) or forskolin (100%) values for individual experiments. 
The Emax value of a test compound was determined as the percentage of normalised 




7.2 Experimental procedure and data for compounds 
as described in chapter 2 
 
7.2.1 Chemical studies  
 
 
tert‐Butyl N‐(8‐aminooctyl)carbamate (2.10)  
The compound was synthesised according to a previously reported literature synthesis of 
2.10.177 To a solution of commercially available 1,8-diaminooctane 2.9 (4.0 g, 27.73 
mmol) in 1,4-dioxane (100 mL) was added dropwise a solution of (Boc)2O (1.27 mL, 
5.55 mmol) in 1,4-dioxane (50 mL) at 0 °C. The reaction mixture was warmed to rt and 
stirred for 12 h. The solvent was removed under reduced pressure and the residue was 
dissolved in DCM (100 mL). The DCM layer was then carefully washed with warm water 
(15 × 100 mL, ~35 °C), brine solution, dried over MgSO4.H2O and concentrated under 
reduced pressure to provide 2.10 as a clear oil (1.02 g, 4.17 mmol, 75%). The liquid 2.10 
slowly turned into a colourless semisolid upon standing at rt. 1H NMR (400 MHz, CDCl3) 
δ 1.19 – 1.49 (m, 23H, C(CH3)3, 6 × CH2 and NH2), 2.64 (t, 2H, J = 6.8 Hz, CH2), 2.97 
– 3.16 (m, 2H, CH2), 4.58 (br s, 1H, NH).
 13C NMR (101 MHz, CDCl3) δ 26.66, 26.71, 
26.76, 28.40, 29.13, 29.22, 29.35, 30.02, 33.72, 40.55, 42.15, 78.90, 155.96. HRMS 
calculated for C13H29N2O2 [M + H]
+, 245.2218; found, 245.2224. 
 
 
tert‐Butyl N‐{2‐[2‐(2‐aminoethoxy)ethoxy]ethyl}carbamate (2.12)  
The compound was synthesised according to a previously reported literature synthesis of 
2.12.178 To a solution of commercially available diamino-3,6-dioxaoctane 2.11 (5.0 g, 
33.73 mmol) in DCM (50 mL) was added dropwise a solution of (Boc)2O (1.5 mL, 6.75 
mmol) in DCM (100 mL) at 0 °C. The reaction mixture was warmed to rt and stirred for 
3 h. The DCM solution was washed with water, NaHCO3 solution, brine solution, dried 
over MgSO4.H2O and concentrated under reduced pressure to provide 2.12 (1.50 g, 6.04 
mmol, 89%) as a clear oil. 1H NMR (400 MHz, CDCl3) δ 1.41 (s, 9H, C(CH3)3), 1.44 (br 
s, 2H, NH2) 2.85 (t, 2H, J = 5.2 Hz, CH2), 3.23 – 3.33 (m, 2H, CH2), 3.45 – 3.55 (m, 4H, 
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2 × CH2), 3.59 (s, 4H, 2 × CH2), 5.15 (br s, 1H, NH). 13C NMR (101 MHz, CDCl3) δ 
28.37, 40.29, 41.69, 70.16, 73.38, 79.09, 155.97. HRMS calculated for C11H25N2O4 [M + 




carbamoyl]ethyl] carbamate (2.15)  
To a solution of commercially available Fmoc-Ala-OH 2.13 (0.5 g, 1.61 mmol) in DMF 
(20 mL) was added HBTU (0.61 g, 1.61 mmol), HOBt.H2O (0.24 g, 1.77 mmol) and 
DIPEA (0.6 mL, 3.44 mmol) under N2 atmosphere and the reaction stirred at 0 °C for 10 
min. Commercially available N-Boc-ethylenediamine 2.14 (0.26 mL, 1.62 mmol) was 
added to the reaction mixture and reaction stirred at rt for 6 h. The reaction mixture was 
diluted with EtOAc. The EtOAc solution was washed with water, saturated solution of 
NH4Cl, brine, dried over MgSO4.H2O, concentrated under reduced pressure and the 
residue purified by silica gel column chromatography (eluting with 70% EtOAc/hexane 
to 5% MeOH/EtOAc) to provide 2.15 (0.63 g, 1.39 mmol, 86%) as a colourless solid. 1H 
NMR (400 MHz, CDCl3) δ 1.23 – 1.58 (m, 12H, CH3 and C(CH3)3), 3.16 – 3.31 (m, 2H, 
NHCH2), 3.29 – 3.47 (m, 2H, NHCH2), 4.14 – 4.29 (m, 2H, NHCHCH3, CH Fmoc), 4.31 
– 4.50 (m, 2H, OCH2 Fmoc), 5.11 (br s, 1H, NH), 5.68 (br s, 1H, NH), 6.93 (br s, 1H, 
NH), 7.24 – 7.34 (m, 2H, Aromatic hydrogen (ArH)), 7.34 – 7.43 (m, 2H, ArH), 7.53 – 
7.62 (m, 2H, ArH), 7.68 – 7.82 (m, 2H, ArH). 13C NMR (101 MHz, CDCl3) δ 19.01, 
28.46, 40.20, 40.82, 47.23, 50.77, 67.15, 67.18, 79.85, 120.09, 125.18, 127.17, 127.83, 
141.39, 143.87, 143.88, 156.11, 157.00, 173.17. HRMS calculated for C25H31N3NaO5 [M 
+ Na]+, 476.2156; found, 476.2125. 
 
 
tert‐Butyl N‐{2‐[(2S)‐2‐aminopropanamido]ethyl}carbamate (2.16) 
To a solution of 2.15 (0.62 g, 1.38 mmol) in DCM (10 mL) was added diethylamine (7.0 
mL) at 0°C. The reaction mixture was warmed to rt and stirred for 12 h. The solvent was 
removed under reduced pressure and the residue was co-evaporated with CHCl3 and 
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toluene to give 2.16 (0.64 g) as a colourless solid, which was not further purified and used 




carbamoyl] ethyl]carbamoyl}ethyl]carbamate (2.17) 
According to the procedure described for 2.15, Fmoc-Ala-OH (0.43 g, 1.38 mmol) was 
reacted with 2.16 (0.32 g, 1.38 mmol), HBTU (0.52 g, 1.37 mmol), HOBt.H2O (0.2 g, 
1.37 mmol) and DIPEA (0.5 mL, 2.75 mmol). Purification of the crude compound by 
silica gel column chromatography (eluting with 20% EtOAc/hexane to 5% 
MeOH/EtOAc) gave 2.17 (0.59 g, 1.13 mmol, 82%) as a colourless solid. 1H NMR (400 
MHz, DMSO-d6) δ 1.09 – 1.29 (m, 6H, 2 × CH3), 1.37 (s, 9H, C(CH3)3), 2.88 – 3.02 (m, 
2H, NHCH2), 3.02 – 3.19 (m, 2H, NHCH2), 3.99 – 4.12 (m, 1H, NHCHCH3), 4.13 – 4.37 
(m, 4H, NHCHCH3, CH Fmoc, OCH2 Fmoc), 6.75 (t, 1H, J = 5.8 Hz, NH), 7.27 – 7.38 
(m, 2H, ArH), 7.38 – 7.47 (m, 2H, ArH), 7.50 – 7.58 (m, 1H, NH), 7.66 – 7.79 (m, 2H, 
ArH), 7.85 (t, 1H, J = 6.0 Hz, NH), 7.87 – 7.97 (m, 3H, NH and ArH). 13C NMR (101 
MHz, DMSO-d6) δ 18.08, 18.39, 28.21, 38.70
*, 39.52*, 46.64, 48.15, 50.02, 65.61, 77.65, 
120.09, 125.28, 127.07, 127.62, 140.70, 143.78, 143.86, 155.57, 155.75, 172.03, 172.13. 
(*underneath DMSO-d6 peaks, identified through gHSQC spectroscopy). HRMS 
calculated for C28H36N4NaO6 [M + Na]





The compound was prepared following the procedure used for the preparation of 2.16, 
using 2.17 (0.47 g, 0.90 mmol), diethylamine (4.0 mL), DCM (3.0 mL) and MeOH (2.0 
mL). Compound 2.18 (0.48 g) was obtained as a colourless solid and used for the next 





3-(2-Aminoethyl)phenol hydrobromide salt (2.20) 
The compound was synthesised according to a previously reported literature synthesis of 
2.20.179 A solution of commercially available 2-(3-methoxyphenyl)ethan-1-amine 2.19 
(5.0 mL, 34.32 mmol) in aq. HBr (30 mL, 48% w/w) was stirred for 7 h at 100 °C. The 
reaction mixture was cooled to rt and the solvent was evaporated under reduced pressure 
to give a whitish-pink solid. The solid was triturated and co-evaporated with toluene to 
give 2.20 (8.0 g, 36.86 mmol, quantitative) as a whitish-pink solid, which was used in the 
next reaction without further purification. 1H NMR (400 MHz, DMSO-d6) δ 2.74 – 2.81 
(m, 2H, CH2), 2.95 – 3.04 (m, 2H, CH2), 6.60 – 6.75 (m, 3H, ArH), 7.03 – 7.17 (m, 1H, 





6-Hydroxy-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid (2.21) 
The compound was synthesised according to a previously reported literature synthesis of 
2.21.180 To a solution of 2.20 (1.0 g, 4.58 mmol) in EtOH (22.0 mL) was added Et3N (0.7 
mL, 5.04 mmol) and the reaction stirred for 10 min. The reaction mixture was cooled to 
4 °C and a solution of glyoxylic acid (0.42 g, 4.58 mmol) in EtOH (5.0 mL) was added 
dropwise and the reaction was stirred for 1 h and then at rt for another 1 h. The resulting 
solid was filtered and washed with EtOH to give the 2.21 (0.63 g, 3.23 mmol, 71%) as a 
colourless solid. 1H NMR (400 MHz, DMSO-d6) δ 2.66 – 2.79 (m, 1H, CH*HCH2), 2.79 
– 2.93 (m, 1H, CHH*CH2), 3.01 – 3.14 (m, 1H, CH2CH*H), 3.26 – 3.34 (m, 1H, 
CH2CHH*), 4.33 (s, 1H, CHCO2H), 6.49 (d, 1H, J = 2.5 Hz, ArH), 6.56 – 6.63 (m, 1H, 
ArH), 7.50 (d, 1H, J = 8.5 Hz, ArH), 8.80 (br m, 2H, NH, OH), 9.37 (br s, 1H, CO2H). (
* 
designates diastereotopic protons). 13C NMR (101 MHz, DMSO-d6) δ 25.25, 57.82, 
113.57, 113.91, 121.19, 129.06, 132.69, 155.88, 167.15. HRMS calculated for C10H10NO3 





Methyl 6-hydroxy-1,2,3,4-tetrahydroisoquinoline-1-carboxylate (2.22) 
To a suspension of 2.21 (6.63 g, 34.32 mmol) in MeOH (150 mL) at 0 °C was added 
dropwise SOCl2 (7.5 mL, 102.95 mmol) under N2 atmosphere. The reaction mixture was 
warmed to rt and stirred for 15 h. The solvent was removed under reduced pressure and 
the resulting solid was dissolved in THF (30 mL) and neutralised with Et3N (15 mL). The 
mixture was filtered to remove Et3N.HCl and the filtrate evaporated under reduced 
pressure to give 2.22 (7.11 g, 34.31 mmol, quantitative) as a yellow solid. 1H NMR (400 
MHz, MeOD-d4) δ 2.66 – 2.79 (m, 2H, CH2*CH2), 2.93 – 3.02 (m, 1H, CH2CH
*H), 3.21 
– 3.30 (m, 1H, CH2CHH
*), 3.74 (s, 3H, OCH3), 4.60 (s, 1H, CHCO2CH3), 6.54 (d, 1H, J 
= 2.6 Hz, ArH), 6.60 (dd, 1H, J = 2.6, 8.4 Hz, ArH), 7.13 (d, J = 8.46 Hz, 1H, ArH). (* 
designates diastereotopic protons). 13C NMR (101 MHz, MeOD-d4) δ 29.49, 41.18, 52.65, 
58.98, 114.60, 116.22, 123.45, 129.77, 137.57, 157.64, 174.89. HRMS calculated for 
C11H14NO3 [M + H]
+, 208.0973; found, 208.0975. The synthesis of 2.22 has previously 
been reported by Ma et al.181 but without spectroscopic data of 2.22.  
 
 
Example of an unoptimised DDQ aromatisation reaction – formation of methyl 6‐
hydroxy‐3,4‐dihydroisoquinoline‐1‐carboxylate (2.23)  
Tetrahydroquninoline 2.22 (0.11 g, 0.57 mmol) was reacted with DDQ (0.26 g, 1.13 
mmol) in a solvent mixture of THF (3 mL) and 1,4-dioxane (10 mL) at 110 °C under N2 
atmosphere for 6 h. The solvent was removed under reduced pressure and the residue was 
diluted with EtOAc and washed three times with saturated aq. NaHCO3 solution. The 
organic washings were combined, washed once with water, brine solution, then dried over 
MgSO4.H2O, concentrated under reduced pressure and purified by silica gel column 
chromatography (30% EtOAc/hexane to 60% EtOAc/hexane) to provide 2.23 (0.03 g, 
0.18 mmol, 32%) as a pale yellow solid was isolated. 1H NMR (400 MHz, CDCl3) δ 2.70 
– 2.80 (m, 2H, CH2), 3.77 – 3.88 (m, 2H, CH2), 3.91 (s, 3H, CH3), 6.71 (d, 1H, J = 2.4 
Hz, ArH), 6.75 – 6.83 (m, 1H, ArH), 7.66 (d, 1H, J = 8.6 Hz, ArH). HRMS calculated for 
C11H12NO3 [M + H]




Optimised DDQ aromatisation reaction - preparation of methyl 6-
hydroxyisoquinoline-1-carboxylate (2.24) 
To a solution of 2.22 (0.17 g, 0.83 mmol) in 1,4-dioxane:THF (10mL 1:1, v:v) at 45 °C 
was added DDQ (0.38 g, 1.67 mmol) and the reaction was stirred vigorously at 45 °C for 
5 h with the mouth of the flask open to the atmosphere to allow mixing of air. 1,4-Dioxane 
(10 mL) was added and the reaction mixture filtered, the filtrate was diluted with EtOAc 
and washed three times with saturated aq. NaHCO3 solution. The organic washings were 
combined, washed once with water, brine solution, then dried over MgSO4.H2O, 
concentrated under reduced pressure and purified by silica gel column chromatography 
(30% EtOAc/hexane to 50% EtOAc/hexane) to provide 2.24 (84 mg, 0.413 mmol, 49 %) 
as an off-white solid. 1H NMR (400 MHz, MeOD-d4) δ 4.04 (s, 3H, OCH3), 7.16 (d, J = 
2.5 Hz, 1H, ArH), 7.28 (dd, 1H, J = 2.5, 9.3 Hz, ArH), 7.73 (d, 1H, J = 5.7 Hz, ArH), 
8.30 (d, 1H, J = 5.7 Hz, ArH), 8.52 (d, 1H, J = 9.3 Hz, ArH). 13C NMR (101 MHz, MeOD-
d4) δ 53.24, 108.72, 122.70, 122.89, 124.25, 129.49, 141.07, 141.83, 149.28, 161.18, 
167.61. HRMS calculated for C11H10NO3 [M + H]
+, 204.0655; found, 204.0647. The 
isoquinoline 2.24 has been reported once before in the literature in a Japanese patent183 
but no spectroscopic data was provided. 
 
 
6-Hydroxyisoquinoline-1-carboxylic acid (2.25) 
To a solution of 2.24 (2.6g, 12.79 mmol) in THF (20 mL) at 0°C was added a solution of 
LiOH (0.92 g, 38.38 mmol) in water (15 mL). The reaction mixture was warmed to rt and 
stirred for another 12 h. The solvent was evaporated under reduced pressure and the 
residue was acidified (pH 2.0-3.0) with 2.0 N aq. HCl. A yellow precipitate formed that 
was collected by filtration, washed with 5.0 N aq. HCl (50 mL) and dried to give 2.25 
(2.3 g, 12.15 mmol, 96%) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 7.24 (d, 
1H, J = 2.5 Hz, ArH), 7.33 (dd, 1H, J = 2.5, 9.2 Hz, ArH), 7.85 (dd, 1H, J = 0.8, 6.0 Hz, 
ArH), 8.33 (d, J = 5.8 Hz,1H, ArH), 8.65 (d, 1H, J = 9.2 Hz, ArH), 10.78 (br s, 1H, 
CO2H). 
13C NMR (101 MHz, DMSO-d6) δ 107.77, 120.06, 121.75, 122.26, 129.11, 
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139.05, 139.42, 149.60, 159.96, 165.99. HRMS calculated for C10H7NNaO3 [M + Na]
+, 




According to a modified literature procedure for the PPA mediated synthesis of 
(benzimidazolyl)isoquinoline,76 a mixture of 2.25 (0.1 g, 0.49 mmol), 3,4-diaminotoluene 
(0.07g, 0.59 mmol) and PPA (polyphosphoric acid, ≥83% phosphate as P2O5 basis) (~5 
g) were heated at 250 °C for 6 h. The resulting viscous black liquid was slowly basified 
(pH = 8.0 - 10.0) with KOH at 0 °C (caution:exothermic) and extracted with EtOAc. The 
EtOAc layer was washed with saturated aq. NaHCO3 solution, water, brine solution, dried 
over MgSO4.H2O  and the residue was purified by silica gel column chromatography 
(10% EtOAc/hexane to 50% EtOAc/hexane) to give  2.26 (24 mg, 0.08 mmol, 18%) as 
an off-white solid. 1H NMR (400 MHz, MeOD-d4) δ 2.48 (s, 3H, CH3), 7.06 – 7.20 (m, 
2H, ArH isoquinoline and ArH benzimidazole), 7.24 – 7.32 (m, 1H, ArH isoquinoline), 
7.47 (br s, 1H, ArH benzimidazole), 7.53 – 7.69 (m, 2H, ArH isoquinoline and ArH 
benzimidazole), 8.40 (d, 1H, J = 5.7 Hz, ArH isoquinoline), 9.20 (d, 1H, J = 9.3 Hz, ArH 
isoquinoline). 13C NMR (101 MHz, MeOD-d4) δ 21.81, 108.74, 121.98, 122.16, 122.94, 
125.91, 130.87, 134.42, 141.02, 142.76, 148.70, 152.04, 160.82. HRMS calculated for 
C17H14N3O [M + H]
+, 276.1131; found, 276.1118. Analytical RP-HPLC Rt = 13.26 min; 




According to the procedure described for 2.26, a mixture of 2.25 (0.2 g, 1.05 mmol) and 
o-phenylenediamine (0.08 g, 0.74 mmol) were reacted to give 2.27 (27 mg, 0.10 mmol, 
21%) as an off-white solid. 1H NMR (400 MHz, MeOD-d4) δ 7.19 (d, 1H, J = 2.5 Hz, 
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ArH isoquinoline), 7.27 – 7.38 (m, 3H, ArH isoquinoline, benzimidazole), 7.55 – 7.88 
(m, 3H, ArH isoquinoline, benzimidazole), 8.46 (d, 1H, J = 5.8 Hz, ArH isoquinoline), 
9.25 (d, 1H, J = 9.3 Hz, ArH isoquinoline). 13C NMR (101 MHz, MeOD-d4) δ 101.42, 
108.77, 122.12, 122.31, 123.03, 130.86, 141.11, 142.86, 148.67, 152.44, 160.97. HRMS 
calculated for C16H12N3O [M + H]
+, 262.0975; found, 262.0967. Analytical RP-HPLC Rt 
= 11.61 min; determined with HPLC method A. 
 
 
tert-Butyl 2-{[1-(1H-1,3-benzodiazol-2-yl)isoquinolin-6-yl]oxy}acetate (2.28) 
A mixture of (benzimidazolyl)isoquinolinol 2.27 (45 mg, 0.172 mmol) and K2CO3 (48 
mg, 0.0.34 mmol) in anhydrous THF (5 mL) were stirred at 60 °C for 20 min under N2 
atmosphere, followed by addition of a solution of tert-butyl bromoacetate (40 µL, 0.26 
mmol) in anhydrous THF (1 mL). The reaction was stirred at 60 °C for 12 h. The solvent 
was removed under reduced pressure and the residue was partitioned between EtOAc and 
saturated aq. NH4Cl, the EtOAc layer was washed further with brine solution, dried over 
MgSO4.H2O and concentrated under reduced pressure. The residue was purified by silica 
gel column chromatography (20% EtOAc/hexane to 30% EtOAc/hexane) to give 2.28 (60 
mg, 0.16 mmol, 93%) as an off-white solid. 1H NMR (400 MHz, CDCl3) δ 1.51 (s, 9H, 
C(CH3)3), 4.69 (s, 2H, CH2), 7.03 (d, 1H, J = 2.6 Hz, ArH benzimidazole), 7.28 – 7.34 
(m, 2H, ArH isoquinoline and ArH benzimidazole), 7.37 – 7.54 (m, 2H, ArH isoquinoline 
and ArH benzimidazole), 7.58 (d, 1H, J = 5.6 Hz, ArH isoquinoline), 7.94 (br s, 1H, ArH 
benzimidazole), 8.47 (d, 1H, J = 5.6 Hz, ArH isoquinoline), 10.17 (d, 1H, J = 9.5 Hz, 
ArH isoquinoline), 11.48 (br s, 1H, NH). 13C NMR (101 MHz, CDCl3) δ 28.20, 65.77, 
82.98, 105.71, 111.28, 120.68, 121.41, 121.82, 122.63, 122.95, 124.24, 131.02, 133.35, 
139.31, 141.95, 144.95, 146.40, 151.48, 159.28, 167.46. HRMS calculated for 
C22H22N3O3 [M + H]







According to the procedure described for 2.28, a mixture of 2.26 (150 mg, 0.54 mmol), 
K2CO3 (151 mg, 1.09 mmol) and tert-butyl bromoacetate (0.12 mL, 0.82 mmol) were 
reacted to give 2.29 (203 mg, 0.521 mmol, 96%) as an off-white solid. 1H NMR (400 
MHz, CDCl3) δ 1.51 (s, 9H, C(CH3)3), 2.50 (s, 3H, CH3), 4.69 (s, 2H, CH2), 7.03 (d, 1H, 
J = 2.7 Hz, ArH isoquinoline), 7.10 – 7.17 (m, 1H, ArH benzimidazole), 7.32 (br s, 1H, 
ArH benzimidazole), 7.48 (dd, 1H, J = 2.7, 9.5 Hz, ArH isoquinoline), 7.57 (d, 1H, J = 
5.6 Hz, ArH isoquinoline), 7.64 – 7.89 (br s, 1H, ArH benzimidazole), 8.45 (d, 1H, J = 
5.6 Hz, ArH isoquinoline), 10.16 (d, 1H, J = 9.5 Hz, ArH isoquinoline), 11.24 (br s, 1H, 
NH). 13C NMR (101 MHz, CDCl3) δ 21.94, 28.20, 65.78, 82.96, 105.71, 111.19, 120.20, 
121.33, 121.63, 122.88, 124.56, 131.09, 133.85, 139.30, 141.89, 146.47, 151.14, 159.27, 
167.47. HRMS calculated for C23H24N3O3 [M + Na]
+, 390.1812; found, 390.1783. 
 
 
2-{[1-(1H-1,3-Benzodiazol-2-yl)isoquinolin-6-yl]oxy}acetic acid (2.30) 
To a solution of 2.28 (50 mg, 0.13 mmol) in DCM (5 mL) at 0 °C was added TFA (1 mL, 
13.32 mmol) and the mixture stirred for 5 h. The DCM and TFA were removed under 
reduced pressure to provide an oil, which solidified to a yellow solid upon co-evaporation 
with CHCl3/hexane. This solid was washed with cold MeOH to give 2.30 (27 mg, 0.08 
mmol, 64%) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 4.91 (s, 2H, CH2), 7.19 
– 7.35 (m, 2H, ArH benzimidazole), 7.42 (d, 1H, J = 2.7 Hz, ArH isoquinoline), 7.52 (dd, 
1H, J = 2.7, 9.5 Hz, ArH isoquinoline), 7.61 (d, 1H, J = 7.8 Hz, ArH benzimidazole ), 
7.83 (d, 1H, J = 8.0 Hz, ArH benzimidazole), 7.87 (d, 1H, J = 5.6 Hz, ArH isoquinoline), 
8.59 (d, 1H, J = 5.6 Hz, ArH isoquinoline), 10.04 (d, 1H, J = 9.5 Hz, ArH isoquinoline), 
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13.17 (br m, 2H, NH and CO2H). 
13C NMR (101 MHz, DMSO-d6) δ 64.64, 105.98, 
112.05, 119.66, 121.12, 121.59, 121.82, 121.93, 123.57, 129.87, 133.99, 138.90, 142.21, 
144.02, 146.10, 151.25, 158.74, 169.65. HRMS calculated for C18H14N3O3 [M + H]
+, 
320.10297; found, 320.1008. 
 
 
2-{[1-(5-Methyl-1H-1,3-benzodiazol-2-yl)isoquinolin-6-yl]oxy}acetic acid (2.31) 
According to the procedure described for 2.30, a mixture of 2.29 (196 mg, 0.503 mmol) 
and TFA gave 2.31 (172 mg, 0.51 mmol, quantitative) as a yellow solid. 1H NMR (400 
MHz, MeOD-d4) δ 2.53 (s, 3H, CH3), 4.90 (s, 2H, CH2), 7.21 – 7.32 (m, 1H, ArH 
benzimidazole), 7.35 (d, 1H, J = 2.6 Hz, ArH isoquinoline or ArH benzimidazole), 7.48 
(dd, 1H, J = 2.6, 9.4 Hz, ArH isoquinoline), 7.56 (s, 1H, ArH benzimidazole), 7.66 (d, 
1H, J = 8.3 Hz, ArH isoquinoline or ArH benzimidazole), 7.85 (d, 1H, J = 5.6 Hz, ArH 
isoquinoline), 8.56 (d, 1H, J = 5.7 Hz, ArH isoquinoline), 9.00 (d, 1H, J = 9.4 Hz, ArH 
isoquinoline). 13C NMR (101 MHz, MeOD-d4) δ 21.79, 65.95, 107.39, 115.10, 115.56, 
123.63, 123.70, 124.56, 128.61, 128.81, 133.62, 135.34, 137.94, 140.84, 143.65, 144.56, 
149.01, 161.33, 171.68. HRMS calculated for C19H15N3NaO3 [M + Na]
+, 356.1006; 






To a solution of 2.31 (32 mg, 0.09 mmol) and HATU (38 mg, 0.10 mmol) in anhydrous 
DMF (1 mL) was added DIPEA (30 µL, 0.19 mmol) and the mixture was stirred for 15 
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min. A solution of 2.10 (70 mg, 0.29 mmol) in DMF (1 mL) was then added and the 
mixture stirred for 4 h. The solvent was removed under reduced pressure and the resulting 
residue partitioned between EtOAc and water. The EtOAc layer was washed three times 
with NH4Cl solution, once with water and brine solution, dried over MgSO4.H2O and the 
solvent evaporated. The residue was purified by silica gel column chromatography (20% 
EtOAc/hexane to 50% EtOAc/hexane) to give 2.32 (37 mg, 0.06 mmol, 69%) as a clear 
oil. 1H NMR (400 MHz, CDCl3) δ 1.08 – 1.32 (m, 8H, 4 × CH2), 1.44 (s, 13H, 2 × CH2 
and C(CH3)3), 2.50 (s, 3H, CH3), 3.05 (q, 2H, J = 6.8 Hz,  CONHCH2 or CH2NHBoc), 
3.35 (q, 2H, J = 6.8 Hz, CONHCH2 or CH2NHBoc), 4.53 (t, 1H, J = 6.0 Hz, NH), 4.66 
(s, 2H, OCH2CO), 6.59 (t, 1H, J = 6.0 Hz, NH), 7.09 (d, 1H, J = 2.7 Hz, ArH 
isoquinoline), 7.11 – 7.18 (m, 1H, ArH benzimidazole), 7.43 (dd, 1H, J = 2.6, 9.5 Hz, 
ArH isoquinoline), 7.50 – 7.75 (m, 3H, ArH isoquinoline and ArH benzimidazole), 8.48 
(d, 1H, J = 5.6 Hz, ArH isoquinoline), 10.18 (d, 1H, J = 9.4 Hz, ArH isoquinoline), 11.16 
(b s, 1H, NH). 13C NMR (101 MHz, CDCl3) δ 21.94, 26.79, 26.88, 28.58, 29.25, 29.27, 
29.63, 30.11, 39.26, 40.68, 67.39, 79.15, 105.92, 120.96, 121.68, 122.97, 124.79, 131.38, 
139.28, 142.27, 146.49, 151.01, 156.14, 158.33, 167.41. HRMS calculated for 
C32H42N5O4 [M + H]




acetamido)ethoxy]-ethoxy}ethyl)carbamate (2.33)  
According to the procedure described for 2.32, a mixture of 2.31 (60 mg, 0.18 mmol), 
2.12 (134 mg, 0.54 mmol), HATU (72 mg, 0.19 mmol) and DIPEA (70 µL, 0.36 mmol) 
gave a residue that was purified by silica gel column chromatography (50% 
EtOAc/hexane to 4% MeOH/EtOAc) to give 2.33 (52 mg, 0.09 mmol, 52%) as a 
colourless solid. 1H NMR (400 MHz, CDCl3) δ 1.42 (s, 9H, C(CH3)3), 2.48 (s, 3H, CH3), 
3.25 – 3.32 (m, 2H, CONHCH2 or CH2NHBoc), 3.45 – 3.63 (m, 10H, 5 × CH2), 4.65 (s, 
2H, OCH2CO), 5.06 (br s, 1H, NH), 6.97 – 7.18 (m, 3H, NH, ArH benzimidazole, ArH 
isoquinoline), 7.28 – 7.79 (m, 4H, ArH benzimidazole, ArH isoquinoline), 8.46 (d, 1H, J 
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= 5.6 Hz, ArH isoquinoline), 10.15 (d, 1H, J = 9.4 Hz, ArH isoquinoline), 11.32 (br s, 
1H, NH). 13C NMR (101 MHz, CDCl3) δ 21.90, 28.51, 39.03, 40.39, 67.34, 69.78, 70.19, 
70.30, 70.35, 79.40, 105.90, 120.92, 121.63, 122.93, 124.96, 131.31, 133.71, 139.23, 
142.18, 146.56, 151.00, 156.08, 158.33, 167.61. HRMS calculated for C30H38N5O6 [M + 
H]+, 564.2817; found, 564.2798. Analytical RP-HPLC Rt = 16.42 min; determined with 





According to the procedure described for 2.32, a mixture of 2.30 (25 mg, 0.08 mmol), 
2.12 (40 mg, 0.16 mmol), HATU (31 mg, 0.08 mmol) and DIPEA (30 µL, 0.19 mmol) 
gave a residue that was purified by silica gel column chromatography (50% 
EtOAc/hexane to 2% MeOH/EtOAc) to provide 2.34 (23 mg, 0.04 mmol, 55%) as pale 
yellow oil. 1H NMR (500 MHz, CDCl3) δ 1.41 (s, 9H, C(CH3)3), 3.28 (q, 2H, J = 5.4 Hz, 
CONHCH2 or CH2NHBoc), 3.44 – 3.70 (m, 10H, 5 × CH2), 4.61 (s, 2H, OCH2CO), 5.06 
(s, 1H, NH), 7.05 (s, 1H, ArH isoquinoline), 7.12 (s, 1H, NH), 7.29 – 7.44 (m, 3H, ArH 
isoquinoline or ArH benzimidazole), 7.62 (d, 1H, J = 5.6 Hz, ArH isoquinoline), 7.73 – 
7.83 (m, 2H, ArH isoquinoline or ArH benzimidazole), 8.36 – 8.49 (m, 1H, ArH 
isoquinoline), 9.77 (d, 1H, J = 9.2 Hz, ArH isoquinoline). 13C NMR (126 MHz, CDCl3) 
δ 28.54, 29.83, 39.15, 40.44, 67.30, 69.70, 70.24, 70.29, 70.38, 79.53, 106.11, 115.86, 
121.64, 122.46, 122.70, 124.41, 130.57, 139.46, 141.55, 145.01, 149.70, 156.20, 158.78, 
167.71. HRMS calculated for C29H35N5NaO6 [M + Na]










According to the procedure described for 2.32, a mixture of 2.31 (45 mg, 0.13 mmol), 
2.18 (122 mg), HATU (54 mg, 0.14 mmol), DIPEA (50 µL, 0.27 mmol) gave a residue 
that was purified by silica gel column chromatography (70% EtOAc/hexane to 4% 
MeOH/EtOAc) to give 2.35 (24 mg, 0.04 mmol, 29%) as a pale yellow solid. 1H NMR 
(500 MHz, MeOD-d4) δ 1.29 – 1.48 (m, 15H, 2 × CH3 alanine and C(CH3)3), 2.50 (s, 3H, 
CH3 benzimidazole), 3.10 – 3.18 (m, 2H, CH2CH2NHBoc or CH2CH2NHBoc), 3.20 – 
3.28 (m, 2H, CH2CH2NHBoc or CH2CH2NHBoc), 4.25 – 4.35 (m, 1H, CHCONH), 4.48 
(q, 1H, J = 7.1 Hz, CHCONH), 4.78 (d, 2H, J = 3.0 Hz, OCH2CO), 7.16 (d, 1H, J = 8.4 
Hz, ArH benzimidazole), 7.32 – 7.36 (m, 1H,  ArH isoquinoline), 7.46 – 7.54 (m, 2H, 
ArH benzimidazole, ArH isoquinoline), 7.60 (br s, 1H, ArH benzimidazole), 7.78 (d, 1H, 
J = 5.69 Hz ArH isoquinoline), 8.52 (d, 1H, J = 5.6 Hz, ArH isoquinoline), 9.42 (d, 1H, 
J = 9.4 Hz, ArH isoquinoline). 13C NMR (126 MHz, MeOD-d4) δ 18.00, 21.83, 28.75, 
40.65, 40.79, 50.51, 50.67, 68.05, 80.14, 107.21, 107.22, 122.18, 122.21, 122.83, 123.91, 
125.75, 130.91, 131.05, 140.70, 143.45, 148.59, 152.01, 158.49, 160.39, 170.43, 174.47, 
175.07. HRMS calculated for C32H40N7O6 [M + H]









To a solution of 2.32 (6 mg, 0.01 mmol) in DCM (2.0 mL) at 0 °C was added TFA (0.5 
mL). The reaction mixture was warmed to rt and stirred for 2 h, volatiles were removed 
under reduced pressure to provide N-(8-aminooctyl)-2-{[1-(5-methyl-1H-1,3-
benzodiazol-2-yl)isoquinolin-6-yl]oxy}acetamide trifluoroacetate in assumed 
quantitative yield as a yellow solid. This trifluoroacetate salt was purified using semi-
preparative RP-HPLC. To a solution of this semi-preparative RP-HPLC purified 
trifluoroacetate salt (3.9 mg, 6.79 µmol) in DMF (200 µL), was added a solution of 
DIPEA (6.42 µL, 36.90 µmol) in DMF (100 µL), followed by addition of solution of 
BOPIPY630/650-SE (1.7 mg, 2.52 µmol) in DMF (700 µL). The reaction was stirred for 
12 h with the exclusion of light then concentrated under reduced pressure and purified by 
RP-HPLC, freeze-dried, neutralised with Amberlyst A21 ion exchange resin to give 2.36 
(0.8 mg, 0.83 µmol, 44%) as a dark blue solid. HRMS calculated for C56H59BF2N8NaO5S 
[M + Na] +, 1027.4292; found, 1027.4322. Analytical RP-HPLC Rt = 22.85 min; 







According to the procedure for 2.36, 2.33 (10 mg, 0.02 mmol) was treated with TFA to 
give N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-2-{[1-(5-methyl-1H-1,3-benzodiazol-2-
yl)isoquinolin-6-yl]oxy}acetamide trifluoroacetate salt in assumed quantitative yield as a 
yellow solid. The trifluoroacetate salt was purified using semi-preparative RP-HPLC. 
This purified trifluoroacetate salt (5.1 mg, 8.83 µmol) on reaction with BOPIPY630/650-
SE (1.2 mg, 1.9 µmol) provided 2.37 (1.0 mg, 0.99 µmol, 54%) as a dark blue solid. 
HRMS calculated for C54H55BF2N8NaO7S [M + Na]
+, 1031.3877; found, 1031.3959. 









According to the procedure for 2.36, 2.34 (10 mg, 0.02 mmol) was treated with TFA to 
give N‐{2-[2-(2-aminoethoxy)ethoxy]ethyl}-2-{[1-(1H-1,3-benzodiazol-2-yl)isoquino-
lin-6-yl]oxy}acetamide trifluoroacetate salt in assumed quantitative yield as a yellow 
solid. The trifluoroacetate salt was purified using semi-preparative RP-HPLC. This 
purified trifluoroacetate salt (5.2 mg, 9.22 µmol) on reaction with BOPIPY630/650-SE 
(1.2 mg, 1.9 µmol) provided 2.38 (2.1 mg, 2.11 µmol, 84%) as a dark blue solid. HRMS 
calculated for C53H53BF2N8NaO7S [M + Na]
+, 1017.3720; found, 1017.3773. Analytical 








According to the procedure for 2.36, 2.35 (15 mg, 0.02 mmol) was treated with TFA to 
give (2S)-N-[(1S)-1-[(2‐aminoethyl)carbamoyl]ethyl]-2-(2-{[1-(5-methyl-1H-1,3-
benzodiazol-2-yl)isoquinolin-6-yl]oxy}acetamido)propanamide trifluoroacetate salt in 
assumed quantitative yield as a yellow solid. The trifluoroacetate salt was purified using 
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semi-preparative RP-HPLC. This purified trifluoroacetate salt (5.5 mg, 8.7 µmol) on 
reaction with BOPIPY630/650-SE (1.2 mg, 1.9 µmol) provided 2.39 (0.63 mg, 0.59 
µmol, 33%) as dark blue solid. HRMS calculated for C56H57BF2N10NaO7S [M + Na]
+, 
1085.4095; found, 1085.4162. Analytical RP-HPLC Rt = 21.05 min; determined with 
HPLC method A. 
 
 
(9H-Fluoren-9-yl)methyl N-[2-(4-hydroxyphenyl)ethyl]carbamate (2.42) 
The compound was synthesised according to a previously reported literature synthesis of 
2.42.180 To a solution of tyramine 2.40 (10 g, 72.95 mmol) and DIPEA (38.1 mL, 218.8 
mmol) in DCM (120 mL) at 0 °C was added a solution of Fmoc-Cl (18.8 g, 72.6 mmol) 
in DCM (90 mL). The reaction mixture was stirred at 0 °C for 15 min and then warmed 
to rt and stirred for 20 h. The reaction mixture was diluted with DCM. The DCM solution 
was washed with saturated solution of NaHCO3 and brine solutions. The DCM layer was 
dried over dried over MgSO4.H2O, concentrated under reduced pressure and the residue 
purified by silica gel column chromatography (30% EtOAc/hexane to 20% 
Acetone/hexane) to provide 2.42 (21.5 g, 59.82 mmol, 82%) as a colourless solid. 1H 
NMR (400 MHz, Methanol-d4) δ 2.67 (t, 2H, J = 7.3 Hz, NHCH2CH2), 3.27 (t, 2H, J = 
7.3 Hz, NHCH2CH2), 4.18 (t, 1H, J = 6.8 Hz, CH Fmoc), 4.32 (d, 2H, J = 6.9 Hz, CH2 
Fmoc), 6.63 – 6.73 (m, 2H, ArH), 7.00 (d, 2H, J = 8.1 Hz, ArH), 7.25 – 7.35 (m, 2H, ArH 
Fmoc), 7.35 – 7.44 (m, 2H, ArH Fmoc), 7.62 (d, 2H, J = 7.5 Hz, ArH Fmoc), 7.79 (d, 2H, 
J = 7.5 Hz, ArH Fmoc). HRMS calculated for C23H21NNaO3 [M + Na]






To a solution of 2.42 (19.7 g, 54.85 mmol) in AcOH/H2SO4 (200 mL, 3:1 v:v) was added 
a solution of glyoxylic acid monohydrate (5.5 g, 92.1 mmol) and stirred for 24 h. The 
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reaction mixture was poured slowly into ice/water (caution: exothermic reaction) and the 
precipitate formed was separated and dried under vacuum oven (60°C, 300 mbar) for 12 
h to give a pinky white solid. This solid was dissolved in DCM and washed with water, 
brine, dried over MgSO4.H2O and solvent evaporated under reduced pressure to give 2-
{[(9H-fluoren-9-yl)methoxy]carbonyl}-7-hydroxy‐1,2,3,4-tetrahydroisoquinoline-1-
carboxylic acid (previously reported by Maillard et al.180) as a pinky white solid (18.4 g) 
which was used in the next reaction without further purification. To a solution of 2-{[(9H-
fluoren-9-yl)methoxy]carbonyl}-7-hydroxy‐1,2,3,4-tetrahydroisoquinoline-1-carboxylic 
acid (18.2 g, 43.81 mmol) in MeOH (200 mL) at 0 °C was added dropwise SOCl2 (6.4 
mL, 87.62 mmol). The reaction mixture was then heated to 60 °C and stirred for 12 h. 
The reaction mixture was cooled to rt then concentrated under reduced pressure to give a 
syrupy residue. This residue was dissolved in EtOAc, washed with saturated aq. NaHCO3 
solution, brine solution, dried over MgSO4.H2O and purified by silica gel column 
chromatography (30% EtOAc/hexane to 40% EtOAc/hexane) to give 2.43 (4.3 g, 10.01 
mmol, 18% from 2.42) as a colourless foamy solid. Rt and high temperature NMR spectra 
revealed the presence of two rotamers in a 2:3 ratio (labelled rotamer A and B). 1H NMR 
(400 MHz, DMSO-d6) δ 2.56 – 2.79 (m, 2H, CH2CH2NFmoc rotamer A and B), 3.45 – 
3.72 (m, 4H, OCH3, CHCO2CH3 rotamer A and B), 4.23 – 4.51 (m, 4H, CH2CH2NFmoc 
and CH2 Fmoc, rotamer A and B), 5.13 – 5.45 (m, 1H, CHFmoc rotamer A and B) 6.61 
– 6.71 (m, 1H, ArH rotamer A and B), 6.81 (dd, J = 2.5, 37.4 Hz, 1H, ArH rotamer A and 
B), 7.00 (t, J = 8.5, 8.5 Hz, 1H, ArH rotamer A and B), 7.26 – 7.38 (m, 2H, ArH rotamer 
A and B), 7.38 – 7.48 (m, 2H, ArH rotamer A and B), 7.57 – 7.71 (m, 2H, ArH rotamer 
A and B), 7.85 – 7.95 (m, 2H, ArH rotamer A and B), 9.39 – 9.46 (m, 1H, OH rotamer A 
and B). HRMS calculated for C26H23NNaO5 [M + Na]
+, 452.1468; found, 452.1443. 
 
 
Methyl 7-hydroxyisoquinoline-1-carboxylate (2.44) 
According to a modified literature procedure,188 tetrahydroisoquinoline 2.43 (4.1 g, 9.55 
mmol), DMSO (20 mL) and MeOH (20 mL) were stirred at 60 °C for 12 h, diluted with 
EtOAc, filtered, the filtrate washed with water and dried over MgSO4.H2O. The solvent 
was evaporated under reduced pressure to give the Fmoc-deprotected product methyl 7-
hydroxy-1,2,3,4-tetrahydroisoquinoline-1-carboxylate, which was then aromatised 
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according to the procedure for 2.24, using DDQ (4.4 g, 19.09 mmol) and 1,4-
dioxane:THF (1:1 v:v, 100 mL). The crude compound was purified by silica gel column 
chromatography (30% EtOAc/hexane to 50% EtOAc/hexane) to provide 2.44 (1.2 g, 5.90 
mmol, 61%) as an off-white solid. 1H NMR (500 MHz, MeOD-d4) δ 4.03 (s, 3H, OCH3), 
7.39 (dd, 1H, J = 2.4, 8.9 Hz, ArH), 7.84 – 7.90 (m, 2H, ArH), 8.01 – 8.06 (m, 1H, ArH), 
8.31 (d, 1H, J = 5.5 Hz, ArH). 13C NMR (126 MHz, MeOD-d4) δ 53.11, 107.81, 125.21, 
125.86, 129.76, 130.23, 133.68, 139.16, 147.02, 159.46, 167.59. HRMS calculated for 
C11H9NNaO3 [M + Na]
+, 226.0475; found, 226.0481. 
 
 
7-Hydroxyisoquinoline-1-carboxylic acid (2.45) 
According to the procedure for 2.25, a solution of 2.44 (1.0 g, 4.92 mmol) and LiOH 
(0.235 g, 9.84 mmol) gave 2.45 (0.65 g, 3.43 mmol, 70%) as yellowish solid. 1H NMR 
(500 MHz, D2O) δ 7.24 – 7.28 (m, 1H, ArH), 7.33 (dd, 1H, J = 2.4, 8.9 Hz, ArH), 7.68 
(d, 1H, J = 5.8 Hz, ArH), 7.80 (d, 1H, J = 9.0 Hz, ArH), 8.09 (d, 1H, J = 5.7 Hz, ArH). 
13C NMR (126 MHz, D2O) δ 110.27, 123.79, 128.39, 128.88, 131.25, 133.19, 139.13, 
158.22, 163.05, 177.87. HRMS calculated for C10H8NO3 [M + H]





According to the procedure described for 2.26, a mixture of 2.45 (200 mg, 1.05 mmol) 
and 3,4-diaminotoluene (130 mg, 1.05 mmol) were reacted to give 2.46 (72 mg, 0.26 
mmol, 24%) as  an off-white solid. 1H NMR (500 MHz, MeOD-d4) δ 2.51 (s, 3H, CH3), 
7.16 (d, 1H, J = 8.2 Hz, ArH benzimidazole), 7.40 (dd, 1H, J = 2.4, 8.9 Hz, ArH 
isoquinoline), 7.49 (br s, 1H, ArH benzimidazole), 7.60 (br s, 1H, ArH benzimidazole), 
7.78 (d, 1H, J = 5.5 Hz, ArH isoquinoline), 7.88 (d, 1H, J = 8.9 Hz, ArH isoquinoline), 
8.44 (d, 1H, J = 5.5 Hz, ArH isoquinoline), 8.74 (d, 1H, J = 2.4 Hz, ArH isoquinoline).  
13C NMR (126 MHz, MeOD-d4) δ 21.82, 49.00, 109.34, 123.37, 124.61, 129.65, 129.98, 
214 
 
133.56, 140.13, 147.22, 158.93. HRMS calculated for C17H14N3O [M + H]
+, 276.1131; 






According to the procedure described for 2.28, a mixture of 2.46 (45 mg, 0.16 mmol), 
K2CO3 (68 mg, 0.49 mmol) and tert-butyl bromoacetate (0.025 mL, 0.17 mmol) were 
reacted to give 2.47 (42 mg, 0.11 mmol, 66%) as an off-white solid. 1H NMR (400 MHz, 
CDCl3) δ 1.52 (s, 9H, C(CH3)3), 2.52 (s, 3H, CH3), 4.88 (s, 2H, CH2), 7.09 – 7.21 (m, 
1H, ArH benzimidazole), 7.28 – 7.45 (m, 1H, ArH benzimidazole), 7.52 (dd, 1H, J = 2.6, 
9.0 Hz, ArH isoquinoline), 7.66 (d, 1H, J = 5.4 Hz, ArH isoquinoline), 7.70 – 7.86 (m, 
2H, ArH isoquinoline and ArH benzimidazole), 8.46 (d, 1H, J = 5.4 Hz, ArH 
isoquinoline), 9.67 – 9.75 (m, 1H, ArH isoquinoline), 10.78 (br s, 1H, NH). 13C NMR 
(101 MHz, CDCl3) δ 22.05, 28.27, 65.77, 82.72, 107.06, 110.63*, 110.98*, 120.20*, 
120.42*, 122.20, 124.08, 124.19*, 125.81*, 127.92, 128.68, 133.47, 134.34, 140.03, 
143.24, 145.19, 151.39, 157.82, 167.83 (*designates carbons linked to broadened 
benzimidazole protons, as determined by gHSQC, gHMBC experiment). HRMS 
calculated for C23H23N3NaO3 [M + Na]
+, 412.1632; found, 412.1602.  
 
 
2-{[1-(5-Methyl-1H-1,3-benzodiazol-2-yl)isoquinolin-7-yl]oxy}acetic acid (2.48) 
According to the procedure described for 2.30, a mixture of 2.47 (350 mg, 0.90 mmol) 
and TFA gave 2.48 (179 mg) as a yellow solid. This compound was used as such for next 







According to the procedure described for 2.32, a mixture of 2.48 (20 mg, 0.06 mmol), 
2.12 (45 mg, 0.18 mmol), HATU (24 mg, 0.06 mmol), DIPEA (20 µL, 0.12 mmol) gave 
a residue that was purified by silica gel column chromatography (50% EtOAc/hexane to 
3% MeOH/EtOAc) to give 2.49 (14 mg, 0.02 mmol, 43%) as a colourless solid. 1H NMR 
(400 MHz, CDCl3) δ 1.42 (s, 9H, C(CH3)3)), 2.50 (s, 3H, CH3), 3.27 (q, 2H, J = 5.5 Hz, 
m, 2H, CH2NH), 3.41 – 3.67 (m, 10H, 5 × CH2), 4.85 (s, 2H, OCH2CO), 5.04 (m, 1H, J 
= 6.7 Hz, NH), 7.14 (dd, 1H, J = 1.5, 8.3 Hz, ArH benzimidazole), 7.19 (br s, 1H, NH), 
7.36 – 7.56 (m, 2H, ArH isoquinoline, ArH benzimidazole), 7.65 (d, 2H, J = 5.5 Hz, ArH 
isoquinoline, ArH benzimidazole), 7.80 (d, 1H, J = 9.0 Hz, ArH isoquinoline), 8.46 (d, 
1H, J = 5.4 Hz, ArH isoquinoline), 9.73 (s, 1H, ArH isoquinoline). 13C NMR (101 MHz, 
CDCl3) δ 21.91, 28.53, 39.06, 40.41, 67.71, 69.94, 70.21, 70.30, 70.32, 79.46, 108.44, 
122.14, 123.32, 125.20, 127.78, 128.89, 133.55, 140.06, 145.21, 150.80, 156.11, 157.05, 
168.02. HRMS calculated for C30H38N5O6 [M + H]
+, 564.2817; found, 564.2769. 











yl)isoquinolin-7-yl]oxy}trifluoroacetate salt in assumed quantitative yield as a yellow 
solid. The trifluoroacetate salt was purified using semi-preparative RP-HPLC. This 
purified trifluoroacetate salt (5.5 mg, 9.52 µmol) on reaction with BOPIPY630/650-SE 
(1.2 mg, 1.9 µmol) provided 2.50 (0.9 mg, 0.89 µmol, 49%) as a dark blue solid. HRMS 
calculated for C54H55BF2N8NaO7S [M + Na]
+, 1031.3877; found, 1031.3969. Analytical 
RP-HPLC Rt = 21.68 min; determined with HPLC method A. 
 
 
6-Hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (2.52) 
The compound was synthesised according to a previously reported literature synthesis of 
2.52.189 To a solution of commercially available (+/-)-m-tyrosine 2.51 (4.0 g, 22.07 mmol) 
in aqueous HCl (50.0 mL, 0.05 M), was added aqueous formaldehyde solution (5.0 mL, 
37% w/w) and the mixture was stirred at 90 °C for 1 h. The reaction mixture was cooled 
to rt, filtered, resulting solid was washed with water, acetone and dried in an oven (90 °C) 
to give 2.52 (2.1 g, 10.88 mmol, 48%) as a colourless solid. 1H NMR (400 MHz, D2O
#) 
δ 2.73 (dd, 1H, J = 11.0, 16.4 Hz, CH*HCHNH), 2.92 (dd, 1H, J = 4.5, 16.5 Hz, 
CHH*CHNH), 3.38 (dd, 1H, J = 4.5, 11.0 Hz, CHNH), 3.73 – 3.9 (m, 2H, NHCH2*), 6.40 
– 6.51 (m, 2H, ArH), 6.87 (d, 1H, J = 8.3 Hz, ArH) (* designates diastereotopic protons). 
13C NMR (101 MHz, D2O
#) δ 32.03, 45.96, 58.01, 117.30, 118.14, 120.55, 127.30, 
135.26, 164.38, 181.23. #Due to the insolubility of 2.52 in MeOD-d4, DMSO-d6 and D2O, 
NMR spectra were obtained by dissolving 31 mg of 2.52 in a solution of basified D2O 
(20 mg KOH in 0.8 mL D2O). HRMS calculated for C10H10NO3 [M – H]
-, 192.0651; 
found, 192.0666.  
 
 
Methyl 6-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (2.53) 
To a solution of 2.52 (2.0 g, 10.35 mmol) in MeOH (50 mL) was added H2SO4 (1.0 mL, 
96% w/w) and the reaction refluxed for 12 h. The reaction mixture was cooled to rt, 
neutralised with NaHCO3 solution and extracted with EtOAc. The EtOAc layer was 
washed with brine solution, dried over MgSO4.H2O  and the solvent removed under 
reduced pressure to give 2.53 (2.05 g, 9.90 mmol, 96%) as an off-white solid. 1H NMR 
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(400 MHz, CDCl3) δ 2.80 – 3.03 (m, 2H, NHCHCH2
*), 3.68 – 3.74 (m, 1H, NHCH), 3.76 
(s, 3H, OCH3), 3.93 – 4.10 (m, 2H, NHCH2
*), 4.68 (br m, 2H, OH, NH), 6.48 (d, 1H, J = 
2.6 Hz, ArH), 6.60 (dd, 1H, J = 2.6, 8.3 Hz, ArH), 6.85 (d, 1H, J = 8.3 Hz, ArH). * 
designates diastereotopic protons. 13C NMR (101 MHz, CDCl3) δ 31.48, 46.66, 52.45, 
55.73, 114.30, 115.62, 125.78, 127.36, 134.12, 154.91, 173.44. HRMS calculated for 
C11H14NO3 [M + H]
+, 208.0968; found, 208.0950. The synthesis of methyl ester 2.53 
from 2.52 has previously been reported182, 190-193 however none of these reports include 
spectroscopic data for 2.53. 
 
 
Methyl 6-hydroxyisoquinoline-3-carboxylate (2.54) 
Following the procedure described for 2.24, a mixture of 2.53 (1.2 g, 5.79 mmol) and 
DDQ (2.63 g, 11.58 mmol) gave 2.54 (0.6g, 2.95 mmol, 52%) as an off-white solid. 1H 
NMR (400 MHz, MeOD-d4) δ 3.99 (s, 3H, OCH3), 7.23 (d, J = 2.3 Hz, 1H, ArH), 7.34 
(dd, J = 8.9, 2.4 Hz, 1H, ArH), 8.01 (d, J = 8.9 Hz, 1H, ArH), 8.37 (s, 1H, ArH), 9.04 (s, 
1H, ArH). 13C NMR (101 MHz, MeOD-d4) δ 53.01, 109.88, 123.57, 123.97, 126.30, 
131.11, 139.25, 141.89, 152.66, 162.04, 167.28. HRMS calculated for C11H9NNaO3 [M 
+ Na]+, 226.0475; found, 226.0462. The synthesis of 2.54 from 2.53 has previously been 
reported182 but without spectroscopic data of 2.54.  
 
 
6-Hydroxyisoquinoline-3-carboxylic acid (2.55) 
Following the procedure described for 2.25, a mixture of 2.54 (0.6 g, 2.95 mmol) and 
LiOH (0.212 g, 8.86 mmol) gave 2.55 (0.5 g, 2.64 mmol, 90%) as yellow solid. 1H NMR 
(400 MHz, DMSO-d6) δ 7.55 – 7.63 (m, 2H, ArH), 8.39 (d, 1H, J = 8.7 Hz, ArH), 8.66 
(s, 1H, ArH), 9.46 (s, 1H, ArH), 11.79 (br s, 1H, CO2H). 
13C NMR (101 MHz, DMSO-
d6) δ 109.88, 122.88, 123.65, 123.92, 132.49, 135.02, 139.40, 148.32, 163.39, 163.77. 
HRMS calculated for C10H8NO3 [M + H]







Following the procedure described for 2.26, a mixture of 2.55 (0.2 g, 1.05 mmol) and 3,4-
diaminotoluene (0.13 g, 1.05 mmol) gave 2.56 (75 mg, 0.27 mmol, 26%) as an off-white 
solid. 1H NMR (400 MHz, MeOD-d4) δ 2.49 (s, 3H, CH3), 7.12 (d, 1H, J = 8.4 Hz, ArH 
isoquinoline or ArH benzimidazole), 7.20 – 7.30 (m, 2H, ArH isoquinoline and ArH 
benzimidazole), 7.44 (s, 1H,  ArH benzimidazole), 7.54 (s, 1H,  ArH benzimidazole), 
7.98 (d, 1H, J = 8.8 Hz, ArH isoquinoline), 8.43 (s, 1H,  ArH isoquinoline), 9.15 (s, 1H,  
ArH isoquinoline). 13C NMR (101 MHz, MeOD-d4) δ 21.78, 109.11, 118.02, 122.20, 
125.57, 131.01, 139.78, 143.17, 152.99, 161.65. HRMS calculated for C17H14N3O [M + 
H]+, 276.1131; found, 276.1114. Analytical RP-HPLC Rt = 13.83 min; determined with 





Following the procedure described for 2.28, a mixture of 2.56 (18 mg, 0.06 mmol), K2CO3 
(25 mg, 0.18 mmol) and tert-butyl bromoacetate (20 µL, 0.13 mmol) gave 2.57 (24 mg, 
0.06 mmol, 94%) as an off-white solid. 1H NMR (500 MHz, CDCl3) δ 1.53 (s, 9H, 
C(CH3)3), 2.50 (s, 3H, CH3), 4.68 (s, 2H, CH2), 7.07 (d, 1H, J = 2.5 Hz, ArH isoquinoline 
or ArH benzimidazole), 7.09 – 7.16 (m, 1H, ArH isoquinoline or ArH benzimidazole), 
7.34 (dd, 1H, J = 2.5, 8.9 Hz, ArH isoquinoline), 7.40 – 7.82 (s, 2H, ArH benzimidazole), 
7.91 (d, 1H, J = 8.9 Hz, ArH isoquinoline), 8.68 (s, 1H, ArH isoquinoline), 9.10 (s, 1H, 
ArH isoquinoline), 10.74 (br s, 1H, NH). 13C NMR (126 MHz, CDCl3) δ 21.92, 28.25, 
65.75, 83.14, 106.05, 107.48, 117.69, 121.32, 125.23, 129.84, 138.22, 142.54, 151.42, 
159.93, 167.31. HRMS calculated for C23H24N3O3 [M + H]






2-{[3-(5-Methyl-1H-1,3-benzodiazol-2-yl)isoquinolin-6-yl]oxy}acetic acid (2.58) 
Following the procedure described for 2.30, a mixture of 2.57 (40 mg, 0.10 mmol) and 
TFA gave 2.58 (70 mg) as a yellow solid. 1H NMR (500 MHz, DMSO-d6) δ 2.43 (s, 3H, 
CH3), 4.91 (s, 2H, CH2), 7.06 (d, 1H, J = 8.2 Hz, ArH isoquinoline or ArH 
benzimidazole), 7.32 – 7.45 (m, 2H, ArH isoquinoline and/or ArH benzimidazole), 7.46 
– 7.55 (m, 2H, ArH isoquinoline and/or ArH benzimidazole), 8.15 (d, 1H, J = 8.9 Hz, 
ArH isoquinoline), 8.66 (s, 1H, ArH isoquinoline), 9.33 (s, 1H, ArH isoquinoline). HRMS 
calculated for C19H14N3O3 [M – H]





According to the procedure described for 2.32, a mixture of 2.58 (17 mg, 0.05 mmol), 
2.12 (38 mg, 0.15 mmol), HATU (20 mg, 0.05 mmol) and DIPEA (20 µL, 0.11 mmol) 
gave a residue that was purified by silica gel column chromatography (50% 
EtOAc/hexane to 10% MeOH/EtOAc) to give 2.59 (11 mg, 0.02 mmol, 39%) as an off-
white solid. 1H NMR (400 MHz, CDCl3) δ 1.42 (s, 9H, C(CH3)3), 2.50 (s, 3H, CH3), 3.23 
– 3.36 (m, 2H, CONHCH2 or CH2NHBoc), 3.47 – 3.65 (m, 10H, 5 × CH2), 4.66 (s, 2H, 
OCH2), 5.04 (br s, 1H, NH), 7.05 (s, 1H, NH), 7.10 – 7.15 (m, 1H, ArH benzimidazole 
or ArH isoquinoline), 7.17 (d, 1H, J = 2.4, 2.5 Hz, ArH benzimidazole or ArH 
isoquinoline), 7.31 (dd, 1H, J = 2.4, 8.9 Hz, ArH isoquinoline), 7.37 – 7.49 (s, 1H, ArH 
benzimidazole), 7.50 – 7.70 (br s, 1H, ArH benzimidazole), 7.94 (d, 1H, J = 9.0 Hz, ArH 
isoquinoline), 8.69 (s, 1H, ArH isoquinoline), 9.12 (s, 1H, ArH isoquinoline). 13C NMR 
(101 MHz, CDCl3) δ 21.91, 28.55, 39.09, 40.46, 67.44, 69.83, 70.35, 70.41, 79.51, 
107.07, 118.46, 118.48, 120.82, 125.28, 125.48, 130.05, 133.97, 138.00, 150.33, 151.61, 
156.14, 159.10, 167.43. HRMS calculated for C30H38N5O6 [M + H]
+, 564.2817; found, 







According to the procedure described for 2.32, a mixture of 2.58 (20 mg, 0.06 mmol), 
2.18 (54 mg,), HATU (24 mg, 0.06 mmol) and DIPEA (20 µL, 0.12 mmol) gave a residue 
that was purified by silica gel column chromatography (50% EtOAc/hexane to 12% 
MeOH/EtOAc) to give 2.60 (16 mg, 0.02 mmol, 37%) as an off-white solid  1H NMR 
(500 MHz, DMSO-d6) δ 1.19 (d, 3H, J = 7.1 Hz, CH3 Alanine), 1.29 (d, 3H, J = 7.1 Hz, 
CH3 Alanine), 1.35 (s, 9H, C(CH3)3), 2.44 (s, 3H, CH3, benzimidazole), 2.91 – 2.99 (m, 
2H, CH2), 3.00 – 3.13 (m, 2H, CH2), 4.18 – 4.26 (m, 1H, CH), 4.36 – 4.44 (m, 1H, CH), 
4.72 – 4.82 (m, 2H, OCH2), 6.74 (t, 1H, J = 5.8 Hz, NH), 7.05 – 7.09 (m, 1H, ArH 
benzimidazole), 7.42 (s, 1H, ArH benzimidazole), 7.45 (dd, 1H, J = 2.4, 8.9 Hz, ArH 
isoquinoline), 7.49 – 7.55 (m, 2H, ArH benzimidazole or ArH isoquinoline), 7.86 (t, 1H, 
J = 5.7 Hz, NH), 8.11 (d, 1H, J = 7.5 Hz, NH), 8.17 (d, 1H, J = 9.0 Hz, ArH isoquinoline), 
8.36 (d, 1H, J = 7.4 Hz, NH), 8.67 (s, 1H, ArH isoquinoline), 9.34 (s, 1H, ArH 
isoquinoline). 13C NMR (126 MHz, DMSO-d6) δ 18.19, 18.21, 21.37, 28.21, 38.73, 
39.52*, 48.09, 48.32, 66.85, 77.65, 106.67, 117.29, 120.94, 124.07, 124.49, 129.79, 
137.57, 142.44, 150.73, 151.60, 155.58, 159.53, 166.84, 171.52, 172.11 (*underneath 
DMSO-d6 peaks, identified through gHSQC experiment). HRMS calculated for 
C32H40N7O6 [M + H]











According to the procedure for 2.36, 2.59 (5.0 mg, 0.01 mmol) was treated with TFA to 
give N‐{2‐[2‐(2‐aminoethoxy)ethoxy]ethyl}‐2‐{[3‐(5‐methyl‐1H‐1,3‐benzodiazol‐2‐
yl)isoquinolin‐6‐yl]oxy}acetamide trifluoroacetate salt in assumed quantitative yield as a 
yellow solid. The trifluoroacetate salt was purified using semi-preparative RP-HPLC.  
This purified trifluoroacetate salt (5.3 mg, 9.17 µmol) on reaction with BOPIPY630/650-
SE (1.7 mg, 2.52 µmol) provided 2.61 (2.2 mg, 2.18 µmol, 86%) as a dark blue solid. 
HRMS calculated for C54H55BF2N8NaO7S [M + Na]
+, 1031.3877; found, 1031.3849. 








According to the procedure for 2.36, 2.60 (9.0 mg, 0.01 mmol) was treated with TFA to 
give (2S)‐N‐[(1S)‐1‐[(2‐aminoethyl)carbamoyl]ethyl]‐2‐(2‐{[3‐(5‐methyl‐1H‐1,3‐
benzodiazol‐2‐yl)isoquinolin‐6‐yl]oxy}acetamido)propanamide trifluoroacetate salt in 
assumed quantitative yield as a yellow solid. The trifluoroacetate salt was purified using 
semi-preparative RP-HPLC. This trifluoroacetate salt (9.2 mg, 14.56 µmol) on reaction 
with BOPIPY630/650-SE (1.7 mg, 2.52 µmol) provided 2.62 (1.9 mg, 1.83 µmol, 73%) 
as a dark blue solid. HRMS calculated for C56H57BF2N10NaO7S [M + Na]
+, 1085.4095; 







Following the procedure described for 2.26, a mixture of A mixture of commercially 
available 2.63 (0.5 g, 2.88 mmol) and o-phenylenediamine (0.31 g, 2.88 mmol) gave 2.6 
(0.27 g, 1.10 mmol, 38%) as an off-white solid.  
1H NMR (400 MHz, Methanol-d4) δ 7.28 – 7.40 (m, 2H, ArH benzimidazole), 7.65 (s, 
1H, ArH benzimidazole), 7.75 – 7.87 (m, 3H, ArH benzimidazole and ArH isoquinoline), 
7.90 (d, 1H, J = 5.9 Hz, ArH isoquinoline), 7.97 – 8.05 (m, 1H, ArH isoquinoline), 8.64 
(d, 1H, J = 5.6 Hz, ArH isoquinoline), 9.45 – 9.54 (m, 1H, ArH isoquinoline). 13C NMR 
(101 MHz, Methanol-d4) δ 123.62, 127.91, 128.25, 128.71, 129.59, 131.88, 138.67, 
142.83, 149.04, 152.34. HRMS calculated for C16H12N3 [M + H]
+, 246.1026; found, 
246.1029. Analytical RP-HPLC Rt = 12.93 min; determined with HPLC method A.  
NMR of this compound was also carried out in DMSO-d6 to compare with literature 
reported data of this compound in DMSO-d6.
 1H NMR spectroscopy data in DMSO-d6 
was consistent with previous literature report (13C NMR data not reported in literature).76 
1H NMR (400 MHz, DMSO-d6) δ 7.22 – 7.36 (m, 2H, ArH benzimidazole), 7.59 – 7.66 
(m, 1H, ArH benzimidazole), 7.80 – 7.91 (m, 3H, ArH benzimidazole and ArH 
benzimidazole), 7.96 – 8.03 (m, 1H, ArH isoquinoline), 8.03 – 8.13 (m, 1H, ArH 
isoquinoline), 8.70 (d, 1H, J = 5.5, ArH isoquinoline), 10.09 – 10.13 (m, 1H, ArH 
isoquinoline), 13.22 (s, 1H, NH). 13C NMR (101 MHz, DMSO-d6) δ 112.05, 119.72, 
121.94, 122.34, 123.63, 125.95, 127.21, 127.82, 128.61, 130.61, 134.02, 136.77, 141.64, 





Excitation and emission spectra of fluorescent compounds  
These experiments were all carried out by members of the Stephen Hill’s research group 
at the University of Nottingham. The excitation and emission spectra for each fluorescent 
compound (10 µM in methanol) were measured in Griener Bio-One white 96 well flat 
bottom plates using a BMG LabTech CLARIOstar read type ‘top optic’ (software version 
5.20 RS; firmware version 1.20) and analysed using BMG MARS (software version 3.10 
RS). Alexa Flour 633 presets were used. Excitation wavelength 540 – 640 nm (1.0 
stepwidth), excitation bandwidth 10 nm, emission wavelength 668 nm, emission 
bandwidth 16 nm, gain 1500, measured 0.2 sec. And excitation wavelength 592 nm 
excitation bandwidth 16 nm, emission wavelength 620 – 700 nm (0.2 stepwidth), 
emission bandwidth 10 nm, gain 1500, measured 0.2 sec.  
 
Excitation and emission maxima data for fluorescent compounds   
Fluorescent compound Excitation (max) (nm) Emission (max) (nm) 
2.36 624 641 
2.37 624 641 
2.38 624 641 
2.39 624 641 
2.50 624 642 
2.61 624 642 





7.3 Experimental procedure and data for compounds 
as described in chapter 3 
 




propanoic acid (3.13)  
This compound was prepared according to a previously reported synthesis of 3.13.86 To 
a solution of 2.12 (0.8 g, 3.22 mmol, synthesis described in section 2.2.1, chapter 2) in 
CHCl3 (20.0 mL) was added succinic anhydride (0.32 g, 3.22 mmol) at 0 °C. The reaction 
was warmed to rt and stirred for 12 h. The reaction solvent was removed under reduced 
pressure and the residue was purified by silica gel column chromatography (eluting with 
20% MeOH/EtOAc) to provide 3.13 (0.73 g, 2.09 mmol, 65%) as a clear oil. 1H NMR 
(400 MHz, CDCl3) δ 1.42 (s, 9H, C(CH3)3), 2.44 – 2.53 (m, 2H, CH2), 2.61 – 2.70 (m, 
2H, CH2), 3.24 – 3.34 (m, 2H, CH2), 3.43 (q, 2H, J = 5.1 Hz, CH2), 3.53 (q, 4H, J = 5.1 
Hz, 2 × CH2), 3.60 (s, 4H, 2 × CH2), 5.17 (br s, 1H, NH), 6.78 (br s, 1H, NH), 7.44 (br s, 




one (3.15)  
This compound was prepared according to a previously reported synthesis of 3.15.234 To 
a suspension of phosphorous pentoxide (0.27 g, 1.90 mmol) in methanesulfonic acid (8.3 
mL, 126.93 mmol) under N2 atmosphere was added commercially available 5‐(2‐
methyloctan‐2‐yl)benzene‐1,3‐diol 3.14 (0.3 g, 1.27 mmol) and 3,3-dimethylacrylic acid 
(0.2 g, 1.90 mmol). The reaction mixture was stirred at 70 °C under N2 atmosphere for 
12 h. Subsequently, the reaction mixture was cooled down, poured into a mixture of 
ice/water and extracted with DCM. The resulting organic layer was then dried over 
MgSO4.H2O, concentrated under reduced pressure and purified by column 
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chromatography (eluting with 1 to 5% EtOAc/hexane) to give 3.15 (0.28 g, 0.88 mmol, 
69%) as pale-yellow oil. 1H NMR (400 MHz, CDCl3) δ 0.77 – 0.88 (m, 3H, CH2CH3 
dimethylheptyl chain), 0.98 – 1.10 (m, 2H, CH2), 1.15 – 1.21 (m, 6H, 3 × CH2), 1.22 (s, 
6H, C(CH3)2 dimethylheptyl chain), 1.46 (s, 6H, OC(CH3)2 pyran ring), 1.49 – 1.57 (m, 
2H, CH2), 2.70 (s, 2H, CH2CO), 6.36 (d, 1H, J = 1.6 Hz, ArH), 6.44 (d, 1H, J = 1.7 Hz, 
ArH), 11.53 (s, 1H, OH). 13C NMR (101 MHz, CDCl3) δ 14.18, 22.75, 24.70, 26.84, 
28.56, 30.03, 31.83, 38.87, 44.14, 48.20, 78.81, 105.39, 105.87, 106.72, 159.66, 161.40, 




dihydro‐2H‐1 benzopyran‐4‐one (3.16)  
Compound 3.16 was prepared according to a literature procedure except using 
conventional heating instead of the reported microwave irradiation.137 A solution of 3.15 
(0.5 g, 1.57 mmol) in THF (6.0 mL) was added to a suspension of NaH (0.37 g, 15.70 
mmol) in THF (5.0 mL) at 0 °C under N2 atmosphere. Upon addition of NaH, the reaction 
mixture turned green, which was then stirred at 45 °C for 15 min, followed by addition 
of ethyl formate (1.51 mL, 18.84 mmol). The reaction mixture was then heated at 65 °C. 
The colour of the reaction mixture changed to orange and rapid evolution of gas was 
observed. The reaction mixture was cooled to rt and stirred for 20 min or until the 
evolution of gas subsided. Now, the reaction mixture was again heated to 65 °C and stirred 
for 6 h. The reaction mixture was acidified to pH 3-5 using aqueous 1M HCl and extracted 
with DCM. The combined organic layer was washed with brine, dried over MgSO4.H2O, 
the solvent removed by evaporation under reduced pressure and purified by column 
chromatography (eluting with 1 to 5% EtOAc/hexane) to give 3.16 (0.382 g, 1.10 mmol, 
70%) as pale yellow oil. 1H NMR (400 MHz, CDCl3) δ 0.80 – 0.88 (m, 3H, CH2CH3 
dimethylheptyl chain), 1.00 – 1.09 (m, 2H, CH2), 1.14 – 1.21 (m, 6H, 3 × CH2), 1.22 (s, 
6H, C(CH3)2 dimethylheptyl chain), 1.50 – 1.56 (m, 2H, CH2), 1.58 (s, 6H, OC(CH3)2 
pyran ring), 6.35 (d, 1H, J = 1.6 Hz, ArH), 6.47 (d, 1H, J = 1.6 Hz, ArH), 7.34 (d, 1H, J 
= 11.6 Hz, CHOH), 11.28 (s, 1H, OH), 13.48 (d, 1H, J = 11.7 Hz, CHOH). 13C NMR 
(101 MHz, CDCl3) δ 14.18, 22.74, 24.69, 28.33, 28.52, 30.02, 31.82, 38.87, 44.15, 78.37, 
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104.96, 106.30, 107.50, 114.46, 158.80, 161.60, 161.73, 162.75, 189.52. HRMS 
calculated for C21H31O4 [M + H]





To a solution of 3.16 (0.3 g, 0.86 mmol) in MeOH (30 mL) was added commercially 
available 4-hydrazinobenzoic acid (0.14 g, 0.95 mmol) followed by addition of two drops 
of concentrated H2SO4 (98% solution). The reaction mixture was stirred at 75 °C for 8 h. 
The reaction solvent was removed by evaporation under reduced pressure and the residue 
was neutralised with saturated NaHCO3 solution. The solution was extracted with EtOAc, 
the combined organic layer was washed with water, brine solution, dried over 
MgSO4.H2O, and the solvent removed by evaporation under reduced pressure. The 
residue was purified by silica gel column chromatography (eluting with 20 to 30% 
EtOAc/hexane) to provide 3.18 (0.25 g, 0.52 mmol, 61%) as a foamy orange solid. 1H 
NMR (400 MHz, CDCl3) δ 0.83 (t, 3H, J = 6.9 Hz, CH2CH3 dimethylheptyl chain), 0.96 
– 1.09 (m, 2H, CH2), 1.17 (s, 6H, C(CH3)2 dimethylheptyl chain), 1.12 – 1.28 (m, 6H, 3 
× CH2), 1.43 – 1.52 (m, 2H, CH2), 1.61 (s, 6H, OC(CH3)2 of pyran ring), 3.84 (s, 3H, 
OCH3), 6.29 (d, 1H, J = 1.7 Hz,  ArH phenol), 6.63 (d, 1H, J = 1.7 Hz, ArH phenol), 6.76 
(br s, 1H, OH), 7.44 (d, 2H, J = 8.6 Hz, ArH methyl benzoate), 7.45 (s, 1H, ArH pyrazole), 
7.95 (d, 2H, J = 8.6 Hz, ArH methyl benzoate). 13C NMR (101 MHz, CDCl3) δ 14.18, 
22.70, 24.67, 27.32, 28.66, 29.99, 31.83, 37.94, 44.44, 52.38, 76.97, 102.44, 107.96, 
108.63, 123.79, 125.19, 128.10, 130.01, 133.31, 134.90, 146.59, 150.73, 153.53, 154.21, 
167.03. HRMS calculated for C29H36N2NaO4 [M + Na]
+, 499.2567; found, 499.2554. 







1‐yl]benzoic acid (3.19)  
To a solution of 3.18 (0.25 g, 0.52 mmol) in THF (3.0 mL) was added a solution of LiOH 
(40 mg, 1.57 mmol) in water (3.0 mL) and the reaction stirred for 12 h. The reaction 
solvent was removed by evaporation under reduced pressure and residue acidified to pH 
2.0-3.0 with aqueous 3M HCl. The resulting precipitate was washed with water (pH 5.0) 
and air dried to give 3.19 (0.24 g, 0.52 mmol, yield quantitative) as light pink solid. 1H 
NMR (400 MHz, MeOD-d4) δ 0.82 – 0.90 (m, 3H, CH2CH3 dimethylheptyl chain), 1.03 
– 1.15 (m, 2H, CH2), 1.18 – 1.29 (m, 12H, C(CH3)2 dimethylheptyl chain and 3 × CH2), 
1.52 – 1.58 (m, 2H, CH2), 1.59 (s, 6H, OC(CH3)2 pyran ring), 6.35 (d, 1H, J = 1.7 Hz, 
ArH phenol), 6.54 (d, 1H, J = 1.8 Hz, ArH phenol), 7.44 (d, 2H, J = 8.8 Hz, ArH benzoic 
acid), 7.63 (s, 1H, ArH pyrazole), 8.06 (d, 2H, J = 8.8 Hz, ArH benzoic acid). 13C NMR 
(101 MHz, MeOD-d4) δ 14.39, 23.60, 25.71, 27.45, 29.24, 30.98, 32.83, 38.74, 45.35, 
77.76, 103.28, 108.33, 108.48, 124.95, 126.10, 131.01, 135.01, 135.81, 147.79, 153.38, 
154.40, 155.54, 169.63. HRMS calculated for C28H35N2O4 [M + H]
+, 463.2591; found, 




1‐yl]benzamide (3.20)  
A solution of DIPEA (0.3 mL, 1.73 mmol) in DMF (2.0 mL) was added to a mixture of 
3.19 (100 mg, 0.21 mmol), NH4Cl (56 mg, 1.08 mmol) and HBTU (82 mg, 0.21 mmol) 
under N2 atmosphere and stirred for 12 h. The reaction solvent was removed under 
reduced pressure and the residue was partitioned between EtOAc and water (pH 2.0). The 
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organic layer was separated, washed with water, brine, dried over MgSO4.H2O, 
concentrated under reduced pressure and residue purified by column chromatography 
(eluting with 5% EtOAc/hexane to 1% MeOH/EtOAc) to give 3.20 (81 mg, 0.17 mmol, 
81%) as pale orange solid. 1H NMR (400 MHz, CDCl3) δ 0.82 (t, 3H, J = 6.9 Hz, CH2CH3 
dimethylheptyl chain), 1.04 (s, 2H, CH2), 1.12 – 1.26 (m, 12H, C(CH3)2 dimethylheptyl 
chain and 3 × CH2), 1.45 – 1.54 (m, 2H), 1.61 (s, 6H, OC(CH3)2 pyran ring), 5.85 (m, 
CONH2), 6.38 (d, 1H, J = 1.7 Hz, ArH phenol), 6.62 (d, 1H, J = 1.6 Hz, ArH phenol), 
6.72 (br s, OH), 7.40 (d, 2H, J = 8.4 Hz, ArH benzamide), 7.54 (s, 1H, ArH pyrazole), 
7.77 (d, 2H, J = 8.5 Hz, ArH benzamide). 13C NMR (101 MHz, CDCl3) δ 14.22, 22.74, 
24.73, 27.32, 28.70, 30.02, 31.86, 38.05, 44.44, 77.36, 102.07, 108.15, 108.50, 124.06, 
125.13, 128.08, 131.02, 134.06, 134.42, 145.56, 151.27, 154.20, 154.39, 169.77. HRMS 




chromeno[4,3‐c]pyrazol‐9‐ol (3.21)  
A solution of 3.20 (0.12 g, 0.27 mmol) in THF (6.0 mL) was added to a suspension of 
LiAlH4 (51 mg, 1.34 mmol) in THF (3.0 mL) at 0 °C under N2 atmosphere. The reaction 
was stirred for 2 h at rt and then for 12 h at 70 °C. The reaction was quenched by adding 
water (3 mL), a solution of 15% NaOH in water (1.0 mL) and then water (5.0 mL) at 0 
°C and the reaction mixture was stirred for 30 min. The resulting suspension was filtered 
through celite and the filtrate was concentrated under reduced pressure and the residue 
was partitioned between EtOAc and water. The organic layer was separated, dried over 
MgSO4.H2O and solvent removed by evaporation under reduced pressure to give 3.21 
(113 mg) as a reddish oil. It was used as such in next reaction without further purification. 










ethoxy)ethoxy]ethyl}carbamate (3.22)  
A solution of 3.13 (50 mg, 0.14 mmol), HBTU (53 mg, 0.14 mmol), DIPEA (0.1 mL, 
0.43 mmol) in DMF (4.0 mL) under N2 atmosphere was stirred for 10 min. A solution of 
benzylamine 3.21 (69 mg, 0.14 mmol) in DMF (1.0 mL) was then added and the reaction 
stirred for 5 h. The reaction solvent was removed under reduced pressure. The residue 
was partitioned between EtOAc and H2O. The organic layer was then washed with 
saturated NH4Cl solution, saturated NaHCO3 solution, water, brine solution, dried over 
MgSO4.H2O and concentrated under reduced pressure. The residue was further purified 
by silica gel column chromatography (eluting with 50% EtOAc/hexane to 7% 
MeOH/EtOAc) to provide 3.22 (38 mg, 0.05 mmol, 34%) as yellowish-orange solid. 1H 
NMR (400 MHz, CDCl3) δ 0.83 (t, 3H, J = 6.9 Hz, CH2CH3 dimethylheptyl chain), 0.98 
– 1.08 (m, 2H, CH2), 1.11 – 1.28 (m, 12H, C(CH3)2 dimethylheptyl chain and 3 × CH2), 
1.42 (s, 9H, C(CH3)3), 1.45 – 1.53 (m, 2H, CH2), 1.60 (s, 6H, OC(CH3)2 pyran ring), 2.42 
– 2.55 (m, 4H, COCH2CH2CO), 3.20 (q, 2H, J = 5.4 Hz, CH2), 3.38 (q, 2H, J = 5.1 Hz, 
CH2), 3.47 – 3.54 (m, 4H, 2 × CH2), 3.55 – 3.63 (m, 4H, 2 × CH2), 4.39 (d, 2H, J = 5.9 
Hz, CH2 benzylacylamide), 5.32 (br s, 1H, NH), 6.36 – 6.43 (m, 1H, ArH phenol), 6.58 
(d, 1H, J = 1.7 Hz,  ArH phenol), 6.79 (br s, 1H, NH), 7.00 (br s, 1H, NH), 7.22 (d, 2H, 
J = 8.1 Hz, ArH benzylacetamide), 7.34 (d, 2H, J = 8.3 Hz,  ArH benzylacetamide), 7.48 
(s, 1H, ArH pyrazole), 7.98 (br s, 1H, OH). 13C NMR (101 MHz, CDCl3) δ 14.05, 22.58, 
24.56, 27.27, 28.42, 28.56, 29.68, 29.89, 31.56, 31.71, 37.74, 39.41, 40.32, 43.19, 44.34, 
69.47, 70.17, 79.51, 92.79, 102.46, 107.76, 107.82, 124.08, 124.39, 127.51, 133.03, 
134.11, 136.87, 142.24, 151.41, 152.81, 153.91, 172.32. HRMS calculated for 
C43H63N5NaO8 [M + Na]
+, 800.4569; found, 800.4494. Analytical RP-HPLC Rt = 26.17 












To a solution of 3.22 (4 mg, 5.14 μmol) in DCM (2.0 mL) at 0 °C was added TFA (0.5 
mL). The reaction mixture was stirred for 2 h, reaction solvent and TFA was removed by 
evaporation under reduced pressure to provide the amine N‐{2‐[2‐(2‐
aminoethoxy)ethoxy]ethyl}‐N'‐({4‐[9‐hydroxy‐4,4‐dimethyl‐7‐(2‐methyloctan‐2‐yl)‐
1H,4H‐chromeno[4,3‐c]pyrazol‐1‐yl]phenyl}methyl)butanediamide in assumed 
quantitative yield as the trifluoroacetate salt. This amino TFA salt was purified using 
semi-preparative RP-HPLC. To a solution of this purified amino TFA salt (3.61 mg, 4.56 
μmol) in DMF (200 μL) was added a solution of DIPEA (1.0 μL, 6.05 μmol) in DMF 
(100 μL), followed by addition of solution of BOPIPY-630/650-SE (1.0 mg, 1.51 μmol) 
in DMF (600 μL) and reaction stirred in the dark for 12 h. The reaction solvents were 
removed under reduced pressure and residue purified by semi-preparative RP-HPLC, 
freeze-dried to give 3.23 (1.92 mg, 1.57 µmol, yield quantitative) as a dark blue solid. 
HRMS calculated for C67H81BF2N8NaO9S [M + Na]
+, 1245.5806; found, 1245.5740. 








c]pyrazol‐1 yl]phenyl}methyl)acetamide (3.25)  
To a solution of 3.21 (33 mg, 0.07 mmol) in DCM (3.0 mL) under N2 atmosphere was 
added solution of Ac2O (20 µL, 0.20 mmol) in DCM (1.0 mL), followed by addition of 
Et3N (50 µL, 0.34 mmol) and reaction mixture was stirred for 12 h. At this point, MS of 
crude reaction mixture indicated the formation of mixture of 3.24 and 3.25. The reaction 
solvent was removed by evaporation under reduced pressure, the residue partitioned 
between EtOAc and water, the EtOAc layer was washed with brine, dried over 
MgSO4.H2O and purified by column chromatography (eluting with 5% EtOAc/hexane to 
100% EtOAc) to give 21 mg of reddish solid containing 3.24 and 3.25 in a ratio of 3:1 
(determined by 1H NMR spectroscopy). A solution of NaOH (5 mg, 0.12 mmol) in water 
(0.5 mL) was added to solution of this reddish solid (10.0 mg) in MeOH (3.0 mL) and 
stirred for 3h. The solvent removed by evaporation under reduced pressure and the residue 
partitioned between EtOAc and saturated NH4Cl solution. The organic layer was 
separated, washed with water, brine, dried over MgSO4.H2O and solvent removed by 
evaporation under reduced pressure to give 3.25 (7 mg, 0.01 mmol, 42% over two steps 
from 3.21) as dark orange solid. 1H NMR (400 MHz, CDCl3) δ 0.83 (t, 3H, J = 6.8 Hz, 
CH2CH3 dimethylheptyl chain), 1.01 – 1.11 (m, 2H, CH2), 1.13 – 1.30 (m, 12H, C(CH3)2 
dimethylheptyl chain and 3 × CH2), 1.47 – 1.55 (m, 2H, CH2), 1.61 (s, 6H, OC(CH3)2 
pyran ring), 1.96 (s, 3H, NHCOCH3), 4.31 (d, 2H, J = 5.8 Hz, CH2NH), 6.22 (t, 1H, J = 
5.8 Hz, NH), 6.36 (d, 1H, J = 1.7 Hz,  ArH phenol), 6.63 (d, 1H, J = 1.6 Hz, ArH phenol), 
7.21 (d, 2H, J = 8.1 Hz, ArH benzylacetamide), 7.37 (d, 2H, J = 8.1 Hz, ArH 
benzylacetamide), 7.49 (s, 1H, ArH pyrazole). 13C NMR (101 MHz, CDCl3) δ 14.22, 
22.74, 23.28, 24.72, 27.42, 28.74, 30.05, 31.88, 37.95, 43.41, 44.48, 77.36, 102.67, 
108.29, 108.56, 124.49, 124.72, 127.76, 133.12, 134.42, 137.01, 142.09, 150.90, 153.26, 
154.08, 170.93. HRMS calculated for C30H40N3O3 [M + H]
+, 490.3064; found 490.3051. 








Carboxylic acid 3.19 (26 mg, 0.05 mmol), 2.12 (28 mg, 0.11 mmol), HATU (22 mg, 0.05 
mmol) and DIPEA (30 µL, 0.16 mmol) were reacted according to the procedure described 
for the preparation of 3.22 and the crude residue purified by silica gel column 
chromatography (eluting with 50% EtOAc/hexane to 4% MeOH/EtOAc) to provide 3.26 
(22 mg, 0.03 mmol, 60%) as an orange solid. 1H NMR (400 MHz, CDCl3) δ 0.76 – 0.90 
(m, 3H, CH2CH3 dimethylheptyl chain), 1.01 – 1.12 (m, 2H, CH2), 1.13 – 1.29 (m, 6H, 3 
× CH2), 1.23 (s, 6H, C(CH3)2 dimethylheptyl chain), 1.39 (s, 9H, C(CH3)3), 1.48 – 1.56 
(m, 2H, CH2), 1.61 (s, 6H, OC(CH3)2 pyran ring), 3.01 (q, 2H, J = 5.1 Hz, CH2), 3.51 (t, 
2H, J = 5.1 Hz, CH2), 3.58 – 3.82 (m, 8H, 3 × CH2), 5.22 (t, 1H, J = 5.3 Hz, NH), 6.46 – 
6.56 (m, 1H, ArH phenol), 6.60 (d, 1H, J = 1.7 Hz, ArH phenol), 7.18 (t, 1H, J = 5.4 Hz, 
NH), 7.48 (d, 2H, J = 8.4 Hz, ArH benzamide), 7.52 (s, 1H, ArH pyrazole), 7.71 (d, 2H, 
J = 8.2 Hz, ArH benzamide), 8.22 (s, 1H, OH). 13C NMR (101 MHz, CDCl3) δ 14.21, 
22.75, 24.74, 27.38, 28.52, 28.75, 30.09, 31.90, 37.96, 39.95, 40.53, 44.62, 69.57, 69.84, 
70.28, 76.99, 77.36, 80.41, 102.52, 107.87, 123.68, 125.00, 127.27, 132.13, 133.29, 
134.86, 145.95, 151.58, 153.16, 154.08, 156.80, 167.56. HRMS calculated for 
C39H56N4NaO7 [M + Na]
+, 715.4041; found, 715.4016. Analytical RP-HPLC Rt = 23.62 
min; determined with HPLC method B. 
 
 
4‐(4‐Hydrazinylphenyl)butanoic acid hydrochloride (3.28)  
This compound was prepared by following a procedure adapted from literature.235-236 A 
suspension of commercially available 4‐(4‐aminophenyl)butanoic acid 3.27 (0.5 g, 2.79 
mmol) and aqueous HCl (37% w/w, 5 mL) was heated at 120 °C for 10 min to give a 
clear solution. This solution was cooled to -5 °C to give a brownish crystalline solid, to 
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which was added a solution of NaNO2 (0.21 g, 3.07 mmol) in water (3 mL) and stirred at 
-5 °C for 20 min. This solution was then added to a solution of SnCl2.2H2O (1.89 g, 8.37 
mmol) in water (2 mL) at -20 °C and stirred for 40 min at -20 °C. A greyish precipitate 
formed which was filtered, washed with cold water, diethyl ether and dried at room 
temperature to give 3.28 (0.32 g, 1.38 mmol, 50%) as colourless crystalline solid. 1H 
NMR (400 MHz, MeOD-d4) δ 1.83 – 1.91 (m, 2H, CH2CH2CH2CO), 2.28 (t, 2H, J = 7.4 
Hz, CH2CH2CH2CO), 2.55 – 2.66 (m, 2H, CH2CH2CH2CO), 6.93 (d, 2H, J = 8.5 Hz, 
ArH), 7.19 (d, 2H, J = 8.5 Hz, ArH). 13C NMR (101 MHz, MeOD-d4) δ 27.95, 34.08, 
35.25, 116.52, 116.49, 130.54, 137.95, 137.79, 144.28, 177.28. HRMS calculated for 
C10H15N2O2 [M + H]




c]pyrazol‐1‐yl]phenyl}butanoate (3.29)  
This compound was prepared following the procedure described for 3.18, using 
compound 3.16 (0.2 g, 0.58 mmol) and 3.28 (0.15 g, 0.63 mmol). The residue was purified 
by silica gel column chromatography (eluting with 10 to 50% EtOAc/hexane) to provide 
3.29 (0.13 g, 0.25 mmol, 43%) as a yellowish orange oil. 1H NMR (400 MHz, CDCl3) δ 
0.77 – 0.89 (m, 3H, CH2CH3 dimethylheptyl chain), 0.97 – 1.12 (m, 2H, CH2), 1.14 – 
1.27 (m, 12H, C(CH3)2 dimethylheptyl chain and 3 × CH2), 1.47 – 1.55 (m, 2H, CH2), 
1.61 (s, 6H, OC(CH3)2 pyran ring), 1.93 – 2.09 (m, 2H, CH2CH2CH2CO), 2.35 (t, 2H, J 
= 7.2 Hz, CH2CH2CH2CO), 2.71 (t, 2H, J = 7.3 Hz, CH2CH2CH2CO), 3.63 (s, 3H, OCH3), 
5.05 (br s, 1H, OH), 6.30 (d, 1H, J = 1.8 Hz, ArH phenol), 6.65 (d, 1H, J = 1.8 Hz, ArH 
phenol), 7.22 (d, 2H, J = 8.3 Hz, ArH phenylbutanoate), 7.36 (d, 2H, J = 8.3 Hz, ArH 
phenylbutanoate), 7.50 (s, 1H, ArH pyrazole). 13C NMR (101 MHz, CDCl3) δ 14.22, 
22.74, 24.71, 26.32, 27.46, 28.72, 30.03, 31.87, 33.57, 35.03, 37.93, 44.45, 51.85, 76.93, 
102.84, 108.66, 109.09, 124.53, 124.67, 129.25, 132.89, 134.41, 140.25, 141.15, 150.13, 
153.17, 154.02, 174.38. HRMS calculated for C32H43N2O4 [M + H]+, 519.3217; found, 





c]pyrazol‐1‐yl]phenyl}butanoic acid (3.30)  
According to procedure described for the preparation of 3.19, 3.29 (0.12 g, 0.23 mmol) 
and LiOH (17 mg, 0.69 mmol) were reacted to give 3.30 (0.1 g, 0.21 mmol, 91%) as a 
yellow solid. 1H NMR (400 MHz, MeOD-d4) δ 0.81 – 0.90 (m, 3H, CH2CH3 
dimethylheptyl chain), 1.02 – 1.14 (m, 2H, CH2), 1.17 – 1.31 (m, 12H, C(CH3)2 
dimethylheptyl chain and 3 × CH2), 1.51 – 1.57 (m, 2H, CH2), 1.59 (s, 6H, OC(CH3)2 
pyran ring), 1.95 (p, 2H, J = 7.3 Hz, CH2CH2CH2CO), 2.33 (t, 2H, J = 7.4 Hz, 7.4, 
CH2CH2CH2CO), 2.66 – 2.75 (m, 2H, CH2CH2CH2CO), 6.33 (d, 1H, J = 1.2 Hz, ArH 
phenol), 6.52 (d, 1H, J = 1.1 Hz, ArH phenol), 7.20 – 7.27 (m, 4H, ArH phenylbutanoic 
acid), 7.53 – 7.57 (m, 1H, ArH pyrazole). 13C NMR (101 MHz, MeOD-d4) δ 14.40, 23.61, 
25.71, 27.51, 27.99, 29.25, 30.99, 32.84, 34.55, 35.77, 38.69, 45.36, 77.69, 103.40, 
108.29, 108.34, 125.33, 125.42, 129.43, 134.81, 134.90, 142.26, 142.47, 153.56, 154.07, 





chromeno[4,3‐c]pyrazol‐1‐yl]phenyl}butanamido)octyl]carbamate (3.31)  
This compound was prepared by following procedure described for the preparation of 
3.22, using 3.30 (25 mg, 0.05 mmol), 2.10 (30 mg, 0.08 mmol, synthesis described in 
section 2.2.1, chapter 2), HBTU (24 mg, 0.05 mmol) and DIPEA (50 µL, 0.15 mmol). 
The residue was purified by silica gel column chromatography (eluting with 70% 
EtOAc/hexane to 2% MeOH/EtOAc) to provide 3.31 (26 mg, 0.03 mmol, 72%) as a pale 
oil. 1H NMR (400 MHz, CDCl3) δ 0.83 (t, 3H, J = 6.8 Hz, CH2CH3 dimethylheptyl chain), 
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0.99 – 1.11 (m, 2H, CH2), 1.12 – 1.22 (m, 12H, C(CH3)2 dimethylheptyl chain and 3 × 
CH2), 1.23 – 1.32 (m, 8H, 4 × CH2), 1.36 – 1.47 (m, 13H, C(CH3)3 and 2 × CH2), 1.48 – 
1.54 (m, 2H, CH2), 1.60 (s, 6H, OC(CH3)2 pyran ring), 1.86 – 1.98 (m, 2H, 
CH2CH2CH2CO), 2.10 (t, 2H, J = 7.2 Hz, CH2CH2CH2CO), 2.64 (t, 2H, J = 7.1 Hz, 
CH2CH2CH2CO), 3.03 (q, 2H, J = 6.7 Hz, CH2NH), 3.15 (q, 2H, J = 6.6 Hz, CH2NH), 
4.59 (br s, 1H, NH), 5.89 (t, 1H, J = 5.8 Hz, NH), 6.39 (d, 1H, J = 1.6 Hz, ArH phenol), 
6.59 (d, 1H, J = 1.6 Hz, ArH phenol), 7.13 (d, 2H, J = 8.1 Hz, ArH phenylbutanamide), 
7.19 (s, 1H, OH), 7.31 (d, 2H, J = 8.1 Hz, ArH phenylbutanamide), 7.47 (s, 1H, ArH 
pyrazole). 13C NMR (101 MHz, CDCl3) δ 14.04, 22.56, 23.48, 24.54, 26.55, 26.71, 26.93, 
27.29, 28.40, 28.54, 29.01, 29.02, 29.39, 29.88, 31.70, 34.72, 35.50, 37.72, 39.52, 40.49, 
41.97, 44.32, 76.63, 102.56, 107.98, 108.15, 124.20, 128.56, 133.12, 133.91, 140.36, 
140.79, 151.19, 152.75, 153.82, 173.22. HRMS calculated for C44H66N4NaO5 [M + Na]+, 







This compound was prepared by following procedure described for the preparation of 
3.22, using 3.30 (25 mg, 0.05 mmol), 2.12 (22 mg, 0.08 mmol), HBTU (24 mg, 0.05 
mmol) and DIPEA (50 µL, 0.15 mmol). Purification was done by silica gel column 
chromatography (eluting with 50% EtOAc/hexane to 3% MeOH/EtOAc) to provide 3.32 
(19 mg, 0.02 mmol, 53%) as pale oily liquid. 1H NMR (400 MHz, CDCl3) δ 0.83 (t, 3H, 
J = 6.8 Hz, CH2CH3 dimethylheptyl chain), 1.00 – 1.11 (m, 2H, CH2), 1.14 – 1.27 (m, 
12H, 2 × C(CH3)2 dimethylheptyl chain and 3 × CH2), 1.43 (s, 9H, C(CH3)3), 1.48 – 1.55 
(m, 2H, CH2), 1.61 (s, 6H, OC(CH3)2 pyran ring), 1.93 – 2.05 (m, 2H, CH2CH2CH2CO), 
2.21 (t, 2H, J = 7.2 Hz, CH2CH2CH2CO), 2.69 (t, 2H, J = 7.1 Hz, CH2CH2CH2CO), 3.15 
(q, 2H, J = 5.3 Hz, CH2), 3.41 (q, 2H, J = 5.3 Hz, CH2), 3.50 (t, 2H, J = 5.2 Hz, CH2), 
236 
 
3.56 (t, 2H, J = 5.0 Hz, CH2), 3.61 (s, 4H, 2 × CH2), 5.16 (br s, 1H, NH), 6.13 (br s, 1H, 
NH), 6.38 (s, 1H, ArH phenol), 6.59 (d, 1H, J = 1.6 Hz, ArH phenol), 7.11 (br s, 1H, OH), 
7.17 (d, 2H, J = 8.0 Hz, ArH phenylbutanamide), 7.33 (d, 2H, J = 8.0 Hz, ArH 
phenylbutanamide), 7.48 (s, 1H, ArH pyrazole). 13C NMR (101 MHz, CDCl3) δ 14.22, 
22.74, 24.71, 27.19, 27.48, 28.56, 28.73, 30.06, 31.88, 34.94, 35.95, 37.89, 39.43, 40.46, 
44.51, 69.75, 70.09, 70.27, 70.36, 76.88, 80.02, 102.80, 108.17, 124.24, 128.72, 133.11, 
134.13, 140.34, 141.14, 151.24, 152.84, 154.02, 156.45, 173.22. HRMS calculated for 
C42H63N4O7 [M + H]
+, 735.4691; found, 735.4675. Analytical RP-HPLC Rt = 23.80 min; 








Following the procedure described for 3.23, 3.32 (4.8 mg, 6.53 µmol) was reacted with 
TFA to give N‐{2‐[2‐(2‐aminoethoxy)ethoxy]ethyl}‐4‐{4‐[9‐hydroxy‐4,4‐dimethyl‐7‐
(2‐ethyloctan‐2‐yl)‐1H,4H‐chromeno[4,3‐c]pyrazol‐1‐yl]phenyl}butanamide 
trifluoroacetate in assumed quantitative yield as yellow solid. This amino TFA salt was 
purified using semi-preparative RP-HPLC. This purified trifluoroacetate salt (4.1 mg, 
5.47 µmol) on reaction with BODIPY-630/650-SE (1.0 mg, 1.51 μmol) gave 3.33 (1.57 
mg, 1.33 μmol, 88%) as a dark blue solid. HRMS calculated for C66H80BF2N7NaO8S [M 
+ Na]+, 1202.5747; found, 1202.5687. Analytical RP-HPLC Rt = 25.32 min; determined 









Fmoc solid-phase synthesis was used for the preparation of 3.38. 1,2-Diaminoethane trityl 
resin (0.70 mg, 0.083 mmol, mmols calculated on the basis of substitution (1.18 mmol/g) 
provided by vendor) was swelled in DMF overnight and then reacted with a solution of 
Fmoc-Ala-OH (0.13 g, 0.41 mmol), HBTU (0.16 g, 0.41 mmol) and DIPEA (0.14 mL, 
0.83 mmol) in DMF (0.9 mL) and mixture shaken for 1 h. The resin was drained under 
low vacuum and then treated again with same quantities of Fmoc-Ala-OH, HBTU and 
DIPEA as described previously. The resin was washed with DMF and drained. The resin 
was capped by treating with a solution of Ac2O (500 µL) and DIPEA (500 µL) in DMF 
(1 mL) for 20 min. The amount of Fmoc-Ala bound to the resin 3.35 determined by a 
Fmoc loading test (described below) was 0.78 mmol/g. The Fmoc was cleaved by treating 
the resin 3.35 with 20% v/v piperidine/DMF solution for 20 min, followed by washing 
the Fmoc deprotected 3.35 with DMF and drying under low vacuum. Reaction of the next 
Fmoc-Ala-OH (0.09 g, 0.31 mmol) with the Fmoc deprotected 3.35 using HBTU (0.12 g, 
0.31 mmol), DIPEA (0.11 mL, 0.61 mmol) and DMF (0.6 mL) gave 3.36, followed by 
Fmoc deprotection (carried out as described previously in this paragraph). Carboxylic 
acid 3.30 (15 mg, 0.03 mmol), HATU (12 mg, 0.03 mmol), DIPEA (0.01 mL, 0.09 mmol) 
and DMF (2.0 mL) were mixed and then reacted with the Fmoc deprotected 3.36 for 4 h. 
The resin (3.37) was drained, washed successively with DMF, DCM, dried under low 
vacuum and transferred to a round bottom flask. A solution of 5% TFA in DCM v/v was 
added to the round bottom flask containing 3.37 and resulting suspension was stirred for 
2 h. The suspension was filtered and the filtrate was concentrated under reduced pressure 
to give 28 mg of light yellow solid, 20 mg of which was purified by semi-preparative RP-
HPLC to give 3.38 trifluoroacetate salt (9 mg, 0.01 mmol) as a colourless solid. 1H NMR 
(400 MHz, MeOD-d4) δ 0.82 – 0.90 (m, 3H, CH2CH3 dimethylheptyl chain), 1.06 – 1.13 
(m, 2H, CH2), 1.17 – 1.26 (m, 12H, C(CH3)2 dimethylheptyl chain and 3 × CH2), 1.35 (s, 
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3H, CH3 alanine), 1.37 (s, 3H, CH3 alanine), 1.51 – 1.56 (m, 2H, CH2), 1.58 (s, 6H, 2 × 
OC(CH3)2 pyran ring), 1.96 (p, 2H, J = 7.6 Hz, CH2), 2.28 – 2.36 (m, 2H, CH2), 2.64 – 
2.75 (m, 4H, 2 × CH2), 3.17 – 3.29 (m, 2H, CH2), 4.20 – 4.33 (m, 2H, CH Ala), 6.32 (d, 
1H, J = 0.9 Hz, ArH phenol), 6.50 (d, 1H, J = 0.9 Hz, ArH phenol), 7.19 – 7.27 (m, 4H, 
ArH 4‐phenylbutanamide), 7.55 (s, 1H, ArH pyrazole). 13C NMR (101 MHz, MeOD-d4) 
δ 14.41, 17.65, 17.88, 23.62, 25.73, 27.50, 28.55, 29.25, 29.27, 31.01, 32.85, 35.90, 36.08, 
38.68, 41.85, 43.17, 45.39, 50.71, 51.01, 77.66, 103.50, 108.09, 108.50, 125.26, 125.40, 
129.43, 134.82, 134.98, 142.17, 142.50, 154.01, 155.54, 175.24, 175.26, 176.30. HRMS 
calculated for C39H57N6O5 [M + H]
+, 689.4385; found, 689.4363. 
 
Fmoc loading test 
A piperidine/DMF solution (20% v/v, 1.0 mL) was added to 7.87 mg of Fmoc-alanine 
bound resin and shaken for 1 h. A portion of this solution (100 µL) was diluted to 10 mL 
with DMF and the absorbance was measured at 301 nm (after baseline correction with 
piperidine/DMF solution (20% v/v)) 
Fmoc-alanine bound to the resin  (mmol/g) =
100 ×  𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒
7.8 ×  𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑟𝑒𝑠𝑖𝑛 (𝑚𝑔)
=  
100 ×  0.48
7.8 ×  7.87





yl]phenyl}butanamide (3.39)  
To a solution of 3.38 (2.0 mg, 3.0 µmol) and Ac2O (0.3 µL, 3.0 µmol) in CHCl3 (3.0 mL) 
was added Et3N (1.2 µL, 9 µmol) and the reaction stirred 2 h. The reaction solvent was 
removed by evaporation under reduced pressure and the residue purified by semi-
preparative RP-HPLC to give 3.39 (2 mg, 2.73 µmol, 94%) as a colourless solid. HRMS 
calculated for C41H58N6NaO6 [M + Na]
+, 753.4315; found, 753.4278. Analytical RP-








3,5,7,9,11‐pentaene‐2,2,2‐triium‐1‐id‐2‐yl)‐λ2‐fluoranide (3.40)  
Following the procedure described for 3.23, 3.38 (3.1 mg, 5.28 µmol) was reacted with 
BODIPY-630/650-SE (1.0 mg, 1.51 μmol) to give 3.40 (0.92 mg, 0.74 µmol, 49%) as a 
dark blue solid. HRMS calculated for C68H82BF2N9NaO8S [M + Na]+, 1256.5965; found, 




c]pyrazol‐1‐yl]benzoate (3.41)  
This compound was prepared by following the procedure described for 3.18, using 3.16 
(100 mg, 0.29 mmol) and commercially available 3-hydrazinobenzoic acid hydrochloride 
(60 mg, 0.31 mmol). The crude compound was purified by silica gel column 
chromatography (eluting with 5% EtOAc/hexane to 15% EtOAc/hexane) to provide 3.41 
(70 mg, 0.14 mmol, 49%) as an orange solid. 1H NMR (400 MHz, CDCl3) δ 0.83 (t, 3H, 
J = 6.9 Hz, CH2CH3 dimethylheptyl chain), 1.00 – 1.09 (m, 2H, CH2), 1.11 – 1.29 (m, 
12H, C(CH3)2 dimethylheptyl chain and 3 × CH2), 1.45 – 1.53 (m, 2H, CH2), 1.62 (s, 6H, 
OC(CH3)2 pyran ring), 3.80 (s, 3H, OCH3), 6.07 (s, 1H, OH), 6.28 (d, 1H, J = 1.7 Hz, 
ArH phenol), 6.64 (d, 1H, J = 1.6 Hz, ArH phenol), 7.37 (t, 1H, J = 7.9 Hz, ArH methyl 
benzoate), 7.46 (s, 1H, ArH pyrazole), 7.52 – 7.58 (m, 1H,  ArH methyl benzoate), 7.86 
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(dt, 1H, J = 1.3 Hz, 7.8 Hz,  ArH methyl benzoate), 8.07 (t, 1H, J = 1.9 Hz,  ArH methyl 
benzoate). 13C NMR (101 MHz, CDCl3) δ 14.20, 22.74, 24.69, 27.44, 28.69, 30.04, 31.86, 
37.92, 44.45, 52.37, 76.96, 102.46, 108.00, 108.82, 124.83, 125.39, 128.29, 128.53, 
128.82, 130.44, 133.11, 134.67, 143.05, 150.45, 153.37, 154.18, 166.87. HRMS 
calculated for C29H36N2NaO4 [M + Na]+, 499.2567; found, 499.2556. Analytical RP-




c]pyrazol‐1‐yl]benzoic acid (3.42)  
According to the procedure described for 3.19, 3.41 (0.14 g, 0.29 mmol) was reacted with 
LiOH (21 mg, 0.88 mmol) to give 3.42 (0.13 g, 0.27 mmol, 93%) as a yellow solid. 1H 
NMR (400 MHz, MeOD-d4) δ 0.82 – 0.89 (m, 3H, CH2CH3 dimethylheptyl chain), 1.04 
– 1.14 (m, 2H, CH2), 1.18 – 1.28 (m, 12H, C(CH3)2 dimethylheptyl chain and 3 × CH2), 
1.51 – 1.58 (m, 2H, CH2), 1.60 (s, 6H, OC(CH3)2 pyran ring), 6.33 (d, 1H, J = 1.8 Hz, 
ArH phenol), 6.53 (d, 1H, J = 1.8 Hz, ArH phenol), 7.45 – 7.54 (m, 2H, ArH benzoic 
acid), 7.60 (s, 1H, ArH pyrazole), 7.97 – 8.04 (m, 2H, ArH benzoic acid). 13C NMR (101 
MHz, MeOD-d4) δ 14.39, 23.62, 25.70, 27.52, 29.23, 31.01, 32.83, 38.71, 45.34, 77.70, 
103.22, 108.30, 108.44, 125.72, 126.52, 129.34, 129.37, 133.69, 135.02, 135.41, 144.56, 










1‐yl]benzamide (3.43)  
This compound was prepared by following the procedure used for the preparation of 3.20, 
using 3.42 (95 mg, 0.20 mmol), DIPEA (0.3 mL, 1.64 mmol), NH4Cl (55 mg, 1.02 mmol) 
and HBTU (78 mg, 0.20 mmol). Purification was done by silica gel column 
chromatography (eluting with 50% EtOAc/hexane to 80% EtOAc/hexane) to provide 
3.43 (72 mg, 0.15 mmol, 78%) as a colourless solid. 1H NMR (400 MHz, CDCl3) δ 0.82 
(t, 3H, J = 6.7 Hz, CH2CH3 dimethylheptyl chain), 0.99 – 1.10 (m, 2H, CH2), 1.10 – 1.30 
(m, 12H, C(CH3)2 dimethylheptyl chain and 3 × CH2), 1.42 – 1.53 (m, 2H, CH2), 1.61 (s, 
6H, 2 × OC(CH3)2 pyran ring), 6.13 (br s, 1H, NH), 6.38 (d, 1H, J = 1.7 Hz, ArH phenol), 
6.59 (br s, 1H, NH), 6.62 (d, 1H, J = 1.6 Hz, ArH phenol), 7.18 (t, 1H, J = 7.9 Hz, ArH 
benzamide), 7.35 (d, 1H, J = 8.1 Hz, ArH benzamide), 7.43 (s, 1H, ArH pyrazole), 7.57 
(d, 1H, J = 7.7 Hz, ArH benzamide), 7.73 (s, 1H, ArH benzamide), 8.11 (br s, 1H, OH). 
13C NMR (101 MHz, CDCl3) δ 14.21, 22.74, 24.73, 27.42, 28.68, 30.04, 31.87, 37.98, 
44.43, 76.80, 102.45, 108.34, 108.48, 122.79, 124.77, 126.32, 127.89, 128.65, 133.56, 
134.51, 142.96, 151.17, 153.78, 154.24, 170.05. HRMS calculated for C28H35N3NaO3 [M 




chromeno[4,3‐c]pyrazol‐9‐ol (3.44)  
According to the procedure for 3.21, using 3.43 (0.11 g, 0.23 mmol) and LiAlH4 (44 mg, 
1.16 mmol) gave 3.44 (105 mg) as a reddish oil, which was used without further 






ethoxy)ethoxy]ethyl}carbamate (3.45)  
According to the procedure described for 3.22, 3.44 (71 mg) was reacted with 3.13 (55 
mg, 0.16 mmol), HBTU (60 mg, 0.16 mmol) and DIPEA (0.1 mL, 0.47 mmol). 
Purification of the crude compound by silica gel column chromatography (eluting with 
50% EtOAc/hexane to 7% MeOH/EtOAc) gave 3.45 (44 mg, 0.06 mmol, 37%) as a 
reddish solid. 1H NMR (400 MHz, CDCl3) δ 0.76 – 0.91 (m, 3H, CH2CH3 dimethylheptyl 
chain), 0.98 – 1.13 (m, 2H, CH2), 1.14 – 1.28 (m, 12H, C(CH3)2 dimethylheptyl chain and 
3 × CH2), 1.43 (s, 9H, C(CH3)3), 1.49 – 1.56 (m, 2H, CH2), 1.61 (s, 6H, OC(CH3)2 pyran 
ring), 2.38 – 2.48 (m, 2H, CH2), 2.48 – 2.58 (m, 2H, CH2), 3.14 – 3.24 (m, 2H, CH2), 3.28 
(q, 2H, J = 5.4 Hz, CH2), 3.42 (t, 2H, J = 5.0 Hz, CH2), 3.47 – 3.69 (m, 6H, 3 × CH2), 
4.28 (d, 2H, J = 5.8 Hz, NHCH2 benzylacetamide), 5.19 (br s, 1H, NH), 6.47 (br s, 1H, 
NH), 6.49 – 6.55 (m, 1H, ArH phenol), 6.61 (d, 1H, J = 1.7 Hz, ArH phenol), 6.65 (br s, 
1H, NH), 7.16 – 7.24 (m, 2H,  ArH  benzylacetamide), 7.30 (t, 1H, J = 7.7 Hz,  ArH  
benzylacetamide), 7.43 – 7.50 (m, 1H, ArH  benzylacetamide), 7.48 (s, 1H, ArH 
pyrazole), 8.12 (br s, 1H, OH). 13C NMR (101 MHz, CDCl3) δ 14.21. 22.75, 24.81, 27.41, 
28.57, 28.77, 30.10, 31.93, 32.02, 37.94, 39.62, 40.49, 43.65, 44.64, 69.37, 70.42, 77.05*, 
79.63*, 102.82, 107.75, 108.04, 122.69, 123.84, 124.62, 126.80, 128.81, 133.00, 134.34, 
138.36, 143.32, 151.70, 153.04, 154.22, 171.96, 172.84, (* denoted carbon observed with 
gHMBC correlation). HRMS calculated for C43H63N5NaO8 [M + Na]+, 800.4569; found, 











Following the procedure described for 3.23, 3.45 (4.0 mg, 5.14 µmol) was reacted with 
TFA to give N‐{2‐[2‐(2‐aminoethoxy)ethoxy]ethyl}‐N'‐({3‐[9‐hydroxy‐4,4‐dimethyl‐7‐
(2‐methyloctan‐2‐yl)‐1H,4H‐chromeno[4,3‐c]pyrazol‐1‐yl]phenyl}methyl)butanedi-
amide trifluoroacetate in assumed quantitative yield as yellow solid. This amino TFA salt 
was purified using semi-preparative RP-HPLC. This purified trifluoroacetate salt (4.5 mg, 
5.68 µmol) on reaction with BODIPY-630/650-SE (1.0 mg, 1.51 μmol) gave 3.46 (0.25 
mg, 0.20 μmol, 14%) as a dark blue solid. HRMS calculated for C67H81BF2N8NaO9S [M 
+ Na]+, 1245.5806; found, 1245.5739. Analytical RP-HPLC Rt = 24.47 min; determined 




c]pyrazol‐1 yl]phenyl}methyl)acetamide (3.47)  
According to procedure described for 3.25, 3.44 (30 mg, 0.07 mmol) was reacted with 
Ac2O (10 µL, 0.10 mmol) and Et3N (50 µL, 0.34 mmol). Analysis of the reaction mixture 
by MS indicated formation of a mixture of monoacetylated-3.44 and diacetylated-3.44. 
The reaction solvent was removed under reduced pressure, the residue dissolved in 
MeOH (3.0 mL) and treated with a solution of NaOH (5.0 mg) in water (0.5 mL) at 0 °C 
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and stirred for 3 h. The reaction solvent was removed under reduced pressure, the residue 
partitioned between EtOAc and saturated NH4Cl solution. The organic layer was 
separated, washed with saturated NaHCO3 solution, water, brine, dried over MgSO4.H2O, 
and solvent removed by evaporation under reduced pressure to give 3.47 (12.0 mg, 0.02 
mmol, 36% over two steps from 3.44) as a light pink solid. 1H NMR (400 MHz, MeOD-
d4) δ 0.81 – 0.90 (m, 3H, CH2CH3 dimethylheptyl chain), 1.03 – 1.15 (m, 2H, CH2), 1.16 
– 1.32 (m, 12H, C(CH3)2 dimethylheptyl chain and 3 × CH2), 1.46 – 1.57 (m, 2H, CH2), 
1.59 (s, 6H, OC(CH3)2 pyran ring), 1.95 (s, 3H, NHCOCH3), 4.38 (s, 2H, CH2NH), 6.32 
(d, 1H, J = 1.8 Hz, ArH phenol), 6.53 (d, 1H, J = 1.8 Hz, ArH phenol), 7.20 – 7.25 (m, 
1H, ArH benzylacetamide), 7.25 – 7.30 (m, 2H, ArH benzylacetamide), 7.33 – 7.39 (m, 
1H, ArH benzylacetamide), 7.58 (s, 1H, ArH pyrazole). 13C NMR (101 MHz, MeOD-d4) 
δ 14.39, 22.61, 23.62, 25.74, 27.50, 29.23, 31.02, 32.87, 38.71, 43.77, 45.38, 77.70, 
103.43, 108.34, 108.45, 124.16, 124.31, 125.63, 127.35, 129.50, 134.89, 135.08, 140.56, 
144.60, 153.46, 154.17, 155.57, 173.11. HRMS calculated for C30H39N3NaO3 [M + Na]+, 





c]pyrazol‐1‐yl]benzoate (3.48)  
According to the procedure for 3.18, 3.16 (0.3 g, 0.86 mmol) was reacted with 
commercially available 2-hydrazinobenzoic acid (0.18 g, 0.95 mmol). Purification was 
done by silica gel column chromatography (eluting with 5% EtOAc/hexane to 30% 
EtOAc/hexane) to provide 3.48 (0.17 g, 0.35 mmol, 41%) as a yellow solid. 1H NMR 
(400 MHz, CDCl3) δ 0.83 (t, 3H, J = 6.9 Hz, CH2CH3 dimethylheptyl chain), 0.95 – 1.08 
(m, 2H, CH2), 1.11 – 1.28 (m, 12H, C(CH3)2 dimethylheptyl chain and 3 × CH2), 1.42 – 
1.52 (m, 2H, CH2), 1.64 (s, 6H, OC(CH3)2 pyran ring), 3.57 (s, 3H, OCH3), 5.71 (br s, 
1H, OH), 6.22 (d, 1H, J = 1.7 Hz, ArH phenol), 6.60 (d, 1H, J = 1.7 Hz, ArH phenol), 
7.35 (dd, 1H, J = 1.2 Hz, 7.9 Hz, ArH methyl benzoate), 7.42 (td, 1H, J = 1.3 Hz, 7.6 Hz, 
ArH methyl benzoate), 7.48 (s, 1H, ArH pyrazole), 7.52 (td, 1H, J = 1.6 Hz, 7.7 HZ, 7.7 
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Hz, ArH methyl benzoate), 7.82 (dd, 1H, J = 1.6 Hz, 7.7 Hz, ArH methyl benzoate). 13C 
NMR (101 MHz, CDCl3) δ 14.05, 22.58, 24.53, 27.43, 28.54, 29.88, 31.71, 37.76, 44.31, 
52.44, 76.72, 102.25, 108.07, 108.48, 123.59, 127.84, 127.98, 128.17, 130.09, 132.23, 
134.23, 134.30, 141.66, 150.32, 153.15, 153.78, 167.17.  HRMS calculated for 
C29H36N2NaO4 [M + Na]
+, 499.2567; found, 499.2528. Analytical RP-HPLC Rt = 22.75 




c]pyrazol‐9‐ol (3.4)  
Following procedure described for 3.18, 3.16 (22 mg, 0.06 mmol) was reacted with 
commercially available 2,4-dichlorophenylhydrazine hydrochloride (54 mg, 0.25 mmol). 
Purification of crude compound was carried out by silica gel column chromatography 
(eluting with 20 to 30% EtOAc/hexane) to provide 3.4 (21 mg, 0.04 mmol, 72%) as a 
reddish orange oil. The synthesis of 3.4 was previously reported with microwave 
irradiation.137 1H NMR (400 MHz, CDCl3) δ 0.83 (t, 3H, J = 7.0 Hz, CH2CH3 
dimethylheptyl chain), 0.92 – 1.07 (m, 2H, CH2), 1.10 – 1.30 (m, 12H, C(CH3)2 
dimethylheptyl chain and 3 × CH2), 1.42 – 1.51 (m, 2H, CH2), 1.64 (s, 3H, OC(CH3CH3) 
pyran ring), 1.65 (s, 3H, OC(CH3CH3) pyran ring), 6.14 (d, 1H, J = 1.7 Hz, ArH phenol), 
6.58 (d, 1H, J = 1.6 Hz, ArH phenol), 7.21 – 7.25 (m, 1H, 8.5 Hz, ArH 2,4-
dichlorobenzene), 7.27 – 7.31 (m, 1H, ArH 2,4-dichlorobenzene), 7.42 (d, 1H, J = 2.2 
Hz, ArH 2,4-dichlorobenzene), 7.50 (s, 1H, ArH pyrazole). 13C NMR (101 MHz, CDCl3) 
δ 14.21, 22.72, 24.67, 27.73, 27.76, 28.61, 28.67, 30.01, 31.86, 37.90, 44.45, 76.70, 
102.25, 107.30, 108.69, 123.18, 127.08, 129.39, 129.49, 132.68, 134.28, 134.61, 139.79, 
150.76, 153.43, 154.05. HRMS calculated for C27H33Cl2N2O2 [M + H]+, 487.1914; found, 









6‐Hydrazinylhexanoic acid hydrochloride (3.50)  
To a solution of hydrazine monohydrochloride (1.76 g, 25.63 mmol) was added NaOH 
(1.43 g, 35.89 mmol) and commercially available 6-bromohexanoic acid 3.49 (1.0 g, 5.13 
mmol) in dioxane (15 mL), water (15 mL) and the reaction mixture stirred at 90 °C for 
20 h. The reaction solvents were removed by evaporation under reduced pressure. The 
residue was dissolved in water, which was removed from the resulting solution by 
evaporation under reduced pressure. This process of co-distillation of the residual reaction 
mixture with water was repeated five times. Next, the residue was acidified (pH 2 - 3) 
with 6M aqueous HCl and diluted with water to give a 30 mL solution, which was then 
extracted with 100 mL mixture of EtOH:EtOAc (25% v/v). The aqueous layer was 
extracted once more with 50 mL EtOAc. The organic layers were combined, washed with 
water (30 mL) and the solvent removed under reduced pressure to give 3.50 (0.57 g) as a 
yellow semisolid, which was used in next reaction without further purification. HRMS 




c]pyrazol‐1‐yl]hexanoate (3.51)  
According to the procedure for 3.18, 3.16 (0.16 g, 0.46 mmol) was reacted with 3.50 (0.25 
g, 1.38 mmol). Purification was done by silica gel column chromatography (eluting with 
10 to 30% EtOAc/hexane) to provide 3.51 (91 mg, 0.19 mmol, 42%) as a pale oil. 1H 
NMR (500 MHz, CDCl3) δ 0.82 (t, 3H, J = 7.0 Hz, CH2CH3 dimethylheptyl chain), 1.01 
– 1.12 (m, 2H, CH2), 1.13 – 1.24 (m, 12H, C(CH3)2 dimethylheptyl chain and 3 × CH2), 
1.25 – 1.32 (m, 2H, CH2), 1.49 – 1.54 (m, 2H, CH2), 1.56 (s, 6H, OC(CH3)2 pyran ring), 
1.58 – 1.64 (m, 2H, CH2), 1.81 – 1.93 (m, 2H, CH2), 2.21 (t, 2H, J = 7.59 Hz, CH2), 3.62 
(s, 3H, OCH3), 4.57 – 4.68 (m, 2H, pyrazole-CH2), 6.52 (d, 1H, J = 1.8 Hz, ArH phenol), 
6.59 (d, 1H, J = 1.8 Hz, ArH phenol), 7.34 (s, 1H, ArH pyrazole), 8.82 (s, 1H, OH). 13C 
NMR (126 MHz, CDCl3) δ 14.18, 22.74, 24.49, 24.73, 26.04, 27.40, 28.75, 29.82, 30.07, 
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31.87, 33.77, 37.83, 44.49, 51.75, 52.96, 76.32, 103.05, 107.68, 108.51, 123.18, 131.97, 
132.91, 151.32, 152.76, 154.28, 175.03. HRMS calculated for C28H43N2O4 [M + H]+, 





1‐yl]hexanoic acid (3.52)  
According to the procedure for 3.19, reaction of 3.51 (67 mg, 0.14 mmol) with LiOH (17 
mg, 0.71 mmol) gave 3.52 (0.05 g, 0.11 mmol, 81%) as a pale yellow solid. 1H NMR 
(400 MHz, MeOD-d4) δ 0.79 – 0.89 (m, 3H, CH2CH3 dimethylheptyl chain), 1.03 – 1.14 
(m, 2H, CH2), 1.17 – 1.33 (m, 14H, C(CH3)2 dimethylheptyl chain and 4 × CH2), 1.52 – 
1.62 (m, 10H, OC(CH3)2 pyran ring and 2 × CH2), 1.80 (p, 2H, J = 7.5 Hz, CH2), 2.21 (t, 
2H, J = 7.4 Hz, CH2), 4.66 (t, 2H, J = 7.4 Hz, pyrazole-CH2), 6.54 (d, 1H, J = 1.8 Hz, 
ArH phenol), 6.58 (d, 1H, J = 1.8 Hz, ArH phenol), 7.61 (s, 1H, ArH pyrazole).  13C NMR 
(101 MHz, MeOD-d4) δ 14.40, 23.61, 25.73, 27.08, 27.29, 29.18, 30.99, 31.06, 32.84, 
34.71, 38.78, 45.34, 53.91, 76.87, 102.78, 108.46, 109.00, 124.76, 131.92, 135.95, 





chromeno[4,3‐c]pyrazol‐1‐yl]hexanamido}ethoxy)ethoxy]ethyl}carbamate (3.53)  
According to the procedure for 3.22, reaction of 3.52 (30 mg, 0.07 mmol), 2.12 (32 mg, 
0.13 mmol), HATU (25 mg, 0.06 mmol) and DIPEA (0.04 mL, 0.19 mmol), followed by 
column purification (eluting with 50% EtOAc/hexane to 5% MeOH/EtOAc) provided 
3.53 (18 mg, 0.02 mmol, 39%) as a yellowish-orange oil. 1H NMR (400 MHz, CDCl3) δ 
0.83 (t, 3H, J = 6.8 Hz, CH2CH3 dimethylheptyl chain), 1.03 – 1.10 (m, 2H, CH2), 1.14 
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– 1.28 (m, 12H, C(CH3)2 dimethylheptyl chain and 3 × CH2), 1.40 – 1.48 (m, 11H, 
pyrazole-CH2CH2CH2 and C(CH3)3), 1.49 – 1.54 (m, 2H, CH2), 1.56 (s, 6H, OC(CH3)2 
pyran ring), 1.69 – 1.81 (m, 2H, pyrazole-CH2CH2CH2CH2), 1.89 – 1.97 (m, 2H, 
pyrazole-CH2CH2), 2.19 (t, 2H, J = 7.8 Hz, pyrazole-CH2CH2CH2CH2CH2), 3.27 – 3.36 
(m, 2H, CH2), 3.49 – 3.72 (m, 10H, 5 × CH2), 4.48 – 4.61 (m, 2H, pyrazole-CH2), 5.01 
(br s, 1H, NH), 6.31 (br s, 1H, NH), 6.52 (d, 1H, J = 1.8 Hz, ArH phenol), 6.55 (d, 1H, J 
= 1.7 Hz, ArH phenol), 7.28 (s, 1H, ArH pyrazole), 9.40 (s, 1H, OH). 13C NMR (101 
MHz, CDCl3) δ 14.23, 22.78, 24.78, 25.20, 27.51, 28.20, 28.55, 28.83, 30.12, 31.92, 
35.71, 37.81, 39.58, 40.51, 44.55, 52.83, 69.87, 70.32, 70.49, 76.38, 103.26, 107.60, 
108.13, 122.80, 132.15, 132.40, 152.41, 154.13, 175.04. HRMS calculated for 
C38H62N4NaO7 [M + Na]
+, 709.4511; found, 709.4529. Analytical RP-HPLC Rt = 22.93 







pentaene‐2,2,2‐triium‐1‐id‐2‐yl)‐λ2‐fluoranide (3.54)  
Following the procedure described for 3.23, 3.53 (4.1 mg, 5.97 µmol) was reacted with 
TFA to give N‐{2‐[2‐(2‐aminoethoxy)ethoxy]ethyl}‐6‐[9‐hydroxy‐4,4‐dimethyl‐7‐(2‐
methyloctan‐2‐yl)‐1H,4H‐chromeno[4,3‐c]pyrazol‐1‐yl]hexanamide trifluoroacetate in 
assumed quantitative yield as yellow solid. This amino TFA salt was purified using semi-
preparative RP-HPLC. This purified trifluoroacetate salt (4.7 mg, 6.70, µmol) on reaction 
with BODIPY-630/650-SE (1.0 mg, 1.51 μmol) gave 3.54 (0.64 mg, 0.56 μmol, 37%) as 
dark blue solid. HRMS calculated for C62H80BF2N7NaO8S [M + Na]+, 1154.5747; found, 







Methyl 6‐bromohexanoate (3.56) 
To a solution of commercially available 6-bromohexanoic acid 3.55 (1.0 g, 5.12 mmol) 
in MeOH (30 mL) was added two drops of conc. H2SO4 (98%). The reaction mixture was 
stirred at 70 °C for 12 h. The reaction solvent was removed under reduced pressure, the 
residue neutralised with saturated sodium NaHCO3 solution and extracted with EtOAc. 
The organic layer was then washed with water, brine solution, dried over MgSO4.H2O, 
solvent removed by evaporation under rescued pressure to provide 3.56 (0.68 g, 3.25 
mmol, 63%) as a clear liquid. NMR spectroscopy data of 3.56 was consistent with a 
previous literature report237. 1H NMR (400 MHz, CDCl3) δ 1.39 – 1.52 (m, 2H, CH2), 
1.58 – 1.67 (m, 2H, CH2), 1.80 – 1.92 (m, 2H, CH2), 2.31 (t, 2H, J = 7.4 Hz, CH2), 3.39 
(t, 2H, J = 6.8 Hz, CH2), 3.65 (d, 3H, J = 1.2 Hz CH3). 
13C NMR (101 MHz, CDCl3) δ 
24.16, 27.74, 32.48, 33.57, 33.91, 51.64, 173.97. 
 
 
 4,4‐Dimethyl‐7‐(2‐methyloctan‐2‐yl)‐2H,4H‐chromeno[4,3‐c]pyrazol‐9‐ol (3.57)  
The synthesis of 3.57 was done following the procedure described for 3.18, using 3.16 
(0.25 g, 0.74 mmol) and hydrazine monohydrochloride (76 mg, 1.11 mmol) except that 
H2SO4 was not used in the reaction. Purification of crude compound was done by silica 
gel column chromatography (eluting with 10 to 50% EtOAc/hexane) to provide 3.57 (0.21 
g, 0.61 mmol, 83%) as a pale solid. Synthesis of 3.57 was previously reported with 
microwave irradiation.137 1H NMR (400 MHz, CDCl3) δ 0.83 (t, 3H, J = 6.9 Hz, CH2CH3 
dimethylheptyl chain), 1.02 – 1.12 (m, 2H, CH2), 1.13 – 1.30 (m, 12H, C(CH3)2 
dimethylheptyl chain and 3 × CH2), 1.50 – 1.58 (m, 2H, CH2), 1.64 (s, 6H, OC(CH3)2 
pyran ring), 6.52 (d, 1H, J = 1.6 Hz, ArH phenol), 6.59 (d, 1H, J = 1.6, ArH phenol), 7.33 
(s, 1H, ArH pyrazole), 8.16 (s, 1H, NH or OH), 9.96 (s, 1H, NH or OH). 13C NMR (101 
MHz, CDCl3) δ 14.23, 22.81, 24.79, 29.02, 29.72, 30.15, 31.92, 38.20, 44.64, 76.96, 
101.12, 106.53, 106.89, 120.14, 122.57, 142.66, 153.17, 153.25, 153.42. HRMS 





Synthesis of methyl 6‐{[4,4‐dimethyl‐7‐(2‐methyloctan‐2‐yl)‐1H,4H‐chromeno[4,3‐
c]pyrazol‐9‐yl]oxy}hexanoate (3.58) and methyl 6‐[9‐hydroxy‐4,4‐dimethyl‐7‐(2‐
methyloctan‐2‐yl)‐2H,4H‐chromeno[4,3‐c]pyrazol‐2‐yl]hexanoate (3.59) 
To a solution of 3.57 (50 mg, 0.15 mmol) and 3.56 (46 mg, 0.22 mmol) in dry THF (12 
mL) was added Cs2CO3 (81 mg, 0.25 mmol) and the reaction mixture stirred at 70 °C for 
12 h under N2 atmosphere. After the completion of the reaction, the solvent was removed 
under reduced pressure and the residue diluted with EtOAc/NH4Cl solution. The organic 
layer was separated, washed with water, brine solution, dried over MgSO4.H2O and 
concentrated under reduced pressure. Purification by silica gel column chromatography 
(eluting with 10 to 25% EtOAc/hexane) provided 3.59 (27 mg, yield 40%) as a pale oil 
and (after continued elution with 25 to 50% EtOAc/hexane) 3.58 (34 mg, 50%) as a 
colourless solid.  
 
 
1H NMR (400 MHz, CDCl3) δ 0.84 (t, 3H, J = 6.8 Hz, CH2CH3 dimethylheptyl chain), 
1.00 – 1.12 (m, 2H, CH2), 1.15 – 1.23 (m, 6H, 3 × CH2), 1.26 (s, 6H, C(CH3)2 
dimethylheptyl chain), 1.49 – 1.60 (m, 4H, 2 × CH2), 1.63 (s, 6H, OC(CH3)2 pyran ring), 
1.70 – 1.79 (m, 2H, CH2), 1.87 – 2.01 (m, 2H, CH2), 2.37 (t, 2H, J = 7.4 Hz, CH2), 3.67 
(s, 3H, OCH3), 4.15 (t, 2H, J = 6.6 Hz, phenol-CH2), 6.47 (d, 1H, J = 1.5 Hz, ArH phenol), 
6.59 (d, 1H, J = 1.4 Hz, ArH phenol), 7.40 (s, 1H, ArH pyrazole), 8.72 (br s, 1H, OH). 
13C NMR (101 MHz, CDCl3) δ 14.21, 22.77, 24.75, 25.84, 28.99, 29.16, 29.50, 30.09, 
31.87, 33.97, 38.45, 44.58, 51.73, 68.24, 77.86, 101.23, 102.00, 108.39, 118.98, 132.57, 
153.21, 153.30, 154.33, 174.11. HRMS calculated for C28H43N2O4 [M + H]+, 471.3217; 






1H NMR (400 MHz, CDCl3) δ 0.83 (t, 3H, J = 6.9 Hz, CH2CH3 dimethylheptyl chain), 
1.00 – 1.11 (m, 2H, CH2), 1.14 – 1.22 (m, 6H, 3 × CH2), 1.24 (s, 6H, C(CH3)2 
dimethylheptyl chain), 1.30 – 1.39 (m, 2H, CH2), 1.50 – 1.57 (m, 2H, CH2), 1.61 (s, 6H, 
OC(CH3)2 pyran ring), 1.60 – 1.73 (m, 2H, CH2), 1.83 – 1.99 (m, 2H, CH2), 2.31 (t, 2H, 
J = 7.3 Hz, CH2), 3.65 (s, 3H, OCH3), 4.11 (t, 2H, J = 6.9 Hz, pyrazole-CH2), 6.48 (d, 
1H, J = 1.6 Hz, ArH phenol), 6.58 (d, 1H, J = 1.6 Hz, ArH phenol), 7.12 (s, 1H, ArH 
pyrazole), 8.30 (s, 1H, OH). 13C NMR (101 MHz, CDCl3) δ 14.23, 22.80, 24.45, 24.79 , 
26.19, 29.04, 29.79, 30.08, 30.15, 31.92, 33.90, 38.15, 44.65, 51.68, 52.03, 76.84, 101.40, 
106.50, 106.71, 120.04, 123.39, 142.45, 152.76, 152.95, 153.31, 174.03. HRMS 
calculated for C28H42N2NaO4 [M + Na]+, 493.3037; found, 493.2993. Analytical RP-
HPLC Rt = 26.63 min; determined with HPLC method B.  
  
 
7‐{[(tert‐Butoxy)carbonyl]amino}heptanoic acid (3.61)  
This compound was synthesised according to a previously reported literature synthesis of 
3.61. 221 To a solution of commercially available 7-aminoheptanoic acid 3.60 (1.0 g, 6.88 
mmol), NaOH (0.27 g, 6.88 mmol) in 1,4-dioxane (20 mL) and water (10 mL) was added 
(Boc)2O (1.65g, 6.88 mmol) in three equal portions each after a delay of 30 min each time 
and the reaction stirred for 20 h. Dioxane was removed under reduced pressure, the 
residue was extracted once with EtOAc. The aqueous layer was acidified (pH 2-3) by 
addition of 1M aqueous HCl and extracted quickly three times with EtOAc. The 
combined organic layers were washed once with water, brine, dried over MgSO4.H2O and 
solvent removed under reduced pressure to give 3.61 (1.66 g, 6.76 mmol, 98%) as a clear 
oil. 1H NMR (400 MHz, CDCl3) δ 1.20 – 1.38 (m, 4H, CH2), 1.39 – 1.53 (m, 11H, CH2 
and C(CH3)3), 1.55 – 1.70 (m, 2H, CH2), 2.32 (t, 2H, J = 7.5 Hz, CH2), 2.94 – 3.20 (m, 
2H, CH2), 4.44 – 4.69 (m, 1H, NH), 10.07 (s, 1H, CO2H). 
13C NMR (101 MHz, CDCl3) 
δ 24.73, 26.53, 28.54, 28.82, 29.95, 34.09, 40.61, 156.18, 179.33. HRMS calculated for 
C12H23NNaO4 [M + Na]





tert‐Butyl N‐{6‐[Methoxy(methyl)carbamoyl]hexyl}carbamate (3.62)  
According to the procedure for 3.22, 3.61 (0.5 g, 2.03 mmol) was reacted with N,O-
dimethylhydroxylamine hydrochloride (0.3 g, 3.06 mmol), HBTU (1.16 g, 3.05 mmol) 
and DIPEA (1.1 mL, 6.11 mmol), except that THF was used as a solvent instead of DMF 
in the reaction. The residue was purified by silica gel column chromatography (eluting 
with 10 to 60% EtOAc/hexane) to provide 3.62 (0.49 g, 1.72 mmol, 85%) as a clear oil. 
NMR spectroscopy data of 3.62 was consistent with a previous literature report238. 1H 
NMR (400 MHz, CDCl3) δ 1.24 – 1.36 (m, 4H, 2 × CH2), 1.37 – 1.51 (m, 11H, CH2 and 
C(CH3)3), 1.53 – 1.68 (m, 2H, CH2), 2.38 (t, 2H, J = 7.6 Hz, CH2), 3.07 (q, 2H, J = 6.7 
Hz, CH2), 3.14 (s, 3H, CH3), 3.65 (s, 3H, CH3), 4.56 (br s, 1H, NH). 
13C NMR (101 MHz, 





2,5‐Dioxopyrrolidin‐1‐yl 7‐{[(tert‐butoxy)carbonyl]amino}heptanoate (3.65) 
According to the procedure for 3.22, 3.61 (0.4 g, 1.63 mmol) was reacted with N-
hydroxysuccinimide (0.24 g, 2.12 mmol), HBTU (0.62 g, 1.63 mmol) and DIPEA (0.9 
mL, 4.89 mmol). Purification was done by silica gel column chromatography (eluting 
with 10 to 45% EtOAc/hexane) to provide 3.65 (0.51 g, 1.47 mmol, 91%) as a clear oil. 
NMR spectroscopy data of 3.65 was consistent with a previous literature report221. 1H 
NMR (400 MHz, CDCl3) δ 1.24 – 1.58 (m, 15H, 3 × CH2 and C(CH3)3), 1.68 – 1.80 (m, 
2H, CH2), 2.59 (t, 2H, J = 7.4 Hz, CH2), 2.76 – 2.92 (m, 4H, 2 × CH2), 3.10 (q, 2H, J = 
6.7 Hz, CH2), 4.55 (br s, 1H, NH). 
13C NMR (101 MHz, CDCl3) δ 24.60, 25.71, 26.34, 








7.3.2 Computational studies 
 
Primary amino acid sequences of the CB1R (Uniprot id – P21554) and CB2R (Uniprot id 
- P34972) for the homology modelling were obtained from UniProt.239 Alignment of 
target receptor amino acid sequence – (CB2R (Uniprot id - P34972)) and template 
receptor’s amino acid sequence –(CB1R (Uniprot id – P21554)) amino acid sequence was 
carried out with a multiple sequence alignment web server T-coffee.213 Structures of the 
ligands were drawn with Avogadro216 (version 1.2) and optimised by energy minimisation 
using the Merck Molecular ForceField (MMFF94). The CB2R homology model was built 
using  Modeller214 (version 9.19) with the CB1R crystal structure (PDB ID: 5XRA)
113 as 
a template. The docking studies were carried out with GOLD217 (version 5.5) using 
ChemPLP scoring method with default settings. In the docking studies, a scaffold 
constraint was used and the binding site for ligands was specified as a 20 Å region around 
the CB1R co-crystallised ligand AM11542 (PDB ID: 5XRA). Docking poses were 
visualised with PyMOL (The PyMOL Molecular Graphics System, version 2.0.3 
Schrödinger, LLC.).  
 
7.3.3 Pharmacological studies 
 
Radioligand binding assays and cAMP functional assays were carried out as described in 
section 7.1.2. In the radioligand binding assay, [3H]-CP55,940 was used in a 
concentration of 2.5 nM per well for determining the CB1R affinity and 1 nM per well for 
determining the CB2R affinity of test compounds. CB1R and CB2R membrane 




7.4 Experimental procedure and data for compounds 
as described in chapter 4 
 





To a solution of 3.21 (44 mg, 0.09 mmol) in DCM (2.0 mL) was added (Boc)2O (25 mg, 
0.11 mmol) followed by addition of Et3N (0.02 mL, 0.15 mmol) at 0 °C; the reaction was 
warmed to rt and stirred for 12 h. The reaction solvent was removed under reduced 
pressure and the residue was partitioned between DCM/H2O. The DCM layer was washed 
with NH4Cl solution, water, dried over MgSO4.H2O, concentrated under reduced 
pressure, and the residue purified by silica gel column chromatography (eluting with 10 
- 40% EtOAc/hexane) to give 4.10 (19 mg, 0.03 mmol, 35%) as a clear oil. 1H NMR (400 
MHz, CDCl3) δ 0.84 (t, 3H, J = 6.8 Hz, CH2CH3), 1.01 – 1.09 (m, 2H, CH2), 1.13 – 1.28 
(m, 12H, 3 × CH2 and C(CH3)2 dimethylheptyl chain), 1.45 (s, 9H, C(CH3)3), 1.48 – 1.55 
(m, 2H, CH2), 1.61 (s, 6H, OC(CH3)2 pyran ring), 4.17 (d, 2H, J = 5.5 Hz, CH2NH), 4.87 
– 4.97 (m, 1H, NH), 6.05 (s, 1H, OH), 6.33 – 6.38 (m, 1H, ArH phenol), 6.64 (d, 1H, J = 
1.5 Hz, ArH phenol), 7.23 – 7.29 (m, 2H, ArH phenol), 7.39 – 7.46 (m, 2H, ArH phenol), 
7.51 (s, 1H, ArH pyrazole). 13C NMR (101 MHz, CDCl3) δ 14.21, 22.73, 24.71, 27.42, 
27.69, 28.56, 28.72, 30.04, 31.87, 37.95, 44.44, 44.51, 102.75, 108.29, 108.81, 124.44, 
124.86, 127.97, 132.89, 134.59, 141.87, 150.56, 153.19, 154.07, 156.37. HRMS 









To a solution of 4.10 (3 mg, 5.47 μmol) in DCM (2.0 mL) at 0 °C was added TFA (0.5 
mL). The reaction mixture was warmed to rt and stirred for 2 h, volatiles were removed 
under reduced pressure to provide 1‐[4‐(aminomethyl)phenyl]‐4,4‐dimethyl‐7‐(2‐
methyloctan‐2‐yl)‐1H,4H‐chromeno[4,3‐c]pyrazol‐9‐ol trifluoroacetate in assumed 
quantitative yield as yellow solid. This amino TFA salt was purified using semi-
preparative RP-HPLC. To a solution of this purified trifluoroacetate salt (2.9 mg, 5.16 
μmol) in DMF (200 μL) was added a solution of DIPEA (1.8 μL, 10.3 μmol) in DMF 
(100 μL), followed by addition of a solution of BOPIPY-FL-SE (1.1 mg, 2.71 μmol) in 
DMF (600 μL) and the reaction was stirred in dark for 12 h. The reaction solvents were 
removed under reduced pressure and the residue purified by semi-preparative RP-HPLC 
and freeze dried to give 4.05 (3.71 mg, 4.95 µmol, quantitative) as an orange solid. HRMS 
calculated for C44H54BF2N5NaO3 [M + Na]
+, 772.4188; found, 772.4211. Analytical RP-









Following the procedure described for 4.05, 3.22 (5.0 mg, 6.42 µmol) was reacted with 
TFA (0.5 mL) to give N‐{2‐[2‐(2‐aminoethoxy)ethoxy]ethyl}‐N'‐({4‐[9‐hydroxy‐4,4‐
dimethyl‐7‐(2‐methyloctan‐2‐yl)‐1H,4H‐chromeno[4,3‐c]pyrazol‐1‐yl]phenyl}methyl)-
butanediamide trifluoroacetate in assumed quantitative yield as yellow solid. This amino 
TFA salt was purified using semi-preparative RP-HPLC. Reaction of this purified 
trifluoroacetate salt (4.7 mg, 5.93 µmol) with BODIPY-FL-SE (1.0 mg, 2.39 μmol) gave 
4.01 (2.98 mg, 3.04 μmol, quantitative) as an orange solid. HRMS calculated for 
C54H72BF2N7NaO7 [M + Na]
+, 1002.5456; found, 1002.5502. Analytical RP-HPLC Rt = 








Following the procedure described for 4.05, 3.22 (4.0 mg, 5.14 µmol) was reacted with 
TFA (0.5 mL) to give N‐{2‐[2‐(2‐aminoethoxy)ethoxy]ethyl}‐N'‐({4‐[9‐hydroxy‐4,4‐
dimethyl‐7‐(2‐methyloctan‐2‐yl)‐1H,4H‐chromeno[4,3‐c]pyrazol‐1‐yl]phenyl}methyl) 
butanediamide trifluoroacetate in assumed quantitative yield as yellow solid. This amino 
TFA salt was purified using semi-preparative RP-HPLC. Reaction of this purified 
trifluoroacetate salt (3.9 mg, 4.87 µmol) with Cy5-SE (1.0 mg, 1.62 μmol) gave 4.02 (2.9 
mg, 2.53 μmol, quantitative) as a bright blue solid. HRMS calculated for C70H92N7O7 
[M]+, 1142.7053; found, 1142.7137. Analytical RP-HPLC Rt = 23.03 min; determined 





6‐{[(tert‐Butoxy)carbonyl]amino}hexanoic acid (4.12)  
This compound was prepared according to a previously reported literature synthesis of 
4.12.221 To a solution of commercially available 6-aminohexanoic acid 4.11 (1.0 g, 7.62 
mmol), NaOH (0.30 g, 7.62 mmol) in 1,4-dioxane (20 mL) and water (10 mL) was added 
(Boc)2O (1.75g, 8.00 mmol) in three equal portions (with a delay of 30 min before 
addition of next portion of (Boc)2O), and reaction stirred for 20 h. Dioxane was removed 
under reduced pressure and the residue was extracted once with EtOAc. The aqueous 
layer was acidified (pH 2-3) by addition of 1M aqueous HCl solution and extracted 
quickly three times with EtOAc. The combined EtOAc layers were washed once with 
water, brine, dried over MgSO4.H2O, and concentrated under reduced pressure to give 
4.12 (1.26 g, 5.44 mmol, 71%) as a clear oil. 1H NMR (400 MHz, CDCl3) δ 1.30 – 1.40 
(m, 2H, CH2), 1.43 (s, 9H, C(CH3)3), 1.47 – 1.51 (m, 2H, CH2), 1.58 – 1.71 (m, 2H, CH2), 
2.34 (t, 2H, J = 7.4 Hz, CH2), 3.11 (d, 2H, J = 6.8 Hz, CH2), 4.57 (s, 1H, NH). HRMS 





ethoxy)ethoxy]ethyl}carbamoyl)pentyl]carbamate (4.13)  
To a solution of 3.22 (12 mg, 0.015 mmol) in DCM (3.0 mL) at 0 °C was added TFA (0.5 
mL). The reaction mixture was warmed to rt, stirred for 3 h and volatiles removed under 
reduced pressure to give N‐{2‐[2‐(2‐aminoethoxy)ethoxy]ethyl}‐N'‐({4‐[9‐hydroxy‐4,4‐
dimethyl‐7‐(2‐methyloctan‐2‐yl)‐1H,4H‐chromeno[4,3‐c]pyrazol‐1‐yl]phenyl}methyl)-
butanediamide trifluoroacetate in assumed quantitative yield as a yellow solid. The 
solution of Boc-deprotected 3.22 trifluoroacetate salt (16 mg) in DCM (1.0 mL) was 
added to a solution of 4.12 (5 mg, 21.61 mmol), TFFH (6 mg, 21.61 mmol) and Et3N 
(0.01 mL, 0.05 mmol) in DCM (2.0 mL) under a N2 atmosphere and the reaction was 
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stirred for 12 h. The reaction solvent was removed under reduced pressure and the residue 
was partitioned between DCM/H2O. The DCM layer was washed with saturated NH4Cl 
solution, water, brine solution, dried over MgSO4.H2O and concentrated under reduced 
pressure. The residue was purified by a short silica gel column (eluting with 40% 
EtOAc/hexane to 8% MeOH/EtOAc) to provide 4.13 (10 mg, 0.01 mmol, 34%) as clear 
liquid. 1H NMR (400 MHz, CDCl3) δ 0.82 (t, 3H, J = 6.9 Hz, CH2CH3), 1.01 – 1.09 (m, 
2H, CH2), 1.12 – 1.32 (m, 14H, 4 × CH2 and C(CH3)2 dimethylheptyl chain), 1.41 (s, 9H, 
C(CH3)3), 1.47 – 1.53 (m, 2H, CH2), 1.59 (s, 8H, CH2 and OC(CH3)2 pyran ring), 1.89 
(s, 2H, CH2), 2.08 (t, 2H, J = 7.5 Hz, CH2), 2.44 – 2.60 (m, 4H, NHCOCH2CH2CONH), 
2.95 – 3.04 (m, 2H, CH2), 3.31 (q, 2H, J = 5.2 Hz, CH2), 3.36 – 3.46 (m, 2H, CH2), 3.48 
– 3.56 (m, 4H, 2 × CH2), 3.59 (s, 4H, 2 × CH2), 4.43 (d, 2H, J = 5.9 Hz, CH2), 4.79 – 
4.89 (m, 1H, NH), 6.42 – 6.47 (m, 1H, ArH phenol), 6.57 (d, 1H, J = 1.6 Hz, ArH phenol), 
6.74 – 6.82 (m, 1H, NH), 6.84 – 6.91 (m, 1H, NH), 6.95 – 7.03 (m, 1H, NH), 7.13 – 7.21 
(m, 2H, ArH phenol), 7.30 – 7.38 (m, 2H, ArH phenol), 7.47 (d, 1H, J = 1.2 Hz, ArH 
pyrazole), 8.12 (br s, 1H, OH). 13C NMR (101 MHz, C3) δ 14.22, 22.75, 24.73, 25.40, 
26.45, 26.45, 27.42, 28.60, 28.74, 29.73, 30.07, 31.83, 31.89, 36.26, 37.92, 39.43, 39.51, 
40.46, 40.55, 43.16, 44.52, 69.69, 69.98, 70.36, 70.43, 102.57, 107.89, 116.50, 124.21, 
124.60, 127.07, 134.31, 136.80, 142.52, 151.70, 152.98, 154.06, 172.67, 172.72, 174.16. 
HRMS calculated for C49H74N6NaO9 [M + Na]






amino)‐10λ4‐xanthen‐10‐ylium (4.03)  
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Following the procedure described for 4.05, 4.13 (4.0 mg, 4.48 µmol) was reacted with 
TFA (0.5 mL) to give N‐{2‐[2‐(2‐aminoethoxy)ethoxy]ethyl}‐N'‐({4‐[9‐hydroxy‐4,4‐
dimethyl‐7‐(2‐methyloctan‐2‐yl)‐1H,4H‐chromeno[4,3‐c]pyrazol‐1‐yl]phenyl}methyl)-
butanediamide trifluoroacetate in assumed quantitative yield as a yellow solid. This 
amino TFA salt was purified using semi-preparative RP-HPLC. Reaction of this purified 
trifluoroacetate salt (4.3 mg, 4.75 µmol) with TAMRA-SE (1.0 mg, 1.89 μmol) gave 4.03 
(3.21 mg, 2.66 μmol, quantitative) as a pink solid. HRMS calculated for C69H86N8NaO11 
[M + Na]+, 1225.6308; found, 1225.6288. Analytical RP-HPLC Rt = 20.06 min; 




yl)carbamoyl] propanoic acid (4.15)  
To a solution of commercially available tert‐butyl N‐(17‐amino‐3,6,9,12,15‐
pentaoxaheptadecan‐1‐yl)carbamate 4.14 (30 mg, 0.08 mmol) in CHCl3 (5.0 mL) was 
added succinic anhydride (83 mg, 0.08 mmol) at 0 °C. The reaction was warmed to rt and 
stirred for 12 h. The reaction solvent was removed under reduced pressure to provide 4.15 
(117 mg) as a colourless solid. This compound was used as such in the next reaction 
without further purification. 1H NMR (400 MHz, CDCl3) δ 1.43 (s, 9H, C(CH3)3), 2.47 – 
2.58 (m, 2H, CH2), 2.60 – 2.70 (m, 2H, CH2), 3.20 – 3.35 (m, 2H, CH2), 3.39 – 3.47 (m, 
2H, CH2), 3.48 – 3.57 (m, 4H, 2 × CH2), 3.58 – 3.77 (m, 16H, 8 × CH2), 5.22 (s, 1H, 
NH), 7.08 (s, 1H, NH). 13C NMR (101 MHz, CDCl3) δ 28.41, 30.47, 30.91, 39.47, 40.31, 
69.58, 70.06, 70.40, 70.53, 79.27, 170.56, 172.88, 174.55. HRMS calculated for 
C21H40N2NaO10 [M + Na]












To a solution of 4.10 (20 mg, 0.03 mmol) in DCM (3.0 mL) at 0 °C was added TFA (0.5 
mL). The reaction mixture was warmed to rt and stirred for 2 h, volatiles were removed 
under reduced pressure to provide 1‐[4‐(aminomethyl)phenyl]‐4,4‐dimethyl‐7‐(2‐
methyloctan‐2‐yl)‐1H,4H‐chromeno[4,3‐c]pyrazol‐9‐ol in assumed quantitative yield as 
trifluoroacetate salt. The solution of Boc-deprotected 4.10 trifluoroacetate salt (22 mg) in 
DCM (2.0 mL) was added to a solution of 4.15 (12 mg, 0.02 mmol), TFFH (7 mg, 0.02 
mmol) and Et3N (0.01 mL, 0.05 mmol) in DCM (2.0 mL) under a N2 atmosphere and the 
reaction was stirred for 12 h. The reaction solvent was removed under reduced pressure 
and the residue was partitioned between DCM/H2O. The DCM layer was washed with 
saturated NH4Cl solution, water, brine solution, dried over MgSO4.H2O and concentrated 
under reduced pressure. The residue was further purified by a short silica gel column 
(eluting with 70% EtOAc/hexane to 12% MeOH/EtOAc) to provide 4.16 as a clear oil (7 
mg, 0.01 mmol, 25%). 1H NMR (400 MHz, MeOD-d4) δ 0.86 (t, 3H, J = 6.7 Hz, 
CH2CH3), 1.04 – 1.14 (m, 2H, CH2), 1.16 – 1.33 (m, 14H, 4 × CH2 and C(CH3)2 
dimethylheptyl chain), 1.43 (s, 9H, C(CH3)3), 1.51 – 1.65 (m, 8H, CH2 and OC(CH3)2 
pyran ring), 2.55 (t, 4H, J = 2.9 Hz, 2 × CH2), 3.20 (t, 2H, J = 5.6 Hz, CH2), 3.35 (d, 2H, 
J = 5.4 Hz, CH2), 3.46 – 3.54 (m, 4H, 2 × CH2), 3.61 (d, 14H, J = 12.6 Hz, 7 × CH2), 
4.42 (s, 2H, CH2), 6.29 – 6.34 (m, 1H, ArH phenol), 6.49 – 6.55 (m, 1H, ArH phenol), 
7.23 – 7.38 (m, 4H, ArH phenol), 7.57 (s, 1H, ArH pyrazole). 13C NMR (101 MHz, 
MeOD-d4) δ 14.41, 23.62, 25.73, 27.51, 28.79, 29.26, 31.01, 32.21, 32.30, 32.85, 38.71, 
40.49, 41.30, 43.67, 45.37, 70.53, 71.06, 71.27, 71.28, 71.52, 71.57, 77.74, 103.45, 
108.37, 125.42, 128.34, 135.03, 139.23, 143.40, 153.46, 154.14, 155.58, 174.61, 174.66. 










boratricyclo[7.3.0.03,7]dodeca‐1(12),4,6,8,10‐pentaen‐1‐ylium‐2‐uide  (4.04)  
Following the procedure described for 4.05, 4.16 (4.5 mg, 4.94 µmol) was reacted with 
TFA (0.5 mL) to give N‐(17‐amino‐3,6,9,12,15‐pentaoxaheptadecan‐1‐yl)‐N'‐({4‐[9‐
hydroxy‐4,4‐dimethyl‐7‐(2‐methyloctan‐2‐yl)‐1H,4H‐chromeno[4,3‐c]pyrazol‐1‐
yl]phenyl}methyl) butanediamide trifluoroacetate in assumed quantitative yield as yellow 
solid. This amino TFA salt was purified using semi-preparative RP-HPLC. Reaction of 
this purified trifluoroacetate salt (4.2 mg, 4.54 µmol) with BODIPY-630/650-SE (1.0 mg, 
1.51 μmol) gave 4.04 (3.53 mg, 2.60 μmol, quantitative) as a dark blue solid. HRMS 
calculated for C73H93BF2N8NaO12S [M + Na]
+, 1377.6599; found, 1377.6560. Analytical 
RP-HPLC Rt = 23.40 min; determined with HPLC method B. 
 
The amino peptide linker conjugates (4.25-4.27) were synthesised using 1,2-
diaminoethane trityl resin (0.1 g) by solid phase peptide synthesis as described for 





c]pyrazol‐1‐yl]phenyl}butanamide (4.06)  
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To a solution of 4.25 (3.0 mg, 3.6 µmol) in CHCl3 (1.0 mL) was added Ac2O (0.3 µL, 3.3 
µmol), Et3N (2.0 µL, 11 µmol) and the reaction stirred for 2 h. The reaction solvent was 
removed by evaporation under reduced pressure and the residue purified by semi-
preparative RP-HPLC to give 4.06 (1.2 mg, 1.60 µmol, 44%) as a colourless solid. HRMS 
calculated for C41H58N6NaO7 [M + Na]+, 769.4259; found, 769.4194. Analytical RP-





c]pyrazol‐1‐yl]phenyl}butanamide (4.07)  
According to procedure described for 4.06, 4.26 (3.0 mg, 3.6 µmol) was reacted with 
Ac2O (0.3 µL, 3.3 µmol) and Et3N (2.0 µL, 11 µmol) to give 4.07 (1.8 mg, 2.40 µmol, 
67%) as a colourless solid. HRMS calculated for C41H58N6NaO7 [M + Na]+, 769.4259; 






yl]phenyl}butanamido) butanediamide (4.08) 
According to procedure described for 4.06, 4.27 (4.0 mg, 4.6 µmol) was reacted with 
Ac2O (0.4 µL, 0.4 µmol) and Et3N (2.0 µL, 14 µmol) to give 4.08 (1.1 mg, 1.39 µmol, 








5‐Hydrazinylpyridine‐2‐carbonitrile (4.29)  
This compound was prepared by modification of a reported literature synthesis of 4.29.222 
To a solution of commercially available 5-amino-2-cyanopyridine 4.28 (0.3 g, 2.51 
mmol) in aqueous HCl (6 M, 10.0 mL) at -10 °C was added a solution of NaNO2 (0.3 g, 
4.35 mmol) in water (3.0 mL) and stirred for 30 min at -10 °C. To the reaction mixture 
was added a solution of SnCl2.2H2O (2.84 g, 12.59 mmol) in water (10 mL) and the 
reaction stirred for at 0 °C for 2 h. The reaction mixture was slowly basified to pH 10.0-
11.0 with aqueous KOH solution (10% w/v) and extracted with EtOAc. The EtOAc layer 
was washed with water, brine, dried over MgSO4.H2O.and removed by evaporation under 
reduced pressure to give 4.29 (0.41 g) as light brown solid. Compound 4.29 slowly 
degrades in to an unknown impurity and was therefore used in the next reaction without 
further purification. HRMS calculated for C6H6N4Na [M + Na]





1‐yl]pyridine‐2‐carbonitrile (4.30)  
To a solution of 3.16 (0.15 g, 0.43 mmol) in MeOH (20 mL) was added 4.29 (0.17 g, 1.02 
mmol), followed by addition of two drops of conc. H2SO4 (98%) and the reaction stirred 
at 70 °C for 2 h. The reaction solvents was removed under reduced pressure, the residue 
neutralised with saturated NaHCO3 solution and extracted with EtOAc. The EtOAc layer 
was then separated, washed with water, brine solution, dried over MgSO4.H2O, 
concentrated under reduced pressure and the residue purified by silica gel column 
chromatography (eluting with 10 – 25% EtOAc/hexane) to give 4.30 (0.16 g, 0.37 mmol, 
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86%) as a light yellow oil. 1H NMR (400 MHz, CDCl3) δ 0.82 (t, 3H, J = 6.9 Hz, 
CH2CH3), 0.96 – 1.09 (m, 2H, CH2), 1.11 – 1.29 (m, 12H, 3 × CH2 and C(CH3)2 
dimethylheptyl chain), 1.42 – 1.52 (m, 2H, CH2), 1.62 (s, 6H, OC(CH3)2 pyran ring), 6.26 
(d, 1H, J = 1.6 Hz, ArH phenol), 6.63 (d, 1H, J = 1.6 Hz, ArH phenol), 6.95 (s, 1H, OH), 
7.61 (s, 1H, ArH pyrazole), 7.82 (d, 1H, J = 8.3 Hz, ArH pyridine), 7.99 – 8.07 (m, 1H, 
ArH pyridine), 8.66 (d, 1H, J = 2.9 Hz, ArH pyridine). 13C NMR (101 MHz, CDCl3) δ 
14.20, 22.73, 24.68, 27.33, 28.64, 29.99, 31.82, 38.02, 44.35, 101.77, 107.70, 109.13, 
116.84, 125.99, 128.83, 130.02, 131.25, 133.62, 136.79, 142.04, 146.44, 150.03, 154.33, 
154.35. HRMS calculated for C27H32N4NaO2 [M + Na]





A solution of 4.30 (0.13 g, 0.30 mmol) in THF (10.0 mL) was added to a solution of 
LiAlH4 in THF (0.6 mL, 1M) at 0 °C under N2 atmosphere. The reaction was warmed to 
rt and stirred for 2 h. The reaction was quenched by adding water (3 mL), a solution of 
15% NaOH in water (1.0 mL) at 0 °C and the mixture stirred at rt for 10 min. The mixture 
was partitioned between EtOAc and water. The EtOAc layer was separated, dried over 
MgSO4.H2O and concentrated under reduced pressure to give amine 4.31 (117 mg) as a 
yellowish solid. This compound was used as such in the next reaction without further 
purification. HRMS calculated for C27H37N4O2 [M + H]





propanamido} ethoxy)ethoxy]ethyl}carbamate (4.09)  
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To a solution of 3.13 (18 mg, 0.05 mmol), HBTU (19 mg, 0.05 mmol) in DMF (1.0 mL) 
was added DIPEA (0.03 mL, 0.15 mmol) under N2 atmosphere and the reaction was 
stirred for 10 min. A solution of amine 4.31 (23 mg) in DMF (1.0 mL) was added to the 
reaction mixture and reaction stirred for 12 h. The reaction solvent was removed under 
reduced pressure and the residue was partitioned between EtOAc/H2O. The EtOAc layer 
was washed with saturated NH4Cl solution, water, brine solution, dried over MgSO4.H2O 
and concentrated under reduced pressure. The residue was purified by silica gel column 
chromatography (eluting with 30% EtOAc/hexane to 5% MeOH/EtOAc) to provide 4.09 
(18 mg, 0.02 mmol, 46%) as a yellow oil. 1H NMR (400 MHz, MeOD-d4) δ 0.86 (t, 3H, 
J = 6.8 Hz, CH2CH3), 1.03 – 1.13 (m, 2H, CH2), 1.15 – 1.33 (m, 12H, 3 × CH2 and 
C(CH3)2 dimethylheptyl chain), 1.35 – 1.49 (m, 9H, C(CH3)3), 1.49 – 1.66 (m, 8H, CH2 
and OC(CH3)2 pyran ring), 2.51 – 2.66 (m, 4H, 2 × CH2), 3.17 – 3.25 (m, 2H, CH2), 3.35 
(t, 2H, J = 5.5 Hz, CH2), 3.45 – 3.56 (m, 4H, 2 × CH2), 3.56 – 3.64 (m, 4H, 2 × CH2), 
4.53 (s, 2H, CH2) 6.30 – 6.38 (m, 1H, ArH phenol), 6.51 – 6.56 (m, 1H, ArH phenol), 
7.44 – 7.53 (m, 1H, ArH phenol), 7.66 (s, 1H, ArH pyrazole), 7.76 – 7.82 (m, 1H, ArH 
pyridine), 8.42 (d, 1H, J = 2.4 Hz, ArH pyridine). 13C NMR (101 MHz, MeOD-d4) δ 
14.40, 23.64, 25.74, 27.51, 28.77, 29.24, 31.04, 32.03, 32.14, 32.23, 32.86, 38.75, 40.43, 
41.22, 45.23, 45.36, 70.59, 71.08, 71.29, 77.75, 102.98, 108.29, 108.62, 122.15, 125.93, 
133.89, 135.31, 136.30, 140.09, 145.35, 153.13, 154.54, 155.61, 157.86, 174.68, 174.99. 
HRMS calculated for C42H62N6NaO8 [M + Na]
+, 801.4521; found, 801.4568. Analytical 
RP-HPLC Rt = 20.53 min; determined with HPLC method B. 
 
7.4.2 Pharmacological studies 
 
Radioligand binding assays and cAMP functional assays were carried out as described in 
section 7.1.2. In the radioligand binding assay, [3H]-CP55,940 was used in a 
concentration of 0.75 nM per well for determining the CB1R affinity and 0.5 nM per well 
for determining the CB2R affinity of test compounds. Both CB1R and CB2R membrane 




7.5 Experimental procedure and data for compounds 
as described in chapter 5 
7.5.1 Chemical studies 
 
 
tert‐Butyl N‐(2‐{2‐[2‐(2‐hydroxyethoxy)ethoxy]ethoxy}ethyl)carbamate (5.11)  
This compound was prepared according to a previously reported synthesis of 5.11.240 To 
a solution of commercially available 2‐{2‐[2‐(2‐aminoethoxy)ethoxy]ethoxy}ethan‐1‐ol 
5.10 (0.4 g, 2.07 mmol) in EtOH (5.0 mL) was added a solution of (Boc)2O (0.5 g, 2.27 
mmol) in EtOH (3.0 mL) at 0 °C. The reaction was warmed to rt and stirred for 12 h. The 
solvent was evaporated under reduced pressure to give 5.11 (0.61 g) as a yellow oil, which 
was used in the next reaction without further purification. 1H NMR (400 MHz, CDCl3) δ 
1.40 (s, 9H, C(CH3)3), 3.26 (q, 2H, J = 6.9 Hz, CH2), 3.42 – 3.52 (m, 2H, CH2), 3.54 – 
3.79 (m, 13H, OH and 6 × CH2), 5.60 (br s, 1H, NH). 13C NMR (101 MHz, CDCl3) δ 
27.45, 28.49, 40.43, 61.66, 70.13, 70.30, 70.49, 70.66, 72.69, 78.99, 85.22, 146.78, 
156.25. HRMS calculated for C13H27NNaO6 [M + Na]




carbamate (5.12)  
To a solution of 5.11 (0.61 g, 2.08 mmol) in DCM (5.0 mL) was added Et3N (0.44 mL, 
3.12 mmol) and MeSO2Cl (0.21 mL, 2.70 mmol) under N2 atmosphere at 0 °C and the 
reaction mixture warmed to rt and stirred for 12 h. The reaction solvent was removed 
under reduced pressure and the residue was partitioned between EtOAc and water. The 
EtOAc layer was dried over MgSO4.H2O, concentrated under reduced pressure and the 
residue was purified by silica gel column chromatography (eluting with 30% 
EtOAc/hexane to 70% EtOAc/hexane) to give 5.12 (0.73 g, 1.98 mmol, 96% over two 
steps from 5.10) as a clear oil. 1H NMR (400 MHz, CDCl3) δ 1.42 (s, 9H, C(CH3)3), 3.05 
(s, 3H, CH3), 3.29 (q, 2H, J = 5.4 Hz, CH2), 3.51 (t, 2H, J = 5.1 Hz, CH2), 3.55 – 3.70 
(m, 8H, 4 × CH2), 3.71 – 3.80 (m, 2H, CH2), 4.30 – 4.41 (m, 2H, CH2), 4.99 (s, 1H, NH). 
13C NMR (101 MHz, CDCl3) δ 28.50, 37.76, 40.42, 69.11, 69.32, 70.29, 70.60, 70.73, 
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79.28, 156.04. HRMS calculated for C14H29NNaO8S [M + Na]




Methyl 5‐hydroxypyridine‐2‐carboxylate (5.14) 
To a solution of commercially available 5‐hydroxypyridine‐2‐carboxylic acid 5.13 (1.0 
g, 7.19 mmol) in MeOH (3.0 mL) was added dropwise SOCl2 (1.0 mL) at 0 °C. The 
reaction mixture was stirred at 75 °C for 12 h. The solvent was removed under reduced 
pressure and the residue was evaporated to give 5.14 (1.2 g) as an off-white solid, which 
was used as such in the next reaction without further purification. 1H NMR (400 MHz, 
MeOD-d4) δ 4.05 – 4.10 (m, 3H, CH3), 8.00 – 8.12 (m, 1H, ArH), 8.37 – 8.50 (m, 2H, 
ArH). HRMS calculated for C7H7NNaO3 [M + Na]




pyridine‐2‐carboxylate (5.15)  
A mixture of 5.14 (0.27 g, 1.76 mmol) and K2CO3 (0.48 g, 3.52 mmol) in dry DMF (2.0 
mL) was stirred at rt under N2 atmosphere for 10 min, followed by addition of a solution 
of 5.12 (0.59 g, 1.58 mmol) in DMF (1.0 mL). The reaction mixture was stirred at 60 °C 
for 7 h. The reaction solvent was removed under reduced pressure and the residue was 
partitioned between EtOAc/water. The EtOAc layer was washed with water, brine 
solution, dried over MgSO4.H2O, concentrated under reduced pressure and the residue 
purified by silica gel column chromatography (eluting with 30% EtOAc/hexane to 2% 
MeOH/EtOAc) to provide 5.15 (0.44 g, 1.02 mmol, 64% over two steps from 5.14) as 
yellow oil. 1H NMR (400 MHz, CDCl3) δ 1.42 (s, 9H, C(CH3)3), 3.30 (q, 2H, J = 5.3 Hz, 
CH2), 3.52 (t, 2H, J = 5.2 Hz, CH2), 3.56 – 3.67 (m, 4H, 2 × CH2), 3.63 – 3.70 (m, 2H, 
CH2), 3.70 – 3.78 (m, 2H, CH2), 3.86 – 3.93 (m, 2H, CH2), 3.97 (s, 3H, CH3), 4.20 – 4.27 
(m, 2H, CH2), 4.99 (s, 1H, NH), 7.28 (dd, 1H, J = 8.7 Hz, ArH), 8.09 (d, 1H, J = 8.7 Hz, 
ArH), 8.41 (d, 1H, J = 2.8 Hz, ArH). 13C NMR (101 MHz, CDCl3) δ 28.55, 40.45, 52.79, 
68.22, 69.56, 70.34, 70.36, 70.72, 70.76, 71.08, 79.31, 120.60, 126.60, 138.72, 140.46, 
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ethoxy} ethyl) carbamate (5.16)  
To a solution of 5.15 (0.33 g, 0.78 mmol) in THF (10.0 mL) at 0 °C was added a solution 
of LiAlH4 (1.2 mL of a 1M solution in THF) under N2 atmosphere. The reaction was 
warmed to rt and stirred for 1 h. The reaction was quenched by adding water (3 mL), a 
solution of 15% NaOH in water (1.0 mL) and then water (3.0 mL) at 0 °C and the reaction 
mixture stirred for 30 min. The resulting suspension was filtered through celite, the filtrate 
was concentrated under reduced pressure and the residue was partitioned between EtOAc 
and water. The EtOAc layer was dried over MgSO4.H2O and solvent removed under 
reduced pressure to give 5.16 (0.3 g) as an orange oil, which was used as such in the next 
reaction without further purification. HRMS calculated for C19H32N2NaO7 [M + Na]
+, 





According to the procedure described for the synthesis of 5.12, reaction of 5.16 (0.25 g, 
0.61 mmol) with MeSO2Cl (0.06 mL, 0.80 mmol) gave 5.17 (0.3 g) as a red liquid, which 




yl]carbamate (5.18)  
To a solution of commercially available 6‐bromohexanoic acid 3.49 (15 mg, 0.07 mmol) 
in DCM (2.0 mL) was added TFFH (20 mg, 0.07 mmol), Et3N (0.02 mL, 0.09 mmol) 
under N2 atmosphere and the reaction stirred at 0 °C for 5 min. A solution of commercially 
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available tert‐butyl N‐(17‐amino‐3,6,9,12,15‐pentaoxaheptadecan‐1‐yl)carbamate 4.16 
(29 mg, 0.07 mmol) in DCM (1.0 mL) was added to the reaction mixture and reaction 
stirred at rt for 5 h. The reaction mixture was concentrated under reduced pressure. The 
residue was partitioned between DCM and H2O. The DCM layer was washed with water, 
saturated NaHCO3 solution, brine solution, dried over MgSO4.H2O and the solvent 
removed under reduced pressure to provide 5.18 (36 mg, 0.06 mmol, 84%) as a clear oil, 
which was used as such in the next reaction without further purification. 1H NMR (400 
MHz, CDCl3) δ 1.33 – 1.52 (m, 11H, C(CH3)3 and CH2), 1.59 – 1.72 (m, 2H, CH2), 1.80 
– 1.91 (m, 2H, CH2), 2.18 (t, 2H, J = 7.5 Hz, CH2), 2.99 (s, 1H, NH), 3.24 – 3.32 (m, 2H, 
CH2), 3.36 – 3.46 (m, 4H, 2 × CH2), 3.48 – 3.56 (m, 4H, 2 × CH2), 3.56 – 3.69 (m, 16H, 
8 × CH2), 6.43 (br s, 1H, NH). 13C NMR (101 MHz, CDCl3) δ 24.87, 27.88, 28.52, 32.57, 
33.79, 36.33, 39.27, 70.02, 70.25, 70.35, 70.59, 70.65, 156.15, 173.02. HRMS calculated 
for C23H45BrN2NaO8 [M + Na]
+, 579.2251; found, 579.2248. 
 
 
4‐(Bromomethyl)naphthalene‐1‐carboxylic acid (5.20)  
This compound was prepared according to according to a previously reported synthesis 
of 5.20.229 A mixture of commercially available 4‐methylnaphthalene‐1‐carboxylic acid 
5.19 (0.5 g, 2.68 mmol), NBS (0.52 g, 2.95 mmol) and AIBN (0.4 mL, 12% w/v solution 
in acetone) in CCl4 (20.0 mL) was stirred at 80 °C for 4 h. The reaction solvent was 
removed under reduced pressure, the residue was partitioned between EtOAc and 15% 
w/v aqueous solution of citric acid. The EtOAc layer was dried over MgSO4.H2O to give 
5.20 (0.91 g) as a colourless solid, which was used as such in next reaction without further 
purification. 1H NMR (400 MHz, MeOD-d4) δ 5.07 (s, 2H, CH2), 7.61 – 7.69 (m, 3H, 
ArH), 8.08 – 8.12 (m, 1H, ArH), 8.24 – 8.29 (m, 1H, ArH), 8.92 – 8.97 (m, 1H, ArH). 
HRMS calculated for C12H8BrO2 [M - H]






4‐[(1H‐1,2,3‐Triazol‐1‐yl)methyl]naphthalene‐1‐carboxylic acid (5.21)  
This compound was prepared according to according to a previously reported synthesis 
of 5.21.230 To a solution of 5.20 (0.5 g, 0.1.88 mmol) in DMF (7.0 mL) was added 1,2,3-
triazoline (0.4 g, 5.66 mmol) under a N2 atmosphere and the reaction was stirred at 50 °C 
for 12 h. The reaction solvent was removed under reduced pressure and the residue was 
acidified to pH 2.0-3.0 with aq. 1M HCl. The resulting precipitate was washed with water 
and air-dried to give 5.21 (0.34 g, 1.34 mmol, 91% over two steps from 4‐
methylnaphthalene‐1‐carboxylic acid) as an off-white solid. 1H NMR (400 MHz, DMSO-
d6) δ 6.20 (s, 2H, CH2), 7.29 (d, 1H, J = 7.5 Hz, ArH naphthalene), 7.60 – 7.74 (m, 2H, 
ArH naphthalene), 7.77 (d, 1H, J = 1.0 Hz, ArH triazoline), 8.09 (d, 1H, J = 7.4 Hz, ArH 
naphthalene), 8.20 (d, 1H, J = 1.0 Hz, ArH triazoline), 8.23 – 8.31 (m, 1H, ArH 
naphthalene), 8.81 – 8.91 (m, 1H, ArH naphthalene), 13.29 (s, 1H, COOH). HRMS 
calculated for C14H11N3NaO2 [M + Na]
+, 276.0743; found, 276.0728. 
 
 
4‐[(1H‐1,2,3‐Triazol‐1‐yl)methyl]naphthalene‐1‐carbonyl chloride (5.22) 
A solution of 5.21 (0.32 g, 1.24 mmol) in SOCl2 (10.0 mL) was stirred at 80 °C for 12 h 
with a water condenser and a CaCl2 guard tube. SOCl2 was removed under reduced 
pressure and the residue was co-evaporated with CHCl3 to give 5.22 (0.34 g) as a yellow 










To a solution of commercially available 6‐chloro‐3‐nitropyridine‐2‐carbonitrile 5.9 (4.0 
g, 21.79 mmol) in dry THF (15.0 mL) at 0 °C was added dropwise a solution of NaOMe 
(5.0 mL, 20% w/v solution in MeOH) in dry MeOH (4.0 mL) over 30 min under N2 
atmosphere. The reaction mixture was stirred at rt for 6 h. The reaction solvent was 
removed under reduced pressure and the residue was partitioned between EtOAc, water. 
The EtOAc layer was washed with saturated solution of NH4Cl, brine, dried over 
MgSO4.H2O, concentrated under reduced pressure, and the residue purified by silica gel 
column chromatography (eluting with 10% EtOAc/hexane to 30% EtOAc/hexane) to 
provide 5.23 (2.41 g, 13.45 mmol, 62%) as a colourless solid. Continued elution (with 
30% EtOAc/hexane) provided side product 5.25 (1.52 g, 7.19 mmol, 33%, spectral data 
reported later). 5.23  1H NMR (400 MHz, CDCl3) δ 4.09 (s, 3H, CH3), 7.11 (d, 1H, J = 
9.2 Hz, ArH), 8.45 (d, 1H, J = 9.2 Hz, ArH). 5.23   13C NMR (101 MHz, CDCl3) δ 55.89, 
114.09, 116.10, 126.84, 135.58, 141.79, 166.37. HRMS calculated for 5.23  C7H5N3NaO3 
[M + Na]+, 202.0223; found, 202.0207. 
 
 
2,6‐Dimethoxy‐3‐nitropyridine (5.24) - side product formed during synthesis of 5.23 
To a solution of commercially available 6‐chloro‐3‐nitropyridine‐2‐carbonitrile 5.9 (0.5 
g, 2.72 mmol) in dry MeOH (3.0 mL) at 0 °C was added a solution of NaOMe (1.9 mL, 
20% w/v solution in MeOH) under N2 atmosphere. The reaction mixture was stirred at rt 
for 6 h. The reaction solvent was removed under reduced pressure and the residue was 
partitioned between EtOAc, water. The EtOAc layer was washed with saturated solution 
of NH4Cl, brine, dried over MgSO4.H2O, concentrated under reduced pressure, and the 
residue purified by silica gel column chromatography (eluting with 10% EtOAc/hexane 
to 20% EtOAc/hexane) to provide 5.24 (0.48 g, 2.59 mmol, 95%) as a light yellow solid. 
1H NMR (400 MHz, CDCl3) δ 4.00 (s, 3H, CH3), 4.10 (s, 3H, CH3), 6.35 (d, 1H, J = 8.8 
Hz, ArH), 8.31 (d, 1H, J = 8.8 Hz, ArH). 13C NMR (101 MHz, CDCl3) δ 54.73, 54.85, 






Methyl 6‐methoxy‐3‐nitropyridine‐2‐carboximidate (5.25) - optimised procedure 
To a solution of commercially available 6‐chloro‐3‐nitropyridine‐2‐carbonitrile 5.9 (48 
mg, 0.26 mmol) in dry MeOH (2.0 mL) at 0 °C was added dropwise a solution of NaOMe 
(0.06 mL, 20% w/v solution in MeOH) in dry MeOH (1.0 mL) over 5 min under N2 
atmosphere and the reaction stirred for 10 min. Another solution of NaOMe (0.06 mL, 
20% w/v solution in MeOH) in dry MeOH (1.0 mL) was added to the reaction mixture. 
The reaction was stirred for 6 h at rt. The reaction solvent was removed under reduced 
pressure, the residue was neutralised with aqueous 0.5M HCl solution and extracted with 
EtOAc. The EtOAc layer was dried over MgSO4.H2O, concentrated under reduced 
pressure to provide 5.25 (52 mg, 0.24 mmol, 94%) as a yellow oil. 1H NMR (400 MHz, 
CDCl3) δ 3.89 (s, 3H, CH3), 4.03 (s, 3H, CH3), 6.87 (d, 1H, J = 8.9 Hz, ArH), 8.06 (d, 
1H, J = 8.9 Hz, ArH). 13C NMR (101 MHz, CDCl3) δ 54.27, 55.03, 113.07, 135.30, 
164.99, 165.78. HRMS calculated for C8H10N3O4 [M + H]




To a solution of 5.23 (2.3 g, 12.84 mmol) in MeOH (15.0 mL) at 0°C was added 
SnCl2.2H2O (17.4 g, 77.03 mmol) and the reaction stirred at rt for 6 h. The reaction 
solvent was removed under reduced pressure; the residue was partitioned between EtOAc 
and aqueous 2M KOH solution. The EtOAc layer was concentrated under reduced 
pressure and the residue was purified by silica gel column chromatography (eluting with 
30% EtOAc/hexane to 50% EtOAc/hexane) to provide 5.26 (1.15 g, 7.71 mmol, 62%) as 
a pale yellow solid. 1H NMR (400 MHz, CDCl3) δ 3.85 (s, 3H, CH3), 5.62 – 5.66 (m, 2H, 
NH2), 6.76 (d, 1H, J = 8.8 Hz, ArH), 7.03 (d, 1H, J = 8.8 Hz, ArH). 
13C NMR (101 MHz, 
CDCl3) δ 53.22, 117.27, 123.74, 130.70, 141.43, 154.34, 170.57. MS calculated for 
C7H8N3O [M + H]






3‐Amino‐6‐methoxypyridine‐2‐carboxylic acid (5.8)  
To a solution of 5.26 (1.1 g, 7.37 mmol) in MeOH (30.0 mL) was added a solution of 
KOH (5.0 g, 89.12 mmol) in water (20.0 mL) and the reaction was stirred at 80 °C for 12 
h. The reaction solvent was removed by evaporation under reduced pressure, the residue 
acidified to pH 2.0-3.0 with aqueous 6M HCl and extracted with a solvent mixture of 
MeOH:EtOAc (20% v/v). The combined organic layers were washed with water, brine, 
dried over MgSO4.H2O to give a brown solid, which after recrystallisation from MeOH 
gave 5.8 (0.73 g, 4.34 mmol, 59%) as a pale yellow solid. 1H NMR (400 MHz, MeOD-
d4) δ 3.92 (s, 3H, CH3), 6.97 (d, 1H, J = 9.0 Hz, ArH), 7.37 (d, 1H, J = 9.0 Hz, ArH). 
13C 
NMR (101 MHz, MeOD-d4) δ 54.52, 119.70, 121.18, 133.13, 143.80, 156.17, 169.21. 
HRMS calculated for C7H9N2O3 [M + H]
+, 169.0608; found, 169.0597. 
 
 
3‐Amino‐N‐(cyclobutylmethyl)‐6‐methoxypyridine‐2‐carboxamide (5.27)  
A solution of 5.8 (0.34 g, 2.03 mmol), HATU (0.85 g, 2.23 mmol), DIPEA (1.1 mL, 6.08 
mmol) in DMF (4.0 mL) under a N2 atmosphere was stirred for 10 min. A solution of 1-
cyclobutylmethanamine hydrochloride (0.27 g, 2.23 mmol) in DMF (1.0 mL) was then 
added and the reaction stirred for 5 h. The reaction solvent was removed under reduced 
pressure. The residue was partitioned between EtOAc and H2O. The organic layer was 
then washed with saturated NH4Cl solution, saturated NaHCO3 solution, water, brine 
solution, dried over MgSO4.H2O and concentrated under reduced pressure. The residue 
was further purified by silica gel column chromatography (eluting with 20% 
EtOAc/hexane to 30% EtOAc/hexane) to provide 5.27 (0.33 g, 1.39 mmol, 68%) as an 
orange solid. 1H NMR (400 MHz, CDCl3) δ 1.69 – 1.87 (m, 2H, CH2 cyclobutane), 1.84 
– 1.97 (m, 2H, CH2 cyclobutane), 2.02 – 2.14 (m, 2H, CH2 cyclobutane), 2.49 – 2.65 (m, 
1H, NHCH2CH), 3.38 – 3.46 (m, 2H, NHCH2), 3.83 (s, 3H, CH3), 5.48 – 5.78 (m, 2H, 
NH2), 6.71 (d, 1H, J = 8.8 Hz, ArH), 7.02 (d, 1H, J = 8.8 Hz, ArH), 7.84 (br s, 1H, NH). 
13C NMR (101 MHz, CDCl3) δ 18.44, 25.72, 35.40, 43.98, 53.13, 116.31, 124.67, 130.80, 







1‐amido}pyridine‐2‐carboxamide (5.3)  
Compound 5.3 was prepared by following a literature procedure reported for the synthesis 
of analogous pyridyl-2-carboxamides.223 To a solution of 5.22 (0.34 g, 1.24 mmol) in 
CHCl3 (10.0 mL) was added a solution of 5.27 (0.19 g, 0.83 mmol), DIPEA (0.45 mL, 
2.47 mmol) in CHCl3 (3.0 mL) at 0°C under N2 atmosphere. The reaction mixture was 
stirred at 80 °C for 4 h. The solvent was removed under reduced pressure and the residue 
was dissolved in EtOAc. The EtOAc solution was washed with saturated NaHCO3 
solution, water, brine, dried over MgSO4.H2O, concentrated under reduced pressure and 
purified by silica gel column chromatography (50% EtOAc/hexane to 70% EtOAc) to 
provide 5.3 (0.35 g, 0.75 mmol, 92%) as a colourless solid.  
This compound was also prepared using 5.31 (0.26 g, 0.64 mmol), 1-
cyclobutylmethanamine hydrochloride (0.08 g, 0.71 mmol), HATU (0.27 g, 0.71 mmol), 
and DIPEA (0.4 mL, 1.93 mmol) according to the procedure described for the synthesis 
of 5.27, to give 5.3 (0.26 g, 0.55 mmol, 86%) as a colourless solid. 
 1H NMR (400 MHz, CDCl3) δ 1.67 – 1.82 (m, 2H, CH2 cyclobutane), 1.83 – 1.97 (m, 
2H, CH2 cyclobutane), 2.03 – 2.14 (m, 2H, CH2 cyclobutane), 2.52 – 2.64 (m, 1H, 26), 
3.37 – 3.44 (m, 2H, NHCH2), 3.94 (s, 3H, OCH3), 6.05 (s, 2H, CH2 triazoline), 7.02 (d, 
1H, J = 9.1 Hz, ArH pyridine), 7.38 (d, 1H, J = 1.0 Hz, ArH triazoline), 7.42 (d, 1H, J = 
7.3 Hz, ArH naphthalene), 7.51 – 7.66 (m, 2H, ArH naphthalene), 7.67 (d, 1H, J = 1.0 
Hz, ArH triazoline), 7.84 (d, 1H, J = 7.3 Hz, ArH naphthalene), 7.95 – 8.02 (m, 1H, ArH 
naphthalene), 8.13 – 8.21 (m, 1H, NH), 8.51 – 8.60 (m, 1H, ArH naphthalene), 9.32 (d, 
1H, J = 9.1 Hz, ArH pyridine), 12.64 (s, 1H, NH). 13C NMR (101 MHz, CDCl3) δ 18.43, 
25.70, 35.06, 44.32, 52.27, 53.58, 115.89, 123.20, 123.61, 124.97, 126.80, 126.88, 
127.71, 127.95, 129.77, 131.03, 131.70, 132.97, 133.25, 133.29, 134.41, 136.38, 157.86, 
167.11, 167.74. HRMS calculated for C26H26N6NaO3 [M + Na]
+, 493.1959; found, 





Methyl 6-methoxy-3-nitropyridine-2-carboxylate (5.28) 
To a cooled (0 °C) solution of 6‐chloro‐3‐nitropyridine‐2‐carbonitrile 5.9 (0.2 g, 1.09 
mmol) in MeOH (10.0 mL) was added dropwise a solution of NaOMe (0.2 mL, 20% w/v 
solution in MeOH) in methanol (4.0 mL) under N2 atmosphere. The reaction mixture was 
stirred at 0 °C for 15 min, followed by addition of another solution of NaOMe (0.3 mL, 
20% w/v solution in MeOH) in methanol (4.0 mL). The reaction mixture was stirred at rt 
for 6 h, followed by dropwise addition of a solution of H2SO4 (0.5 mL, 96% w/w) in water 
(4.0 mL). The reaction was stirred for 2 h. The solvent was removed under reduced 
pressure and the residue neutralised with saturated NaHCO3 solution, extracted with 
EtOAc. The EtOAc layer was washed with brine, dried over MgSO4.H2O, concentrated 
and the residue purified by silica gel chromatography (10 to 30% EtOAc/hexane) to 
provide 5.28 (0.16 g, 0.76 mmol, 70% over two steps from 6-methoxy-3-nitropyridine-2-
carbonitrile) as yellow oil. 1H NMR (400 MHz, CDCl3) δ 4.01 (s, 3H, CO2CH3), 4.06 (s, 
3H, 9, OCH3), 6.90 (d, 1H, J = 9.1 Hz, ArH), 8.33 (d, 1H, J = 9.2 Hz, ArH). 
13C NMR 
(101 MHz, CDCl3) δ 53.48, 55.28, 112.80, 135.03, 136.72, 146.44, 164.95, 166.27. 
HRMS calculated for C8H8N2NaO5 [M + Na]
+, 235.0325; found, 235.0333. 
 
 
Methyl 3-amino-6-methoxypyridine-2-carboxylate (5.29) 
According to the procedure described for 5.26, 5.28 (0.14 g, 0.66 mmol) was reacted with 
SnCl2.2H2O (1.5 g, 6.60 mmol). The crude compound was purified by silica gel 
chromatography (10% EtOAc/hexane to 30% EtOAc/hexane) to provide 5.29 (0.09 g, 
0.47 mmol, 72%) as pale yellow solid. 1H NMR (400 MHz, CDCl3) δ 3.91 (s, 3H, 
CO2CH3), 3.92 (s, 3H, OCH3), 5.44 (s, 2H, NH2), 6.80 (d, 1H, J = 8.9 Hz, ArH), 7.04 (d, 
1H, J = 8.9 Hz, ArH). 13C NMR (101 MHz, CDCl3) δ 52.23, 53.41, 118.11, 122.41, 
130.17, 142.88, 155.12, 168.13. HRMS calculated for C8H10N2NaO3 [M + Na]
+, 






According to the procedure described for 5.3, 5.29 (71 mg, 0.39 mmol) was reacted with 
5.22 (182 mg, 0.67 mmol) and DIPEA (0.2 mL, 1.17 mmol). The crude compound was 
purified by silica gel chromatography (50% EtOAc/hexane to 100% EtOAc/hexane) to 
provide 5.30 (112 mg, 0.27 mmol, 69%) as a colourless solid. 1H NMR (400 MHz, 
CDCl3) δ 3.94 (s, 3H, CO2CH3), 3.99 (s, 3H, OCH3), 6.06 (s, 2H, CH2), 7.08 (d, 1H, J = 
9.2 Hz, ArH pyridine), 7.39 – 7.43 (m, 2H, ArH naphthalene and triazoline), 7.56 – 7.64 
(m, 2H, ArH naphthalene), 7.68 (s, 1H, ArH triazoline), 7.82 (d, 1H, J = 7.3 Hz, ArH 
naphthalene), 7.99 – 8.06 (m, 1H, ArH naphthalene), 8.48 – 8.57 (m, 1H, ArH 
naphthalene), 9.26 (d, 1H, J = 9.2 Hz, ArH pyridine), 11.42 (s, 1H, NH). 13C NMR (101 
MHz, CDCl3) δ 52.13, 53.11, 53.82, 117.00, 123.22, 123.65, 124.89, 126.50, 126.63, 
127.85, 128.05, 128.84, 130.88, 131.62, 132.66, 133.42, 134.40, 135.97, 158.75, 167.49, 
168.23. HRMS calculated for C22H19N5NaO4 [M + Na]




pyridine-2-carboxylic acid (5.31) 
To a solution of compound 5.30 (378 mg, 0.91 mmol) in THF (7 mL) was added a solution 
of KOH (254 mg, 4.53 mmol) in water (5.0 mL) at 0°C. The reaction mixture was stirred 
at rt for 12 h. The solvent was removed under reduced pressure and the residue was 
acidified (pH 2.0-3.0) with aqueous 2.0 M HCl solution resulting in the appearance of a 
colourless precipitate which was collected by filtration and washed with water. The 
precipitate was air dried to give 5.31 (317 mg, 0.78 mmol, 87%) as a colourless solid. 1H 
NMR (400 MHz, DMSO-d6) δ 3.92 (s, 3H, OCH3), 6.20 (s, 2H, CH2), 7.18 (d, 1H, J = 
277 
 
9.0 Hz, ArH pyridine), 7.41 (d, 1H, J = 7.4 Hz, ArH naphthalene), 7.62 – 7.73 (m, 2H, 
ArH naphthalene), 7.77 (s, 1H, ArH triazoline), 7.85 (d, 1H, J = 7.3 Hz, ArH 
naphthalene), 8.23 (s, 1H, ArH triazoline), 8.29 (d, 1H, J = 7.9 Hz, ArH naphthalene), 
8.40 (d, 1H, J = 8.6 Hz, ArH naphthalene), 8.66 (d, 1H, J = 8.9 Hz, ArH pyridine), 11.16 
(s, 1H, NH), 13.36 (s, 1H, CO2H).
 13C NMR (101 MHz, DMSO-d6) δ 50.49, 53.58, 
115.29, 123.75, 125.05, 125.35, 125.84, 126.02, 127.25, 129.92, 130.77, 131.11, 133.56, 
133.81, 134.47, 134.76, 134.79, 158.57, 166.77, 167.69. HRMS calculated for 
C21H17N5NaO4 [M + Na]





This compound was prepared according to previously published synthesis of 5.32.223 A 
mixture of 5.3 (0.33 g, 0.69 mmol) and pyridine hydrochloride (0.80 g, 6.97 mmol) was 
heated at 180 °C for 5 h. Water was slowly added to the hot reaction mixture (to prevent 
formation of solid cake), and diluted reaction mixture neutralised with NaHCO3 solution, 
extracted with EtOAc. The EtOAc layer was washed with water, brine, dried over 
MgSO4.H2O and purified by silica gel column chromatography (eluting with 50 to 70% 
EtOAc/hexane) to give 5.32 (0.162 g, 0.35 mmol, 51%) as a colourless solid. 1H NMR 
(400 MHz, CDCl3) δ 1.55 – 1.71 (m, 2H, CH2 cyclobutane), 1.72 – 1.88 (m, 2H, CH2 
cyclobutane), 1.91 – 2.06 (m, 2H, CH2 cyclobutane), 2.37 – 2.54 (m, 1H, NHCH2CH), 
3.31 (t, 2H, J = 6.6 Hz, NHCH2), 6.05 (s, 2H, CH2 triazoline), 6.98 (d, 1H, J = 9.1 Hz, 
ArH pyridine), 7.33 – 7.40 (m, 1H, ArH naphthalene), 7.44 (s, 1H, ArH triazoline), 7.51 
– 7.62 (m, 2H, ArH naphthalene), 7.71 (s, 1H, ArH triazoline), 7.83 (d, 1H, J = 7.3 Hz, 
ArH naphthalene), 7.91 – 7.99 (m, 1H, ArH naphthalene), 8.30 – 8.44 (m, 1H, NH), 8.55 
(d, 1H, J = 8.3 Hz, ArH naphthalene), 9.22 – 9.34 (m, 1H, ArH pyridine), 9.51 – 9.94 (m, 
1H, OH), 12.60 (s, 1H, NH). 13C NMR (101 MHz, CDCl3) δ 18.31, 25.73, 25.86, 34.90, 
44.54, 52.27, 115.07, 122.93, 124.05, 124.90, 126.70, 126.74, 127.71, 127.94, 129.67, 
130.89, 131.46, 132.18, 132.60, 133.80, 134.04, 136.30, 157.43, 166.62, 167.55. HRMS 
calculated for C25H24N6NaO3 [M + Na]







To a solution of 5.32 (25 mg, 0.05 mmol) in DMF (2.0 mL) was added 5.12 (31 mg, 0.08 
mmol), NaI (25 mg, 0.16 mmol), Ag2CO3 (76 mg, 0.27 mmol) and the reaction mixture 
stirred at 90 °C for 3 h. The reaction mixture was filtered to remove inorganic salts, the 
filtrate was evaporated under reduced pressure and the residue dissolved in EtOAc. The 
EtOAc solution was washed with water, brine, dried over MgSO4.H2O and concentrated 
under reduced pressure. The residue was purified by silica gel column chromatography 
(eluting with solvent mixture of 80% EtOAc, 10% THF and 10% hexane (solvent 
combination identified by TLC for the optimal separation of 5.33 and 5.12)) to give 5.33 
(10 mg, 0.01 mmol, 25%) as a clear oil. 1H NMR (400 MHz, CDCl3) δ 1.44 (s, 9H, 
C(CH3)3), 1.67 – 1.80 (m, 2H, CH2 cyclobutane), 1.83 – 1.99 (m, 2H, CH2 cyclobutane), 
2.03 – 2.15 (m, 2H, CH2 cyclobutane), 2.50 – 2.64 (m, 1H, NHCH2CH), 3.21 – 3.37 (m, 
2H, CH2), 3.37 – 3.46 (m, 2H, NHCH2), 3.48 – 3.58  (m, 2H, CH2), 3.59 – 3.81 (m, 8H, 
4 × CH2), 3.86 – 3.97 (m, 2H, CH2), 4.39 – 4.50 (m, 2H, CH2), 5.01 (br s, 1H, NH), 6.06 
(s, 2H, CH2 triazoline), 7.06 (d, 1H, J = 9.2 Hz, ArH pyridine), 7.38 (s, 1H, ArH 
triazoline), 7.43 (d, 1H, J = 7.3 Hz, ArH naphthalene), 7.53 – 7.64 (m, 2H, ArH 
naphthalene), 7.68 (s, 1H, ArH triazoline), 7.85 (d, 1H, J = 7.2 Hz, ArH naphthalene), 
7.96 – 8.03 (m, 1H, ArH naphthalene), 8.11 (t, 1H, J = 5.9 Hz, NH), 8.51 – 8.58 (m, 1H, 
ArH naphthalene), 9.33 (d, 1H, J = 9.2 Hz, ArH pyridine), 12.64 (s, 1H, NH). 13C NMR 
(101 MHz, CDCl3) δ 18.43, 25.74, 28.57, 35.08, 44.35, 52.27, 65.62, 69.63, 70.39, 70.75, 
70.80, 71.02, 116.22, 123.21, 123.60, 124.97, 126.80, 126.89, 127.72, 127.96, 129.68, 
131.03, 131.70, 132.97, 133.28, 133.41, 134.41, 136.37, 157.31, 167.08, 167.74. HRMS 
calculated for C38H49N7NaO8 [M + Na]
+, 754.3535; found, 754.3482. Analytical RP-







Hydroxy pyridine 5.32 (20 mg, 0.04 mmol), 5.17 (23 mg), NaI (19 mg, 0.13 mmol), and 
Ag2CO3 (60 mg, 0.22 mmol) were reacted according to the procedure described for the 
preparation of 5.33 and the crude residue was purified by silica gel column 
chromatography (eluting with 30% EtOAc/hexane to 100% EtOAc) to provide 5.34 (24 
mg, 0.03 mmol, 64%) as red liquid. 1H NMR (400 MHz, CDCl3) δ 1.42 (s, 9H, C(CH3)3), 
1.67 – 1.81 (m, 2H, CH2 cyclobutane), 1.83 – 1.98 (m, 2H, CH2 cyclobutane), 2.01 – 2.14 
(m, 2H, CH2 cyclobutane), 2.50 – 2.63 (m, 1H, NHCH2CH), 3.23 – 3.33 (m, 2H, CH2), 
3.34 – 3.42 (m, 2H, NHCH2), 3.52 (t, 2H, J = 5.1 Hz, CH2), 3.57 – 3.78 (m, 8H, 4 × CH2), 
3.83 – 3.92 (m, 2H, CH2), 4.12 – 4.23 (m, 2H, CH2), 5.02 (br s, 1H, NH), 5.40 (s, 2H, 
CH2 short pyridyl linker), 6.04 (s, 2H, CH2 triazoline), 7.10 (d, 1H, J = 9.1 Hz, ArH 
pyridine), 7.20 – 7.25 (m, 1H, ArH short pyridyl linker), 7.33 – 7.46 (m, 3H, ArH short 
pyridyl linker, ArH naphthalene, ArH triazoline), 7.51 – 7.64 (m, 2H, ArH naphthalene), 
7.67 (s, 1H, ArH triazoline), 7.82 (d, 1H, J = 7.3 Hz, ArH naphthalene), 7.96 – 8.04 (m, 
1H, ArH naphthalene), 8.21 – 8.35 (m, 2H, NH and ArH short pyridyl linker), 8.47 – 8.58 
(m, 1H, ArH naphthalene), 9.32 (d, 1H, J = 9.1 Hz, ArH pyridine), 12.61 (s, 1H, NH). 
13C NMR (101 MHz, CDCl3) δ 18.42, 25.81, 28.54, 35.08, 44.50, 52.23, 68.06, 68.93, 
69.70, 70.35, 70.71, 70.75, 71.02, 115.84, 122.05, 122.46, 123.17, 123.60, 124.94, 
126.75, 126.85, 127.67, 127.91, 129.82, 130.98, 131.65, 132.94, 133.27, 133.32, 134.37, 
136.30, 137.44, 149.48, 154.56, 156.09, 156.70, 167.06, 167.70. HRMS calculated for 
C44H54N8NaO9 [M + Na]
+, 861.3906; found, 861.3876. Analytical RP-HPLC Rt = 17.89 








pentaoxaheptadecan‐1‐yl}carbamate (5.35)  
Hydroxy pyridine 5.32 (18 mg, 0.04 mmol), 5.18 (21 mg, 0.04 mmol), NaI (19 mg, 0.13 
mmol), and Ag2CO3 (60 mg, 0.22 mmol) were reacted according to the procedure 
described for the preparation of 5.33 and the crude residue was purified by silica gel 
column chromatography (eluting with 50% EtOAc/hexane to 6% MeOH/EtOAc) to 
provide 5.35 (21 mg, 0.02 mmol, 56%) as clear, oily liquid. 1H NMR (400 MHz, CDCl3) 
δ 1.43 (s, 9H, C(CH3)3), 1.48 – 1.59 (m, 2H, CH2), 1.67 – 1.78 (m, 4H, CH2), 1.79 – 1.98 
(m, 4H, 2 × CH2), 2.02 – 2.13 (m, 2H, CH2), 2.23 (t, 2H, J = 7.5 Hz, CH2), 2.50 – 2.64 
(m, 1H, NHCH2CH), 3.19 – 3.35 (m, 2H, CH2), 3.36 – 3.42 (m, 2H, NHCH2 
cyclobutane), 3.43 – 3.48 (m, 4H, 2 × CH2), 3.49 – 3.58 (m, 4H, 2 × CH2), 3.58 – 3.74 
(m, 14H, 7 × CH2), 4.25 (t, 2H, J = 6.4 Hz, CH2), 5.08 (br s, 1H, NH), 6.05 (s, 2H, CH2 
triazoline), 6.22 (br s, 1H, NH), 6.99 (d, 1H, J = 9.2 Hz, ArH pyridine), 7.38 (s, 1H, ArH 
triazoline), 7.43 (d, 1H, J = 7.3 Hz, ArH naphthalene), 7.52 – 7.63 (m, 2H, ArH 
naphthalene), 7.68 (s, 1H, ArH triazoline), 7.84 (d, 1H, J = 7.2 Hz, ArH naphthalene), 
7.95 – 8.03 (m, 1H, ArH naphthalene), 8.13 (t, 1H, J = 5.8 Hz, NH), 8.50 – 8.59 (m, 1H, 
ArH naphthalene), 9.30 (d, 1H, J = 9.2 Hz, ArH pyridine), 12.63 (s, 1H, NH). 13C NMR 
(101 MHz, CDCl3) δ 18.41, 25.52, 25.69, 26.00, 28.56, 28.82, 35.05, 36.56, 39.29, 44.29, 
52.26, 66.11, 70.08, 70.33, 70.38, 70.64, 70.66, 70.68, 70.69, 70.72, 115.97, 123.18, 
124.94, 126.78, 126.87, 127.67, 127.92, 129.78, 131.01, 131.67, 132.92, 133.09, 133.16, 
136.39, 156.13, 157.65, 167.12, 167.68, 172.98. HRMS calculated for C48H68N8NaO11 
[M + Na]+, 955.4900; found, 955.4918. Analytical RP-HPLC Rt = 19.03 min; determined 










boratricyclo[7.3.0.03,7]dodeca‐1(12),4,6,8,10‐pentaen‐1‐ylium‐3‐ide (5.36)  
To a solution of 5.35 (3 mg, 3.21 μmol) in DCM (2.0 mL) at 0 °C was added TFA (0.5 
mL). The reaction mixture was stirred for 2 h, the solvent and TFA were removed by 
evaporation under reduced pressure to provide the amine 6‐({5‐[(17‐amino‐3,6,9,12,15‐
pentaoxaheptadecan‐1‐yl)carbamoyl]pentyl}oxy)‐N‐(cyclobutylmethyl)‐3‐{4‐[(1H‐
1,2,3‐triazol‐1‐yl)methyl]naphthalene‐1‐amido}pyridine‐2‐carboxamide trifluoroacetate 
in assumed quantitative yield as yellow solid. This trifluoroacetate salt was purified using 
semi-preparative RP-HPLC. To a solution of this purified trifluoroacetate salt (3.61 mg, 
3.81 μmol) in DMF (100 μL) was added a solution of DIPEA (1.0 μL, 6.05 μmol) in DMF 
(100 μL), followed by addition of solution of BOPIPY630/650-SE (1.0 mg, 1.51 μmol) 
in DMF (800 μL) and the reaction stirred in the dark for 12 h. The reaction solvents were 
removed under reduced pressure and the residue was purified by semi-preparative RP-
HPLC to give 5.36 (1.21 mg, 0.87 µmol, 58%) as a dark blue solid. HRMS calculated for 
C72H86BF2N11NaO12S [M + Na]
+, 1400.6143; found, 1400.6126. Analytical RP-HPLC Rt 








yl)methyl]naphthalene‐1‐amido}pyridin‐2‐yl}oxy)acetate (5.37)  
Hydroxy pyridine 5.32 (87 mg, 0.19 mmol), tert-butyl bromoacetate (112 mg, 0.57 
mmol), and Ag2CO3 (263 mg, 0.95 mmol) were reacted according to the procedure 
described for the preparation of 5.33 except that NaI was not added. The crude residue 
was purified by silica gel column chromatography (eluting with 50% EtOAc/hexane to 
70% EtOAc/Hexane) to provide 5.37 (102 mg, 0.18 mmol, 94%) as colourless solid. 1H 
NMR (400 MHz, CDCl3) δ 1.41 (s, 9H, C(CH3)3), 1.68 – 1.83 (m, 2H, CH2 cyclobutane), 
1.84 – 2.00 (m, 2H, CH2 cyclobutane), 2.04 – 2.20 (m, 2H, CH2 cyclobutane), 2.50 – 2.65 
(m, 1H, NHCH2CH), 3.31 – 3.50 (m, 2H, NHCH2), 4.67 (s, 2H, CH2CO), 6.06 (s, 2H, 
CH2 triazoline), 7.14 (d, 1H, J = 9.1 Hz, ArH pyridine), 7.36 – 7.40 (m, 1H, ArH 
triazoline), 7.43 (d, 1H, J = 7.3 Hz, ArH naphthalene), 7.53 – 7.65 (m, 2H, ArH 
naphthalene), 7.65 – 7.72 (m, 1H, ArH triazoline), 7.85 (d, 1H, J = 7.3 Hz, ArH 
naphthalene), 7.92 – 8.07 (m, 2H, NH and ArH naphthalene), 8.50 – 8.61 (m, 1H, ArH 
naphthalene), 9.40 (d, 1H, J = 9.2 Hz, ArH pyridine), 12.67 (s, 1H, NH). 13C NMR (101 
MHz, CDCl3) δ 18.39, 25.83, 28.11, 35.02, 44.63, 52.25, 64.77, 76.84, 77.16, 77.48, 
82.43, 115.78, 123.21, 123.62, 124.99, 126.77, 126.84, 127.74, 127.97, 129.36, 131.01, 
131.69, 133.06, 133.64, 133.95, 134.41, 136.24, 156.19, 166.91, 167.78, 168.67. HRMS 
calculated for C31H34N6NaO5 [M + Na]
+, 593.2483; found, 593.2474. Analytical RP-




naphthalene‐1‐amido}pyridin‐2‐yl}oxy)acetic acid (5.38)  
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To a solution of 5.37 (39 mg, 0.07 mmol) in DCM (2 mL) at 0 °C was added TFA (2 mL, 
26.13 mmol) and the mixture was stirred for 5 h. DCM and TFA were removed under 
reduced pressure and the residue was co-evaporated with CHCl3 to provide 5.38 (33 mg, 
0.06 mmol, 95%) as a colourless solid. 1H NMR (400 MHz, CDCl3) δ 1.61 – 1.75 (m, 
2H, CH2 cyclobutane), 1.77 – 1.92 (m, 2H, CH2 cyclobutane), 1.98 – 2.11 (m, 2H, CH2 
cyclobutane), 2.49 – 2.62 (m, 1H, NHCH2CH), 3.25 – 3.38 (m, 2H, NHCH2), 4.83 (s, 2H, 
CH2CO), 6.07 (s, 2H, CH2 triazoline), 7.17 (d, 1H, J = 9.2 Hz, ArH pyridine), 7.41 (d, 
1H, J = 7.3 Hz, ArH naphthalene), 7.45 (s, 1H, ArH triazoline), 7.56 – 7.65 (m, 2H, ArH 
naphthalene), 7.78 (s, 1H, ArH triazoline), 7.84 (d, 1H, J = 7.2 Hz, ArH naphthalene), 
7.91 (t, 1H, J = 5.9 Hz, NH), 7.94 – 8.00 (m, 1H, ArH naphthalene), 8.49 – 8.58 (m, 1H, 
ArH naphthalene), 9.41 (d, 1H, J = 9.2 Hz, ArH pyridine), 12.67 (s, 1H, NH). 13C NMR 
(101 MHz, CDCl3) δ 18.40, 25.71, 34.82, 44.63, 52.60, 63.37, 115.91, 123.01, 124.17, 
125.05, 126.80, 126.98, 127.91, 128.18, 129.48, 131.00, 131.58, 132.50, 133.60, 133.93, 
134.17, 136.31, 155.87, 166.79, 167.85, 172.43. HRMS calculated for C27H26N6NaO5 [M 





ethoxy}ethoxy)ethyl]carbamate (5.39)  
A solution of 5.38 (22 mg, 0.04 mmol), HBTU (16 mg, 0.04 mmol), DIPEA (22 μL, 0.13 
mmol) in DMF (1.0 mL) under N2 atmosphere was stirred for 5 min. A solution of 2.12 
(13 mg, 0.05 mmol) in DMF (1.0 mL) was then added and the reaction stirred for 12 h. 
The reaction solvent was removed under reduced pressure. The residue was dissolved in 
water and EtOAc was added. The EtOAc layer was then washed with saturated NaHCO3 
solution, water, brine solution, dried over MgSO4.H2O and concentrated under reduced 
pressure. The residue was purified by silica gel column chromatography (eluting with 
30% EtOAc/hexane to 5% MeOH/EtOAc) to provide 5.39 (19 mg, 0.02 mmol, 59%) as 
a colourless solid. 1H NMR (400 MHz, CDCl3) δ 1.44 (s, 9H, C(CH3)3), 1.67 – 1.80 (m, 
2H, CH2 cyclobutane), 1.83 – 1.99 (m, 2H, CH2 cyclobutane), 2.02 – 2.16 (m, 2H, CH2 
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cyclobutane), 2.51 – 2.67 (m, 1H, NHCH2CH), 3.18 – 3.35 (m, 2H, CH2), 3.36 – 3.42 (m, 
2H, NHCH2 cyclobutane), 3.44 – 3.65 (m, 10H, 5 × CH2), 4.74 (s, 2H, OCH2CO), 5.01 
(br s, 1H, NH), 6.06 (s, 2H, CH2 triazoline), 6.77 (br s, 1H, NH), 7.13 (d, 1H, J = 9.1 Hz, 
ArH pyridine), 7.39 (d, 1H, J = 0.9 Hz, ArH triazoline), 7.43 (d, 1H, J = 7.3 Hz, ArH 
naphthalene), 7.54 – 7.63 (m, 2H, ArH naphthalene), 7.68 (d, 1H, J = 0.9 Hz, ArH 
triazoline), 7.84 (d, 1H, J = 7.3 Hz, ArH naphthalene), 7.97 – 8.03 (m, 1H, ArH 
naphthalene), 8.03 – 8.15 (m, 1H, NH), 8.49 – 8.60 (m, 1H, ArH naphthalene), 9.41 (d, 
1H, J = 9.1 Hz, ArH pyridine), 12.70 (s, 1H, NH). 13C NMR (101 MHz, CDCl3) δ 18.39, 
25.79, 28.55, 34.94, 39.04, 40.42, 44.68, 52.23, 66.24, 69.80, 70.18, 70.33, 70.40, 115.57, 
123.23, 123.65, 125.02, 126.67, 126.80, 127.76, 127.98, 129.82, 130.98, 131.68, 133.16, 
133.71, 134.17, 134.41, 136.06, 155.54, 156.09, 166.80, 167.83, 168.86. HRMS 
calculated for C38H48N8NaO8 [M + Na]
+, 767.3487; found, 767.3485. Analytical RP-







uide (5.40)  
Following the procedure described for 5.36, 5.39 (3.0 mg, 4.02 µmol) was reacted with 
TFA (0.5 mL) to give 6‐[({2‐[2‐(2‐aminoethoxy)ethoxy]ethyl}carbamoyl)methoxy]‐N‐
(cyclobutylmethyl)‐3‐{4‐[(1H‐1,2,3‐triazol‐1‐yl)methyl]naphthalene‐1‐amido}pyridine‐
2‐carboxamide trifluoroacetate in assumed quantitative yield as a yellow solid. This 
trifluoroacetate salt was purified using semi-preparative RP-HPLC. Reaction of this 
purified trifluoroacetate salt (3.1 mg, 4.08 µmol) with BODIPY-630/650-SE (1.0 mg, 
1.51 μmol) gave 5.40 (1.76 mg, 1.47 μmol, 98%) as a dark blue solid. HRMS calculated 
for C62H66BF2N11NaO9S [M + Na]+, 1212.4729; found, 1212.4701. Analytical RP-HPLC 






amido}pyridine‐2‐carboxamide trifluoroacetate (5.44)  
According to the Fmoc solid phase peptide synthesis described for the preparation of 3.38 
in chapter 7, section 7.3.1, reaction of 5.38 (70 mg, 0.13 mmol) and Fmoc deprotected 
resin-bound 5.42 (143 mg) and then purification of the crude compound by RP-HPLC 
gave 5.44 (20 mg, 0.02 mmol) as a colourless solid. 1H NMR (400 MHz, DMSO-d6) δ 
1.14 – 1.28 (m, 6H, 2 × CH3 alanines), 1.61 – 1.73 (m, 2H, CH2 cyclobutane), 1.75 – 1.84 
(m, 2H, CH2 cyclobutane), 1.87 – 2.00 (m, 2H, CH2 cyclobutane), 2.54 (s, 1H, 
NHCH2CH), 2.79 – 2.87 (m, 2H, 2 × NH), 3.23 – 3.32 (m, 6H, 3 × CH2), 4.14 – 4.24 (m, 
1H, CHCONH), 4.30 – 4.40 (m, 1H, CHCONH), 4.78 – 5.00 (m, 2H, OCH2CO), 6.21 (s, 
2H, CH2 triazoline), 7.28 (d, 1H, J = 9.1 Hz, ArH pyridine), 7.38 (d, 1H, J = 7.4 Hz, ArH 
naphthalene), 7.63 – 7.72 (m, 2H, ArH naphthalene), 7.74 (m, 2H, NH2), 7.78 (d, 1H, J = 
1.0 Hz, ArH triazoline), 7.85 (d, 1H, J = 7.3 Hz, ArH naphthalene), 8.00 (t, 1H, J = 5.7 
Hz, NH), 8.26 (d, 1H, J = 1.0 Hz, ArH triazoline), 8.28 – 8.33 (m, 1H, ArH naphthalene), 
8.36 – 8.43 (m, 1H, ArH naphthalene), 8.69 – 8.78 (m, 1H, NH), 9.18 (d, 1H, J = 9.1 Hz, 
ArH pyridine), 12.63 (s, 1H, NH). HRMS calculated for C35H43N10O6 [M + H]
+, 





naphthalene‐1‐amido}pyridine‐2‐carboxamide (5.45)  
To a solution of 5.44 (16 mg, 0.02 mmol) in DMF (2.0 mL) was added (Boc)2O (5 mg, 
0.02 mmol), followed by addition of Et3N (4.1 µL, 0.03 mmol), and the reaction was 
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stirred for 12 h. The solvent was removed under reduced pressure and a portion of the 
obtained residue (6.0 mg from total 28 mg crude residue) was purified by semi-
preparative RP-HPLC to give 5.45 (1.3 mg, 1.62 µmol, 38%) as a colourless solid. HRMS 
calculated for C40H50N10NaO8 [M + Na]+, 821.3705; found, 821.3716. Analytical RP-








Following the procedure described for 5.36, 5.44 (3.7 mg, 4.55 µmol) was reacted with 
BODIPY-630/650-SE (1.0 mg, 1.51 μmol) to give 5.46 (0.24 mg, 0.19 μmol, 13%) as a 
dark blue solid. HRMS calculated for C64H68BF2N13NaO9S [M + Na]
+, 1266.4947; found, 
1266.4891. Analytical RP-HPLC Rt = 19.63 min; determined with HPLC method B. The 
low yield of the reaction was due to the poor solubility of 5.46 in DMSO-water solution, 
which made purification by semi-preparative RP-HPLC challenging.  
 
 
Quinoline‐4‐carbonyl chloride (5.48) 
According to the procedure described for the preparation of 5.22, commercially available 
quinoline‐4‐carboxylic acid 5.47 (0.2 g, 1.07 mmol) was reacted with SOCl2 (5.0 mL) to 





Methyl 6-methoxy-3-[(quinoline-4-carbonyl)amino]pyridine-2-carboxylate (5.49) 
To a solution of 5.48 (0.2 g, 1.07 mmol) in CHCl3 (7.0 mL) was added a solution of 5.29 
(0.13 g, 0.71 mmol) and DIPEA (0.4 mL, 2.14 mmol) in CHCl3 (3.0 mL) at 0°C under 
N2 atmosphere. The reaction mixture was warmed to rt and stirred for 7 h. The solvent 
was removed under reduced pressure and the residue was dissolved in EtOAc. The EtOAc 
layer was washed with saturated NaHCO3 solution, water, brine, dried over MgSO4.H2O, 
concentrated under reduced pressure and the residue purified by silica gel 
chromatography (50% EtOAc/hexane to 100% EtOAc) to provide 5.49 (0.19 g, 0.58 
mmol, 82%) as a colourless solid. 1H NMR (400 MHz, CDCl3) δ 3.96 (s, 3H, CO2CH3), 
4.00 (s, 3H, OCH3), 7.09 (d, 1H, J = 9.2 Hz, ArH pyridine), 7.62 – 7.67 (m, 1H, ArH 
quinoline), 7.69 (d, 1H, J = 4.3 Hz, ArH quinoline), 7.76 – 7.84 (m, 1H, ArH quinoline), 
8.19 (d, 1H, J = 8.5 Hz, ArH quinoline), 8.44 (d, 1H, J = 8.2 Hz, ArH quinoline), 9.07 (d, 
1H, J = 4.3 Hz, ArH quinoline), 9.25 (d, 1H, J = 9.2 Hz, ArH pyridine), 11.56 (s, 1H, 
NH). 13C NMR (101 MHz, CDCl3) δ 53.23, 53.88, 117.09, 118.69, 124.60, 125.48, 
128.05, 129.07, 130.18, 130.27, 132.65, 134.05, 141.36, 149.17, 150.16, 159.00, 165.88, 
168.29. HRMS calculated for C18H15N3NaO4 [M + Na]
+, 360.0955; found, 360.0928. 
 
 
6-Methoxy-3-[(quinoline-4-carbonyl)amino]pyridine-2-carboxylic acid (5.50) 
According to the procedure for 5.31, a solution of 5.49 (0.19 g, 0.57 mmol) and KOH 
(0.16 g, 2.84 mmol) gave 5.50 (0.18 g, 0.57 mmol, quantitative) as yellow solid. 1H NMR 
(400 MHz, DMSO-d6) δ 3.92 (s, 3H, OCH3), 7.18 (d, 1H, J = 8.9 Hz, ArH pyridine), 7.67 
– 7.76 (m, 1H, ArH quinoline), 7.80 (d, 1H, J = 4.3 Hz, ArH quinoline), 7.83 – 7.92 (m, 
1H, ArH quinoline), 8.14 (d, 1H, J = 8.3 Hz, ArH quinoline), 8.35 (d, 1H, J = 8.2 Hz, 
ArH quinoline), 8.49 (d, 1H, J = 8.9 Hz, ArH pyridine), 9.08 (d, 1H, J = 4.3 Hz, ArH 
quinoline), 11.19 (s, 1H, NH). 13C NMR (101 MHz, DMSO-d6) δ 53.67, 115.04, 119.16, 
123.93, 125.50, 127.76, 129.33, 129.82, 130.24, 135.49, 135.75, 141.40, 147.94, 150.34, 
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159.18, 165.21, 167.44. HRMS calculated for C17H12N3O4 [M - H]






According to the procedure described for 5.27, 5.50 (0.17 g, 0.53 mmol) was reacted with 
1-cyclobutylmethanamine hydrochloride (0.07 g, 0.58 mmol), HATU (0.2 g, 0.53 mmol) 
and DIPEA (0.3 mL, 1.58 mmol). Purification of the crude compound by silica gel 
column chromatography (eluting with 10% EtOAc/hexane to 60% EtOAc/hexane) gave 
5.6 (0.19 g, 0.49 mmol, 93%) as a colourless solid. 1H NMR (400 MHz, CDCl3) δ 1.69 – 
1.80 (m, 2H, CH2 cyclobutane), 1.82 – 2.00 (m, 2H, CH2 cyclobutane), 2.03 – 2.19 (m, 
2H, CH2 cyclobutane), 2.48 – 2.65 (m, 1H, NHCH2CH), 3.38 – 3.45 (m, 2H, NHCH2), 
3.94 (s, 3H, OCH3), 7.03 (d, 1H, J = 9.1 Hz, ArH pyridine), 7.58 – 7.65 (m, 1H, ArH 
quinoline), 7.70 (d, 1H, J = 4.4 Hz, ArH quinoline), 7.74 – 7.81 (m, 1H, ArH quinoline), 
8.10 – 8.22 (m, 2H, NH and ArH quinoline), 8.47 (d, 1H, J = 9.3 Hz, ArH quinoline), 
9.04 (d, 1H, J = 4.3 Hz, ArH quinoline), 9.29 (d, 1H, J = 9.1 Hz, ArH pyridine), 12.82 (s, 
1H, NH). 13C NMR (101 MHz, CDCl3) δ 18.41, 25.68, 35.03, 44.33, 53.59, 115.91, 
118.78, 124.74, 125.63, 127.81, 129.92, 130.05, 132.92, 133.16, 141.56, 149.12, 150.26, 
158.03, 166.01, 167.03. HRMS calculated for C22H22N4NaO3 [M + Na]
+, 413.1584; 






According to the procedure described for 5.32, 5.6 (0.18 g, 0.47 mmol) was reacted with 
pyridine hydrochloride (1.09 g, 9.47 mmol). Purification of the crude compound by silica 
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gel column chromatography (eluting with 30% EtOAc/hexane to 70% EtOAc/hexane) 
gave 5.51 (0.11 g, 0.29 mmol, 63%) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 
1.61 – 1.73 (m, 2H, CH2 cyclobutane), 1.75 – 1.86 (m, 2H, CH2 cyclobutane), 1.90 – 2.02 
(m, 2H, CH2 cyclobutane), 3.24 – 3.31 (m, 3H, NHCH2 and NHCH2CH), 7.03 (d, 1H, J 
= 8.9 Hz, ArH pyridine), 7.66 – 7.75 (m, 1H, ArH quinoline), 7.80 (d, 1H, J = 4.3 Hz, 
ArH quinoline), 7.84 – 7.92 (m, 1H, ArH quinoline), 8.14 (d, 1H, J = 8.4 Hz, ArH 
quinoline), 8.30 – 8.38 (m, 1H, 9, ArH quinoline), 8.66 (t, 1H, J =  5.6 Hz, NH), 9.01 (d, 
1H, J = 7.1 Hz, ArH pyridine), 9.09 (d, 1H, J = 4.3 Hz, ArH quinoline), 11.12 (s, 1H, 
OH), 12.63 (s, 1H, NH). 13C NMR (101 MHz, DMSO-d6) δ 17.73, 25.11, 34.40, 43.73, 
118.84, 123.71, 125.29, 127.76, 129.54, 130.13, 131.46, 141.16, 148.21, 150.55, 164.66. 
HRMS calculated for C21H19N4O3 [M - H]




yl}oxy) acetate (5.52)  
According to the procedure described for 5.33, 5.51 (32 mg, 0.08 mmol) was reacted with 
tert-butyl bromoacetate (25 mg, 0.13 mmol), NaI (38 mg, 0.25 mmol), and Ag2CO3 (117 
mg, 0.42 mmol). Purification of the crude compound by silica gel column 
chromatography (eluting with 20% EtOAc/hexane to 30% EtOAc/hexane) gave 5.52 (39 
mg, 0.08 mmol, 94%) as a clear oil. 1H NMR (400 MHz, CDCl3) δ 1.41 (s, 9H, C(CH3)3), 
1.68 – 1.82 (m, 2H, CH2 cyclobutane), 1.84 – 2.00 (m, 2H, CH2 cyclobutane), 2.03 – 2.18 
(m, 2H, CH2 cyclobutane), 2.51 – 2.63 (m, 1H, J = 7.6 Hz, NHCH2CH), 3.36 – 3.46 (m, 
2H, J = 7.3 Hz, NHCH2), 4.67 (s, 2H, OCH2CO), 7.14 (d, 1H, J = 9.1 Hz, ArH pyridine), 
7.58 – 7.67 (m, 1H, ArH quinoline), 7.70 (d, 1H, J = 4.4 Hz, ArH quinoline), 7.73 – 7.81 
(m, 1H, ArH quinoline), 7.96 (t, 1H, J = 6.0 Hz, NH), 8.13 – 8.20 (m, 1H, ArH quinoline), 
8.43 – 8.50 (m, 1H, ArH quinoline), 9.04 (d, 1H, J = 4.3 Hz, ArH quinoline), 9.37 (d, 1H, 
J = 9.1 Hz, ArH pyridine), 12.85 (s, 1H, NH). 13C NMR (101 MHz, CDCl3) δ 18.38, 
25.82, 28.10, 35.01, 44.64, 64.78, 76.84, 77.16, 77.48, 82.45, 115.82, 118.79, 124.72, 
125.61, 127.87, 129.56, 130.09, 130.10, 133.60, 141.46, 149.14, 150.27, 156.41, 166.10, 
166.85, 168.60. HRMS calculated for C27H30N4NaO5 [M + Na]






acid (5.53)  
According to the procedure for 5.38, a solution of 5.52 (21 mg, 0.04 mmol) and TFA (2.0 
mL, 17.54 mmol) gave 5.53 (27 mg) as a yellow solid. Compound 5.53 was used as such 
for next reaction without further purification. HRMS calculated for C23H21N4O5 [M - H]
-




amido)pyridin‐2‐yl}oxy)acetamido]ethoxy}ethoxy)ethyl]carbamate (5.54)  
According to the procedure described for 5.27, 5.53 (22 mg, 0.05 mmol) was reacted with 
2.12 (18 mg, 0.07 mmol), HBTU (19 mg, 0.05 mmol) and DIPEA (30 µL, 0.15 mmol). 
Purification of the crude compound by silica gel column chromatography (eluting with 
50% EtOAc/hexane to 5% MeOH/EtOAc) gave 5.54 (21 mg, 0.03 mmol, 62%) as a 
colourless solid. 1H NMR (400 MHz, CDCl3) δ 1.44 (s, 9H, C(CH3)3), 1.69 – 1.81 (m, 
2H, CH2 cyclobutane), 1.85 – 1.97 (m, 2H, CH2 cyclobutane), 2.06 – 2.15 (m, 2H, CH2 
cyclobutane), 2.54 – 2.65 (m, 1H, NHCH2CH), 3.25 – 3.36 (m, 2H, CH2), 3.38 – 3.45 (m, 
2H, NHCH2, cyclobutane), 3.47 – 3.65 (m, 10H, 5 × CH2), 4.75 (s, 2H, OCH2CO), 5.00 
(br s, 1H, NH), 6.76 (br s, 1H, NH), 7.14 (d, 1H, J = 9.1 Hz, ArH pyridine), 7.60 – 7.67 
(m, 1H, ArH quinoline), 7.71 (d, 1H, J = 4.4 Hz, ArH quinoline), 7.75 – 7.83 (m, 1H, 
ArH quinoline), 8.02 – 8.12 (m, 1H, NH), 8.18 (d, 1H, J = 8.5 Hz, ArH quinoline), 8.46 
(d, 1H, J = 8.5 Hz, ArH quinoline), 9.05 (d, 1H, J = 4.4 Hz, ArH quinoline), 9.38 (d, 1H, 
J = 9.1 Hz, ArH pyridine), 12.89 (s, 1H, NH). 13C NMR (101 MHz, CDCl3) δ 18.40, 
25.81, 28.56, 34.95, 44.72, 66.29, 69.83, 70.21, 70.42, 115.64, 118.84, 124.74, 125.56, 
127.97, 130.03, 130.22, 133.73, 141.45, 149.04, 150.23, 166.14, 166.77. HRMS 
calculated for C34H44N6NaO8 [M + Na]
+, 687.3113; found, 687.3124. Analytical RP-









Following the procedure described for 5.36, 5.54 (3.0 mg, 4.51 µmol) was reacted with 
TFA (0.5 mL) to give N‐{6‐[({2‐[2‐(2‐aminoethoxy)ethoxy]ethyl}carbamoyl)methoxy]‐
2‐[(cyclobutylmethyl) carbamoyl]pyridin‐3‐yl}quinoline‐4‐carboxamide trifluoroacetate 
salt in assumed quantitative yield as yellow solid. This trifluoroacetate salt was purified 
using semi-preparative RP-HPLC. Reaction of this purified trifluoroacetate salt (3.1 mg, 
4.56 µmol) with BODIPY-630/650-SE (1.0 mg, 1.51 μmol) gave 5.55 (1.89 mg, 1.70 
μmol, quantitative) as a dark blue solid. HRMS calculated for C58H62BF2N9NaO9S [M + 
Na]+, 1132.4354; found, 1132.4330. Analytical RP-HPLC Rt = 19.37 min; determined 





7.5.2 Computational studies 
 
Docking studies were carried out using GOLD217 (version 5.5; ChemPLP scoring method, 
default settings) using crystal structure of CB1R (PDB ID: 5XRA) published by Hua et 
al.113. The ligand 5.3 was drawn with MarvinSketch225224224224 (version 16.10). The lowest 
energy conformation of 5.3 (was obtained from a conformational search carried out with 
MarvinSketch (using Merck Molecular ForceField – MMFF94 with default settings 
(optimization limit strict, maximum number of conformers 10) and option “return only 
the lowest conformation found” selected), shown in Figure 5.1, chapter 5) was used for 
docking studies with and without restricting the bonds from rotation. The Cambridge 
Structural Database (CSD173; version 5.38 November 2016 + 2 updates) was searched 
using ConQuest (version 1.19) for three-dimensional structures of compounds similar to 
5.3 using substructure queries shown in chapter 5, Figure 5.2.  The binding site in the 
receptor was defined as the 15 Å region around the CB1R co-crystallised ligand AM11542 
(PDB ID: 5XRA) in the docking studies. Docking poses were visualised with PyMOL 
(The PyMOL Molecular Graphics System, version 2.0.3 Schrödinger, LLC.).  
 
7.5.3 Pharmacological studies 
 
Radioligand binding assays and cAMP functional assays were carried out as described in 
section 7.1.2. In the radioligand binding assay, [3H]-CP55,940 was used in a 
concentration of 0.75 nM per well for determining the CB1R affinity and 0.5 nM per well 
for determining the CB2R affinity of test compounds. Both CB1R and CB2R membrane 







Figure A.1 Representative excitation and emission spectra: Panel (A-B) – Fluorescent ligand 2.38 (chapter 
2, section 2.2.2) and Panel (C-D) – 2.37 (chapter 2, section 2.2.2). Data is generated by members of the 




NMR spectra of (benzimidazolyl)isoquinolinol 2.26 
 
























Figure A.8 HEK-293 cells stably transfected with N-terminally NLuc-labelled hA1AR were treated with increasing concentrations of fluorescent ligand and the BRET ratio 
measured after direct addition of the NLuc substrate furimazine (10μM).90 Non-specific binding was assessed in the absence and presence of 1M DPCPX. Pooled raw BRET 
ratio’s were baseline corrected (minus vehicle + furimazine BRET ratios) with data expressed as fold increase in BRET ratios over basal. Data represents five - seven independent 




Figure A.9 HEK-293 cells stably transfected with N-terminally NLuc-labelled hA3AR were treated with increasing concentrations of fluorescent ligand and the BRET ratio 
measured after direct addition of the NLuc substrate furimazine (10μM).90 Non-specific binding was assessed in the absence and presence of 1M MRS1220. Pooled raw BRET 
ratio’s were baseline corrected (minus vehicle + furimazine BRET ratios) with data expressed as fold increase in BRET ratios over basal. Data represents five - seven independent 







Figure A.10 HEK-293 cells stably expressing N-terminal NLuc tagged hA1AR were co-incubated with a fixed concentration of CA200645 (25nM) and increasing concentrations 
of unlabelled ligand (1h at 37°C). The A1AR selective antagonist DPCPX was included as a positive control. Total CA200645 binding and vehicle are shown by the black and 
white bars respectively. Data was pooled from five independent experiments and is expressed as mean ± SEM. Data generated by members of the Professor Stephen Hill’s 




Figure A.11 cAMP BRET assay screen of fluorescent ligands (at 10 μM) – 4.01 panel A, 4.02 panel B, 
4.03 panel C, 4.04 panel D, and 4.05 panel E at WT HEK-293 cells. Data is representative of a single 






Figure A.12 cAMP BRET assay screen of fluorescent ligands 4.01 (3 μM) panel A and (1 μM) panel B at 
HEK-293 cells stably expressing hCB2R. Data is representative of a single experiment carried in duplicate 













Figure A.13 cAMP BRET assay screen of 5.3 (10 μM) panel A, 5.33 (10 μM) panel B, 5.35 (10 μM) panel 
C, 5.34 (10 μM) panel D, and 5.37 (10 μM) panel E at WT HEK-293 cells. Data is representative of a single 
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